ESCMID Global

Preliminary Programme

36th Congress of the European Society of Clinical Microbiology and Infectious Diseases

Munich, Germany

17–21 April 2026

2026

Friday, 17 April 2026

EW006 | **08:30 – 10:30** | **Hall A1-4**

AMR IPC PHEI

2-hour Educational Session

Outbreak investigation: through the eyes of a field epidemiologist and public health microbiologist

Chairs *Angela Novais (Porto, Portugal)*
Yassen Tcholakov (Montréal, Canada)

W0081	**08:30**	**Field epidemiology: principles and the 10 steps of outbreak investigation** *Ricardo Mexia (Lisbon, Portugal)*
W0082	**08:50**	**Public health microbiology: practical applications of epidemiological markers and key tools for outbreak response** *João Pires (Oslo, Norway)*
W0083	**09:10**	**Real case study of healthcare-associated infection outbreak** , *Vera Manageiro (Lisbon, Portugal), Alma Tostmann (Nijmegen, The Netherlands)*

Co-organised with: EPIET alumni network (EAN), ESCMID Study Group for Epidemiological Markers (ESGEM)

EW004 | **08:30 – 10:30** | **Hall B0-1**

AMR CLN DX

2-hour Educational Session

The antibiogram: from theory to clinical practice

Chairs *Giulia De Angelis (Rome, Italy)*
Holger Rohde (Hamburg, Germany)

W0073	**08:30**	**The antibiogram demystified: principles, methods, and clinical significance** *Paul Christoffer Lindemann (Bergen, Norway)*
W0074	**08:50**	**Interpreting Gram-negative antibiograms** *Katy Jeannot (Besançon, France)*
W0075	**09:10**	**Interpreting Gram-positive antibiograms** *Stefania Stefani (Catania, Italy)*
W0076	**09:30**	**From the antibiogram to antibiotic choice: clinical reasoning in action** *Robin Howe (Cardiff, United Kingdom)*

Co-organised with: ESCMID AMR Action Subcommittee

EW005 | **08:30 – 10:30** | **Hall B0-2**

CLN IPC

2-hour Educational Session

Prevention and treatment for specific intra-abdominal infections

Chairs *Alida C.M. Veloo (Groningen, The Netherlands)*
Birgit Willinger (Vienna, Austria)

W0077	**08:30**	**Prevention of postoperative infection in bowel surgery: mechanical and/or oral antibiotics: what and when?** *Christian Eckmann (Hannover, Germany)*
W0078	**08:50**	**Selective decontamination: benefits and resistance development** *Nick Daneman (Ontario, Canada)*
W0079	**09:10**	**Necrotising pancreatitis and antibiotics: prophylaxis or early therapy?** *Hjalmar Van Santvoort (Utrecht, The Netherlands)*
W0080	**09:30**	**Diverticulitis: exact diagnosis and indications for antibiotic therapy** *Massimo Sartelli (Macerata, Italy)*

Co-organised with: Österreichische Gesellschaft für Antimikrobielle Chemotherapie (ÖGACH), ESCMID Study Group for Anaerobic Infections (ESGAI)

EW001 | **08:30 – 10:30** | **Hall ICM 13a**

TRN

2-hour Educational Session

Strategies to tackle biofilm-associated infections

Chairs *Arnaldo Lopes Colombo (São Paulo, Brazil)*
Luís Melo (Coimbra, Portugal)

W0061	**08:30**	**Pathogenesis of biofilm-associated infections** *Kimberly Kline (Geneva, Switzerland)*
W0062	**08:50**	**Viral therapies to tackle biofilm-associated infections** *Joana Azeredo (Braga, Portugal)*
W0063	**09:10**	**Molecular basis of tolerance and resistance in biofilms** *Tom Coenye (Ghent, Belgium)*
W0064	**09:30**	**Assessing *in vivo* anti-biofilm activity** *Valerie Waters (Toronto, Canada)*

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)

EW002 | **08:30 – 10:30** | **Hall ICM 13b**

PRO

2-hour Educational Session

Overcoming ongoing challenges in CM/ID publishing

Chairs *Kirsten Bibbins-Domingo (Chicago, United States)*
Leonard Leibovici (Yahud, Israel)

W0065	**08:30**	**Peer-review: the future?** *Amelia Joseph (Nottingham, United Kingdom)*
W0066	**08:50**	**Preparing the next generation of peer reviewers** *Preeti Malani (Ann Arbor, United States)*
W0067	**09:10**	**Efforts to make the literature unbiased** *Ursula Hofer (London, United Kingdom)*
W0068	**09:30**	**From authors to peer reviewers to editors: how should we handle the use of AI in publishing?** *Robert C. Read (Southampton, United Kingdom)*

Co-organised with: CMI Board of Editors, CMI Communications Board of Editors

---

EW003 | **08:30 – 10:30** | **Hall ICM 5**

IPC PHEI TRN

2-hour Educational Session

A gentle introduction to bioinformatics for microbial genomics

Chair *John W. A. Rossen (Groningen, The Netherlands)*
TBA

W0069	**08:30**	**Quality control of whole genome sequencing data** *Tarah Lynch (Calgary, Canada)*
W0070	**08:50**	**Genome assembly, read mapping and variant calling** *Torsten Seemann (Melbourne, Australia)*
W0071	**09:10**	**Species determination, genotyping and AMR prediction** *Andreas Stroehlein (Berlin, Germany)*
W0072	**09:30**	**Understating trees: phylogenomics for infection control** *Zoe Anne Dyson (London, United Kingdom)*

TEST2

10:00 – 11:00

1-hour Case Session

TEST2FB

TESTPC01	**Test intervention 01** *Pauline Cazanova (Nice, France)*
TESTPC02	**Test PC02** *Florence Boinnot (Nice, France)*
TESTPC03	**Test PC02 assigned to Flo 2** *Florence Boinnot Test (France)*

TEST1

11:00 – 12:00

ePoster Flash Session

TEST1FB

279	**10:00**	**Test Thibault** *Florence Boinnot Test (France)*
P9999	**10:12**	**This is a test abstract from Pauline - To keep please for testing purposes** *P. Cazanova* (Nice, France)*
PC01	**10:24**	**test**
PC02	**10:36**	**Test2** *Sabrina Stefanelli (Basel, Switzerland)*
TESTPC001	**10:48**	**Test Pauline 02** *Pauline Cazanova (Nice, France)*

ME013 | **11:00 – 12:00** | **Hall A1-4**

Meet-the-Expert

IPC PHEI

Legionnaires' disease: insights from recent large outbreaks

M0001	**11:00**	*Maria Scaturro* (*Rome, Italy*)
M0002	**11:12**	*Florian Heger* (*Vienna, Austria*)

Co-organised with: ESCMID Study Group for Legionella Infections (ESGLI)

ME010 **11:00 – 12:00** **Hall B0-1**

Meet-the-Expert

CLN PRO

Useful endpoints for antimicrobial therapy and stewardship: what if not only mortality mattered?

M0025	**11:00**	*Esther Calbo* (*Terrassa, Spain*)
M0026	**11:12**	*Antonios Katsounas* (*Bochum, Germany*)

ME012 **11:00 – 12:00** **Hall B0-2**

Meet-the-Expert

AMR DX IPC

How best to detect ESBL and carbapenemase producers

M0029	**11:00**	*Orjan Samuelsen* (*Tromso, Norway*)
M0030	**11:12**	*Shiri Navon-Venezia* (*Ariel, Israel*)

Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), EUCAST Steering Committee

---

ME007 **11:00 – 12:00** **Hall ICM 13a**

Meet-the-Expert

CLN IPC

Nosocomial infections in ECMO: clinical challenges and case-based discussion

M0019	**11:00**	*Konstanty Szuldrzynski* (*Mazowieckie, Poland*)
M0020	**11:12**	*Marta Hernández-Meneses* (*Barcelona, Spain*)

Co-organised with: European Extracorporeal Life Support Organization

---

ME008 **11:00 – 12:00** **Hall ICM 13b**

Meet-the-Expert

PED PRO

Designing and conducting clinical trials in paediatric infectious diseases: barriers and challenges

M0021	**11:00**	*Emmanuel Roilides* (*Thessaloniki, Greece*)
M0022	**11:12**	*Irja Lutsar* (*Tartu, Estonia*)

ME009 **11:00 – 12:00** **Hall ICM 5**

Meet-the-Expert

CLN DX

Travel, migration and immunosuppression: a two-way challenge

M0023	**11:00**	*Martin Peter Grobusch* (*Amsterdam, The Netherlands*)
M0024	**11:12**	*María Velasco* (*Madrid, Spain*)

Co-organised with: Federation of European Societies for tropical medicine and international health (FESTMIH)

EW018 **13:30 – 15:30** **Hall A1-4**

2-hour Educational Session

PRO

Method morsels: breaking trial methodology down into digestible components

Chairs *Amelia Joseph* (*Nottingham, United Kingdom*)
Navaneeth Narayanan (*New Brunswick, United States*)

W0015	**13:30**	**How much is enough? Old and new methods for calculating sample size** *Yin Mo* (*Singapore, Singapore*)
W0016	**13:50**	**Bayesian versus frequentist statistics: differences and advantages** *Tom Snelling* (*Sydney, Australia*)
W0017	**14:10**	**Immortal time bias: avoiding, recognising, and addressing it** *Emily Mcdonald* (*Montreal, Canada*)
W0018	**14:30**	**Open the DOOR and win? How to understand and interpret novel outcome measures** *Sean Wei Xiang Ong* (*Toronto, Singapore*)

Co-organised with: CMI Communications Board of Editors

EW017 **13:30 – 15:30** **Hall B0-1**

2-hour Educational Session

CLN DX PED

Advancing paediatric infectious disease management: from stewardship to precision therapeutics

Chairs *Luise Martin* (*Berlin, Germany*)
João Paulo Telles (*São Paulo, Brazil*)

W0011	**13:30**	**Paediatric antimicrobial stewardship: evidence-based interventions and practical barriers** *Johannes Hübner* (*Munich, Germany*)
W0012	**13:50**	**Optimising treatment in infants with access to newer antimicrobials** *Aspasia Katragkou* (*Morristown, United States*)
W0013	**14:10**	**Modelling and simulation for optimising initial paediatric and neonatal dosing** *Agathe Béranger* (*Paris, France*)
W0014	**14:30**	**Rapid identification and resistance profiling in neonates** *Surbhi Malhotra-Kumar* (*Antwerp, Belgium*)

Co-organised with: German Society for Pediatric Infectious Diseases (DGPI), ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

EW016 **13:30 – 15:30** **Hall ICM 5**

2-hour Educational Session

CLN DX

Clinical challenges in tropical medicine: lessons for global health

Chairs *Hilmir Asgeirsson* (*Stockholm, Sweden*)
Maria Cristina Loader (*London, United Kingdom*)

W0007	**13:30**	**Clinical impact of hybrid *Leishmania* strains** *Özgür Kurt* (*Istanbul, Türkiye*)
W0008	**13:50**	**Hybrid Schistosoma: what's the real picture?** *Bonnie Webster* (*London, United Kingdom*)
W0009	**14:10**	**Therapeutic challenges for nematode and trematode infections** *Carlos Seas* (*Lima, Peru*)
W0010	**14:30**	**Imported tropical diseases: what clinicians need to know** *Camilla Rothe* (*Munich, Germany*)

Co-organised with: Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V, ESCMID Study Group for Clinical Parasitology (ESGCP)

ME015 **13:30 – 14:30** **Hall B0-2**

Meet-the-Expert

DX IPC

Genomics in clinical microbiology and virology across settings: hype, hope, or a game-changer?

M0005	**13:30**	*Abhilasha Karkey* (*Kathmandu, Nepal*)
M0006	**13:42**	*Judith Breuer* (*London, United Kingdom*)

Co-organised with: ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS), European Society of Clinical Virology

---

ME011 **13:30 – 14:30** **Hall ICM 13a**

Meet-the-Expert

ANT CLN

Different sets of diagnostic tools for endocarditis: how to resolve

discrepancies and make them work?

M0027 **13:30** *Thomas Wouter Van Der Vaart* (*Asmterdam, The Netherlands*)
M0028 **13:42** *Marta Hernández-Meneses* (*Barcelona, Spain*)

ME014 **Hall ICM 13b**
13:30 – 14:30
Meet-the-Expert
CLN DX

How to approach pneumonia in patients with neutropaenia

M0003 **13:30** *Mark Reinwald* (*Brandenburg, Germany*)
M0004 **13:42** *Johan Maertens* (*Leuven, Belgium*)

ME021 **Hall B0-2**
14:45 – 15:45
Meet-the-Expert
AMR CLN

Optimising treatment of severe infections due to DTR organisms

M0035 **14:45** *Jean-Francois Timsit* (*Paris, France*)
M0036 **14:57** *Lowell Ling* (*Hong Kong, Hong Kong*)

Co-organised with: ESCMID Study Group for Critically Ill Patients (ESGCIP), European Society of Intensive Care Medicine

---

ME019 **Hall ICM 13a**
14:45 – 15:45
Meet-the-Expert
CLN IPC PRO

Ethical discourse on isolation precautions: to isolate or not to isolate that is the question!

M0031 **14:45** *Babette Rump* (*Middelburg, The Netherlands*)
M0032 **14:57** *Angelo Pan* (*Cremona, Italy*)

Co-organised with: ESCMID Ethics Advisory Committee (EEAC)

ME020 **Hall ICM 13b**
14:45 – 15:45
Meet-the-Expert
CLN DX

Hepatitis in the immunocompromised host: is it infection?

M0033 **14:45** *Susanne Gjeruldsen Dudman* (*Oslo, Norway*)
M0034 **14:57** *Oana Sandulescu* (*Bucharest, Romania*)

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH), ESCMID Study Group for Viral Hepatitis (ESGVH), Viral Hepatitis Society of Türkiye (VHSD)

EW027 **Hall B0-1**
16:15 – 18:15
2-hour Educational Session
AMR DX

Overcoming resistant *Candida* infections

Chairs *Alexandre Alanio* (*Paris, France*)
Nelesh Govender (*Johannesburg, South Africa*)

W0051 **16:15** **Global epidemiology of antifungal resistance in *Candida*: trends and hotspots** *Arnaldo Lopes Colombo* (*São Paulo, Brazil*)
W0052 **16:35** **Next-generation diagnostics: rapid tests and molecular methods** *Cornelia Lass-Flörl* (*Innsbruck, Austria*)
W0053 **16:55** ***Candida auris* and *Candida parapsilosis* resistance and transmission** *Anuradha Chowdhary* (*Delhi, India*)
W0054 **17:15** **Adopting guidelines and resources for *Candida* diseases in LMICs** *Methee Chayakulkeeree* (*Bangkok, Thailand*)

Co-organised with: German-Speaking Mycological Society, ÖGACH, EFISG, Portuguese Society of Infectious Diseases and Clinical Microbiology, Hellenic Society of Medical Mycology, Turkish Society of Paediatric Infectious Diseases

---

EW025 **Hall ICM 13a**
16:15 – 18:15
2-hour Educational Session
IPC PRO

Enhancing infection prevention and control through implementation science: the REVERSE experience

Chairs *Tatjana Lejko Zupanc* (*Ljubljana, Slovenia*)
Walter Zingg (*Zurich, Switzerland*)

W0043 **16:15** **Embedding implementation science in infection prevention and control** *Kathrin Blum* (*Zurich, Switzerland*)
W0044 **16:35** **Culture as a determinant of IPC implementation** *Diana Gabriela Iacob* (*Bucharest, Romania*)
W0045 **16:55** **Boundary spanning as a prerequisite to IPC implementation** *María Teresa Pérez-Rodríguez* (*Vigo, Spain*)
W0046 **17:15** **When implementation leadership facilitates IPC implementation** *Davide Mangioni* (*Milan, Italy*)

Co-organised with: ESCMID Study Group for Antimicrobial stewardship (ESGAP), Swiss Society for Infectious Diseases (SSID), ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee

---

EW026 **Hall ICM 5**
16:15 – 18:15
2-hour Educational Session
PED VAX

Vaccines for children: innovations, impact, and future directions

Chairs *Ilias P. Iosifidis* (*Thessaloniki, Greece*)
Hanna M. Nohynek (*Helsinki, Finland*)

W0047 **16:15** **New and emerging frontiers in paediatric vaccinology** *Paolo Palma* (*Antwerp, Italy*)
W0048 **16:35** **Beyond the needle: innovative delivery systems for paediatric vaccines** *Ulrich Heininger* (*Basel, Switzerland*)
W0049 **16:55** **Direct and indirect roles for vaccines against antimicrobial resistance** *Vana Spoulou* (*Athens, Greece*)
W0050 **17:15** **Vaccines and innate immunity: harnessing trained immunity in early life** *Elisabeth Dulfer* (*Nijmegen, The Netherlands*)

ME024 **Hall A1-4**
16:15 – 17:15
Meet-the-Expert
AMR DX

Quality controlled AST: use your cell phone and your data

M0041 **16:15** *Onur Karatuna* (*Växjö, Sweden*)
M0042 **16:27** *Iva Butic* (*Zagreb, Croatia*)

Co-organised with: Mèdecins Sans Frontières (MSF), CAESAR Network, ESCMID Education Subcommittee

---

ME023 **Hall B0-2**
16:15 – 17:15
Meet-the-Expert
ANT CLN

PK/PD-based dose optimisation in challenging patient groups

M0039 **16:15** *Birgit Koch* (*Rotterdam, The Netherlands*)
M0040 **16:27** *Christina König* (*Hamburg, Germany*)

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

ME022 **Hall ICM 13b**
16:15 – 17:15
Meet-the-Expert
TRN

Multi-omics dissection of bacterial pathogenesis and host-microbiome interactions

M0037 16:15 *Virginie Stévenin* (*Toulouse, France*)
M0038 16:27 *Romain Guérillot* (*Melbourne, Australia*)

ME030 **17:30 – 18:30** Hall A1-4

DX PHEI **Meet-the-Expert**

How to prepare for pathogen X emergence: a practical approach

M0059 17:30 *David Chien Lye* (*Singapore, Singapore*)
M0060 17:42 *David Hayman* (*Palmerston North, New Zealand*)

ME029 **17:30 – 18:30** Hall B0-2

ANT CLN **Meet-the-Expert**

Overcoming challenges to implementing system-wide antimicrobial stewardship

M0057 17:30 *Sara Cosgrove* (*Baltimore, United States*)
M0058 17:42 *Paul Turner* (*Oxford, United Kingdom*)

Co-organised with: British Society for Antimicrobial Chemotherapy (BSAC)

ME028 **17:30 – 18:30** Hall ICM 13b

CLN DX **Meet-the-Expert**

De-escalation or escalation: using rapid diagnostics in patients with sepsis

M0055 17:30 *Pierluigi Viale* (*Bologna, Italy*)
M0056 17:42 *Ana Gales* (*São Paulo, Brazil*)

Saturday, 18 April 2026

EW040 **08:30 – 10:30** Hall A2-1

ANT TRN **2-hour Educational Session**

Next-generation therapies against infectious diseases

Chairs *Nicolas Mueller* (*Zurich, Switzerland*)
Sebastian Wicha (*Hamburg, Germany*)

W0204 08:30 **Cellular therapies targeting infectious diseases** *Lukas Jeker* (*Basel, Switzerland*)
W0205 08:50 **Discovery of new antibody-based anti-infectives** *Jan Rybniker* (*Köln, Germany*)
W0206 09:10 **Proteasome-derived defence peptides** *Yifat Merbl* (*Rehovot, Israel*)
W0207 09:30 **Neutralising antibodies for treatment of vector borne pathogens** *Davide Filippo Robbiani* (*Bellinzona, Switzerland*)

Co-organised with: Swiss Society for Infectious Diseases (SSID), ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group of Forensic and Post-Mortem Microbiology (ESGFOR)

EW039 **08:30 – 10:30** Hall ICM 13a

PHEI TRN **2-hour Educational Session**

Milk matters: risks and safe practices in a changing global landscape

Chairs *Sally Jane Cutler* (*London, United Kingdom*)
Ana Raquel Freitas (*Porto, Portugal*)

W0200 08:30 **Raw milk misconceptions: health benefits vs risks** *Enda Cummins* (*Dublin, Ireland*)
W0201 08:50 **Brucellosis and bovine tuberculosis in LMICs** *Elaine Maria Seles Dorneles* (*Lavras, Minas Gerais, Brazil*)
W0202 09:10 ***Coxiella burnetii* in milk and cheese** *Loïc Epelboin* (*Cayenne, French Guiana*)
W0203 09:30 **Unexpected surprises in milk: avian influenza to *Listeria monocytogenes*** *Nicole Martin* (*Ithaca, United States*)

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Veterinary Microbiology (ESGVM)

OS001 **08:30 – 10:30** Hall A1-2

AMR DX IPC **2-hour Oral Session**

Novel insights and tools to tackle hospital outbreaks

Chairs *Fusun Can* (*Istanbul, Türkiye*)
Rekha Pai Mangalore (*Melbourne, Australia*)

O0001 08:30 **A pathogen-agnostic machine learning framework for precision outbreak detection in hospital and community settings** *K. Ko** (*Singapore, Singapore*), *C. Suphavilai, P. Boonsimma, H. Yingtaweesittikul, K.M. Lim, U. Shanmugam, W.E. Ong, J.H. Yeo, T.H.N. Wong*
O0002 08:42 **Towards data-driven refinement of an automated hospital outbreak detection system: validation of expert classification through genotypic evidence in neonatology wards** *F.D. Ruether** (*Berlin, Germany*), *B. Piening, F. Maechler, A. Weber, C. Geffers, S.J.S. Aghdassi*
O0003 08:54 **Designing and evaluating an infection prevention and control (IPC) dashboard to track and interrupt spread of healthcare-associated infections** *A. Luk** (*Oxford, United Kingdom*), *D. Adlard, H. Thai, G. Durant, S.A. Walker, D. Eyre*
O0004 09:06 **Ceftazidime/avibactam-resistant *Klebsiella pneumoniae* driven by multiple β-lactamase mutation: a hospital outbreak report** *W. Yang** (*Shanghai, China*), *C. Tang, Q. Shi, H. Ou, D. Yin, R. Han, J. Chen, Y. Guo, F. Hu*
O0005 09:18 **Comparative evaluation of the IR Biotyper and whole genome sequencing for detecting bacterial outbreak** *C. Sakr** (*Creteil, France*), *C. Subramanian, F. Cizeau, D. Ducellier, M. Danjean, J.W. Decousser*
O0006 09:30 **Nosocomial outbreak by NDM- and OXA-48-producing hypermucoviscous high-risk ST383 *Klebsiella pneumoniae* clone** *J. Sanchez Calvo** (*Jerez De La Frontera, Spain*), *J.M. Sánchez-Calvo, S. López-Cárdenas, J.A. Córdoba Doña, M. Murillo-Pineda, R. Lobato-Cano, I.M. Santiago Soler, I. Pozo Jiménez, M. Coppi, I. Baccani, A. Antonelli, G.M. Rossolini, N. Zuabi, J. Rodríguez-Baño, P. Retamar*
O0007 09:42 **Chasing accuracy: does 1% really change the story in an ExPEC outbreak?** *T. Severs** (*Zwolle, The Netherlands*), *A.J. Gebbink, A.K.P.K. Bari, H. Gremmels, S. Debast, J.H.E. De Lange, B. Sinha, J.W.A. Rossen, B.B. Xavier*
O0008 09:54 **Whole genome sequencing (WGS) and improved diagnostics uncover a multispecies plasmid-borne GES-5/OXA-917 carbapenemase outbreak driven by the *Citrobacter freundii* complex** *A. Rath** (*Regensburg, Germany*), *N. Förster, N. Pfennigwerth, C. Keller, B. Neumann, A. Caplunik-Pratsch, B. Lenker, A. Eichner, J. Fritsch, W. Schneider-Brachert, B. Kieninger*
O0009 10:06 **Development of outbreak-specific TaqMan PCR assays for tracking vancomycin-resistant *Enterococcus faecium* in Dutch hospitals** *A.J. Sabat** (*Groningen, The Netherlands*), *J. Flipse, C.J.H. Von Wintersdorff, A. Pettersson, V. Akkerboom, W.C. Van Der Zwet, P.H.M. Savelkoul, A. Voss, E. Bathoorn*
O0010 10:18 **Beyond species: integrated bacterial and OXA-48 plasmid clustering with EPISEQ® reveals a polyclonal, multi-species hospital outbreak** *L. Aguilera Muros** (*Granada, Spain*), *M.A. Roldán Ruiz, A. Badillo Carrasco, C. Roldán Fontana, F. García García, N. Chueca Porcuna*

OS002 **08:30 – 10:30** Hall A1-3

ANT CLN TRN **2-hour Oral Session**

Three viruses, one winter: what we miss, what we treat, what comes next

Chairs *Christopher Chiu* (*London, United Kingdom*)
Neven Papic (*Zagreb, Croatia*)

O0011 08:30 **Pathogen-specific viral infections among adults hospitalised with severe acute respiratory infection: European multi-centre surveillance study, 2024–2025 (id.DRIVE)** *K. Newell** (*Rotterdam, The Netherlands*), *N. Vroom, C. Marques, E. Maslova, F. Khan, K.Y. Ngew, H.R. Volkman, C. Wang, J.V. Hernandez-Villena, N. Aliabadi, E. Begier, J. Nguyen, H. Dunford, S. Basu, A. Antón, I. Casas, B. Grüner, G. Icardi, F.M. Torres, A. Mira-Iglesias, C.M. Oñoro López, A. Orrico-Sánchez, O. Parés-Badell, W. Gleiber, A. Torres, K. Bollaerts*

O0012 08:42 **Predictors of severe outcomes in hospitalised patients with viral respiratory tract infections: a prospective cohort study** *O. Usta** (*Istanbul, Türkiye*), *Ö. Aktaş, B. Çakan, A. Ardalı, Y. Beşli, Ö. Ergönül, Ş. Keske*

O0013 08:54 **Zelicapavir decreases symptom duration, hospitalisation and viral load in a global, randomised, double-blinded, placebo-controlled phase II trial of high-risk adults with RSV** *S. Rottinghaus** (*Watertown, Massachusetts, United States*), *C. Harris, J. Devincenzo, S. Chen, T. Ngo, A. Ahmad, M. Turnak*

O0014 09:06 **Postmortem study: analysis of mortality associated with respiratory viruses in four seasons of influenza** *M. Olazabal** (*Pamplona, Spain*), *L. Argente, A. Navascues, I. Martinez-Baz, C. Trabajo, J. Castilla, M.E. Portillo*

O0015 09:18 **Antiviral efficacy of baloxavir marboxil, favipiravir, and oseltamivir in adults with acute non-severe influenza virus infection: an open-label, phase II, randomised, controlled, adaptive platform trial** *S.J. Leopold** (*Bangkok, Thailand*), *P. Jittamala, K. Kotchum, P. Wongnak, T. Asawasriworanan, T. Seers, S. Boyd, E. Beer, S. Singh, E. Batty, K. Chotivanich, S. Pukrittayakamee, A.M. Dondorp, N.P. Day, A. Karkey, M.M. Teixeira, E.A. Ashley, M. Imwong, W. Phumratanaprapin, J.A. Watson, W.H. Schilling, N.J. White*

O0016 09:30 **A sequence-based update on mutations in influenza polymerase acidic protein in Europe conferring resistance to baloxavir from 2009 to 2025: the old, the new, and the emerging mutations** *A. Martín-Toribio** (*Valladolid, Spain*), *M. Toquero-Asensio, S. Garcia-Díaz, J. Sanchez-Martinez, C. Rodriguez-Crespo, I. Inchausti-Moya, S. Rojo-Rello, M. Dominguez-Gil, E. Nistal-Villán, M. Hernandez-Perez, J.M. Eiros, I. Sanz-Muñoz*

O0017 09:42 **Effectiveness of nirmatrelvir/ritonavir in preventing severe COVID-19 outcomes: national multi-year real-world data from Greece** *E.G. Kostaki** (*Athens, Greece*), *M. Gkova, K. Mathioudakis, D. Menegas, V. Grammelis, V. Kossyvaki, I. Antoniou, P. Nikolopoulou, L. Puzniak, T. Bergroth, D. Paraskevis*

O0018 09:54 **Phase II study of secutrelvir, a second-generation 3C-like protease inhibitor as oral treatment for COVID-19** *S. Kezbor** (*Florham Park, United States*), *E. Mitchell, Y. Iwasaki, G. Ichihashi, T. Baba, S. Lacey, H. Nobori, A.C. Hurt, A. Fukushi, Y. Takeda*

O0019 10:06 **Macrophage and platelet activation drive inflammation in people living with Long COVID, irrespective of symptom cluster** *E. Wall** (*London, United Kingdom*), *D. Greenwood, G. Ahimbisibwe, C. Dubois, I. Aniq, O. Haguge, A. Parabita, G. Prescott, M. Skehl, M. Scully, T. Hillman, A. Banerjee, E. Carr*

O0020 10:18 **MDL-001, an oral direct-acting Thumb-1 polymerase inhibitor, demonstrates broad-spectrum activity against influenza viruses, respiratory syncytial virus, and SARS-CoV-2 with oral proof-of-concept in mice** *D. Haders** (*La Jolla, United States*), *V. Woods, T. Umansky, S. Russell, A. Goodman, M. Bobardt, B. Mcgovern, M. Rodriguez, A. García-Sastre, K. White, W. Brubaker, P. Gallay, D. Smith*

OS003 **Hall A1-4**

08:30 – 10:30

AMR PHEI

2-hour Oral Session

Driving global AMR action through data, economics, and policy

Chairs *Diane Ashiru-Oredope* (*London, United Kingdom*)
Chantal Morel (*Bonn, Germany*)

O0021 08:30 **Past, present and future of bacterial antimicrobial resistance (AMR) in the WHO Eastern Mediterranean Region: comprehensive AMR burden modelling from 1990 to 2021 with forecasts to 2050** *T. Mestrovic** (*Varaždin, Croatia*), *T. Meštrović, M. Naghavi, G. Robles Aguilar, N.D. Weaver, L.R. Swetschinski, D.T. Araki, E.E. Wool, A. Gray, A. Gershberg Hayoon, C. Han, K.S. Ikuta, E. Rosenblad, R.L. Hsu, B.S. Cooper, C. Dolecek, B. Sartorius, S. Hay, C.J.L. Murray*

O0023 08:42 **Mapping and synthesising global antibiotic use datasets to improve evidence for surveillance, modelling, and policy** *K. Zay Ya** (*London, United Kingdom*), *K. B Pouwels, M. Sharland, D. R M Smith, A. Cook*

O0024 08:54 **The cost-effectiveness of a personalised *in vitro* antibiotic combination testing (iACT) service for treatment of carbapenem-resistant *Pseudomonas aeruginosa* (CRPA) infections** *Y. Cai** (*Singapore, Singapore*), *T.P. Lim, W. Lee, J.Q. Teo, A.L. Kwa, N. Graves*

O0025 09:06 **Costs of hospital admissions linked with Gram-negative bloodstream infections among adults in England: an analysis using health resource groups** *K. Hayes** (*London, United Kingdom*), *L. Miller, L. Uwais, E. Agnew, S. Evans, E. Van Leeuwen, J. Robotham*

O0026 09:18 **Beyond the tip of the iceberg: quantifying the effect of MDRO-carriage on postacute inpatient rehabilitation** *H. Kaba** (*Goettingen, Germany*), *P. Wenzlaff-Lodge, S. Scheithauer*

O0027 09:30 **Mind the governance gap: a One Health systematic review of national AMR performance indicators** *E. O'neill** (*London, United Kingdom*), *U. Shafaque, V. Karadimitris, B. Hill, S. Ranganathan, E. Mossialos, M. Anderson*

O0028 09:42 **Benchmarking AWaRe: estimating expected need of AWaRe antibiotic use in 186 countries based on infection and resistance burden** *A. Cook** (*London, United Kingdom*), *B. Cooper, K. Pouwels, M. Sharland*

O0029 09:54 **Interactive causal inference framework for assessing policy and consumption effects on antimicrobial resistance** *A. Gupta** (*Natick, United States*), *C. Vania*

O0030 10:06 **UKHSA's contribution to the UK Antimicrobial Rresistance National Action Plan 2024–2029 (year one)** *C. Brown** (*London, United Kingdom*), *R. Hope, V. Finistrella, J. Conneely, G. Eldridge, J. Charlesworth, S. De Cordova, E. Ombakho, F. Ambreen, J. Gritton*

LB001 **Hall A3-1**

08:30 – 10:30

ANT CLN

2-hour Oral Session

Late-breaking vaccine trials

Chairs *Zitta Barrella Harboe* (*Hillerød, Denmark*)
Maheshi Ramasamy (*Oxford, United Kingdom*)

L0001 08:30 **Impact of colonisation acquisition and PCV15 on symptoms following serotype 3 experimental human pneumococcal challenge (EHPC): results from a phase IV double-blind randomised clinical trial** *J. Lustosa Martinelli** (*Oxford, United Kingdom*), *J.L. Martinelli, Y. Ni, K. Tanha, R. Huq, B. Rocha De Macedo, C. Solórzano, A. Hyder-Wright, R. Mahmud, H. Gill, R. White, A. Singha, F. Elterish, T. Condreanu, B. Urban, E. Mitsi, X. Liu, A.M. Collins, D.M. Ferreira, S.B. Drysdale*

L0002 08:42 **Updated safety and immunogenicity results from a UK-based phase I clinical trial of the Nipah virus candidate vaccine ChAdOx1 NipahB** *D. Jenkin** (*Oxford, United Kingdom*), *R. Kenneil, N. Marchevsky, I. Haeusler, L. Saldana Ortega, R. White, Y. Zhang, E. Morey, T. Madupuri, N. Panchal, E. Sheehan, J. Wright, E. Vannaxay, H. Zhang, S. Kelly, L. Hahn, D. Pulido-Gomez, G. Morshead, A. Boyd, A. Pollard, T. Lambe, S. Gilbert, B. Angus*

L0003 08:54 **High-dose influenza vaccine effectiveness in immunosuppressed older adults: an individual-level pooled analysis (FLUNITY-HD)** *A.M. Reimer Jensen** (*Copenhagen, Denmark*), *N.D. Johansen, J. Pardo-Seco, C. Rodriguez-Tenreiro-Sánchez, M.M. Loiacono, R.C. Harris, K. Sharff, J.A. Hill, Y. Huang, R. Van Aalst, A. Chit, C.S. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, B.L. Claggett, K.H. Janstrup, C. Duran-Parrondo, M. Piñeiro-Sotelo, M. Cribeiro-González, M. Conde-Pájaro, S. Mirás-Carballal, J.M. González-Pérez, S.D. Solomon, P. Sivapalan, C.J.M. Martel, J.U.S. Jensen, F. Martinón-Torres, T. Biering-Sørensen*

L0004 09:06 **Safety, tolerability and immunogenicity of SPVX02, a**

fridge-free thermostable tetanus-diphtheria vaccine compared to Tetadif and diTeBooster: a multi-centre, phase I, blinded, randomised clinical trial *S.N. Faust** (*Southhampton, United Kingdom*), *T.A.N. Reed, P. Clarke, M. Razzaque, J. De La Torre Arrieta, A. Garcia De Castro, R. Alexiev, C. Panainte, N. Khan, L. Grey, M. Matheson, H. Cuthbertson, O. Tuncer, S. Chatfield, B. Roser, A. Boyd, J.S. Nguyen-Van Tam, K. O'hanlon, A.P. Dale*

L0005 **09:18** **Safety and immunogenicity of a heterologous protein prime/MVA boost therapeutic hepatitis B vaccine: first results of the *TherVacB* phase Ia trial** *M. Addo** (*Hamburg, Germany*), *M. Schunk, S.D. Jeske, N. Körber, S. Hardtke, H.M. Weichel, T. Bauer, F. Thiele, M. Wiegand, M. Hoelscher, U. Protzer*

L0006 **09:30** **Safety and immunogenicity of heterologous RSV revaccination with mRNA-1345 after primary vaccination with protein-based vaccine** *M. Desai** (*Cambridge, United States*), *J. Cardona, S. Khetan, S. Mehta, A. Kapoor, A. Okparavero, Z. Lin, F. Priddy*

L0007 **09:42** **A double-blind randomised controlled trial on baloxavir marboxil and flufenamic acid combination for severe hospitalised influenza infection** *W. Chu** (*Hong Kong, Hong Kong*), *I.F. Hung, J. Choi, T. Anthony*

L0008 **09:54** **First-in-human study of EVT894, a monoclonal antibody against chikungunya virus** *H. Watson** (*Lyon, France*), *K. Miller, A. Safder, S. Raja, L. Jordan, M. Mack, X. Boulenc, M. Mandron, M. Gordon, M. Jahromi, S. Woodson*

L0009 **10:06** **Sequential administration of an mRNA-based seasonal influenza vaccine in older adults** *E. Malkin** (*Cambridge, United States*), *A. Kohli, R. Chen, E. Du, A. Pucci, R. Das, E. Wilson*

L0010 **10:18** **Longitudinal B cell immunity after adjuvanted respiratory syncytial virus (RSV) vaccination in high-risk transplant recipients** *M. Kern-Smith** (*Toronto, Canada*), *P.M. Lavoie, A. Humar, D. Kumar, J. Mattsson, V.G. Hall, V.H. Ferreira*

SY035 **08:30 – 10:30** **Hall A1-1**

2-hour Symposium

AMR TRN

Microbial interactions and bacterial adaptation in the microbiome

Chairs *Zuzanna Drulis-Kawa* (*Wroclaw, Poland*)
Mauricio Farfan (*Santiago, Chile*)

S0183 **08:30** **The interplay of genetic drift and bacterial adaptation in skin microbiomes** *Julia Oh* (*Durham, United States*)

S0184 **09:00** **Pathways of adaptive evolution in chronic lung infections** *Helle Krogh Johansen* (*Copenhagen, Denmark*)

S0185 **09:30** **Bacteriophages and their interaction with the gut microbiome** *Naama Geva-Zatorsky* (*Haifa, Israel*)

S0186 **10:00** **Quantifying microbiome-host interactions in the human gut** *Markus Arnoldini* (*Zurich, Switzerland*)

SY036 **08:30 – 10:30** **Hall A1-5**

2-hour Symposium

DX PHEI

Recent advances in malaria molecular surveillance: experiences from malaria endemic countries

Chairs *Abdoulaye Djimde* (*Bamako, Mali*)
Martin Peter Grobusch (*Amsterdam, The Netherlands*)

S0187 **08:30** **Malaria molecular surveillance in the Horn of Africa using the MAD4HatTeR amplicon sequencing panel** *Fitsum Tadesse* (*Addis Ababa, Ethiopia*)

S0188 **09:00** **A field-based nanopore amplicon sequencing (NOMADS) assay for malaria parasites and vectors** *Mulenga Chilumba Mwenda* (*Lusaka, Zambia*)

S0189 **09:30** **Molecular surveillance in Africa using the Pf-SMARRT assay** *Ronald Futila Kyong-Shin* (*Chapel Hill, United States*)

S0190 **10:00** **Genetic surveillance of *P. vivax* in the Greater Mekong Subregion using the Pv microhaplotype AmpSeq assay** *Thanh Thuy Nhien Nguyen* (*Ho Chi Minh City, Vietnam*)

SY037 **08:30 – 10:30** **Hall A3-2**

2-hour Symposium

PHEI VAX

Unmet SDGs: Europe's struggle with HIV, TB, hepatitis and STIs

Chairs *Tomislav Mestrovic* (*Varaždin, Croatia*)
Anastasia Pharris (*Stockholm, Sweden*)

S0191 **08:30** **Current epidemiological concerns and key gaps in progress towards the SDGs: where should Europe focus efforts to achieve maximum impact?** *Anastasia Pharris* (*Stockholm, Sweden*)

S0192 **09:00** **Prevention of STIs across Europe: what is working and how to stem the tide?** *Nicola Low* (*Bern, Switzerland*)

S0193 **09:30** **Equity in treatment: why is Europe lagging behind in terms of optimal TB care and access to all necessary medical products?** *Christophe Perrin* (*Paris, France*)

S0194 **10:00** **Migration and the importance of an international approach to tackling the SDGs for TB, HIV and hepatitis** *Dominik Zenner* (*London, United Kingdom*)

Co-organised with: European Centre for Disease Prevention and Control (ECDC)

SY033 **08:30 – 10:30** **Hall B0-1**

2-hour Symposium

CLN

AI-enhanced sepsis care: from early detection to long-term follow-up

Chairs *Michele Bartoletti* (*Milan, Italy*)
Damien Ming (*London, United Kingdom*)

S0175 **08:30** **Early recognition and decision-making in sepsis: the role of AI-enhanced clinical pathways** *Sylvain Meylan* (*Lausanne, Switzerland*)

S0176 **09:00** **Initial and adaptive antimicrobial therapy in sepsis: personalisation and stewardship in the age of AI** *Shruti Gohil* (*Irvine, United States*)

S0177 **09:30** **From stabilisation to supportive care: integrating the ICU-level multimodal strategy** *Eric Kipnis* (*Lille, France*)

S0178 **10:00** **Beyond survival: post-sepsis care, risk stratification, and AI-driven follow-up models** *Hannah Wozniak* (*Geneva, Switzerland*)

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES)

SY034 **08:30 – 10:30** **Hall B0-2**

2-hour Symposium

CLN DX

Rapid pathogen sequencing for patient management: advancing diagnostic implementation

Chairs *Claudio Neidhöfer* (*Basel, Switzerland*)
Torsten Seemann (*Melbourne, Australia*)

S0179 **08:30** **State-of-the-art methodologies for clinical pathogen sequencing: bridging technology and application** *Oon Tek Ng* (*Singapore, Singapore*)

S0180 **09:00** **Ensuring reliability: validation, regulation, and quality control in pathogen sequencing** *Paula Mölling* (*Örebro, Sweden*)

S0181 **09:30** **From data to decision: clinical interpretation and integration of pathogen sequencing in patient pathways** *Luke Blagdon Snell* (*London, United Kingdom*)

S0182 **10:00** **Genotypic predictions of antimicrobial resistance: unlocking the power of sequencing for treatment decisions** *Lorena Diaz* (*Santiago, Chile*)

Co-organised with: UK National Health Service Genomic Network of Excellence; Consortium for Clinical Metagenomics in Infectious Diseases (CCMID), ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Trainee Association of ESCMID (TAE) Steering Committee

---

SY031 **08:30 – 10:30** **Hall ICM 13b**

2-hour Symposium

IPC

Biofilms, the hidden threat in healthcare environment: unveiling detection, control and prevention strategies

Chairs *Joana Azeredo* (*Braga, Portugal*)
Claus Moser (*Copenhagen, Denmark*)

S0167 **08:30** **Tackling dry surface biofilms** *Jean-Yves Maillard* (*Cardiff, United Kingdom*)

S0168 **09:00** **That slimy stuff in water pipes!** *Michael Weinbren* (*London, United Kingdom*)

S0169 **09:30** **Skin and soft tissue microbiomes and biofilms** *Blaine Fritz* (*Copenhagen, Denmark*)

S0170 **10:00** **Biofilm coats catheters** *Gordon Ramage* (*Glasgow, United Kingdom*)

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Nosocomial Infections (ESGNI)

SY032 **08:30 – 10:30** **Hall ICM 5**

CLN DX VAX

2-hour Symposium

Beyond recovery: post-acute syndromes after respiratory viral infections

Chair *Paraskevi C. Fragkou* (*Markopoulo Mesogeion, Greece*)
TBA

S0171 **08:30** **Post-COVID-19 syndrome: respiratory and multisystem sequelae** *Ziyad Al-Aly* (*Saint Louis, United States*)

S0172 **09:00** **Post-influenza syndromes: a hidden burden in clinical practice** *Sotirios Tsiodras* (*Athens, Greece*)

S0173 **09:30** **RSV and other endemic respiratory viruses: what comes after acute infection?** *Chrysanthi Skevaki* (*Marburg, Germany*)

S0174 **10:00** **Genetic basis of post-acute viral syndromes** *Hanna Ollila* (*Helsinki, Finland*)

Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), European Respiratory Society (ERS)

EW038 **08:30 – 11:30** **Hall ICM 1**

AMR DX

3-hour Educational Session

EUCAST user workshop

Chairs *Marlene Amara* (*Paris, France*)
Alasdair Peter Macgowan (*Bristol, United Kingdom*)

W0195 **08:30** **EUCAST Update** *Sören Gatermann* (*Bochum, Germany*)

W0196 **09:00** **Challenges of testing beta-lactam/beta-lactamase inhibitors** *Mandy Wootton* (*Cardiff, United Kingdom*)

W0197 **09:30** **When do you need an MIC** *Barbara Juliane Holzknecht* (*Copenhagen, Denmark*)

W0198 **10:00** **Challenges of setting up a NAC in a large country** *Qiwen Yang* (*Beijing, China*)

W0199 **10:30** **The role of clinical data in setting breakpoints** *Jesús Rodríguez-Baño* (*Seville, Spain*)

Co-organised with: EUCAST Steering Committee

EF004 **08:30 – 09:30** **Arena 1**

ANT

ePoster Flash Session

Beyond guidelines: how behaviour and social context shape antimicrobial prescribing

Chair *Jaap Ten Oever* (*Nijmegen, The Netherlands*)

E0031 **08:30** **Prescribing inequities: evaluating under- and over-treatment across patient and neighborhood factors** *C. Evans** (*Chicago, United States*), *S. Reddy, M. Dhanani, A. Rivera, D. Glover, G. Wilson, S. Balbale, M. Keintz, K. Suda, J. Marcelin*

E0032 **08:36** **Understanding what matters to patients in antimicrobial stewardship in hospitals: a mixed-method study** *B. Jacob** (*Dublin, Ireland*), *A. Kurian, A. Walsh, E. De Barra*

E0033 **08:42** **Impact in capacity building of an online training program and evaluation of factors related to behavioural change in infection prevention and control and antimicrobial stewardship practices** *O. Neth** (*Seville, Spain*), *W. Goycochea-Valdivia, A. Gâchet, M. Amores, I. Kopsidas, G. Brigadoi, E. Barbieri, M. Bason, D. Kousi, M. Aboza, V. Serena, D. Daniele, T. Grammatiki-Christina, A. Arias, L. Cantarutti, C. Gianquinto, I. Gastesi, P. Rojo, C. Epalza*

E0034 **08:48** **Reframing antimicrobial stewardship by empowering stakeholders through the One Health lens** *C. Mulrooney** (*Waterford, Ireland*), *Z. Ramsamaroo, J. Britton, H. Awad, G. Rothwell-Kelly, M. Doyle, G. Chan*

E0035 **08:54** **Evaluating primary care antimicrobial stewardship through simulated patient visits: a scoping review and application of patient management indicators in an intervention evaluation in two LMIC** *B. Ingelbeen** (*Antwerpen, Belgium*), *D. Valia, V. Bertels, B. Mbangi, E. Tiendrebeogo, S. Declercq, D. Phanzu, H. Tinto*

E0036 **09:00** **Beyond the algorithm: human factors driving AI-adoption in antimicrobial stewardship (AMS)** *D. Yii** (*Singapore, Singapore*), *S. Tang, L. Loo, J. Chung, W. Lee, A. Kwa, E. Lum*

E0037 **09:06** **Knowledge and attitudes of allied healthcare professionals towards antibiotic use and antimicrobial resistance: questionnaire-development and a quantitative, cross-sectional study** *M. Gajdács** (*Szeged, Hungary*), *Z.L. Szabó, E.R. Major, R. Finta, E. Paulik*

E0038 **09:12** **Patients' and the public's knowledge and understanding of antimicrobial resistance and antimicrobial stewardship: a systematic review and meta-analysis** *B. Jacob** (*Dublin, Ireland*), *A. Kurian, A. Walsh, E. De Barra*

E0039 **09:18** **Behavioural determinants of hospital antimicrobial prescribing in italy: a multi-centre COM-B and TDF-informed study** *M. Torre** (*Rome, Italy*), *A. Bandera, S. Leone, A. Tedesco, A. Capone, S. Tedeschi, A. Mularoni, A. Cona, R. Murri, C. Torti, S. Cicalini*

EF005 **08:30 – 09:30** **Arena 2**

ANT TRN

ePoster Flash Session

Old viruses, new weapons: emerging antiviral therapies from bench to bedside

Chair *Heli Harvala* (*Turku, Finland*)

E0040 **08:30** **MDL-001, an oral direct-acting Thumb-1 polymerase inhibitor, demonstrates single-agent efficacy against HCV/HBV co-infection *in vitro*, and achieves HCV and HBV preclinical proof-of-concept** *D. Haders** (*San Diego, United States*), *V. Woods, T. Umansky, S. Russell, A. Goodman, M. Bobardt, W. Brubaker, P. Gallay, D. Smith*

E0041 **08:36** **Real-world effectiveness of extended use of letermovir among adult allogeneic haematopoietic cell transplant recipients: a systematic review and meta-analysis of observational studies** *R. Chemaly** (*Houston, United States*), *A. Vyas, H. Appaneal, A. Beyer*

E0042 **08:42** **Antiviral efficacy of a single dose of EV25, a novel antibody recruiting molecule, in a human influenza A/H3N2 challenge trial** *A. Cohen** (*The Sea Ranch, United States*), *A. Wozniak, M. Niedrauer, S. Low, A. Blouin, C.L. Campbell, I. Shahriar, J. Nielsen, P.S. Low*

E0043 **08:48** **Zelicapavir demonstrates high clinical and functional barrier against antiviral resistance: results from a randomised double-blind placebo-controlled paediatric RSV antiviral clinical trial** *J. Devincenzo** (*Watertown, Ma, United States*), *M. Rhodin, T. Ngo, A. Ahmad, C. Harris, R. Levene, S. Rottinghaus*

E0044 **08:54** **Safety, tolerability, and pharmacokinetics of secutrelvir: single and multiple oral doses, and drug-drug interaction with midazolam** *H. Koshimichi** (*Osaka, Japan*), *T. Sonoyama, R. Yonemoto, R. Kubota*

E0045 **09:00** **Identification and structural characterisation of CID-375076 as a promising small molecule inhibitor of HCV NS3 protease** *D. Diksha** (*Rishikesh, India*), *S.K. Gupta, Y.P. Mathuria*

E0046 **09:06** **Next-generation alkaloid entry inhibitors against emerging flaviviruses and coronaviruses: a step toward broad-spectrum antivirals** *S. Sadhu** (*Faridabad, India*), *A. Awasthi*

E0047 09:12 **DEN-HOST: a randomised, adaptive phase III trial evaluating host-directed therapeutics for moderate and severe dengue** *A. Mcbride* (Oxford, United Kingdom), L. Peto, H.Q. Chanh, P.K. Lam, J. Cattrall, N.L. Vuong, P.Y. Chia, A. Rojek, J. Whitehorn, L. Villar, P. Horby, T.W. Yeo, J. Watson, E. Kestelyn, S. Yacoub*

E0048 09:18 **Factors influencing ganciclovir trough concentrations during prophylaxis or therapy of CMV infections** *O. Epaulard* (Grenoble, France), C. Massebeuf, L. Liaigre, C. Chapuis, R. Le Cras, R. Germi, E. Gautier-Veyret*

EF006 **Arena 4**

08:30 – 09:30

CLN DX PHEI

ePoster Flash Session

Trending topics in TB and other mycobacterial infections

Chair *Hanif Esmail (London, United Kingdom)*

E0049 08:30 **CRISPR and phage footprints reveal an aquatic ancestry for the tuberculosis pathogen** *A. Ghodousi* (Milan, Italy), M. Omrani, C. Gaudin, M. Marceau, P. Supply, D.M. Cirillo*

E0050 08:36 **Developing a 2-gene host-response lateral flow test for TB** *R. Reid* (London, United Kingdom), C. Patwardhan, R. Armiger, J. Sturgeon, J. Herberg*

E0051 08:42 **Asymptomatic is not less infectious: school-based study using targeted maximum likelihood estimation method highlights critical role of asymptomatic TB in transmission** *Q. Ruan* (Shanghai, China), S. Ge, Y. Ren*

E0052 08:48 **Seeing what symptoms can't: community-based PDX screening as a game-changer for asymptomatic TB diagnosis in Nigeria** *S. Batur* (Abuja, Nigeria), A. Okoh, M. Sheshi*

E0053 08:54 **Asymptomatic mediastinal tuberculosis (TB) emerging in non-TB clinical pathways: findings from a multi-centre UK EBUS cohort** *F. Fama* (London, United Kingdom), A. Read, J. Murray, D. Creer, M. Belton, M. Brown, A. Garcia Mingo, J. Goldring, P. Gothard, H. Ip, H. Jarvis, S. Lee, Z. Mangera, R. Moores, N. Navani, A. Patel, R. Thakrar, C. Tweed, C. Valerio, S. Bamunugama, H. Sansum, R. Bhatia, P. Papineni, A. Whittington, M. Burman, S. Moody, N. Kakkar, A. Houston, M. Ye, O. Kon, A. Alexiadis, R. Merriman, F. Perrin, H. Burgess, G. Santis, H. Kunst, J. Brown, R. Gupta, S. Joseph, A. Daunt, J. Potter, S. Capocci, M. Lipman*

E0054 09:00 **Comparative transmissibility of bacteriologically confirmed vs clinically diagnosed pulmonary TB in school settings: implications for contact screening strategies** *C. Chu* (Shanghai, China), Y. Ren*

E0056 09:06 **Pre-existing isoniazid resistance and acquired rifampicin-resistant tuberculosis** *R. Spies* (Ho Chi Minh City, Vietnam), N.H. Hanh, P.T. Phu, N.L. Quang, D.D.A. Thu, T.T.B. Tram, V.T.N. Ha, G. Thwaites, M. Choisy, N.T.T. Thuong, J. Watson, T. Walker*

E0057 09:12 **Longitudinal imaging reveals severe lung pathology in preclinical *M. avium* BALB/c mouse model using hypervirulent clinical isolates** *T. Van Win* (Leuven, Belgium), W. Brangers, G.J. Wijnant, A. Reséndiz Sharpe, G. Vande Velde, E. André*

OS007 **Hall A2-2**

09:30 – 10:30

CLN DX

1-hour Case Session

Bad to the bone

Chair *Erlangga Yusuf (Rotterdam, The Netherlands)*
TBA

O0058 09:30 **Disseminated MDR tuberculosis manifesting as Pott's disease with tuberculous septic ankle arthritis: an uncommon sequential dual-site involvement** *J. Muqtadir* (Rochester, United States), I. Batool*

O0059 09:41 ***Bacteroids fragilis* an unsual cause of bone and joint infection in children, a case report** *H. Al Dhanhani* (Abu Dhabi, United Arab Emirates), N. Elsayed, E. Shebany*

O0060 09:52 **A rare aetiology of periprosthetic joint infection in a patient from a rural area** *C. Gay González* (Logroño, Spain), I. Arregui García, J.A. Madrigal Cruz, J.R. Blanco Ramos*

O0061 10:03 **Extensive tibial and calcaneal osteomyelitis with bilateral knee septic arthritis caused by Burkholderia thailandensis** *K.V. Abalajon* (Pasig City, Philippines), K.E. Henson*

O0062 10:14 **Conventional and unconventional use of a coomercial panel in paediatric patients with severe infections: the experience of the paediatric hospital of Padua, Italy** *D. Doni* (Padua, Italy), B. Veronica, M. Sciro, C. Mariachiara, M. De Pieri, G. Brigadoi, D. Donà*

SY041 **Hall ICM 14**

09:30 – 10:30

IPC

1-hour Symposium

Year in infection control

Chairs *Ermira Tartari (Msida, Malta)*
Walter Zingg (Zurich, Switzerland)

S0208 09:30 - *Nico Tom Mutters (Bonn, Germany)*

S0209 10:00 - *Maaike Van Mourik (Utrecht, The Netherlands)*

EF008 **Arena 3**

09:30 – 10:30

AMR

ePoster Flash Session

Genomic and epidemiological patterns of antimicrobial resistance

Chair *Filip Bielec (Łódź, Poland)*

E0063 09:30 **Epidemiologic shift in MRSA bacteraemia in Chile: clinical impact of emerging community strains** *B. Conrads* (Osorno, Chile), L. Rojas, A. Peters, J. Martinez, L. Rivas, A. Aguayo, P. Garcia, M.L. Rioseco, P. Rojas, J. Moreno, J.M. Munita, L. Diaz*

E0066 09:42 **Is the high prevalence of antibiotic resistance in LMICs the result of local or global emergence?** *S. Benvari* (St Andrews, United Kingdom), M. Holden, K. Keenan, A. Sandeman*

E0067 09:48 **The effects of broad-spectrum antibiotics vs placebo on antimicrobial resistance of faecal *Escherichia coli*** *A. Hakanen* (Turku, Finland), A. Pajander, T. Kallonen, S. Vanhatalo, S. Hurme, M. Gunell, R. Penttinen, E. Munukka, J. Haijanen, S. Sippola, P. Salminen*

E0068 09:54 **Sentinel surveillance of macrolide resistance in *Salmonella*: genomic prevalence and phenotypic expression** *A. Robinson* (London, United Kingdom), S. Nair, C. Maguire, A. Levy, D. Powell, A. Ismailahmed, M.A. Chattaway*

E0069 10:00 **Epidemiological evolution of shigellosis after COVID-19: data from a tertiary hospital in Spain** *L. Argente Colás* (Pamplona, Spain), L. Argente, G. Martinez, I. Beguiristain, C. Martin, M. Elia, M.E. Portillo*

E0070 10:06 **Genomic epidemiology and plasmid architecture of NDM carbapenemase-producing Enterobacterales in Germany (2015–2021)** *M. Elbediwi* (Oldenburg, Germany), J. Sattler, A.F. Wendel, B. Bader, J. Müller, S. Peter, A. Hamprecht*

OS013 **Hall A1-4**

11:00 – 12:00

CLN DX

1-hour Case Session

Life-threatening fungal infections

Chairs *Daniel Aguilar-Zapata (Mexico City, Mexico)*
Armelle Villalobos (Winnipeg, Canada)

O0072 11:00 **Importance of source control in prosthetic fungal endocarditis: multiple antifungal therapy failures, including breakthrough infection under long-term suppressive rezafungin therapy** *C. Colarossi* (Piacenza, Italy), G. Priante, V. Lepera, L. Gerra, D. Aschieri, S. El Qarra, F. Nicolini, G. Lo Cascio, F. Trapani*

O0073 11:11 **Recurrent prosthetic valve endocarditis by *Candida parapsilosis* with *de novo* azole resistance: a five-thousand-day clinical evolution confirmed by genomic sequencing** *A.D. Vera Mendoza* (Madrid, Spain), P. Merino Amador, F. Gonzalez Romo, J. Marroyo Laso,*

I. Vilacosta, C. Olmo, O. Zaragoza

O0074 **11:22** **Disseminated mucormycosis in an apparently immunocompetent adult: case report and systematic review** *S. Rao Kordcal** (*New Delhi, India*), *A. Sengupta, R. Sarda, G. Singh, M. Soneja*

O0075 **11:33** **Cerebral histoplasmosis in a patient under ibrutinib therapy: diagnostic challenges and paradoxical radiological progression after treatment initiation** *G. Thizy** (*Paris, France*), *M. Schmitt, S. Hamane, A. Alanio, B. Denis*

O0076 **11:44** **Disseminated aspergillosis and cryptococcal meningitis in patients treated for immunotherapy-related myocarditis and myocarditis-myositis-myasthenia gravis (Triple M) overlap syndrome: an unmet need for antifungal prophylaxis?** *J. Cruise** (*Liverpool, United Kingdom*), *L. Cossar, T. Guinan, A. Johnson, B.A.B. Opawole, A. Howard, L. Turtle, N. Garbutt, A. Olsson-Brown*

OS010 **Hall A1-1**

11:00 – 12:00

ANT TRN

1-hour Oral Session

Exploiting biology for therapy: novel approaches against antimicrobial-resistant pathogens

Chairs *Katy Jeannot* (*Besançon, France*)
Robert C. Read (*Southampton, United Kingdom*)

O0077 **11:00** **Calcium phosphate nanostructures: alternative approach against antibiotic-resistant *Staphylococcus aureus* and *Pseudomonas aeruginosa*** *M. Mariotti** (*Rome, Italy*), *D. Squitieri, L. Degli Esposti, C. Fusacchia, R. Torelli, M. Sanguinetti, M. Iafisco, F. Bugli*

O0078 **11:12** **AMR-endemic flies represent an underexplored reservoir of lytic bacteriophages** *W. Martins** (*Oxford, United Kingdom*), *C. Rubio, K. Cook, T. Iannetelli, S. Premchand-Branker, E. Portal, G. Jordao, T. Beard, A. Lankapalli, K. Iregbu, S. Afegbua, A. Aliyu, Y. Mohammed, I. Nwafia, O. Oduyebo, A. Ibrahim, Z. Tanko, T. Walsh, C. Achi, K. Sands*

O0079 **11:24** **Neutrophil peptidyl-arginine deiminase enzymes as dual anti-bacterial and anti-biofilm agents** *R. Baird** (*Dublin, Ireland*), *D. Gogoi, L. Forde, M. Niu, S.W. Ahmed, F. Fitzpatrick, E.P. Reeves*

O0080 **11:36** **Af-DAP10-CD3z-CAR-NK92 cells exert enhanced antifungal activity against A. fumigatus** *M. Mauget** (*Rennes, France*), *A.L. Schmitt, H. Einsele, M. Hudecek, J. Löffler, M. Seif*

O0081 **11:48** **Characterisation of novel vibrio phages as biocontrol agents against *Vibrio alginolyticus* and insights into its phage-resistant mutant** *R. Nepal** (*Battery Point, Australia*), *T. Charles, R. Taylor, J. Wynne*

OS011 **Hall A1-2**

11:00 – 12:00

TRN VAX

1-hour Oral Session

Mechanisms of hypervirulence and resistance in *Klebsiella pneumoniae*

Chairs *Alessandra Carattoli* (*Rome, Italy*)
Yunn-Hwen Gan (*Singapore, Singapore*)

O0082 **11:00** **Immunotherapeutic monoclonal antibodies against antibiotic-resistant *Klebsiella pneumoniae* derived from glycoconjugate-based immunisation** *B. Fries** (*Yes, United States*), *K. Mihooliya, C. Boniche-Alfaro, T. Imeraj*

O0083 **11:12** **The plasmid-borne lytic transglycosylase PLT-1 augments virulence in ST11 carbapenem-resistant hypervirulent *Klebsiella pneumoniae* by exacerbating immune responses and macrophage death** *P. Jia** (*Beijing, China*), *W. Yu, Q. Yang*

O0084 **11:24** **Differences in basal adaptation of core proteome expression between hypervirulent and multidrug-resistant *Klebsiella pneumoniae* lineages** *P. Miguela-Villoldo** (*Madrid, Spain*), *D. Fousteris, I. Alonso-González, L. Vaughan, A. Tajuelo, B. Cano-Castaño, S. Prieto Martín-Gil, E. Gato, A. Peláez-García, V. Martín, A. Pérez, A.J. Martín-Galiano*

O0085 **11:36** **The virulence related response of Hypervirulent *Klebsiella pneumoniae* to phagocytosis by murine macrophage** *S. Belge** (*Istanbul, Türkiye*), *C. Vatansever, Ö. Albayrak, S. Yalçın, A. Akpınar, F. Can*

O0086 **11:48** **Genetically-defined hypervirulent carbapenem-resistant *Klebsiella pneumoniae* (Hv-CRKP) exhibited diverse biological phenotypes: evidence from different clades of ST11-KL64, the most prevalent hv-CRKP strains in China** *X. Chu** (*Beijing, China*), *Q. Zhang, W. Yu, Y. Zhu, X. Jia, Q. Yang*

OS012 **Hall A1-3**

11:00 – 12:00

CLN

1-hour Oral Session

Sexually transmitted infections: typing to therapy

Chairs *Nicola Low* (*Bern, Switzerland*)
Aaron Schembri (*Attard, Malta*)

O0087 **11:00** **Optimising multi-modal surveillance of drug-resistant *Neisseria gonorrhoeae*** *N. Sherry** (*Melbourne, Australia*), *C. Glover, P. Roydhouse, H. Shrestha, M. Wilmot, N. Higgins, M. Chen, M. Ivan, B. Howden*

O0088 **11:12** **Towards global harmonisation of the mgpB typing scheme for *Mycoplasma genitalium*: updating the PubMLST platform to enable effective surveillance** *S. Manoharan-Basil** (*Antwerp, Belgium*), *I. De Baetselier, S. Pereyre, J. Guiraud, L. Piñeiro, J. Danielewski, M.J. Borrego, N. Adriaens, J.S. Jensen, N. Nordal-Budinsky, K. Imai, R. Dumke, O. Harrison*

O0089 **11:24** **Benzathine penicillin G plus doxycycline vs benzathine penicillin G alone for early syphilis in people with HIV: interim analysis** *K.Y. Lin** (*Taipei, Taiwan*), *C.P. Chen, C.S. Tsai, M.S. Tsai, P.L. Lu, K.H. Chen, P.L. Chen, Y.W. Weng, H.J. Tang, C.C. Hung*

O0090 **11:36** **Advancing STI care in low- and middle-income countries: development of a multiplex lateral flow assay for gonorrhoea and chlamydia** *B. Blumel** (*Geneva, Switzerland*), *H. Ramachandraiah, B. Gleeson, V. Chuchu, S. Mchugh, M. Lear, E. Cruz-Andres, K. Keith, J. D. Klausner*

O0091 **11:48** **Syphilis in bone and joint: what the skeletons tell us and why it matters today** *F. Spada** (*Naples, Italy*), *N. Schiano Moriello, J. Kowalska, G. Monsel, K. Roberts, M. Augello, F.B. Farkas, M. Farajova, A. Harxhi, A. Fidji Glaria Campo, I. Gentile*

OS014 **Hall A1-5**

11:00 – 12:00

ANT CLN

1-hour Oral Session

Turning AMS evidence to action

Chairs *Sara Cosgrove* (*Baltimore, United States*)
Flaminia Olearo (*Berlin, Germany*)

O0092 **11:00** **Bridging surveillance and stewardship: using the ECRAID Emerging Resistance Index to prioritise reserve antibiotics when guidelines offer equivalent options** *M.D. Pezzani** (*Verona, Italy*), *D. Ortiz, J. Garlasco, K. Odoj, F. Arieti, M. Morra, E. Addis, M. Tebon, O. Awwad, A. Cassini, S. Harbarth, E. Presterl, G. Kahlmeter, A. Savoldi, E. Tacconelli*

O0093 **11:12** **A cluster-randomised controlled pragmatic trial to evaluate antibiotic stewardship strategies for short-course and oral-switch antibiotic therapy for Enterobacterales bloodstream infections** *C.Y.G. Lui** (*Hong Kong, Hong Kong*), *C.M.T. Li, M. Mung, C. Cheung, C.T. Au-Yeung, H.Y. Ho, W.L.F. Luk, C.M. Leung, C. Lai, V. Chow*

O0094 **11:24** **Active auditing in antimicrobial stewardship programs improves appropriateness of prescribing: an observational cohort study** *C. Chen** (*Melbourne, Australia*), *N. Sivapragasam, N. White, C. Ierano, R. James, L. Marquart-Wilson, L. Hall, K. Thursky*

O0095 **11:36** **Multidrug-resistant Gram-negative bacteria screening to guide perioperative prophylaxis in colorectal surgery: a multi-centre quasi-experimental study** *D. Fasan** (*Verona, Italy*), *M. Morra, M. Da Meda, M.D. Pezzani, M. Tebon, V. Mengardo, A. Di Gioia, M. Genna, S. Zerva, A.R. Andritsos, I.M. Fieraru, D. Costin, I. Salcedo-Leal, C. Díaz-López, A. Sonpar, J. Rodríguez-Baño, P. Retamar-Gentil, N. Zuabi-Garcia, A. Hristea, C.M. Niculae, W. Zingg, E. Tacconelli, E. Carrara*

O0096 **11:48** **An electronic medical record-based 'persuasive' antimicrobial stewardship intervention to align**

bloodstream infection treatment duration with evidence from the BALANCE trial *J. Bramwell** (*Melbourne, Australia*), *J. Hinh, S. Koning, K. Horne, L. Upjohn, J. Hughes, R. Junckerstorff, B. Rogers*

OS015 **11:00 – 12:00** **Hall A2-2**

CLN TRN VAX

1-hour Oral Session

Burden, immunity and management of viral infections in immunocompromised hosts

Chairs *Jon Salmanton-García (Cologne, Germany)*
Carla Walti (Basel, Switzerland)

O0097 **11:00** **Durability of immunity six months after adjuvanted respiratory syncytial virus (RSV) vaccination in high-risk transplant recipients** *V. Hall** (*Melbourne, Australia*), *A. Alexander, F. Mavandadnejad, M. Kern-Smith, R. Kang, X. Dang, P. Lavoie, S. Humar, P. Winichakoon, R. Johnstone, M. Aversa, I. Novitzky-Basso, D. Kumar, J. Mattsson, V.H. Ferreira*

O0098 **11:12** **Adoptive transfer of polyomavirus-specific T cells in progressive multifocal leukoencephalopathy: a multi-centre retrospective real-world analysis** *G. Martin-Blondel** (*Toulouse, France*), *A. Chevalier, B. Bonneau, L. Grote-Levi, N. Möhn, P. Cinque, J. Rubinstein, R. Wicklein, T. Pfeiffer, B. Omer, M. Steinhardt, J.J. Tudesq, N. Testard, P. Chevallier, R. Bernard-Valnet, M. Le Maréchal, G. Catalano, B. Pignolet, A. Sommet, B. Eiz-Vesper, P. Comoli, T. Skripuletz, I. Cortese, D. Bensoussan*

O0099 **11:24** **Cytomegalovirus infections after bispecific antibodies for relapsed/refractory multiple myeloma** *J.S. Little** (*Boston, United States*), *I.A. Perez Villa, E. Arbona Haddad, E.B. Kim, A.J. Yee, O. Nadeem, S. Midha, A.S. Sperling, N. Munshi, N.S. Raje, D.D. Cirstea, S.P. Hammond*

O0100 **11:36** **Therapeutic drug monitoring of letermovir in allogeneic haematopoietic stem cell transplant (allo-HSCT) recipients: a prospective, two-centre observational study** *J.S. Tang** (*Taipei, Taiwan*), *T.Y. Pai, Y.W. Wang, C.Y. Chen, H.A. Hou, B.S. Ko, P.Y. Chen, Y.J. Liu, H.Y. Lin, Y.H. Wu, Y.J. Chen, S.W. Lin*

O0101 **11:48** **Target trial emulation of viral infection vs no infection and risk of invasive fungal disease after haematopoietic stem cell transplantation** *L. Bussini** (*Pieve Emanuele, Milan, Italy*), *D.F. Bavaro, D. Sacchet, F. Medioli, F. Berardi, M. Ronconi, P. Crombie, F.M.P. Tordato, B. Varisco, L. Diella, D. Mannina, J. Mariotti, C. Scuderi, M. Calabrò, R. Renzulli, V. Cento, S. Bramanti, M. Bartoletti*

OS016 **11:00 – 12:00** **Hall A3-2**

AMR

1-hour Oral Session

Resistance trends in *Candida* species

Chairs *Maiken Cavling Arendrup (Copenhagen, Denmark)*
Jean-Pierre Gangneux (Rennes, France)

O0102 **11:00** **Activity of comparator antifungal agents against drug-resistant *Candida glabrata*** *M. Winkler** (*North Liberty, United States*), *A. Klauer, S. Edeker, H. Kimbrough, P. Rhomberg, M. Castanheira*

O0103 **11:12** **Clinical emergence and spread of *Candidozyma auris* outbreak-adapted lineages harboring mutations in RBA1** *L. Doorley** (*Memphis, United States*), *A. La Bella, S. Jones, G. Zhao, M. Asadzadeh, Q. Choudhury, S. Ahmad, E. Mokaddas, I. Al-Obaid, W. Alfouzan, K. Al-Banwan, T. O'meara, F. Santiago-Tirado, A. Flores-Mireles, J. Rybak*

O0104 **11:24** **Genomic analysis of *Candida parapsilosis* over a decade across multiple hospitals highlights clonal persistence and increasing fluconazole resistance** *S. Srivastava** (*Delhi, India*), *N. Shukla, P. Kagra, K. Jain, A. Chowdhary*

O0105 **11:36** **Calcineurin mediates caspofungin heteroresistance, a precursor to stable resistance in *Nakaseomyces glabratus*** *Y. Su** (*Beijing, China*), *Y. Li, Y. Xu*

O0106 **11:48** **Comparison of manogepix activity against 8,722 community-acquired and nosocomial yeast isolates from the SENTRY Antimicrobial Surveillance Program (2017-2024)** *M. Winkler** (*North Liberty, United States*), *M. Huband, P. Rhomberg, S. Edeker, A. Klauer, M. Castanheira*

OS009 **11:00 – 12:00** **Hall ICM 13b**

ANT

1-hour Oral Session

Tomorrow's antibiotics today: from first-in-human to phase III

Chairs *Daniele Roberto Giacobbe (Genoa, Italy)*
Erin Mccreary (Pittsburgh, United States)

O0107 **11:00** **Efficacy and safety of cefepime/nacubactam and aztreonam/nacubactam vs best available therapy in adults with cUTI/AP, HABP/VABP, cIAI due to carbapenem resistant Enterobacterales: integral-2, single-blind, randomised phase III trial** *R. Takaya** (*Tokyo, Japan*), *K. Yanagihara, K. Tateda, H. Huang, H. Mukae, H. Ohge, Y. Doi, S. Takahashi, M. Yasuda, K. Matsumoto, M. Sumiya, K. Suwada, S. Kamiyabu, Y. Sasagawa, T. Minamida, S. Kato, K. Kondo, T. Naruse, H. Mikamo*

O0108 **11:12** **Subgroup analysis of tebipenem pivoxil efficacy in patients with complicated urinary tract infection or acute pyelonephritis: results from the phase III PIVOT-PO study** *S. Ascioglu** (*London, United Kingdom*), *D. Hong, T. Otiker, Y. Sánchez-Pearson, A.J. Sheets, M. Sprys, N.E. Scangarella-Oman, N. Bhatt, I.A. Critchley, L.B. Gasink, K.A. Hamed, D. Sotolongo, K. Wrzosek, A. Peppercorn*

O0109 **11:24** **Characterisation of *Pseudomonas aeruginosa* isolates from bronchiectasis patients in a phase II trial of a bispecific monoclonal antibody: GREAT-2** *R.C. Hull** (*Dundee, United Kingdom*), *M.B. Long, A. Gilmour, I. Petrou, R. Galloway, K. Viligorska, H. Richardson, J.M. New, C. Hennayake, E. Johnson, E. Mcintosh, Z. Eke, H. Lind, M. Band, H. Bandara, G. Martin, S. Aliberti, M. Vendrell, E. Polverino, G. Suarez-Cuartin, M.R. Loebinger, M. Tunney, K. Cartwright, R. Hughes, A. Digiandomenico, M.G. Belvisi, W. Brailsford, C. Haworth, O. Sibila, J. Stobo, J.D. Chalmers*

O0110 **11:36** **Overall response and microbiological eradication of cefepime/enmetazobactam vs piperacillin/tazobactam in patients with acute pyelonephritis: a post-hoc subgroup analysis from the ALLIUM phase III trial** *J. Quevedo Marin** (*Cartagena, United Kingdom*), *J. Quevedo, N. Dunkel, N. Jemmely, S. Cure*

O0111 **11:48** **Evaluating the efficiency of platform trial designs relative to stand-alone trials: a simulation study for the evaluation of new antibacterials** *M. Hardy** (*Herston, Australia*), *P. Harris, Y. Mo, D. Paterson*

SY046 **11:00 – 12:00** **Hall A2-1**

PHEI

1-hour Symposium

Engaging citizens in infectious disease surveillance, prevention, and research

Chairs *Tyra Grove Krause (Copenhagen, Denmark)*
Joel Mossong (Luxembourg, Luxembourg)

S0105 **11:00** **Digital countermeasures for epidemic control** *Emmanuel André (Leuven, Belgium)*

S0106 **11:30** **Virus monitoring at workplaces** *Tine Graakjær Larsen (Værløse, Denmark)*

SY047 **11:00 – 12:00** **Hall A3-1**

CLN DX

1-hour Symposium

Diagnostic stewardship: asking the right questions to measure clinical impact - a pro/con debate

Chairs *Adarsh Bhimraj (Houston, Texas, United States)*
Bhanu Sinha (Groningen, The Netherlands)

S0107 **11:00** **Diagnostic stewardship is an important part of quality of care and has clinical impact** *Heiman Wertheim (Nijmegen, The Netherlands)*

S0108 **11:30** **Diagnostic stewardship is an auxiliary to antimicrobial stewardship, but has no impact on quality of care** *Evelina Tacconelli (Verona, Italy)*

SY044 **11:00 – 12:00** **Hall B0-1**

1-hour Symposium

AMR IPC

The hospital bathroom as a hotspot for AMR

Chairs *Fidelma Fitzpatrick (Dublin, Ireland)*
Juliette Severin (Rotterdam, The Netherlands)

S0101 **11:00** **The sink: design and behavioural aspects to mitigate risks: towards a "sink bundle"** *Hillary Craddock (Dublin, Ireland)*

S0102 **11:30** **Toilets: flushing and spread of pathogens** *Kalisvar Marimuthu (Singapore, Singapore)*

SY045 **11:00 – 12:00** **Hall B0-2**

1-hour Symposium

CLN

Updates on severe pneumonia

Chairs *Antonios Katsounas (Bochum, Germany)*
Preeti Malani (Ann Arbor, United States)

S0103 **11:00** **Severe community-acquired pneumonia** *Pedro Povoa (Lisbon, Portugal)*

S0104 **11:30** **Severe hospital-acquired pneumonia** *Jordi Rello (Barcelona, Spain)*

Co-organised with: ESCMID Study Group for Critically Ill Patients (ESGCIP), ESCMID Study Group for Infections in the Elderly (ESGIE), European Extracorporeal Life Support Organization, European Society of Intensive Care Medicine

---

SY043 **11:00 – 12:00** **Hall ICM 13a**

1-hour Symposium

CLN DX

Top papers in imported tropical diseases and diagnosis of parasitic infections

Chairs *Miriam José Alvarez Martinez (Barcelona, Spain)*
Ferenc Balázs Farkas (Budapest, Hungary)

S0099 **11:00** **Top papers in tropical diseases** *Pedro Legua (Lima, Peru)*

S0100 **11:30** **Top papers in diagnosis of imported parasitic diseases** *Charlotte Sriruttan-Nel (Johannesburg, South Africa)*

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)

EF017 **11:00 – 12:00** **Arena 2**

ePoster Flash Session

PHEI VAX

Update in mosquito-borne infections and vector control

Chair *Gathsaurie Neelika Malavige (Nugegoda, Sri Lanka)*

E0112 **11:00** **A one health regional framework for predictive dengue surveillance and early warning in Southeast Asia** *S. Sidhik* (Phnom Penh, Cambodia), S. Boyer*

E0113 **11:06** **Blood-stage controlled human malaria infection in Tanzanian adults to assess the protective effect of the malaria vaccine candidates R78C and/or RH5.1 in a matrix adjuvant** *J. Van Heerden* (Oxford, United Kingdom), A.E. Kahatano, S. Silk, C. Rigby, S. Pollock, N. Lilolime, L. Batao, J. Salkeld, N. Kamau, R. Roberts, H. Msami, N. Urasa, E. Kenya, M. Mohamed, I. Mtaka, C. Carnrot, C. Nielsen, M. Mpina, S. Draper, A. Minassian, A. Olotu*

E0114 **11:12** **Humoral and cellular immune responses to an intradermal live attenuated tetravalent dengue vaccine: a pilot study among healthy adults** *T. Khaimook* (Hat Yai, Thailand), S. Chusri, N. Pinpathomrat, P. Siripaitoon, N. Kositpantawong, S. Kanchanasuwan, S. Chittrakarn, S. Uppanisakorn*

E0115 **11:18** **Immune response to TAK-003: updated results from the DENG-VAC Study** *A. D'abramo* (Rome, Italy), L. Ponzetta, F. Colavita, S. Vita, E. Cimini, P. De Marco, L. Rosa, M. Tiberi, F. Maggi, D. Goletti, E. Nicastri*

E0119 **11:24** **Rollout of seasonal R21 malaria vaccination and chemoprevention for children in Kule Refugee Camp in Gambela, Ethiopia during the 2024 malaria season** *Y. Atnafu* (Addis Ababa, Ethiopia), Y. Girma, K. Siferaw, K. Lavilla, A. Tawassar, D. Koang, D. Tugizimana, A. Dirks, M. Ayalew, J. Loonen, C. Ariti, G. Mapiye, W. Mulanda, A.D.L. Pereira, A. Bestman, K. Velivela, B. Rao, B. Stringer, R. Wilson, A. Abbara, P. Keating*

EF018 **11:00 – 12:00** **Arena 4**

ePoster Flash Session

AMR PHEI

Socioeconomic and structural drivers of AMR

Chair *Sara Tomczyk (Berlin, Germany)*

E0121 **11:00** **National priority assessment of multidrug-resistant microorganisms based on the multicriteria decision analysis** *Y.K. Yoon* (Seoul, Korea, Republic of), S.Y. Yu, E.Y. Bae, H. Seok, Y.J. Choe, S.J. Choi, H.S. Oh, J.W. Suh, J.Y. Kim*

E0122 **11:06** **Socioeconomic inequality and corruption as determinants of antibiotic access and AMR burden** *S. Saeedi Moghaddam* (Kiel, Germany), M. Stolpe*

E0123 **11:12** **Everyday realities of antibacterial drug resistance in Uganda: an ethnographic study of social and economic impacts** *S. Nayiga* (London, United Kingdom), A. Namajja, C. Chandler*

E0124 **11:18** **"Bacteria and the Resistance": a microbial comic book** *G. Greub* (Lausanne, Switzerland), C. Aubry*

E0125 **11:24** **Critical levels of multidrug resistance in pathogens circulating in the Niger river: implications for public health surveillance** *C. Touré* (Bamako, Mali), T. Cheick*

E0126 **11:30** **A case study on effective student engagement in antimicrobial resistance: the Makerere University AMR club model** *V. Nabisere* (Kampala, Uganda), C. Akello*

E0127 **11:36** **Sex, gender, and antimicrobial resistance: evidence and gaps across across infection, selection and transmission** *G. Knight* (London, United Kingdom), O. Edun, A. Kjaersgaard, K. Horton, K. Keenan, J. Robotham, C. Wenham, C. Chandler*

E0128 **11:42** **Caste-based disparities and AMR risks** *S. Goel* (Bengaluru, India), R. Bhagawati, A. Banerji, D. Batheja*

E0129 **11:48** **Integrating antibiotic stewardship within a One Health framework: a pilot study on knowledge, attitude and practice questionnaire in companion animal veterinary medicine of Northern Italy** *F. Compostella* (Verona, Italy), M. Domaschio, D. Fasan, F. Sbardellati, E. Tacconelli, E. Carrara*

KN042 **11:00 – 12:00** **Hall ICM 14**

Keynote lecture

AMR IPC

Containment of MRSA in hospitals: past, present, future

Chairs *Robert Leo Skov (Copenhagen, Denmark)*
Margreet C. Vos (Rotterdam, The Netherlands)

K0098 **11:00** *Susan Huang (Irvine, United States)*

ME048 **11:00 – 12:00** **Hall ICM 5**

Meet-the-Expert

IPC PHEI

Viral threats and antibiotic resistance in wastewater in the postpandemic era

M0109 **11:00** *Steen Ethelberg (Copenhagen, Denmark)*

M0110 **11:12** *Henry-Michel Cauchie (Belvaux, Luxembourg)*

FO049 **11:00 – 12:00** **Arena 1**

Open Forum

PRO

Sharing made simple: how standardised data exchange improves infectious diseases research and care

Chair *Marc J.M. Bonten (Utrecht, The Netherlands)*

F0111 11:00 **Sharing clinical laboratory and infectious disease data in the European Health Data Space for primary and secondary use** *Hynek Kruzik* (*Prague, Czechia*)

F0112 11:10 **Using standards to bridge the divide between clinical trials and cohort studies: the ECRAID Base experience** *Ankur Krishnan* (*Heidelberg, Germany*)

F0113 11:20 **Standardised sharing of national AMR surveillance data: showcase Netherlands** *Bram Lestrade* (*Roermond, The Netherlands*)

F0114 11:30 **Standardised exchange of microbiological data for patient care, research and surveillance** *Alexandra Hoffmann* (*Berlin, Germany*)

Co-organised with: ESCMID Study Group for AI and Digitalisation (ESGAID), European Clinical Research Alliance on Infectious Diseases (ECRAID), EU Lab Semantic WG HL7

FO050 **11:00 – 12:00** **Arena 3**

PRO

Open Forum

Sharpening communication and leadership skills in CM/ID

Chair *Mary Horgan* (*Dublin, Ireland*)

F0115 11:00 **Communication skills for culturally competent infectious disease care** *Muge Cevik* (*Edinburgh, United Kingdom*)

F0116 11:10 **Becoming doctor-influencers for better redefining CM/ID professionalism** *Akshatha Ravindra* (*Karnataka, India*)

F0117 11:20 **Dealing with the Imposter syndrome** *Maeve Doyle* (*Waterford, Ireland*)

Co-organised with: ESCMID Parity Commission, ESCMID Professional Affairs Subcommitte, ESCMID Education Subcommittee, TAE Steering Committee

---

OS021 **13:30 – 14:30** **Hall A3-1**

AMR CLN

1-hour Oral Session

Clinical impact of drug resistance in Gram-negative infections

Chairs *Lorena Diaz* (*Santiago, Chile*)
Helena Zemlickova (*Prague, Czechia*)

O0130 13:30 **Clinical Impact of Delayed Appropriate Antibiotic Therapy in Bloodstream Infections Caused by WHO Critical Priority Gram-Negative Pathogens: A Target Trial Emulation** *L. Mezzadri** (*Singapore, Singapore*), *W.C. Tan, X. Hao, J. Quah, A. Manesh, Y.T. Chang, A.T.K. Nguyen, Y. Ding, Y. Cao, Y. Cai, S. Kitsaran, H.H. Chua, S. Bory, S.S.L.S. Ponnampalavanar, S. Anunnatsiri, M.Z. Mazlan, A.K. Dhiloo, R. Plongla, A.L.H. Kwa, S. Faisal Mahmood, A.D. Roman, L. Thwaites, P.V. Tho, S. Wu, D. Chotiprasitsakul, K.J. Wong, H. Wijaya, C.L. Abad, M.O. Rehman Khalid, G.M. Salahuddin Mamun, G.S. Rajahram, H. Guterres, H.N. Hon, T. Van Giang, N.T. Pham, A. Karkey, S. Gunasekara, R. Hamers, R. Sinto, I.N.D. Lubis, M. Wang, M. Moni, P.Y. Liu, Y. Xiao, B. Khanal, N.L. Priya, Y. Doi, H. Hitoshi, B. Baljin, U. Gurjav, R. Asli, L. Ling, A. Dhungana, L.Y. Hsu, D. Paterson, Y. Mo*

O0131 13:42 **Impact of third-generation cephalosporin resistance on mortality in Enterobacterales bloodstream infections: an individual participant data meta-analysis** *M. Guedes** (*Seville, Spain*), *M.E.A. De Kraker, N. Hassoun-Kheir, E. Salamanca, E. Rubio, A.D.L.S. Bazan, L.B. Pulido, A. Dambrauskiene, J. Rodríguez-Baño*

O0132 13:54 **Antibiotic prescribing for presumed *Stenotrophomonas maltophilia* infections in the United States using Epic Cosmos** *S. Boettcher** (*Detroit, United States*), *R. Kenney, R. Tibbetts, A. Shallal, G. Suleyman, S. Davis, M. Veve*

O0133 14:06 **Colonisation with multidrug-resistant Gram-negative bacteria in a low endemic country is associated with substantial morbidity: a population-based observational study** *V. Andrews** (*Lund, Sweden*), *M. Inghammar, E. Senneby, O. Ljungquist*

O0134 14:18 **Comparison of mortality after bloodstream infection with piperacillin/tazobactam-resistant vs -susceptible *Escherichia coli* and *Klebsiealla pneumoniae*: a nationwide cohort study in Denmark, 2018-2024** *E. Tusch** (*Copenhagen, Denmark*), *B. Holzknecht, M. Lindegaard, R. Thoft Nielsen, U. S. Justesen, K. Kobberøe Søgaard, T.S. Kostyanev, F. Boetius Hertz, M. Pedersen, R. B. Dessau, S. Skovgaard, J. Gitz Holler, L. Lützen, S. Ellermann-Eriksen, B. Kristensen, R. Skov, L. Engbo Christensen, A. Rhod Larsen, A. Hviid, A. Hammerum, P. Bager*

OS022 **13:30 – 14:30** **Hall A3-2**

PRO

1-hour Oral Session

Game on: leveling up education through simulation and serious play

Chairs *Anette Friedrichs* (*Kiel, Germany*)
Daniel Grupel (*Jerusalem, Israel*)

O0135 13:30 **Enhancing infectious diseases clinical practice through in situ simulation: a feedback-based evaluation** *R. Francis** (*Nottingham, United Kingdom*), *Y. Milnes, P. Bailey*

O0137 13:42 **Design and Development of an Educational Card Game on Infectious Diseases for Anaesthesiology Residents: An Innovative Approach to Medical Education** *P. Lunenborg** (*Groningen, The Netherlands*), *W. Bult, H. Aardema, G. Wietasch, C. Van Den Berg*

O0138 13:54 **Septris 2.0: A Mixed-Methods Multinational Evaluation of a Gamified Digital Tool for Sepsis Education and Quality Improvement** *S. Meylan** (*Lausanne, Switzerland*), *S. Gupta, I. Pottmeyer, N. Mischler, E. Moulin, R. Williams, L. Shieh*

O0139 14:06 **First implementation of an educational ecape room for the key symptom "diarrhea"within the course "key symptoms of internal medicine" of the medical curriculum at Christian-Albrechts-University Kiel to strengthen diagnostic and therapeutic reasoning and teamwork skills** *C. Kujat** (*Kiel, Germany*), *N. Mirwald, U. Macioszek, A. Friedrichs*

OS020 **13:30 – 14:30** **Hall B0-1**

CLN IPC

1-hour Oral Session

From risk to resilience: advances in catheter-related infections across care settings

Chairs *Shruti Gohil* (*Irvine, United States*)
Pilar Retamar Gentil (*Seville, Spain*)

O0140 13:30 **Risk of catheter-related infections with peripherally vs centrally inserted central catheters in critically ill patients: a propensity score-matched emulated target trial** *N. Boulet** (*Nimes, France*), *A. Friggeri, A. Gavoille, M. Gautier, B. Louart, A. Machut, A. Lepape, C. Roger*

O0141 13:42 **Incidence, risk factors and mortality of catheter-related bloodstream infections: retrospective single centre study in non-ICU wards** *L. Gazzola** (*Milano, Italy*), *V. Vitaletti, E. Pezzoli, A. Tavelli, G.C. Marchetti*

O0142 13:54 **Impact of a National Quality-Improvement Programme on CLABSI Reduction in Ten Greek Hospitals: Results from the GRIPP-SNF Consortium** *I. Kopsidas** (*Athens, Greece*), *G.C. Tsopela, A. Moutou, P. Varda, P. Pantelidou, D. Kousi, E. Kourkouni, A. Karaiskou, E. Thireos, D. Kaitelidou, A. Koutsoukou, T. Zaoutis*

O0143 14:06 **Epidemiology and Outcomes of Nosocomial Infections in Patients Undergoing ECMO Support: An Eight-Year Retrospective Cohort Study** *M. Oliveira** (*Sao Paulo, Brazil*), *R. Lobo, F. Galas, C. Sambo, L. Pastore, N. Matos, E. Costa, H. Fernandes, D. Araujo, L. Cardoso, A.R. Guedes*

O0144 14:18 **Genomic characterisation and molecular epidemiology of *Ralstonia thomasii* catheter-related bloodstream infections: report of an outbreak after disruption of the standardised process for venous catheter care** *M. Delaye Martinez** (*Mexico City, Mexico*), *M.A. Delaye-Martínez, P. Volkow-Fernández, E. López-Jácome, J. Ortíz-Álvarez, C. Velazquez-Acosta, M.D.L. García-Hernández, M. Hernández-Durán, C.F. Hernández-Pérez, M.D.R. Vázquez-Olivares, C.U. Franco-Frias, P. Cornejo-Juárez, F.M. Medina-Aguilar, D. Vilar-Compte*

OS019 **13:30 – 14:30** **Hall ICM 13a**

1-hour Oral Session

AMR PED PHEI

AMR in paediatric populations: from dynamic acquisition to predictive models

Chairs *Johannes Hübner (Munich, Germany)*
Theresa J. Ochoa (Lima, Peru)

O0145 **13:30** **Modelling the acquisition of extended-spectrum β-lactamase (ESBL)-producing *Enterobacteriaceae* in neonates in Madagascar households** *M. Alexa* (Paris, France), A.L. Beaumont, A. Harimanana, A. Rakotondrasoa, L. Odile Rivoarilala, A. Criscuolo, E. Fara Nandrasana Rakotomanana, P. Herindrainy, J.M. Collard, T. Crucitti, B.T. Huynh, L. Opatowski*

O0146 **13:42** **Intestinal acquisition and clearance dynamics of extended-spectrum β-lactamase-producing Enterobacterales in hospitalised Kenyan children: a longitudinal, multi-site follow-up study** *R. Aizouk* (Oxford, United Kingdom), C. Tigoi, S. Yan, M. Timbwa, M. Shalton, M. Ngari, R. Musyimi, H. Browne, J. Walson, T. Lawley, N. Stoesser, E. Van Kleef, J. Berkley*

O0147 **13:54** **Global surveillance gaps in maternal antimicrobial resistance: insights from isolate-level data on Gram-negative bacteria in LMICs** *L. Hookham* (Falmer, United Kingdom), J. Alger, F.A. Dávila Ramírez, O. Dissanayake, J.A. Frem, O. Herrera, O. Makanjuola, I. Martin-Jorge, J. Leach, J.H. Cross, J.R. Price, M. Sekikubo*

O0148 **14:06** **Multidrug-resistant bacterial and fungal colonisation and transmission dynamics in hospitalised neonates** *R. Kelleghan* (Sydney, Australia), M. Aberoumand, J. Beardsley, L.T. Cao, C. Duc Pham, T.M. Duong Nu, P.T. Hang, M. Harrison, L. Howie, M.H. Le, K. Luu Boi, N. Ngo, T. Ngo, T.M.A. Nguyen, T.A. Nguyen, P.A. Pham Dinh, A.T. Pham, V.A. Nguyen, T.D. Thi Hoang, P. Williams*

O0149 **14:18** **Artificial intelligence to predict antimicrobial resistance in Gram-negative bloodstream infections among paediatric onco-haematology patients** *I. Sartini* (Bologna, Italy), E. Rocchi, C. Campoli, C. Bonazzetti, D. Leardini, F. Baccelli, L. Chiusaroli, D. Zama, M. Spadea, G. Tridello, P. Viale, S. Cesaro, M. Giannella*

SY052 **13:30 – 14:30** **Hall A2-2**

1-hour Symposium

CLN PED

Mycobacterial infections in childhood

Chairs *Elisabeth Schölvinck (Groningen, The Netherlands)*
Delane Shingadia (London, United Kingdom)

S0087 **13:30** **New treatments and management of Tuberculous meningitis in children** *Diana Gibb (London, United Kingdom)*

S0088 **14:00** **Optimising the diagnosis of NTM infections in childhood** *Jakko Van Ingen (Nijmegen, The Netherlands)*

Co-organised with: European Society of Paediatric Infectious Diseases (ESPID)

YIA **13:30 – 14:30** **Hall ICM 1**

Awards

Young Investigator Award lecture

Chairs *Jon S. Friedland (London, United Kingdom)*
Jan A.J.W. Kluytmans (Utrecht, The Netherlands)

A001 **13:30** **Re-thinking diagnostics to improve care in resource-limited settings** *Grace Androga (Blantyre, Malawi)*

A002 **13:42** **Antibiotics on target: predicting efficacious dosing in challenging patient populations** *Iris K. Minichmayr (Vienna, Austria)*

A003 **13:54** **Can we develop better tests to measure individual infectiousness in respiratory virus infections?** *Daniel Pan (Leicester, United Kingdom)*

A004 **14:06** **Beyond the mould: shifting diagnosis and therapy through host immunity** *Sarah Delliere (Paris, France)*

A005 **14:18** **Host-directed therapies and patient stratification for common bacterial diseases** *Clark Russell (Edinburgh, United Kingdom)*

EF023 **13:30 – 14:30** **Arena 1**

ePoster Flash Session

CLN IPC TRN

Gut microbiota-based interventions against gastrointestinal pathogens and antibiotic resistance

Chair *Marcela Krutova (Prague, Czechia)*

E0151 **13:36** **Tolerance and efficacy of the *Faecalibacterium prausnitzii* EXL01 strain for preventing recurrence of *Clostridioides difficile* infection: results from a multi-centre phase I study** *N. Benech* (Lyon, France), P. Guarino-Vignon, P. Mclellan, S. Truong, A. Delmeule, C. Landman, A. Bourrier, L. Alric, J. Scanzi, N. Cassir, A. Dureault, E. Piet, S. Gallet, E. Botelho-Nevers, M. Guillet, F. Ader, H. Sokol*

E0152 **13:42** **Impact of a defined bacterial consortium on host immune response and gut function in patients with *Clostridioides difficile* infection (CDI)** *J. Norman* (Cambridge, United States), R. Menon, S. Bhattarai, A. Prince, Y. Huang, M. Giddins, V. Bucci, B. Olle, J.L. Silber, J. Faith*

E0153 **13:48** **A global evaluation of the use of faecal microbiota transplant** *B. Merrick* (Harrow, United Kingdom), B.H. Mullish, S.D. Goldenberg, S. Khanna, V. Ahuja, C.L. Hvas, G.K. Makharia, H.R.T. Williams*

E0154 **13:54** **Investigation of enterococcus colonisation impact on *Clostridioides difficile* disease severity** *T. Eubank* (Houston, United States), A. Mai, A. Horvath, K. Begum, T. Horvath, K. Garey*

E0155 **14:00** **Faecal microbiota transplantation in paediatric patients: the first national experience** *B. Szabo* (Budapest, Hungary), B.G. Szabó, D. Korózs, J. Czelecz, L. Takács, Á. Visnyovszki, K. Csordás, C. Kassa, G. Kriván*

E0156 **14:06** **Faecal microbiota transplantation in patients with irritable bowel syndrome profoundly reshapes the gut microbiome, but does not have any detectable clinical effects** *O. Cinek* (Prague, Czechia), J. Vejmelka, K. Hubáčková, K. Litosova, L. Hlinakova, M. Kulich, P. Kohout, J. Hurych*

E0157 **14:12** **Improved clinical outcomes and shifts in intestinal microbiome and metabolites following intestinal microbiota transplantation in patients colonised with multidrug-resistant organisms** *R. Ghani* (London, United Kingdom), J. Bilinski, L. Martinez-Gili, P. Takis, J. Miguens Blanco, N. Geva-Zatorsky, H. Bar-Yoseph, M.R. Thursz, F. Davies, B.H. Mullish, J.R. Marchesi*

EF024 **13:30 – 14:30** **Arena 3**

ePoster Flash Session

CLN DX TRN

Molecular insights and surveillance of parasitic diseases

Chair *Özgür Kurt (Istanbul, Türkiye)*

E0160 **13:30** **Integrating PCR on Giemsa-Stained Smears for accurate diagnosis of cutaneous leishmaniasis** *F. Maatallah* (Tunis, Tunisia), W. Aissi, N. Boulehmi, O. Souissi, A. Bouratbine, K. Aoun*

E0161 **13:36** **Protein-protein network is responsible for artemisinin induced cyto-toxic effects in liver cells** *E. Dodwani* (Guwahati, India), V. Trivedi*

E0163 **13:42** **Dengue mortality rates in the elderly population of Brazil and Colombia, 2019 and 2020** *A. Rodriguez-Morales* (Pereira, Colombia), J.A. Cardona-Ospina, C.E. Perez, T.D.S.S. Chaves, P. Quispe, R.N. Angerami*

E0164 **13:48** **Proteomic profiling of eluted Schistosoma antigens for enhanced diagnostic sensitivity** *B. Babalola* (Ondo, Nigeria), K. Sulaiman, T. Oriade, O. Oyeyemi*

E0165 **13:54** **Molecular characterisation of *Cryptosporidium* infections in a tertiary hospital in Barcelona during three years of post-COVID19 pandemic period** *M. Alguacil Guillén* (Barcelona, Spain), M. Alguacil-Guillén, P. Köster, S. Sánchez-Prieto, P. Juan-Pardo, C. Aylagas, M.R. Ferré, J. Barrachina, P. Rodriguez,*

L. Horvath, J. Iglesias, M. Espasa, M.E. Valls, D. Carmena, M.J. Álvarez-Martínez

E0166 **14:00** **Ten-year retrospective surveillance of *Cryptosporidium* spp., Giardia lamblia and Entamoeba histolytica in the Netherlands** *E.M.J. Groenen* (Bilthoven, The Netherlands), T.J. Roodsant, A. Al-Dawaf, A. Bart, G.J.H. Bastiaens, M. Berends, D.A.T. Hanssen, J.J. Van Hellemond, S.D. Kuil, S. Lekkerkerk, J.D. Machiels, B. Mulder, M.R. Ramos Diaz, E. Ruizendaal, J.M. Da Silva, S. Slavenburg, D. Souverein, E. Schaftenaar, K. Tassche-Borggreve, E. Vermeer, J.J. Verweij, A.L.M. Vlek, L.J. Wammes, R. Zonneveld, J.J. Hofstra, L. Mughini-Gras, I.H.M. Friesema*

EF025 **13:30 – 14:30** **Arena 4**

AMR DX PHEI

ePoster Flash Session

Molecular diagnostic innovations across specimens

Chair *Mario Ramirez (Lisbon, Portugal)*

E0168 **13:30** **PCNE: a tool for plasmid copy number estimation** *R. Bollini* (Pavia, Italy), V. Cento*

E0169 **13:36** **Cerebrospinal fluid lipidome in central nervous system infections: A study of diagnostic accuracy** *S. Staal* (Amsterdam, The Netherlands), S. Olie, J.B. Van Klinken, M. Van Weeghel, F. Vaz, J. Bodilsen, H. Nielsen, D. Van De Beek, M. Brouwer*

E0170 **13:42** **Use of a multiplex joint infection PCR panel on non-synovial fluids: comparing PCR vs culture** *G.M. Chuang* (Singapore, Singapore), S.Y.L. Tan, Y.E. Tan, K.S. Chan, L.L.E. Oon*

E0171 **13:48** **Clinical evaluation of the OCEAN Dx culture-free assay for early detection of bacteraemia in critically ill patients** *A. Dewitte* (Bordeaux, France), J. Thierry, S. Cronier, O. Peuchany, V. Dubois, M. Mamani*

E0172 **13:54** **Performance assessment of a real-time test for intrapartum detection of group B *Streptococcus* vaginal colonisation** *A. Tazi* (Paris, France), M. Selmi, S. Snoussi, C. Poyart, C. Plainvert*

E0173 **14:00** **Breath aerosol PCR for detection of lower respiratory tract infections: evaluation of a non-invasive face mask collector in pneumonia patients** *M. Osthoff* (Basel, Switzerland), S. Dräger, K. Tiseo, H. Santhosh Kumar, M. Alkhazashvili, A. Hammann, P. Risch, R. Willi, T. Mkhatvari, C. Fialová, C. Adlhart, D. Szabó, M. Suknidze, I. Pachkoria, T. Broger, E. Ivanova Reipold, K. Varshanidze*

E0174 **14:06** **Enhancing molecular and genomic approaches for *Bordetella pertussis* investigation and public health surveillance in Victoria, Australia** *L. Sadeesh Kumar* (Melbourne, Australia), M. Sait, J. Merrett, J. Lacey, S. Baines, J. Strachan, N. Sherry, B. Howden*

E0175 **14:12** **Viral dominance in CNS infections: five-year epidemiological surveillance using multiplex PCR panel** *Z. Tsinaris* (Thessaloniki, Greece), A. Tychala, G. Kagkalou, K. Kouirouxis, O. Vasilaki, P. Mantzana, L. Skoura, E. Protonotariou*

E0176 **14:18** **Impact of rapid multiplex PCR testing on the clinical and therapeutic management of pneumonia: a prospective randomised study** *A. Galar* (Madrid, Spain), E. Bouza, A. Álvarez-Uría, P. Martín-Rabadán, E. Cercenado, M. Ferris-Villanueva, L. Martín-Aguilera, J. Serrano, L. Alcalá, M.L. Sánchez-Alegre, J. De La Torre Fernández, J.J. García-López, L. Puente, P. Muñoz*

JS001 **13:30 – 14:30** **Hall A2-1**

CLN IPC

Journal Session

Late-breaking research from JAMA: novel insights on treating and preventing infections around the world

Chairs *Kirsten Bibbins-Domingo (Chicago, United States)*
Preeti Malani (Ann Arbor, United States)

J0001 **13:30** **Treatment of sinusitis in adults** *Timothy Savage (Boston, United States)*

J0002 **13:45** **Long term effects of childhood malaria** *Chandy John (Indianapolis, United States)*

J0003 **14:00** **Dalbavancin for *Staphylococcus aureus* bacteraemia** *Thomas Holland (Durham, United States)*

J0004 **14:15** **Rapid susceptibility testing for bacteraemia** *R. Banerjee* (Nashville, United States), L. Komarow, Y. Li, D. Mau, A. Dodd, H. Geres, K. Greenwood-Quaintance, A. Adler, S. Baliga, M. Chowers, G. Chrysos, M. Paul, S. Pournaras, D. Sousa Regueiro, S. Evans, H. Chambers, V. Fowler, Jr, R. Patel*

KN051 **13:30 – 14:30** **Hall ICM 14**

PED PHEI

Keynote lecture

Rheumatic heart disease: a global problem

Chairs *Fidelma Fitzpatrick (Dublin, Ireland)*
Annelies Zinkernagel (Zurich, Switzerland)

K0086 **13:30** *Liesl Zuhlke (Cape Town, South Africa)*

ME055 **13:30 – 14:30** **Hall B0-2**

CLN DX

Meet-the-Expert

Changing landscape of fungal infections in the solid organ transplant recipient

M0093 **13:30** *Alessandra Mularoni (Palermo, Italy)*
M0094 **13:42** *John Baddley (Baltimore, United States)*

ME053 **13:30 – 14:30** **Hall ICM 13b**

AMR IPC PHEI

Meet-the-Expert

***Candida auris* surveillance: when, how and why**

M0089 **13:30** *Joseph Meletiadis (Athens, Greece)*
M0090 **13:42** *Giulia De Angelis (Rome, Italy)*

Co-organised with: Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie (SIMPIOS), International Society of Human and Animal Mycology (ISHAM), EUCIC Steering Committee

---

ME054 **13:30 – 14:30** **Hall ICM 5**

CLN IPC

Meet-the-Expert

LVAD infections: practical approaches to a complex challenge

M0091 **13:30** *Saima Aslam (San Diego, United States)*
M0092 **13:42** *Margaret Hannan (Dublin, Ireland)*

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), ESCMID Study Group for Implant-associated Infections (ESGIAI)

FO056 **13:30 – 14:30** **Arena 2**

AMR

Open Forum

Moving ahead with the AMR agenda in a changing environment

Chair *Benedikt Huttner (Geneva, Switzerland)*

F0095 **13:30** **From 'making the economic case' for AMR to securing financing for core interventions** *Chantal Morel (Bonn, Germany)*

F0096 **13:40** **Reaching out to those who need to act: education and pre-service training of health workforce** *Li Yang Hsu (Singapore, Singapore)*

F0097 **13:50** **Progress in measuring prevalence and impact on human health** *Olga Tosas Auguet (Geneva, Switzerland)*

Co-organised with: World Health Organisation (WHO)

WT002 **13:30 – 14:30** **Poster area**

Poster Walkthrough

DX

Innovations in infectious disease diagnostics and surveillance

Chair *Fusun Can (Istanbul, Türkiye)*

R0011 **P0192 - Targeted metagenomic sequencing of respiratory infections from UK healthcare workers in the SIREN study, winter 2023 - 2024** *Marissa Knoll (Hinxton, United Kingdom)*

R0012 **P2505 - Deep learning model for rapid outbreak detection in a rapid phenotypic AST system** *Christer Malmberg (Uppsala, Sweden)*

R0013 **P2439 - Evolution of respiratory virome profile in children under five years with persistent low respiratory symptoms** *Niloofar Hejazifar (Milan, Italy)*

R0014 **P4371 - Climate-driven expansion and clinical risk of Vibrio vulnificus: integrating global genomics, environmental reservoirs, and adaptive transcriptomics** *Yaovi M. Gildas Hounmanou (Frederiksberg, Denmark)*

R0015 **P2489 - Enhancing urine culture diagnostics with image analysis powered by AI: a novel approach** *Yasmeen Vincent Marbaniang (Etobicoke, Canada)*

R0016 **P4355 - Uptake of antibacterial vaccines and the effects on antimicrobial resistance associated mortality in children under five in Sub-Saharan Africa** *Oyewole Oyedele (Abuja, Nigeria)*

R0017 **P2399 - Global population structure and convergent MDR-hypervirulence in high-risk *Pseudomonas aeruginosa* lineages** *Riccardo Bollini (Pieve Emanuele, Italy)*

R0018 **P2111 - Optimising the blood culture pathway (BCP) through multidisciplinary team collaboration: a two-year quality improvement initiative** *Suryabrata Banerjee (Newcastle Upon Tyne, United Kingdom)*

R0019 **P0459 - VEGF-A-induced tissue factor vesicle release as a hallmark of vascular dysregulation in long COVID** *Samuel Benarroch (Ile-De-France, France)*

R0020 **P2299 - Real-world diagnostic performance and antimicrobial stewardship impact of the fsyndromic multiplex PCR panel for meningitis/encephalitis in adult patient** *Marisa Del Lujan Sanchez (Buenos Aires, Argentina)*

WT001 **13:30 – 14:30** **Poster area**

Poster Walkthrough

DX

Emerging vector-borne and zoonotic diseases: surveillance, diagnostics, and clinical management in a changing world

Chair *Luisa Barzon (Padua, Italy)*

R0001 **P0322 - Identifying emerging vector-borne pathogens in a time of climate change, the ARBO-WATCH network** *Silvia Bianchi (Milano, Italy)*

R0002 **P0261 - Wolbachia deployment in Aedes aegypti: a meta-analysis of dengue reduction in endemic regions** *Abdullah Al Owesie (Martin, Slovakia)*

R0003 **P0275 - Antibodies to non-structural protein 1 in tick-borne encephalitis: long-term kinetics in serum and cerebrospinal fluid** *Sara Morgardt (Trollhättan, Sweden)*

R0004 **P0276 - Clinical course and outcome of tick-borne encephalitis in immunocompromised patients** *Daša Stupica (Ljubljana, Slovenia)*

R0005 **P0320 - Factors associated with death or neurological sequalae in a cohort of patients hospitalised for West Nile virus infection in a non-endemic area in Southern Italy** *Pierantonio Grimaldi (Naples, Italy)*

R0006 **P0317 - Rapid diagnosis by metagenomics analysis of zoonotic orf virus in human cases using a nanopore sequencing workflow** *Elif Neyligül Arslan (Istanbul, Türkiye)*

R0007 **P0280 - Development and external validation of the early mortality score (EMS) for Crimean-Congo haemorrhagic fever, with comparative evaluation against the severity scoring index (SSI)** *Deniz Güllü (Istanbul, Türkiye)*

R0008 **P0283 - Western equine encephalitis outbreak in Argentina 2023–2024: multi-centre clinical and epidemiological analysis of human cases** *Sofia Elena Echazarreta (CABA (CABA), Argentina)*

R0009 **P0297 - Rodent reservoirs and high human exposure to hantaviruses in a rural agricultural area of Sri Lanka: a One Health perspective** *Rydhnieya Vijeyakumaran (Peradeniya, Sri Lanka)*

R0010 **P0306 - Epidemiological overview of local transmission of chikungunya in mainland France in 2025** *Clémentine Calba (Marseille, France)*

WT003 **13:30 – 14:30** **Poster area**

Poster Walkthrough

PHEI

Of lice and laundry: data-driven public health around the globe

Chair *Joel Mossong (Luxembourg, Luxembourg)*

R0021 **P4435 - Strengthening scientific advice for pandemic decision-making: insights from interdisciplinary tabletop simulation exercises** *Femke Overbosch (Rotterdam, The Netherlands)*

R0022 **P4387- Genomic investigation of crocodile-to-human occupational transmission of *Vibrio cholerae*** *Isca Hershkowitz (Jerusalem, Israel)*

R0023 **P4356 - Learning from the past: historical lessons on non-pharmaceutical interventions in the United Kingdom and Hong Kong** *Mi Joo Choi (Leicester, United Kingdom)*

R0024 **P4308 - Parental views towards childhood vaccination in the United States before and after the COVID-19 pandemic** *Amanda Eiden (Glenside, United States)*

R0025 **P4298 - Estimating measles containing vaccine-induced immunity waning and future prediction in South Korea: a mathematical modeling study** *Sol Kim (Seoul, Korea, Republic of)*

R0026 **P4373 - Pathogen-specific effects of PM2.5 on pneumococcal pneumonia in a low-pollution microstate: a population-based time-series analysis** *Cristina Royo-Cebrecos (Escaldes-Engordany, Andorra)*

R0027 **P4324 - Early implementation outcomes of a nurse-led antenatal immunisation service: improving access, experience, and vaccine uptake in a metropolitan health service** *Dorothy Ling (Victoria, Australia)*

R0028 **P4486 - Identifying active paragonimiasis in rural Nagaland in North Eastern India: results from a community-based cross-sectional study** *Rohan Michael Ramesh (Vellore, India)*

R0029 **P4384 - Genomic diversity of *Campylobacter jejuni* and *Campylobacter coli* from human clinical isolates and swine/poultry industry associated sources in Latvia, 2022 – 2025** *Inara Kampenusa (Riga, Latvia)*

WT004 **13:30 – 14:30** **Poster area**

Poster Walkthrough

PHEI

Changing landscape of parasitic diseases: genes, screens, and scenes

Chair *Carlos Seas (Lima, Peru)*

R0031 **P3442 - Visceral leishmaniasis in Northern Brazil (2000–2023): an ageing epidemic with rising case-fatality** *Lorenzo Brando Lundgren (Varese, Italy)*

R0032 **P3431 - HLA-linked genetic susceptibility in alveolar echinococcosis** *Lynn Peters (Ulm, Germany)*

R0033 **P3457 - Systematic investigation of suspected angiostrongyliasis cases in Réunion Island** *Wacil Patel (France, France)*

R0034 **P3453 - Clinical profile and epidemiology of granulomatous *Acanthamoeba encephalitis*: a systematic review** *Nitin Gupta (Manipal, India)*

R0035 **P3447 - CE acquired in England: signs of emergence?** *Stephanie Harris (London, United Kingdom)*

R0036 **P3535 - Review of malaria diagnosis, severity, and management, 2019–2023, University Hospital Galway** *Ellen Sugrue (Kerry, Ireland)*

R0037 **P3531 - Risk behaviours and health problems in**

international travellers: prospective questionnaire study *Milan Trojanek* (*Prague, Czechia*)

R0038 **P3528 - Implementation of a screening programme among migrants to Italy: key challenges and prevalence results** *Stefania Caronni* (*Milan, Italy*)

R0039 **P3484 - Correlation between PCR CT values, microscopy parasitaemia and RDT results in imported malaria** *Harold Alfredo Bermúdez Marval* (*Alcalá De Henares, Spain*)

R0040 **P3443 - Scabies is strongly associated with rheumatic heart disease: evidence from cross-sectional studies of school children in Tonga** *Saptorshi Gupta* (*Auckland, New Zealand*)

OS030 **14:45 – 15:45** **Hall A2-1**

1-hour Case Session

DX

Unmasking infectious diseases through genomic approaches

Chairs *Judith Breuer* (*London, United Kingdom*)
Sandra Reuter (*Freiburg, Germany*)

O0177 **14:45** **Shotgun metagenomics for CSF diagnostics guides targeted therapy in culture-negative bacterial meningitis caused by *Capnocytophaga canimorsus*** *G. Lorenzin** (*Trento, Italy*), *M. Bertoldi, F. Bonaffini, M. Carlin, C. Scarparo*

O0178 **14:56** **Genomic characterisation of an extensively drug-resistant *Shigella sonnei* carrying $bla_{CTX\text{-}M\text{-}15}$ in a sexually transmitted infection in an MSM patient in Spain** *N. Valcárcel Fraile** (*Santander, Spain*), *N. Fraile-Valcárcel, B.M. Armas-Luján, D. Fernández-Vecilla, M.J. Urrutikoetxea-Gutiérrez, J. Rodríguez Grande, C. Ruiz De Alegría Puig, S. Labrador Descalzo, E. Mesa Santana, S. Riesco Alonso, A. Ocampo-Sosa, M.P. Roiz Mesones*

O0179 **15:07** **Dual enterococcal bacteraemia with central nervous system infection by *Enterococcus faecium* ST117: a whole genome analysis** *M. Roch** (*Geneva, Switzerland*), *R. Sierra, P. Vetter, D. Neofytos, C. Van Delden, K.A. Kline, D.O. Andrey*

O0180 **15:18** **Unmasking the pathogen: how metagenomics enables the diagnosis of hard-to-detect infections** *A. Belati** (*Bergamo, Italy*), *L.B. Giva, R. Bruschi, T. Perrone, M. Bartoli, M. Mazzoni, G. Albano, P.G.G. Panisi, M. Sampaolo, N. Clementi, V. Cento, M. Bartoletti, C. Filippi*

O0181 **15:29** **Chronic Mycobacterium kansasii pleural infection mimicking metastatic breast cancer: a seven-year diagnostic odyssey and the critical role of metagenomic sequencing** *Q. Miao** (*Shanghai, China*), *T. Fang, P. Hu, Y. Zhang, B. Hu*

OS027 **14:45 – 15:45** **Hall ICM 13b**

1-hour Case Session

CLN

Unusual causes of broken heart: cardiac infections

Chairs *Diane Ashiru-Oredope* (*London, United Kingdom*)
Margaret Hannan (*Dublin, Ireland*)

O0182 **14:45** **Outbreak investigation of non-tuberculous mycobacteria (NTM) sepsis following cardiac surgery in an LMIC tertiary care centre: implication of contaminated heater-cooler units** *M. Khan** (*Peshawar, Pakistan*)

O0183 **14:56** **Beyond the usual suspects: three cases of infective endocarditis by rare pathogens** *N. Pansari** (*Ahmedabad, India*), *S. Madan, B. Thacker, M. Chag, D. Shah, K. Gupta*

O0184 **15:07** **Disseminated BCG infection with cardiac device involvement and immune thrombocytopenia** *A. Bergas Farrés** (*Barcelona, Spain*), *A. Bergas, R. Vila-Olives, S. Molinos, M.D. Quesada, A. Sarrias, R. Villuendas, A. Peris, A. Antuori, E. Berastegui, N. Fernández-Hidalgo, M.T. Tórtola, J.J. López-González, M.L. Pedro-Botet, R. Paredes, L. Mateu*

O0185 **15:18** **Bartonella henselae a great mimicker: endocarditis, bone marrow infiltration and glomerulonephritis mimicking vasculitis ANCA-positive** *J. Alza Arcila** (*Medellín, Colombia*), *J. Alza-Arcila, S. Cobaleda-Cano, C. Rincón-Márquez, J.M. Bacca-Gonzalez*

O0186 **15:29** **Intracardiac cysticercosis: a case report and diagnostic challenge** *R. Manchon** (*Paris, France*), *N. Argy, A. Sivapathasundaram, D. Lussato, J. Feignoux, D. Attias, P. Le Besnerais, J. Rousseau, S. Lariven, N. Peiffer-Smadja*

LB002 **14:45 – 15:45** **Hall A1-4**

1-hour Oral Session

PHEI

Late-breaking public health challenges

Chairs *David Fisman* (*Toronto, Canada*)
Ricardo Mexia (*Lisbon, Portugal*)

L0011 **14:45** **Stress testing acute care chains for high-volume war-related trauma and MDROs** *A. Tostmann** (*Nijmegen, The Netherlands*), *B. Beishuizen, V. Stirler, E. Ruizendaal, D. De Jong, E. Tan, C. Rovers*

L0012 **14:57** **Imported MERS-CoV cases in France, November 2025: diagnosis, management and public health response** *A. Bal** (*Lyon, France*), *L. Van-Den-Bogaart, A. Maisa, S. Dan, M. Bouscambert-Duchamp, S. Burrel, A. Avondo, A. Cossard, E. Fougere, Z. Boudalaa, C. Castor, E. Hope-Rapp, C. Durand, J.S. Casalegno, L. Josset, A. De-Clercq, H. Regue, D. Nguyen, C. Vignals, L. Rojas-Lopez, A. Oblette, A. Brinza, A. Massardier-Pilonchery, C. Dananche, P. Fascia, J. Godon, M. Simon, M.A. Rameix Welti, J.M. Turmel, N. Leveque, D. Perez-Bercoff, B. Lina, A. Lapendry, X. Lescure, M. Mailhe, F. Ader, B. Coignard, A. Gaymard, T. Perpoint*

L0013 **15:09** **Measles hospitalisations during an outbreak in Jerusalem, 2025** *O. Gordon** (*Jerusalem, Israel*), *G. Oren, O. Itamar, S. Dorozhko, S. Zahran, E. Roda, N. Peled, A. Bracha Moshe, N. Juven Wetzler, D. Averbuch, S. Hashavya, U. Pollak, D. Wolf, J. Strahilevitz, Y. Oster, N. Abramson, Z. Mor, N. Bar Zeev, O. Megged, R. Brooks, A. Tenenbaum*

L0014 **15:21** **Epidemic of *Chlamydia pneumoniae* infections in France in 2024** *S. Trombert Paolantoni** (*Frepillon, France*), *S. Trombert-Paolantoni, L. Baussant, K. Sood, E. Hedbaut, A. Bergeron, Y. Tandjaoui-Lambiotte, B. Visseaux*

L0015 **15:33** **Scrub typhus in children: an emerging under-recognised threat: seroprevalence, demographic trends, co-infections and cross-reactions in a tertiary care paediatric institute in North India** *N. Sumi** (*Uttar Pradesh, India*), *S. Nandwani, J. Sachdev, A. Puri, R. Edoliya, N. Perween, D.K. Singh, D.K. Sahu*

OS029 **14:45 – 15:45** **Hall B0-2**

1-hour Oral Session

VAX

Respiratory viral infection prevention across age groups

Chairs *Christopher Chiu* (*London, United Kingdom*)
Simona Ruta (*Bucharest, Romania*)

O0187 **14:45** **Maternal RSV vaccination and reduced risk of hospitalisation for babies in England, 2024/25** *M. Wilson** (*London, United Kingdom*), *H. Whitaker, J. Walker, E. Heymer, A. Cobbold, C. Watson, N. Andrews*

O0188 **14:57** **Impact of universal infant immunisation with nirsevimab on RSV-related hospitalisation beyond the first season: the NIRSE-GAL study** *F. Martinón-Torres** (*Santiago De Compostela, Spain*), *J.L. Razzini, I. Giné-Vázquez, J. Jin, M.I. Santiago-Pérez, O. Pérez-Martínez, M.T. Otero-Barrós, N. Suárez-Gaiche, R. Kramer, L. Platero-Alonso, R.M. Álvarez-Gil, O.M. Ces-Ozores, V. Nartallo-Penas, S. Mirás-Carballal, M. Piñeiro-Sotelo, J.M. González-Pérez, C. Rodríguez-Tenreiro-Sánchez, Á. Manzanares-Casteleiro, A.I. Dacosta-Urbieta, C. Álverez-Smith, I. Rivero-Calle, A. Salas, C. Durán-Parrondo, N. Mallah*

O0189 **15:09** **Real-world emergence of nirsevimab resistance in RSV-B breakthrough infections** *S. Fourati** (*Créteil, France*), *A. Reslan, J. Bourret, J.S. Casalegno, Y. Rahou, L. Softic, L. Chollet, P. Tremeaux, B.M. Imbert-Marcille, S. Pillet, N. Veyrenche, A. Boudet, L. Deroche, S. Burrel, L. Mouna, T. Cocherie, A. Schnuriger, C. Pronier, L. Handala, F. Gallais, S. Larrat, A. Regueme, N.C. Dossou, A. Henry, E. Gault, C. Hartard, S. Brichler, A. Moisan, V. Avettand-Fenoel, C.*

Lefeuvre, I. Engelmann, S. Castelain, A. Mirand, M. Salmona, M.C. Jaffar-Bandjee, P. Cappy, C. Rodriguez, G. Dos Santos, S. Berreira Ibrahim, K. Da Silva, A. Recoing, J.M. Pawlotsky, F. Lemoine, E. Audureau, M.A. Rameix-Welti

O0190 **15:21** **Immunogenicity, reactogenicity, and safety of an mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine, mRNA-1083, in adults aged =50 years in Japan** *L. Kostanyan* (Cambridge, United States), H. Fukase, A. Rumyantsev, O. Kogawara, K. Hashizume, S. Osibajo*

O0191 **15:33** **High-dose vs standard-dose influenza vaccination across laboratory-confirmed influenza severity levels in older adults: the DANFLU-2 randomised trial** *F.S. Davidovski* (Hellerup, Denmark), N.D. Johansen, N. Shaikh, R. Harris, D. Modin, P.S. Wolff, K.G. Skaarup, C.S. Søndergaard, M. Loiacono, Y. Huang, J. Bartelt-Hofer, C.S. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, B. Claggett, K. Janstrup, R. Jessen, N. Steenhard, K. Bartholdy, K. Bernholm, J. Borchsenius, L. Davodian, M. Dons, L. Duus, C. Espersen, F. Fussing, A.M. Jensen, N. Landler, A. Langhoff, M. Lassen, A.B. Nielsen, C. Ottosen, M. Sengeløv, S. Solomon, M. Landray, G. Gislason, L. Køber, P. Sivapalan, C. Martel, J.U. Jensen, T.B. Sørensen*

OS026 **14:45 – 15:45** **Hall ICM 13a**

1-hour Oral Session

CLN

Redefining care in bacterial meningitis: new approaches and emerging clinical evidence

Chairs *Tuyen Nguyen (Laval, Canada)*
Charlotte Sriruttan-Nel (Johannesburg, South Africa)

O0192 **14:45** **Continuous intracranial pressure monitoring in acute bacterial meningitis: a nationwide multi-centre cohort study** *J. Karlsson Valik* (Stockholm, Sweden), A. Grahn, M. Veje, P. Alpqvist, C. Åkerlund, J. Widén, G. Westman*

O0193 **14:57** **Addition of daptomycin in the treatment of pneumococcal meningitis in adults: results of the phase II AddaMap trial** *T. Sixt* (Dijon, France), T. Sixt*, I. Fournel, A. Bourredjem, M. Blot, B. Mourvillier*, D. Grandgirard*, S. Leib*, X. Duval, L. Piroth, P. Chavanet**

O0194 **15:09** **Effectiveness of ceftriaxone in the management of neurosyphilis: experience of a UK tertiary centre** *L. Carson* (Cambridge, United Kingdom), B. Warne, O. Sule, C. Krause, M. Routledge*

O0195 **15:21** **Early oral step-down therapy in pyogenic brain abscesses: a bicentric retrospective study** *J. Brouard* (Clichy, France), D. Morizet, R. Rahli, A. Lefort, P. Decq, H. Kimseng, A.L. Munier, V. De Lastours*

O0196 **15:33** **Continued corticosteroids for non-pneumococcal bacterial meningitis in adults: a target trial emulation** *E. Eriksen* (Aalborg, Denmark), K.F. Greve, S.Ø. Larsen, L. Larsen, M. Storgaard, H. Mens, L. Wiese, M.P.G. Jepsen, B.R. Hansen, H.R. Lüttichau, H. Nielsen, J. Bodilsen*

OS028 **14:45 – 15:45** **Hall ICM 5**

1-hour Oral Session

CLN DX

From overuse to optimisation: smarter diagnostics in practice

Chairs *Gloria Cordoba (Copenhagen, Denmark)*
Polona Maver Vodicar (Ljubljana, Slovenia)

O0197 **14:45** **The implementation of electronic clinical decision tools to reduce inappropriate urine and swab requests: a diagnostic stewardship intervention to reduce the environmental impact of laboratory testing** *R. Shorten* (Manchester, United Kingdom), S. Shafiq, L. Roberts, G. Williams*

O0198 **14:57** **Diagnostic stewardship in critical care: should overexpressed AmpC Enterobacterales detected on rectal screening be reported? predictive value for infection and comparison with ESBL** *A. Mizrahi* (Paris, France), G. Péan De Ponfilly, M. Holub, T. Genty, F. Philippart, C. Couzigou, B. Pilmis, A. Le Monnier*

O0199 **15:09** **Development of an infectious diseases diagnostic excellence program using the centres for Disease Control and Prevention (CDC) core elements** *T. Jenkins* (Denver, United States), M. Cooper, K. Shihadeh, L. Triplett, L. Fish, M. Wolfe, A. Penick, M. Wilson*

O0200 **15:21** **Optimising blood cultures: a diagnostic stewardship intervention** *L. Mejdoubi* (Vienna, Austria)*

O0201 **15:33** **Reducing CoNStant testing: Impact of a diagnostic stewardship intervention targeting coagulase-negative staphylococci in blood cultures on vancomycin, daptomycin and linezolid consumption** *K. Tanida* (Hamburg, Germany), B. Berinson, M. Florey, L. Middendorf, C. Sommer, M. Aepfelbacher, H. Rohde, M. Christner*

SY060 **14:45 – 15:45** **Hall A2-2**

1-hour Symposium

DX

Precision diagnostics for neonatal sepsis: from biomarkers to the bedside

Chairs *Ilias P. Iosifidis (Thessaloniki, Greece)*
Birgit Willinger (Vienna, Austria)

S0123 **14:45** **Rapid diagnostic tools for neonatal sepsis: from biomarkers to AI-powered screening** *Mohan Pammi (Bellaire, United States)*

S0124 **15:15** **How to differentiate viral vs. bacterial infections in neonates?** *Marieke Emonts (Newcastle Upon Tyne, United Kingdom)*

SY061 **14:45 – 15:45** **Hall A3-1**

1-hour Symposium

AMR CLN

Bridging the gap: aligning EUCAST standards with antimicrobial stewardship practice

Chairs *Esther Calbo (Terrassa, Spain)*
Paul Christoffer Lindemann (Bergen, Norway)

S0125 **14:45** **From report to treatment: challenges in applying AST results in clinical practice** *Benedikt Huttner (Geneva, Switzerland)*

S0126 **15:15** **Enhancing clinical relevance: EUCAST's vision for improving AST interpretability** *Marlene Amara (Paris, France)*

SY062 **14:45 – 15:45** **Hall A3-2**

1-hour Symposium

ANT CLN

Closing the antiviral gap: broadening treatment options for emerging and neglected viruses

Chairs *Julie Bines (Parkville, Australia)*
Jan Felix Drexler (Berlin, Germany)

S0127 **14:45** **New host-directed approaches against emerging viral infections** *Rainer Koenig (Jena, Germany)*

S0128 **15:15** **Outlook of new antiviral molecules in the pipeline** *Javier Sánchez Céspedes (Seville, Spain)*

SY059 **14:45 – 15:45** **Hall B0-1**

1-hour Symposium

PHEI

Climate change, biodiversity loss, and the future of infectious diseases

Chairs *Marion Koopmans (Rotterdam, The Netherlands)*
Tyra Grove Krause (Copenhagen, Denmark)

S0121 **14:45** **Impact of climate change on infections** *Kimberly Fornace (Singapore, Singapore)*

S0122 **15:15** **Biodiversity loss and risk of spill-over events and epidemics** *Carsten Rahbek (Copenhagen, Denmark)*

SY058 **14:45 – 15:45** **Hall ICM 1**

1-hour Symposium

CLN DX PHEI

Chemsex, HIV and STIs: so little time, so much to do

Chairs *Ivana Gmizic (Belgrade, Serbia)*
Lorenzo Rabbi (Berlin, Germany)

S0119 14:45 **Chemsex plus STIs syndemic: how to test and how to treat** *Zulma Vanessa Rueda* (*Winnipeg, Canada*)

S0120 15:15 **Chemsex and the costs of its ignorance: example from Central and Eastern Europe** *Sime Zekan* (*Zagreb, Croatia*)

Co-organised with: ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC), ESCMID Study Group for Sexually Transmitted Infections (ESTISG), ESCMID Study Group for Viral Hepatitis (ESGVH), Euroguidelines in Central and Eastern Europe Network Group

---

EF031 **14:45 – 15:45** **Arena 1**

CLN TRN

ePoster Flash Session

Infection risk, response, and recovery in the immunocompromised host

Chair *Michael Boeckh* (*Seattle, United States*)

E0202 14:45 **Long-term prognosis of patients surviving progressive multifocal leukoencephalopathy** *N. Lambert** (*Liège, Belgium*), *M. El Moussaoui, A. Le Guilloux, M. Joly, M.D.C. Garcia Martearena, R. Bernard-Valnet, C. Pinnetti, K.F. Greve, X. Brousse, W.F. Westendorp, M.T. Wijburg, L. Grote-Levi, N. Moehn, V. Pourcher, S. Gressens, C.V. Cruz, V. Van Pesch, M. Vidal, C. Morvan, A. Makinson, A.M. Konitsioti, B. Hoellinger, L. Nitsch, D.E. Ney, E. Faure, K.B. Alstadhaug, M. Martinot, F. Genderini, J. Legras, M. Garzaro, S. Blanchi, S. Gazaignes, S. Borrelli, S. Patrat-Delon, D. Vydrář, P. Nicolas-Vullierme, M. Moutel, T. Cartau, F. London, A. Cabié, K. Bouiller, A. Montcuquet, P. Loubet, N. Sayre, P. Maquet, G. Darcis, M. Le Marechal, D.B. Clifford, T. Skripuletz, M.C. Brouwer, J. Bodilsen, R. Du Pasquier, P. Cinque, A. Sommet, G. Martin-Blondel*

E0203 14:51 **Pritelivir demonstrated superior lesion healing with extended treatment compared to investigator's choice for refractory herpes simplex virus infection in immunocompromised patients in the PRIOH-1 phase III trial** *R. Chemaly** (*Houston, United States*), *J.M. Molina, K. Workowski, R. Avery, Y.J. Lee, K. Peggs, D. Neofytos, M. Yong, J. Sasadeusz, R. Maves, B. Gaborit, D. Teschner, A. Perez-Rios, A. Birkmann, C. Wat, D.C. Herath, A. Marini, B. Surujbally, M. Sumner, A. Wald, G.A. Papanicolaou*

E0204 14:57 **Impaired type I interferon response early after SARS-CoV-2 infection is associated with the occurrence of persistent COVID-19 in solid organ transplanted recipients** *Q. Richier** (*Paris, France*), *K. Zafilaza, M. Briard, V. Bondet, M. Robert, V. Leducq, A. Fauchois, E. Ghidaoui, S. Sayon, C. Dorival, C. Lusivika-Nzinga, Y. Yordanov, G. Martin-Blondel, F. Carrat, A.G. Marcelin, C. Soulie, K. Lacombe, D. Duffy*

E0205 15:03 **Blood virome and acute graft vs host disease** *K. Hosszu-Fellous** (*Geneva, Switzerland*), *S. Cordey, M. Gumowski, F. Laubscher, L. Royston, S. Masouridi-Levrat, Y. Chalandon, D. Neofytos, L. Kaiser*

E0206 15:09 **Towards personalised empirical antibiotic therapy in febrile neutropaenia: a theoretical model based on machine learning and prior colonisation with multidrug-resistant Gram-negative bacilli** *A. Gallardo-Pizarro** (*Barcelona, Spain*), *C. Teijón-Lumbreras, T.F. Aiello, P. Monzó-Gallo, A. Martinez-Urrea, C. Terrones-Campos, A. Castiella, G. Cuervo, L. Morata, P. Castro, C. Casals, M. Espasa, J. Esteve, J.M. Nicolas, J. Mensa, A. Soriano, C. Garcia-Vidal*

E0207 15:15 **Burden and clinical outcomes of hospital-coded respiratory virus infection in patients with haematological malignancy: a longitudinal multi-centre cohort study from 2011-2023** *V. Hall** (*Melbourne, Australia*), *T. Spelman, A.P. Ng, M.K. Yong, M.A. Slavin, B.W. Teh*

E0208 15:21 **Steroid-linked invasive fungal infections after CAR-T: insights from a national Australian cohort** *G. Reynolds** (*Heidelberg, Australia*), *M. Dowling, S. Belbachir, N. Perera, J. Li, J. Valencia-Klug, B.W. Teh, M.A. Anderson, A. Barraclough, C. Tam, P.J. Ho, S.J. Harrison, A.S. Henden, M. Slavin*

E0209 15:27 **Role of colonising multidrug-resistant bacteria in haematological patients: a retrospective observational study** *A. Lovecchio** (*Trieste, Italy*), *N. Benvenuto, S. Babich, A. Misin, S. Mohamed, G. Sanson, S. Di Bella*

E0210 15:33 **Serious infection risk with advanced therapies across immune-mediated inflammatory diseases** *V. Allen** (*London, United Kingdom*), *M. Gibson, M. Russell, K. Bechman, M. Adas, S. Norton, I. Muzafar, R. Chavali, S. Muzafar, N. Suresh, Y. Yoon, L. De Gracia, D. Phillippo, A. Goodman, J. Galloway*

EF032 **14:45 – 15:45** **Arena 2**

CLN DX

ePoster Flash Session

Beyond the culture plate: a multi-modal overview of recent advances in gastrointestinal testing

Chair *Mauricio Farfan* (*Santiago, Chile*)

E0211 14:45 **Evaluation of Copan FecalSwab™ Collection and Transport device for molecular applications** *F. Bonometti** (*Brescia, Italy*), *S. Savi, C. Sabelli*

E0212 14:51 **Efficient and easy preparation of stool specimens for molecular diagnostics without nucleic acid purification** *T. Schuurman** (*Dordrecht, The Netherlands*), *M. Pellikaan, I. Huijskens*

E0213 14:57 **A multi-centre clinical trial evaluating molecular mini-panels for bacterial gastrointestinal pathogen detection** *A. Nenninger** (*San Diego, United States*), *C. Remillard, Y. Liu, A. Menez*

E0214 15:03 **Diagnostic efficacy of two immunochromatographic tests for the rapid detection of rotavirus, adenovirus, and norovirus compare** *G. Sánchez De Luis** (*Madrid, Spain*), *R. Blázquez Batanero, A.I. Peñalver López, H. Bermúdez Marval, V.A. Robles Curvelo, C. Rescalvo-Casas, M. Hernando-Gozalo, A. Rojas Díaz, F. Pérez-García, Á. Irigoyen-Von-Sierakowski, B. Rodríguez-Ponga, J.A. Cuadros-González, R. Pérez-Tanoira*

E0215 15:09 **Comparative evaluation of diagnostic methods for Entamoeba histolytica: A Four-Year retrospective study** *B. Dinc** (*Ankara, Türkiye*), *F. Demirel, S. Cebeci, U. Berberoğlu, B. Dinç*

E0216 15:15 **Bristol-scale guided using a POCT vs non-POCT molecular syndromic testing and clinical outcomes in traveler's diarrhoea** *M. Bugés Bascompte** (*Barcelona, Spain*), *M. Bugés-Bascompte, S.M. San José Villar, N. Vila-Olmo, P. García-Mellado, M. Muixí-Duran, I. Oliveira-Souto, P. Nadal-Barón, M. Vicente-Ciurans, A. Canals, V. Rodríguez-Garrido, C. Arconada-Rojano, C. Rubio-Maturana, L. Goterris-Bonet, E. Sulleiro*

E0217 15:21 **Optimising bacterial stool diagnostics: PCR-guided culture improves sensitivity and accelerates result reporting** *G. Hagn** (*Munich, Germany*), *T. Fleige*

E0218 15:27 **Clinical validation of the BB-ELISA for predicting recurrent *Clostridioides difficile* infection study** *E. Basseres** (*Houston, United States*), *H. Yu, R. Lee, S. Kumari, J. Fowler, A. Saint Fleur, T. Eubank, Y. Zhang, E. Von Rosenvinge, K. Garey, Z. Yang, H. Feng*

EF033 **14:45 – 15:45** **Arena 3**

AMR TRN

ePoster Flash Session

Preclinical data and fundamental science on fungi and antifungals

Chair *Lysangela Ronalte Alves* (*Curitiba, Brazil*)

E0220 14:45 **Impact of azithromycin on neutrophil-mediated immune responses against *Aspergillus* fumigatus** *R. Manchon** (*Paris, France*), *E. Dudoignon, A. Agathe, W. Sarah, Q. Jessica, D. Sarah*

E0221 14:51 **A novel infection model to study immunobiology, antifungal pharmacotherapy, and immunomodulatory therapy of invasive pulmonary aspergillosis in mice with acute myeloid leukemia** *S. Wurster** (*Houston, United States*), *N.D. Albert, J. Pantaleon Garcia, L. Matula, S. Evans, D.P. Kontoyiannis*

E0222 14:57 **Efficacy of BAL2062 in immunosuppressed mice infected with azole-sensitive and azole-resistant *Aspergillus* fumigatus** *A. Ibrahim** (*Allschwil, Switzerland*), *T. Gebremariam, S. Alkhazraji, Y. Gu, E. Youssef, S. Nabeela, T. Elsayed, S. Dolati, K. Litherland*

E0223 15:03 **Invasive pulmonary mucormycosis is associated with siderophore secretion, neutrophil recruitment, and lipid remodelling in the lungs** *D. Luptáková** (*Prague 4, Czechia*), *T. Hřivnová Juříková, M. Petřík, K.*

Dvořáková Bendová, B. Neužilová, H. Marešová, A. Palyzová, M. Lackner, P. Hubáček, V. Havlíček

E0224 **15:09** **Once-daily SCY-247 as oral and intravenous formulations has linear pharmacokinetics and is efficacious in a murine model of invasive *Candida* glabrata infection** *N. Wiederhold* (San Antonio, United States), L. Najvar, S. Wring, K. Borroto-Esoda, D. Angulo, R. Jaramillo, M. Olivo, T. Patterson*

E0225 **15:15** **Phenotypic and genotypic characterisation of multiple *Candida albicans* laboratory-induced drug resistant isolates reveals convergent and divergent responses to resistance** *R. Khalaf* (Byblos, Lebanon), M. Abbas, S. El Hachem, C. Chedraoui, I. Bitar, N. Fattouh*

E0226 **15:21** **Engineered CAR-T Cells Targeting Fungal Cell Wall Show Limited Antifungal Activity** *E. Dolader Ballesteros* (Zaragoza, Spain), E. Dolader-Ballesteros, S. Redrado, D. Sánchez-Navarro, M.P. Domingo, P. Esteban, M. Arias, J. Paul-Bernal, V. Taleb, A. Ramirez, R. Hurtado, J. Pardo, E.M. Gálvez*

E0227 **15:27** **Azole-induced in-host microevolution of *Candida parapsilosis* drives MRR1-mediated antifungal resistance** *R. Zhang* (Beijing, China)*

EF034 **14:45 – 15:45** **Arena 4**

AMR ANT IPC

ePoster Flash Session

Innovations in antimicrobial stewardship across diverse settings

Chair *Nathan Peiffer-Smadja (Paris, France)*

E0229 **14:45** **Strengthening infection control and antimicrobial stewardship through quality improvement in a refugee-serving hospital: lessons from Nakivale, Uganda** *Z. Nahumuza* (Entebbe, Uganda), M. Umar*

E0230 **14:51** **From culture positives to positive culture: changing behaviour around ASB treatment** *M. Arandjelovic* (Aveiro, Portugal), L. Maia, A. Ribeiro, T. Mariano, M. Santos, F. Freitas*

E0231 **14:57** **"No breakpoints? no problem!" evaluating gentamicin perioperative prophylaxis for *Pseudomonas aeruginosa* asymptomatic bacteriuria before urological surgery** *N. Reidy* (London, United Kingdom), S. Dewan, A. Saiyed, A. Raza, D. Smith, A. Lima Soares, G. Pollara, R. Ghani*

E0232 **15:03** **A multi-seasonal mixed-method point-prevalence study of antibiotic prescription patterns in a tertiary healthcare facility in India** *A. Mukherjee* (New Delhi, India), V. Modgil, R. Surial, O. Sinha, S. Kumar, S. Raina, R. Chauhan, S. Sahay*

E0233 **15:09** **TDM (Therapeutic Drug Monitoring)-guided meropenem therapy for bone and joint infections caused by Gram-negative bacilli** *M. Sanz De Mena* (Barcelona, Spain), M. Sanz-De Mena, S. Luque, L. Sorlí, D. Pérez-Prieto, A. Alier, G. Rodriguez-Cabalé, I. Pelegrín, M. Montero, J.P. Horcajada, J. Gómez-Junyent*

E0234 **15:15** **Antimicrobial Stewardship (AMS) program in Lombardy Region: analysis of effectiveness and costs** *G. Renisi* (Milano, Italy), A. Comelli, L. Scudeller, A. Mazzone, G. Macaluso, M. Zanforlini, S. Schiatti, D. Cereda, G. Del Castillo, U. Restelli, S. Silvola, N. De Fazio, P. Bonfanti, M. Bartoletti, A. Tebaldi, S. Piconi, M. Puoti, A. Castagna, P. Grossi, G.C. Marchetti, A. Regazzetti, F. Castelli, A. Zoncada, B. Castiglioni, L. Pusterla, R. Bruno, S. Rusconi, S. Antinori, A. Muscatello, A. Gori, A. Bandera, S. Chiappetta*

E0235 **15:21** **Disparities in Infection Prevention and Control, and Antimicrobial Stewardship Practices across Healthcare Settings with Varied Resource Levels: Findings from the BALANCE Study** *R. Farzana* (Oxford, United Kingdom), N. Haque, S.B. Shahid, G. Ferdous, N. Haque, M. Rahman, S. Afroj, E. Carretto, D.B. Roatti, E. Kibaru, L. Kiguongo, G. Ganda, D. Adera, C. Achi, K. Iregbu, P. Nwajiobi-Princewill, O.E. Ben, A. Aminu, F.H. Auwal, I.N. Nwafia, O.S. Ukaegbu, R. Zahra, M. Hamza, B. Hassan, A. Naqvi, G. Guljanan, K. Shafique, M. Nawaz, M. Idrees, M. Umair, A. Zukowska, A. Zukowska, M. Zukowski, M. Borowiak, O. Ergonul, L.S. Gucer, Ö.K. Azap, N. Sari, E.T. Tigen, B.E. Sengel, M. De Kraker, S. Harbarth, N. Hassoun-Kheir, K. Onjuro, E. Owinoh, T. Walsh*

E0236 **15:27** **Addressing prescribing behaviour to reduce broad-spectrum antibiotic use** *V. Chorro-Mari* (Ashford, United Kingdom), A. Dalton, S. Yan, S. Glass, L. White*

KN057 **14:45 – 15:45** **Hall ICM 14**

CLN TRN

Keynote lecture

From molecules to ministries: a life in the fight against malaria

Chairs *Anu Kantele (Helsinki, Finland)*
Carlos Seas (Lima, Peru)

K0118 **14:45** *Abdoulaye Djimde (Bamako, Mali)*

SY069 **16:15 – 17:15** **Hall A3-2**

TRN VAX

1-hour Symposium

Outsmarting ticks: decoding tick-host-pathogen interactions and advancing vaccines against tick-borne diseases

Chairs *Anna J. Henningsson (Jönköping, Sweden)*
Ryan Rego (Ceske Budejovice, Czechia)

S0153 **16:15** **Insights into tick immune-developmental pathways impacting vector biology and pathogen persistence** *Chrysoula Kitsou (College Park, United States)*

S0154 **16:45** **Counter-attacking the tick bite: anti-tick vaccines to prevent tick-borne diseases** *Joppe Willem Robert Hovius (Amsterdam, The Netherlands)*

Co-organised with: ESCMID Study Group for Lyme Borreliosis (ESGBOR)

EW072 **16:15 – 18:15** **Hall A2-1**

CLN TRN

2-hour Educational Session

The microbiome and response to cancer treatment

Chairs *Nicolas Benech (Lyon, France)*
Lina Cavaco (Copenhagen, Denmark)

W0163 **16:15** **How the microbiome can impact response to cancer treatment** *Gal Markel (Petach Tikva, Israel)*

W0164 **16:35** **How antibiotic treatment can impact response to immunotherapy** *Lisa Derosa (Villejuif, France)*

W0165 **16:55** **How to preserve the microbiome during infection management in cancer patients?** *Arielle Elkrief (Montréal, Canada)*

W0166 **17:15** **How the gut microbiome influences chemotherapy tolerance and efficacy** *Cindy Neuzillet (Saint Cloud, France)*

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI)

EW071 **16:15 – 18:15** **Hall B0-1**

CLN PRO

2-hour Educational Session

Adaptive platform trials in infectious diseases

Chairs *Marc J.M. Bonten (Utrecht, The Netherlands)*
Dafna Yahav (Ramat-Gan, Israel)

W0159 **16:15** **One and the same, or two and different? History and definitions of adaptive and platform trials** *Holly Jackson (Singapore, Singapore)*

W0160 **16:35** **BALANCE PLUS: a platform trial answering challenging questions on Gram-negative infections** *Nick Daneman (Ontario, Canada)*

W0161 **16:55** **Keeping it going: lessons learned from REMAP-CAP** *Marc J.M. Bonten (Utrecht, The Netherlands)*

W0162 **17:15** **Getting it off the ground: successes and failures from the SNAP platform** *Josh Davis (Newcastle, Australia)*

Co-organised with: CMI Communications Board of Editors

EW070 **16:15 – 18:15** **Hall ICM 13b**

CLN IPC VAX

2-hour Educational Session

Building a safer journey from candidate to organ transplant recipient

Chairs *Wanessa Clemente (Belo Horizonte, Brazil)*
Victoria Hall (Melbourne, Australia)

W0155 **16:15** **Ready for the fight: candidate evaluation and vaccination** *Maha Alamri (Riyadh, Saudi Arabia)*

W0156 **16:35** **It starts with the donor: minimising the risk of donor-derived infections** *Oscar Len (Barcelona, Spain)*

W0157 **16:55** **At the table: surgical and perioperative challenges for infection control** *Maddalena Giannella (Bologna, Italy)*

W0158 **17:15** **Traveling the world and safe living post-transplant** *Priscilla Rupali (Vellore, India)*

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH)

SY067 **16:15 – 18:15** **Hall A2-2**

CLN PHEI

2-hour Symposium

Can you see me? HIV among underserved populations

Chairs *Magdalena Rosińska (Warsaw, Poland)*
Milena Stevanovikj (Skopje, North Macedonia)

S0145 **16:15** **Learning from Malta's experience on HIV care for refugees and migrants** *Aaron Schembri (Attard, Malta)*

S0146 **16:45** **HIV transmission and intimate partner violence in South America** *Claudia Cortes (Santiago, Chile)*

S0147 **17:15** **Can people in homelessness crisis be effectively treated for HIV? a voice from Canada** *Yoav Keynan (Winnipeg, Manitoba, Canada)*

S0148 **17:45** **STIs, HIV and hepatitis in penitentiary system: how to test and treat them all?** *Justyna Kowalska (Warsaw, Poland)*

SY068 **16:15 – 18:15** **Hall A3-1**

IPC PED

2-hour Symposium

Novel approaches to preventing neonatal infections beyond antibiotics

Chairs *Angelika Berger (Vienna, Austria)*
Pablo Sanchez (Columbus, Ohio, United States)

S0149 **16:15** **Lactoferrin: a natural defense against neonatal sepsis and necrotising enterocolitis** *Theresa J. Ochoa (Lima, Peru)*

S0150 **16:45** **Immunometabolic approaches to prevent neonatal sepsis** *Duc Ninh Nguyen (Frederiksberg, Denmark)*

S0151 **17:15** **Human milk oligosaccharides and the microbiome in preterm infants: mechanisms and evidence for infection protection** *Moran Yassour (Jerusalem, Israel)*

S0152 **17:45** **Human fortifier to prevent infections in preterm infants: clinical data and future perspectives** *Boris Kramer (Poznan, Poland)*

SY066 **16:15 – 18:15** **Hall B0-2**

AMR PHEI TRN

2-hour Symposium

Barriers, drivers and maintenance: molecular mechanisms behind AMR gene mobility

Chairs *Louise Roer (Copenhagen, Denmark)*
Jozsef Soki (Szeged, Hungary)

S0141 **16:15** **Classification and typing of plasmids carrying multi-drug resistance** *Alessandra Carattoli (Rome, Italy)*

S0142 **16:45** **Plasmid-host co-evolution that stabilises antibiotic resistance** *Javier De La Fuente (Barcelona, Spain)*

S0143 **17:15** **The evolution and transmission of multi-drug-resistant *Escherichia coli* and *Klebsiella pneumoniae*: complexity of clones and plasmids** *Alan Mcnally (Birmingham, United Kingdom)*

S0144 **17:45** **Antibiotic resistance plasmids in a One Health context** *Michael Brouwer (Utrecht, The Netherlands)*

Co-organised with: ESCMID Study Group for Anaerobic Infections (ESGAI), ESCMID Study Group for Mobile Elements and Plasmids (ESGMAP)

SY063 **16:15 – 18:15** **Hall ICM 1**

ANT CLN

2-hour Symposium

Cracking the phage code: from clinical insights to precision design

Chairs *Tristan Ferry (Lyon, France)*
Jean-Paul Pirnay (Brussels, Belgium)

S0129 **16:15** **Designing clinical trials around phage therapy** *Pranita Tamma (Philadelphia, United States)*

S0130 **16:45** **Randomised controlled trials of phage therapy in diabetic foot ulcers** *Ran Nir-Paz (Jerusalem, Israel)*

S0131 **17:15** **AI for host-phage interaction prediction** *Michiel Stock (Ghent, Belgium)*

S0132 **17:45** **Towards cell-free production and selection of therapeutic phages** *Antoine Levrier (Montpellier, France)*

Co-organised with: ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)

SY064 **16:15 – 18:15** **Hall ICM 13a**

CLN PED TRN

2-hour Symposium

Global perspectives on tuberculosis

Chairs *Laura Ferreras-Antolin (London, United Kingdom)*
Lorenzo Guglielmetti (Negrar Di Valpolicella, Verona, Italy)

S0133 **16:15** **Computer modelling to improve TB outcomes: progress and problems** *Rada Savic (San Francisco, California, United States)*

S0134 **16:45** **Contribution of asymptomatic TB to the global TB burden** *Hanif Esmail (London, United Kingdom)*

S0135 **17:15** **The Brazil-wide TBPed study on active and latent tuberculosis in childhood** *Marcelo Scotta (Porto Alegre, Brazil)*

S0136 **17:45** **Radical shortening of the duration of TB treatment: here and now?** *Nicholas Paton (Singapore, Singapore)*

Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), International Society of Pediatric Respiratory Diseases (INSPiRED)

SY065 **16:15 – 18:15** **Hall ICM 5**

TRN VAX

2-hour Symposium

Harnessing antibody response against viral and bacterial infections

Chairs *Luisa Barzon (Padua, Italy)*
Silvio Daniel Brugger (Zurich, Switzerland)

S0137 **16:15** **Mechanisms and clinical relevance of antibody response during viral infection** *Irene A Abela (Zürich, Switzerland)*

S0138 **16:45** **Mechanistic insights into human antibody responses to bacterial virulence factors** *Alexander Simonis (Cologne, Germany)*

S0139 **17:15** **Bacterial cell wall polysaccharides as strategies against invasive bacterial infection** *Nina Van Sorge (Amsterdam, The Netherlands)*

S0140 **17:45** **Advances in antibody-based strategies for combating HIV infection** *Florian Klein (Cologne, Germany)*

EF035 **16:15 – 17:15** **Arena 4**

DX PHEI

ePoster Flash Session

From surveillance to diagnosis: catching hepatitis viruses before they catch us

Chair *Arjan Harxhi (Tirana, Albania)*

E0238 **16:15** **A One Health, pan-European network strengthening surveillance, clinical management and control of zoonotic hepeviruses** *I. Hasanoglu* (Ankara, Türkiye), A. Elena Anita, F. Abravanel, G. Reuter, S. Dudman, N. Kamar, L. Jemeršić, I. Di Bartolo, N. Cook, S. Ruta, I. Nauwelaers, L. Milojević, E. Todorovska, S. Mojsova, A. Zerja, A. Avellon, R. Hakze, B. Velebit, R. Johne, J. Mesquita, A. Rivero-Juarez*

E0239 **16:21** **Tracing rat-to-human transmission of hepatitis E virus within a One Health framework** *H.K.E. Shun* (Hong Kong, Hong Kong), S.F.S. Ho, X. Ma, S. Sridhar*

E0240 **16:27** **Epidemiology of hepatitis E infection in England between 2014/15 and 2024/25** *A.A. Datoo* (London, United Kingdom), A. Yunusa, S. Ijaz, B. Haywood, R. Pudney, D. Chudasama*

E0241 **16:33** **Prospective characterisation of hepatitis delta in Spain: insights from the nationwide DDR cohort** *A. Alberola* (Granada, Spain), A. Vázquez Blanquiño, A. De Salazar, R. Carracedo, A. Fuentes, L. Chaves Blanco, L. Gozalo Álvarez, W. Sanchez-Yebra, C. Freyre, B. Becerril, I. Viciana, I. López Rodríguez, T. Trujillo Soto, A.M. Domínguez Castaño, M.D.P. Luzón-García, E. Ramírez Arellano, C. Liébana, F. Franco Álvarez De Luna, M.C. Lozano, B. Palop, A. Sampedro, A.B. Pérez, S. Algarate, S. Rojo Alba, P. Fraile, D. Ocete, M.J. Alcaraz, J.C. Rodríguez, F.J. Hernández-Felices, O. Martínez, V. Domínguez, N. Orta, D. Gómez, C. Cortell Cortell, J. Camacho Marín, S. Sabater, L.Á. Iglesias Sánchez, Y. Martín, A. Vallejo, L. Molina, M. Aroca, T. Tosco, M. Lara, M.J. Pena, D. Pablo Marcos, A. González Praetorius, J.J. Blas, A. Beteta, C. Gómez, M.J. Rodríguez, M. González, M. Abreu, J. García Díez, I. Beltrán, M. Sandoval Torrientes, R. Sáez, T. Martín, P. Tajada Alegre, B. Lorenzo, M.T. García Valero, I. Jiménez Sansegundo, S. García-De Cruz, S. Garcinuño, M.Á. Sáiz, A.M. Blázquez, I. Fernández, H.M. Lorenzo Juanes, M.R. Vidal-Acuña, L.M. Moldes, N. Calvo, M. Trigo, M.J. Gude, P. Ordóñez, S. Cortizo, M. Blasco, M. Sigcha, I. Falces, L. Martínez, A. Arribi, R. Alonso, A. Iborra, M.J. Del Amor Espín, E. Cascales, C. Pérez, P. Fernández, M.D. Navarro, M.L. Núñez, M. Cámara, L.J. Gil-Gallardo, A. Miqueleiz, G. Reina, L. Elorduy, M. Macho, C. Gómez, P. Liendo, M. Aranzamendi Zaldumbide, A. Aguilera, F. García*

E0242 **16:39** **The future of HDV testing: saliva-based PCR for scalable and field-friendly detection** *S.K. Rawat* (Sagar, India), N. Mishra, R.K. Nema, I. Hasanoğlu*

E0243 **16:45** **Impact of nucleic acid extraction methods on the quantitative detection of hepatitis delta virus RNA by real-time PCR: a comparative evaluation of manual and automated systems** *H. Alonso* (San Mateo De Gállego, Spain), M. López, N. Gil*

E0244 **16:51** **Are we screening or wasting? The hidden burden of repeat anti-HCV testing in the hepatitis elimination era** *A. Sertçelik* (Ankara, Türkiye), R. Güner, İ. Hasanoğlu, E. Güney, A. Kaya, F. Eser, B. Dinç, B. Kayaaslan*

E0245 **16:57** **Impact of screening and direct-acting antiviral treatment of hepatitis C among people who inject drugs in Singapore: a mathematical modelling study** *J.J. Ong* (Singapore, Singapore), W.Y. Lim, S. -, B. Choh, C. Gao, C.S. Wong, J. Tay, A. Han*

E0246 **17:03** **Comparison of lyophilised vs native samples for hepatitis B surface antibody testing across four fully automated immunoassays** *M. Obermeier* (Berlin, Germany), J. Wenzlaff, J. Geisler, R. Ehret, I. Schellenberg, P. Kaiser, V. Lindig, U. Dühring, S. Samuleit, M. Kammel*

EF036 **17:15 – 18:15** **Arena 1**

ePoster Flash Session

CLN TRN

Skin and soft tissue infections haunting us

Chair *Angelo Pan (Cremona, Italy)*

E0247 **17:15** **Mpox-HIV syndemics in the 2024–2025 clade Ib outbreak: a framework for understanding synergistic vulnerabilities, clinical trajectories, and interventions in high-burden African settings** *U. Muhumuza* (Kampala, Uganda), B.B. Nanyange, Z. Nahumuza*

E0248 **17:21** **Hand infections: epidemiology and adverse prognostic factors in a six-year retrospective single-centre study of 496 patients** *M. Pellegrino* (Modena, Italy), G. Franceschi, L. Benassi, S. Generoso, M. Sarti, A. Leti Acciaro, M.C. Gagliano, C. Mussini, A. Bedini*

E0249 **17:27** **Urease is key factor in the pathogenicity of *Staphylococcus aureus* in atopic dermatitis** *M. Araújo* (Oeiras, Portugal), N. A. Faria, M. Gonçalo, J. Nakonieczna, C. Torres, F. Campanile, K. Netto Dos Santos, R. Sobral, M. Miragaia*

E0250 **17:33** **MSSA-ST398: a lineage highly adapted to the atopic dermatitis skin environment** *D. Caieiro* (Lisbon, Portugal), N. A. Faria, M. Araújo, A. Botelho, M. Gonçalo, L. Ramos, M. Miragaia*

E0251 **17:39** **Recurrent facial folliculitis by *Klebsiella aerogenes* ST117 in men who have sex with men: an emerging sexually transmitted SSTI?** *A. Bleibtreu* (Paris, France), G. Monsel, C. Emeraud, B. Rached, V. Bérot, L. Porter, N. Yin, J. Krygier, F. Durupt, M. Jachiet, M. Godinot, V. Pourcher, O. Chosidow, L. Dortet*

E0253 **17:51** **Clinical and inflammatory predictors of treatment failure in uncomplicated skin and soft tissue infections: a multi-centre study from Türkiye** *M.N. Özçelik* (Tekirdag, Türkiye), M.S. Sayar, N.N. Aydın, D. Başkol Elik, Ö. Günal, P. Yürük Atasoy, A. Tuna, C. Semet, S. Erol, A. Yetişen, Y. Gezer, M.R. Tayşi, N.B. Baysal, G. Eser Karlıdağ, M. Çelik, E. Aydin, Y. Kürekçi, Y. Akkoyunlu, Ö. Akyıldız, A.S. Özel, O. Yapıcı, D. Özer, Ş. Kaya, T. Damar Çakırca, Ş. Balın Özer, İ.N. Hakyemez*

E0254 **17:57** **Skin and soft tissue infections in UK Armed Forces populations: the past, the present and the future** *A. Mason* (Camberley, United Kingdom), L. Lamb, W. Nevin, K. Morris, S. Pallett, M. Riley, T. Davey, J. Fallowfield, S. Sriskandan, E. Jauneikaite, S. D'arc, M. Dermont, G. Holden, K. Wilkinson, D. Tupper, H. Taylor*

E0255 **18:03** **Chronic non-puerperal mastitis: a complex condition, a new multidisciplinary approach** *M. Arias* (London, United Kingdom), A. Brown, L. Ragad, A. Boyd, C. Shah, G. Weston-Petrides, J. Galloway*

EF037 **17:15 – 18:15** **Arena 2**

ePoster Flash Session

AMR IPC

Hospital surfaces: a touching subject

Chair *Sinead O'donnell (Dublin, Ireland)*

E0256 **17:15** **Metagenomics vs Culture: Identification of priority bacterial pathogens on hospital surfaces** *R. Lins De andraDe* (São Paulo, Brazil), R.L. Andrade, R.A. Tavella, M.S. Constâncio, A.P. Christoff, A.F.R.S. Sereia, B.L. Teixeira, L.F.V. Oliveira, J.F. Ribeiro, T.C.R.L. Nogueira, G.J. Oliveira, A.C. Gales*

E0257 **17:21** ***Klebsiella pneumoniae* biofilm formation and biocide tolerance on hospital surface materials: the influence of matrix components** *M. Nieto Rosado* (Oxford, United Kingdom), M. Nieto-Rosado, K.M. Thomson, L.C. Powell, B. Hassan, R. Zahra, E. Rashid, M.I. Shah, M.H. Hamid, S. Shabbir, M. Bashir, R. Temur, A. Balqees, A. Ali, T.R. Walsh, G. Zaborskytė, K. Sands*

E0258 **17:27** **Environmental reservoir driving hospital endemicity of a multispecies *bla*$_{NDM-1}$ IncC plasmid** *A. Anantharajah* (Brussels, Belgium), F. Goormaghtigh, A. Vanderheeren, W. Abdel Hadi, M. Argudin, N. Olive, E. Nguvuyla Mantu, A. Demur, C. Schirvel, A. Verroken, F. Van Bambeke, H. Rodriguez-Villalobos*

E0259 **17:33** **Patient-environment transmission dynamics of multidrug resistant *Enterobacteriaceae* in two Dutch intensive care units: a longitudinal retrospective and prospective analysis in a non-outbreak setting** *C. Rossel* (Sittard-Geleen, The Netherlands), E.R. Heddema, R.M. Koeck, P.H.M. Savelkoul, L.B. Van Alphen*

E0260 **17:39** **Genomic comparison of carbapenemase-producing *Enterobacter* species isolated from patients and hospital environments, 2019-2024, reveals striking overlap between these niches** *E. Cronin* (Galway, Ireland), A. O'connor, M. Maguire, C. Clarke, A. Tuohy, M. Cormican, M.J. Dorman, L.P. Burke*

E0261 **17:45** **Bacteriophage-based environmental decontamination to reduce carbapenem-resistant *Klebsiella pneumoniae*: results from the FagoLimp, a cluster-randomised controlled crossover study** *A. Gales* (Sao Paulo, Brazil), T. Fagolimp*

E0262 **17:51** **Gold nanocluster-based bactericidal surface coatings: A novel approach to combat healthcare-**

associated bacterial infections and antimicrobial resistance *K. Burdova* (London, United Kingdom), S. Ali, N. Kapil, M.O. Coppens*

E0263 **17:57** **Impact of probiotic-based cleaning in intensive care units on the acquisition of *Pseudomonas aeruginosa* and multidrug-resistant organisms: an interrupted time-series analysis** *L.A. Denkel* (Berlin, Germany), F. Schwab, S. Wolke, G. Zakonsky, B. Raguse, P. Gastmeier, C. Geffers*

E0264 **18:03** **Underfloor heating as a potential ally against *Candida auris* and *Candida albicans* surface contamination: impact on cleaning and disinfection effectiveness** *A. Clifford* (Vienna, Austria), B. Leeb-Zatorska, K. Nikolova, J. Zottl, E. Presterl*

EF038 **17:15 – 18:15** **Arena 3**

ANT CLN TRN

ePoster Flash Session

Advances in clinical and pre-clinical PK/PD

Chair *Iris K. Minichmayr (Vienna, Austria)*

E0265 **17:15** **Synergistic activity of Pep16 with cefiderocol against cefiderocol-resistant *Escherichia coli*** *I. Bourdalis* (Paris, France), E. O Van Den Daele, I. El Meouche, S. Magreault, M.C. Verdier, F. Guerin, A. Jousset, A. Birgy, B. Fantin, V. Cattoir, V. De Lastours*

E0266 **17:21** **Pharmacodynamic evaluation of aztreonam/avibactam and aztreonam plus ceftazidime/avibactam against clinical *Stenotrophomonas maltophilia* isolates in hollow fibre infection models** *C. Wu* (Lexington, United States), A. Kunz Coyne, R. Gray, P. Gonnabathula, E. May*

E0267 **17:27** **Microdialysis Assessment of Gentamicin for Second-Line Antimicrobial Prophylaxis in Abdominal Surgery** *Q. Saint-Genis* (Poitiers, France), S. Marchand, A. Chauzy, H. Mirfendereski, N. Gregoire, M. Boisson*

E0268 **17:33** **Population pharmacokinetic model of ceftolozane/tazobactam and ceftazidime/avibactam in plasma and ELF administered by continuous infusion in ICU patients with nosocomial pneumonia: are the standard doses adequate?** *S. Luque Pardos* (Barcelona, Spain), S. Luque, A. Benítez-Cano, A. Araiz, I. Ramos, R. Adalia, E. Navarrete, J.P. Horcajada, M. Montero, J. Gomez-Junyent, R. Barquin, A. Juanes, J. Roberts, L. Sorli*

E0269 **17:39** **Long-acting antibiotics in osteoarticular infections: clinical outcomes and the role of therapeutic drug monitoring and serum bactericidal titre** *F. Petrucci* (Rome, Italy), G. Iaiani, D. De Meo, A. Lesina, M. Rivano Capparuccia, C. Luceri, A. Lorusso, B.M. Goffredo, S. Cairoli, M. Raponi, F. Sacco, C.M. Mastroianni, A. Oliva*

E0270 **17:45** **PK/PD-based optimisation of temocillin dosing for the treatment of complicated urinary tract infections in non-ICU patients according to their renal function** *J. Ermtraud* (Hamburg, Germany), G.J. Wijnant, S. Vervaeke, W. Follens, L. Dedeene, L. Goeman, G. Devos, M. Boeykens, V. Miendjedeyi, A. Reschner, C. Necsoi, D. Konopnicki, S. Vandecasteele, V. Grootaert, F. Van Bambeke, S.G. Wicha*

E0271 **17:51** **Daptomycin levels in vancomycin-resistant Enterococcus bloodstream infections (DELIVRE-BSI)** *K. Cairns* (Melbourne, Australia), Z.X. Mun, A.A. Udy, T.N. Peel, M.J. Dooley, J. Coutsouvelis, S. Patil, B. Mcwhinney, C.B. Landersdorfer, A.Y. Peleg*

E0272 **17:57** **Adapting meropenem administration to the constraints of home nursing care for OPAT: PK/PD evaluation of a new regimen for the administration of 2g 3x/day in non-critically ill patients** *F. Van Bambeke* (Brussels, Belgium), C. Briquet, P. Ngougni Pokem, X. Liu, G.J. Wijnant, O. Cornu, H. Yildiz, A. Verroken, J.A. Roberts, J.C. Yombi*

E0273 **18:03** **Piperacillin/tazobactam and meropenem exposure–outcomes relationship in patients with Gram-negative sepsis: results from the BLING III PK/PD sub-study** *J. Roberts* (Brisbane, Australia)*

EW080 **08:30 – 10:30** **Hall A2-2**

AMR PHEI

2-hour Educational Session

Modelling approaches to estimate and predict the burden of AMR

Chairs *Anna Both (Hamburg, Germany)*
Tomislav Mestrovic (Varaždin, Croatia)

W0307 **08:30** **Methodological approach and pressing data need to model the burden of AMR** *Mohsen Naghavi (Seattle, United States)*

W0308 **08:50** **A comprehensive approach to estimate the AMR burden using IHME data** *Gisela Robles Aguilar (Oxford, United Kingdom)*

W0309 **09:10** **Expanding use of AMR burden data to influence policy and practice - the experience of the Fleming Fund** *Toby Joseph Leslie (London, United Kingdom)*

W0310 **09:30** **Interventions to improve targeted access to effective antibiotics** *Ert Kalanxhi (Washington, United States)*

Co-organised with: ESCMID AMR Action Subcommittee

EW079 **08:30 – 10:30** **Hall B0-2**

CLN DX PHEI

2-hour Educational Session

Europe's overlooked threat: the rise of zoonotic hepatitis E

Chairs *Gülşen Özkaya Şahin (Lund, Sweden)*
Sumit Kumar Rawat (Sagar, India)

W0303 **08:30** **Zoonotic hepatitis E reservoirs and transmission in Europe from a One Health perspective** *Hao Wang (Gothenburg, Sweden)*

W0304 **08:50** **When the liver is just the beginning: a zoonotic journey beyond the liver** *Yasemin Balaban (Ankara, Türkiye)*

W0305 **09:10** **Epidemiological features of hepatitis E virus infection in Sub-Saharan Africa** *Richard Njouom (Yaounde, Cameroon)*

W0306 **09:30** **The rise of rat HEV: a new zoonotic herpevirus** *Antonio Rivero-Juarez (Córdoba, Spain)*

Co-organised with: ESCMID Study Group for Veterinary Microbiology (ESGVM), ESCMID Study Group for Viral Hepatitis (ESGVH), Study Group of Viral Hepatitis of the Spanish Society of Infectious Diseases and Clinical Microbiology, Turkish Association for the Study of the Liver (TKAD), Society on Liver Diseases in Africa (SOLDA)

EW078 **08:30 – 10:30** **Hall ICM 1**

CLN

2-hour Educational Session

Duration of IV antibiotics in older adults for various infections

Chairs *Efthymia Giannitsioti (Athens, Greece)*
Jordi Rello (Barcelona, Spain)

W0299 **08:30** **Duration of therapy and oral switch for Gram-positive bacteraemia** *Giusy Tiseo (Pisa, Italy)*

W0300 **08:50** **Duration of therapy and oral switch for mycobacterial and nocardial infections** *Ili Margalit (Ramat Gan, Israel)*

W0301 **09:10** **Duration of therapy, suppressive therapy and oral switch for endovascular infections** *Barbara Hasse (Zurich, Switzerland)*

W0302 **09:30** **Duration of therapy, suppressive therapy and oral switch for orthopaedic infections** *Marjan Wouthuyzen-Bakker (Groningen, The Netherlands)*

Co-organised with: ESCMID Study Group for Infections in the Elderly (ESGIE)

OS039 **08:30 – 10:30** **Hall A3-1**

CLN DX TRN

2-hour Oral Session

Sepsis at the frontline: diagnosis, therapy, and outcome in critical care

Chairs *Despoina Koulenti (London, United Kingdom)*
Tim Rahmel (Bochum, Germany)

O0274 **08:30** **Real-world longitudinal validation of high-income-**

country-derived sepsis endotypes in Sub-Saharan Africa: a nested prospective multi-centre study *O. Turgman** (*Amsterdam, The Netherlands*), *J. Butler, P. Haguma, S. Nyesiga, J. Phulusa, L. Carey, J. Rylance, T. Van Der Poll, J. Wiersinga, S. Jacob*

O0275 **08:42** **ARMOR-BSI: a nationwide analysis of the incidence and risk factors of ICU-acquired bloodstream infections in a multidrug-resistant organisms endemic country** *C. Genovese** (*Milan, Italy*), *M. Offer, E. Palomba, G. Scaglione, F. Dore, G. Montrucchio, G. Monti, B. Viaggi, A. Gori, S. Finazzi, M. Colaneri*

O0276 **08:54** **Multi-centre quality improvement intervention to optimise blood culture use among adults in medical intensive care units and wards at four university hospitals** *V. Fabre** (*Baltimore, United States*), *Y.J. Hsu, A. Xie, A. Salinas, E. Gettler, J.K. Johnson, R. Moehring, A. Ressler, G. Rodriguez-Nava, J. Salinas, G. Schrank, A. Wasylyshyn, S. Cosgrove*

O0277 **09:06** **Diagnostic efficacy and impacts on antibiotic use of digital droplet PCR in patients with suspected sepsis: the PROGRESS randomised, open-labeled, multi-centre trial** *X. Xu** (*Shanghai, China*), *H. Zhang, K. Lin, J. Ai, R. Wang, W. Zhang*

O0278 **09:18** **Early targeted therapy guided by rapid phenotypic antimicrobial susceptibility testing in critically ill patients with Gram-negative bloodstream infections: a case-control study** *R. Morena** (*Catanzaro, Italy*), *S. Rotundo, A. Russo, E. Garofalo, H.L. Morrone, G. Mazza, G. Neri, N. Marascio, A. Bruni, G. Matera, A. Quirino, F. Serapide*

O0279 **09:30** **Differential expression of miRNAs involved in shock are able to characterise mortality** *I. Rebollo Mato** (*Valladolid, Spain*), *A. García Concejo, L. Polo Sánchez, R.D. Prieto Utrera, P.J. Martínez De Paz, M. Álvarez Bardón, J. Matesanz Isabel, H. Gonzalo Benito, R.M. Cobo Zubia, E. Gómez Sánchez, M. Martín Fernández, E. Tamayo Gómez*

O0280 **09:42** **High-dose vs standard-dose intermittent meropenem in critically ill patients: an observational cohort study** *F. Bergmann** (*Vienna, Austria*), *M. Prager, L. Pracher, K. Kumpf, M. Zeitlinger, A. Jorda*

O0281 **09:54** **Impact of appropriateness and type of empirical antibiotic therapy on outcomes of intensive care unit patients with bacteraemia by carbapenem-resistant *A. baumannii*** *S. Karakonstantis** (*Heraklion, Greece*), *E. Kritsotakis, E. Petrakis, N.R. Tziolos, D. Kypraiou, S. Papazisi, S. Anagnostou, E. Kondili, D. Kofteridis*

O0282 **10:06** **Therapeutic approaches and predictors of mortality in colistin-resistant *Klebsiella* bloodstream infections: a real-world study** *N. Korkmaz** (*Ankara, Türkiye*), *G.Ç. Şentürk, F. Aycan, G. Kul, B. Güldoğan, H.M. Yılmaz, F.Z. Şahin, H. Ertekin, A.H. Solay, S. Kuzi, D. Bulut, E.E. Tütüncü*

O0283 **10:18** **Mortality attributable to mismatch with *in vitro* susceptibility of empirical antibiotics in patients with bacterial bloodstream infections** *G.K. Zheng** (*Hong Kong, Hong Kong*), *W. Zhang, J. Blais, P. Wu, B. Cowling*

OS040 **Hall A3-2**

08:30 – 10:30

2-hour Oral Session

ANT TRN

Expanding the antimicrobial arsenal: from dual-action compounds to predictive AI

Chairs *Shampa Das* (*Liverpool, United Kingdom*)
Markus Zeitlinger (*Vienna, Austria*)

O0284 **08:30** **3A11, an antibacterial molecule that reveals a dual mechanism of action** *A. Jouault** (*Rennes, France*), *B. Durand, N. Amiot, S. Ray, V. Bordeau, Y. Augagneur, G. Lina, V. Cattoir*

O0285 **08:42** ***In vitro* activity of a new antibiotic derivative of the lactivicin class, FPI-2119, tested against a challenge set of multidrug-resistant Enterobacterales clinical isolates** *R. Mendes** (*North Liberty, United States*), *G. Morgan, R. Jankowska, Y. Edah, R. Brieanna, S. Charbon, S. Salama*

O0286 **08:54** **Antimicrobial activity of short ionic peptides is defined by fibre architecture, not charge** *N. Dad** (*Manchester, United Kingdom*), *G. Humphreys, A. Pluen, M. Elsawy, A. Mcbain*

O0287 **09:06** **OMN6: a novel antimicrobial peptide demonstrating LPS sequestration and *in vivo* efficacy in LPS-induced sepsis model** *N. Bachnoff** (*Jerusalem, Israel*), *O. Heyman, O. Mayost Lev-Ari, N. Nur Maymon, S. Mandel, J. Zazoun, A. Ben Dror, T. Shachar, M. Cohen-Kutner*

O0288 **09:18** **Augmenting cytotoxicity of pathogen-specific antibodies that initiate complement activation independent of the classical pathway against *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Streptococcus pneumoniae*, and *Neisseria meningitidis*** *T. Walsh** (*Richmond, United States*), *Y.M. Ali, M. Yabuki, C. Arachchilage, K. Priyanka, N.J. Lynch, S. Bruchmann, A. Weimann, K. Brown, R.A. Floto, J. Parhill, D.E. Briles, L.S. Macdaniel, H. Utsugi, G. Gragerova, R. Petraitiene, V. Petraitis, A. Misquith, C. Doulami, G. Demopulos, W. Schwaeble*

O0289 **09:30** **Chalcone-based scaffolds as promising antibacterial agents against clinical *Staphylococcus aureus* strains** *A. Israyilova** (*Baku, Azerbaijan*), *M. Uygun, N. Atac, A. Huseynzada, K. Shahverdiyeva, F. Can, U. Hasanova*

O0290 **09:42** **Fighting Carbapenem-resistant *Klebsiella pneumoniae* (CR-Kp): mechanistic insights into a novel metal-based complex** *R. Almeida** (*Oeiras, Portugal*), *N.A. Faria, B. Royo, O. Lenis-Rojas, M. Miragaia*

O0291 **09:54** **Reviving antibiotic potency: pharmacological assessment of JS238 a newly designed potentiator against *P. aeruginosa*** *P. Rasouli** (*Brussels, Belgium*), *J.M. Brunel, H. Rodriguez-Villalobos, J.H. Lorent, F. Van Bambeke*

O0293 **10:18** **A hypergraph neural-network framework for predicting synergistic and antagonistic antimicrobial combinations: a triplet-based approach integrating antimicrobial peptides, antibiotics, and bacterial taxonomy** *A. Khavaran** (*Philadelphia, United States*), *F. Midjani, M. Malekpour, A.H. Rajabi, F.Z. Keshtkar, F. Golabi, A. Abbasi, M. Farhadi, B. Khosravi, A. Amanati*

SY077 **Hall A2-1**

08:30 – 10:30

2-hour Symposium

AMR PHEI

Antimicrobial resistance on the menu: global risks across the food chain

Chairs *Yesim Besli* (*Istanbul, Türkiye*)
Merica Carev (*Split, Croatia*)

S0295 **08:30** **Global risk mapping of XDR Typhoid: from genomic insights to possible threats** *Megan Carey* (*Amsterdam, The Netherlands*)

S0296 **09:00** **Global resistance trend of *Campylobacter*, predictive modelling and novel intervention strategies** *Bruno Lopes* (*Middlesbrough, United Kingdom*)

S0297 **09:30** **Exploring the rise of AMR in invasive NTS: mechanisms, mobility, and global trends** *Sandra Van Puyvelde* (*Wilrijk, Belgium*)

S0298 **10:00** **Silent spreaders: tracking carbapenemase-producing Enterobacterales in the food chain** *Valeria Bortolaia* (*Copenhagen, Denmark*)

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

SY076 **Hall B0-1**

08:30 – 10:30

2-hour Symposium

CLN TRN VAX

What drugs are missing? Exploring adjuvant therapies in immunosuppressed patients

Chairs *Effrossyni Gkrania-Klotsas* (*Cambridge, United Kingdom*)
Nina Khanna (*Basel, Switzerland*)

S0291 **08:30** **Immunotherapy meets infection: the case for host-directed treatment strategies** *Patrizia Comoli* (*Pavia, Italy*)

S0292 **09:00** **Too little or too much? Balancing immune modulation in transplant and oncology patients** *Carlota Gudiol* (*Barcelona, Spain*)

S0293 **09:30** **Adjuvant therapies in practice: lessons from mycobacteria** *Graeme Ayton Meintjes* (*Observatory, South Africa*)

S0294 10:00 **What drugs are missing? Unmet needs and promising directions in the immunocompromised host** *Michael Boeckh* (*Seattle, United States*)

SY073 **Hall ICM 13a**

08:30 – 10:30

AMR PHEI VAX

2-hour Symposium

Infections with no borders: challenges in South and Central-Eastern Europe in the context of travel, migration and war

Chairs *Marco Falcone* (*Pisa, Italy*)
Christian Wejse (*Aarhus, Denmark*)

S0279 08:30 **Epidemiology and burden of imported travel related infectious diseases in the CEE region** *Botond Lakatos* (*Budapest, Hungary*)

S0280 09:00 **The impact of armed conflicts and migration on antimicrobial resistance** *Vodianyk Arkadii* (*Kyiv, Ukraine*)

S0281 09:30 **Leishmaniasis outbreaks in conflict zones** *Aula Abbara* (*London, United Kingdom*)

S0282 10:00 **"Threat of spread": vaccine preventable diseases in the CEE region** *Simona Ruta* (*Bucharest, Romania*)

Co-organised with: ESCMID Study Group for Infections in Travellers and Migrants (ESGITM), Hungarian Society of Infectious Diseases and Clinical Microbiology, International Society of Antimicrobial Chemotherapy (ISAC), ESCMID Study Group for Epidemiological Markers (ESGEM)

SY074 **Hall ICM 13b**

08:30 – 10:30

PHEI

2-hour Symposium

The rise of tick-borne diseases: why are things changing?

Chairs *Sally Jane Cutler* (*London, United Kingdom*)
Alice Raffetin (*Villeneuve-Saint-Georges, France*)

S0283 08:30 **Urban green spaces, fragmented forests and the transmission of tick-borne pathogens** *Olaf Kahl* (*Berlin, Germany*)

S0284 09:00 **Automated classification of disease vectors** *Rodrigo Gurgel-Gonçalves* (*Brasília, Brazil*)

S0285 09:30 **Hitching a ride: role of migratory birds in transferring ticks to new habitats** *Ilaria Pascucci* (*Pesaro, Italy*)

S0286 10:00 **'Seek and thou shall find': harnessing the power of citizen science** *Éva S. Szabó* (*Budapest, Hungary*)

Co-organised with: ESCMID Study Group for Lyme Borreliosis (ESGBOR)

SY075 **Hall ICM 5**

08:30 – 10:30

AMR IPC PED

2-hour Symposium

Protecting the most vulnerable: infection prevention in neonatal and paediatric critical care

Chairs *Bianca Albers* (*Zurich, Switzerland*)
Angelika Berger (*Vienna, Austria*)

S0287 08:30 **Biofilm related infections in children** *Ojan Assadian* (*Wiener Neustadt, Austria*)

S0288 09:00 **Multidrug-resistant infections in the neonatal and paediatric ICU: how can we prevent outbreaks?** *Pablo Sanchez* (*Columbus, Ohio, United States*)

S0289 09:30 **Surveillance and stewardship in the NICU/PICU: what works and what doesn't?** *Julia Anna Bielicki* (*London, United Kingdom*)

S0290 10:00 **Neonatal skin, device, and environmental hygiene: how to translate evidence into practice?** *Andreas F. Widmer* (*Füllinsdorf, Switzerland*)

EF041 **Arena 2**

08:30 – 09:30

CLN

ePoster Flash Session

Short- and long-term consequences of viral infections

Chair *Bettie Voordouw* (*Culemborg, The Netherlands*)

E0294 08:30 **Breath-based volatile organic compound signatures for long COVID identification: a machine learning approach for differential diagnosis** *P. Esteban Sánchez** (*Zaragoza, Spain*), *S. Letona, M.P. Domingo, D. Recalde, E. Morte, G. Pellejero, A. Ramirez, R. Sanz-Pamplona, J. Pardo, J.R. Paño, E. Del Corral Beamonte, E.M. Gálvez*

E0295 08:36 **Time-stratified, variant-specific risks of major adverse cardiovascular events following COVID-19 across α-omicron variants: a nationwide matched cohort study in Japan** *K. Ikeuchi** (*Tokyo, Japan*), *S. Harada, R. Sekiya, Y. Arisato, S. Matsumoto, T. Kishida, A. Kado, K. Okushin, H. Yotsuyanagi, T. Tsutsumi*

E0296 08:42 **Metformin and ursodeoxycholic acid for the treatment of post-acute sequelae of COVID-19: a randomised clinical trial** *S.Y. Lim** (*Seoul, Korea, Republic of*), *J. Lee, E. Chang, J.S. Kwon, C.Y. Jang, Y. Seo, J.J. Park, S.H. Na, H. Park, H.M. Jang, S.C. Yun, S.H. Kim*

E0297 08:48 **T cell exhaustion and gut microbiota in HIV/SARS-CoV-2 co-infection** *X. Yan** (*Shanghai, China*), *X. Zhang, Y. Shen*

E0298 08:54 **Maternal and fetal outcomes of Crimean-Congo haemorrhagic fever in pregnancy: an individual patient data meta-analysis** *D. Güllü** (*Istanbul, Türkiye*), *B. Donk, A.M. Cırık, H. Alay, F. Karakeçili, K. Özden, F. Kesmez Can, O. Barkay, N. Pshenichnaya, Ö. Ergönül*

E0299 09:00 **Myocarditis in chikungunya virus infection: a systematic review and meta-analysis** *S. Shah** (*Kathmandu, Nepal*)

E0300 09:06 **Predictors and clinical spectrum of long-term sequelae after tick-borne encephalitis: results of a prospective multi-centre cohort study** *M. Slížek** (*Prague, Czechia*), *D. Smíšková, O. Džupová, L. Chovanec, V. Pražák, A. Chrdle, K. Pohludková, L. Petroušová, J. Sečník*

E0301 09:12 **Epidemiological, clinical, and virological findings in 1600 patients with West Nile virus infection, Northern Italy, 2008–2025** *L. Barzon** (*Padua, Italy*), *M. Pacenti, S. Vogiatzis, C. Lucca, E. Dal Molin, A. Sinigaglia, A. Giaretta, V. Lisi, S. Simonato, S. Satto, J. Rampazzo, C. Boldrin, M. Cattai*

E0302 09:18 **Mpox-related ocular disease: a prospective cohort study in South-Kivu, Democratic Republic of Congo** *C. Van Dijck** (*Antwerp, Belgium*), *T. Kabesha, S. Mudwanga, S. Houben, Y. Mujula Kanundey, P. Munganga, S. Yeh, N. Kabedi, V. Nussenblatt, O. Tshiani Mbaya, I. Crozier, S. Sabiti Nundu, J. Kindrachuk, P. Mbala Kingebeni, L. Liesenborghs*

EF042 **Arena 3**

08:30 – 09:30

DX PED TRN

ePoster Flash Session

How viral and host genomics shape infection and immune response

Chair *Victoria Hall* (*Melbourne, Australia*)

E0303 08:30 **Distinct antigenic signatures and neutralising antibody responses following MVA-BN vaccination and monkeypox virus infection** *U.M. Chan** (*Taipei, Taiwan*), *T.L. Chao, W.D. Liu, C.C. Hung, S.Y. Chang*

E0304 08:36 **NGS sequencing with application of different methods and phylogenetic analyses in MPXV positive samples in Berlin 2022 to 2025** *R. Ehret** (*Berlin, Germany*), *Ö. Yildirim, M. Lautner, M. Prentice, M. Obermeier*

E0305 08:42 **Emerging human spillovers of H5N1: viral adaptations and pandemic preparedness** *J. Acosta España** (*Quito, Ecuador*), *J.D. Acosta-España, J.B. Altamirano-Jara, D.K. Bonilla-Aldana, A. Rodríguez-Morales*

E0306 08:48 **Clinical significance of viral DNA findings by mNGS in a large cohort of patients** *T. Schroeder** (*Nuertingen, Germany*), *J. Baake, M. Eliwi Alsaffan, A. Dervishi, P. Kawaletz, H. Stäudle*

E0309 09:06 **Acute hepatitis of unknown origin in the paediatric population: clinical, virological and genetic characterisation in a prospective case series** *D. Henares Bonilla** (*Pallejà, Spain*), *D. Henares, A. Avellon, I. Loverdos, M. Pons-Espinal, M. Muñoz-Chimeno, A. Garcia-Soler, E. Ruiz De Pedro, C. Molera, P. Brotons, M.F. De Sevilla, J. Martinez-Laso, C. Muñoz-Almagro*

E0310 **09:12** **From pol to whole genome: advancing HIV drug resistance testing** *F. Stefanelli* (Genoa, Italy), N. Randazzo, G. Guarona, B. Galano, S. Ferrari, R. Qosja, A. Di Biagio, A. Domnich, N. Nigro, B. Bruzzone*

EF043 **09:30 – 10:30** **Arena 1**

IPC PHEI

ePoster Flash Session

Tracking respiratory virus outbreaks in a changing world: from hospitals to wastewater

Chair *Magdalena Rosińska (Warsaw, Poland)*

E0312 **09:30** **Comparing COVID-19, influenza, and RSV positivity from a longitudinal cohort with US national surveillance data** *D. Nash* (New York, United States), M.S. Rane, K. Penrose, K.E. Allen, F.R. Ernst, A. Srivastava, Y. Shen, M.M. Robertson, J. Zamparo, S.G. Kulkarni, L. Puzniak*

E0314 **09:36** **Hospitalisation and healthcare consumption burden of respiratory syncytial virus (RSV) in older adults in France** *M. Vacheret* (Paris, France), S. Fievez, E. Blanc, L. Watier, L. Baschet, C. Bignon-Favary, P. Mckelvie-Sebileau, P. Loubet*

E0315 **09:42** **Incidence of human metapneumovirus (hMPV) and respiratory syncytial virus (RSV) among adults 50 years and older in the outpatient setting in the US: interim results from the ARIA study** *M. Schmidt* (POrtland, Or, United States), H. Groom, N. Smith, J. Meece, R. Mularski, W. Hu, M. O'keeffe-Rosetti, N. Klein, K. Jacobson, C. Oxandale, A. Wiesner, L. Glasser, S. Venkatesan, C. Talarico, J. Kuntz*

E0316 **09:48** **Using latent class analysis to improve classification of nosocomial SARS-CoV-2 infections in Ontario, Canada** *N. Wilson* (Toronto, Canada), C.E. Lee, D. Fisman*

E0318 **09:54** **Self-testing for five respiratory viruses in adults =50 years of age in Germany for longitudinal monitoring of community-acquired acute respiratory infections** *J.A. Nacov* (Cologne, Germany), J. Salmanton-García, J. Jakobs, M. Anggitakirana, S. Grimm, J. Leckler, K. Köbe, L. Cremer, P. Wipfler, J. Stemler, H.J. Schmitt, U. Bethe, O. Cornely*

E0319 **10:00** **Comparison of emergency department indoor air and citywide wastewater for respiratory and enteric virus surveillance using hybrid-capture viral metagenomics** *M. Karatas* (Leuven, Belgium), S. Gorissen, C. Geenen, J. Swinnen, E. Hosten, K. Van Dyck, L. Cuypers, M. Bloemen, E. Wollants, M. Van Ranst, B. Verschueren, M. Sabbe, J. Matthjnssens, E. André*

E0320 **10:06** **Detection of SARS-CoV-2 variants of concern in Swiss wastewater without prior lineage classification** *R. Kociurzynski* (Freiburg, Germany), T. Donker*

KN081 **09:30 – 10:30** **Hall ICM 14**

DX PHEI VAX

Keynote Scientific Interview

Integrating technology and capacity building to strengthen disease surveillance and prevention in low-resource settings

Chair *Jon S. Friedland (London, United Kingdom)*

K0311 **09:30** *Senjuti Saha (Dhaka, Bangladesh)*

OS044 **11:00 – 12:00** **Hall A1-1**

TRN

1-hour Oral Session

Mechanisms of pathogenesis across different pathogens

Chairs *Elisa Borghi (Milan, Italy)*
Anna Norrby-Teglund (Stockholm, Sweden)

O0321 **11:00** **A systems serology approach to identify antibodies to PfEMP1 that correlate with protection from paediatric cerebral malaria in Malawi** *P. Banda* (Blantyre, Malawi), I. Walker, C. Juwawo, W. Hasang, D. Mathanga, T. Taylor, T. Nyirenda, E. Aitken, S. Rogerson, K. Seydel*

O0322 **11:12** **Wzi modulates immune evasion of hypervirulent *Klebsiella pneumoniae* in a CPS-dependent and independent manner** *K. Zhou* (Shenzhen, China), S. Wei, T. Xu*

O0323 **11:24** **Binding of host glycans and vitronectin drive *Neisseria gonorrhoeae* pathogenesis and reveal potential vaccine targets** *E. Macdonald* (Bristol, United Kingdom), S. Savino, W. Pansegrau, D. Hill*

O0324 **11:36** **A 3D-Bioprinted human skin model to study *Candida* colonisation and species-dependent phenotypes** *M. Cacaci* (Rome, Italy), D. Squitieri, G. Artemi, F. Bugli, R. Torelli, M. Papi, V. Palmieri, A. Augello, C. Perfili, M. De Spirito, R. Benvenuto, E. Stigliano, E. Benini, P. Fazi, M. Sanguinetti*

O0325 **11:48** **Host-specific platelet-activating factor acetylhydrolase selectively remodels diacylglycerophospholipids to control schistosome development** *F.U. Prodjinotho* (Munich, Germany), J. Ertl, Z. Rao, A. Anisuzzaman, J. Schluckebier, Y. Hamway, P. Baar, M. Haslbeck, C.G. Grevelding, S. Haeberlein, F.H. Falcone, S. Schulz, A. Koeberle, C. Prazeres Da Costa*

OS045 **11:00 – 12:00** **Hall A1-3**

CLN VAX

1-hour Oral Session

Invasive fungal infections: therapeutic strategies and emerging options

Chairs *Oliver A. Cornely (Cologne, Germany)*
Cornelia Lass-Flörl (Innsbruck, Austria)

O0326 **11:00** **Invasive Aspergillosis in Chronic Lymphocytic Leukemia: Case-Control Study** *B.S. Bisono Garcia* (Rochester, United States), K.G. Rabe, S.A. Parikh, P. Vergidis*

O0327 **11:12** **Olorofim for the treatment of invasive *Aspergillus* in haematology patients with limited or no treatment options: sub-analysis of an open-label, single-arm, phase IIb trial (Study32; NCT03583164)** *J. Maertens* (Leuven, Belgium), S. Hammond, G. Rahav, A. Bruns, O. Uspenskaya, M. Chayakulkeeree, V. Mehra, A. Spec, J.M. Aguado, J. Fortun, C. Heath, M.H. Nguyen, J. Schaenman, S. Schwartz, M. Miceli, M. Moussa, O. Marin Fernandez, D. Zinzi, J. Rex*

O0328 **11:24** **Fosmanogepix expanded access in patients with invasive mould infections from Germany, Austria, and Switzerland** *J. Stemler* (Cologne, Germany), J. Prattes, N. Khanna, H. Schlamm*

O0329 **11:36** **Immunisation against *Aspergillus* is associated to poor outcome and higher mortality in patients with idiopathic pulmonary fibrosis: The Asp-IPF study** *J.P. Gangneux* (Rennes, France), H. Guegan, F. Reizine, P. Chauvin, F. Robert-Gangneux, M. De Saint Jore, T. Guy, A. Mabo, Y. Bazin, M. Kerjouan, S. Jouneau*

O0330 **11:48** **Oteseconazole concentrations in plasma and CSF in HIV-related cryptococcal meningitis** *M. Nicol* (Minneapolis, United States), M. Rutakingirwa, M. Kabahubya, T. Mugabi, J. Gakuru, S. Namombwe, F. Ssekindi, S. Kimuda, C.P. Skipper, M. Abassi, S.R. Brand, D.B. Meya, D.R. Boulware*

OS046 **11:00 – 12:00** **Hall A1-4**

CLN TRN

1-hour Oral Session

Translational science in mycobacterial infections

Chairs *Deborah Chong (London, United Kingdom)*
Delia Goletti (Rome, Italy)

O0331 **11:00** **Increased cAMP levels compromise cell wall integrity by promoting the production of reactive oxygen species in *Mycobacterium tuberculosis*** *Y. Li* (Guangzhou, China), J. Wan, X. Xia, X. Deng, G. Tian, L. Zhong, S. Feng*

O0332 **11:12** **Spatial single-cell transcriptomic analysis reveals elevated platelet-neutrophil interaction and platelet-derived MMP-1 secretion in human CNS-TB granulomas** *Y.H. Wong* (Singapore, Singapore), H. Lee, F.K. Loh, B. Chen, T.H. Hu, H.T. Chong, C.L. Tan, A.F. Vallejo, C.W.M. Ong*

O0333 **11:24** **Characterisation and genetic engineering of a novel mycobacteriophage for therapeutic use** *A. Bonacorsi* (Pisa, Italy), A. Fusco, D. Manessi, F. Filippini, G.*

Delogu, I. Palucci, M. Lai, G. Freer, S. Dominici, F. Pratesi, G. Hatfull, A. Tavanti, L. Rindi, M. Di Luca

O0334 **11:36** **BCG vaccination induces partial NK cell tolerance in people with HIV-1 on suppressive ART** *C. Dollé* (Zurich, Switzerland), T. Tutumlu, D. Russenberger, M. Zeeb, E. West, D. Braun, H. Günthard, J. Nemeth*

O0335 **11:48** **Persister cells are highly prevalent across *Mycobacterium abscessus* clinical isolates** *L. Geerts* (Wilrijk, Belgium), L. De Vooght, G.J. Wijnant, E. André, N. Lorent, P. Cos*

OS047 **11:00 – 12:00** **Hall A1-5**

1-hour Oral Session

CLN DX

Diagnosing respiratory infections: from PCR to metagenomics

Chairs *Gilbert Greub (Lausanne, Switzerland)*
Qiwen Yang (Beijing, China)

O0336 **11:00** **Machine learning-driven daily VAP risk stratification for real-time ICU decision support** *Y. Fromage* (Limoges, France), A. Hernandez Padilla, J. Vaidie, H. Sayadi, A. Barac, O. Cremer, D. Garot, A. Rouzé, T. Daix, L. Vintcent, H. Jackson, M. De Karker, H. Van Werkhoven, J.B. Woillard, B. François*

O0337 **11:12** **Novel thermo-induced switching probes enable dual-target detection per fluorescence channel for seven respiratory viral targets in a one-tube multiplex PCR assay** *J. Lee* (Jeonju, Korea, Republic of), J. Yoon, H. Kim*

O0338 **11:24** **The first national EQA for clinical metagenomics: design, delivery and results** *A. Alcolea Medina* (London, United Kingdom), L.B. Snell, R. Doyle, V. Patel, R. Chang, M. Gumbanmarasigan, V. Vorslava, B. Leta, D. Ward, J. Brown, A. Kopec, S. Rock, M. Valappil, K. Laws, S. Parmar, S. May, P. Patel, M. Ibrahim, S. Green, K. Saeed, N. Norton, C. Reid, A. Every, A. Hughes, A. Kottara, K. Nelson, B. Browne, P. Grant, G. Nebbia, R. Batra, J. Edgeworth, A. Alcolea-Medina*

O0339 **11:36** **Whole genome sequencing of *Mycoplasma pneumoniae* directly from clinical samples using a novel target sequence capture probe panel** *C. Dixon* (Cardiff, United Kingdom), N. Couto, M. Ramirez, R. Mamede, H. Milton, M. Maiwald, C. Moore, S. Sidorov, J. Flipse, R. Nir-Paz, A. Michael-Gayego, J. Moran-Gilad, D. Kese, G. Greub, P.M. Meyer Sauteur, M.L. Beeton*

OS048 **11:00 – 12:00** **Hall A2-1**

1-hour Oral Session

PHEI

Field investigations of community-acquired infections

Chairs *Aula Abbara (London, United Kingdom)*
Steen Ethelberg (Copenhagen, Denmark)

O0341 **11:00** **Rapid deployment of a large epidemiological investigation: lessons learnt from a mains water outbreak of *Cryptosporidium parvum*, South West UK, 2024** *P. Charlotte* (London, United Kingdom), C. Patterson, B. Winer, M. Bardsley, F. Halford, S. Bird, N. Verlander, R. Chalmers, E. Smout, R. Kwiatowska, N. Young*

O0342 **11:12** **A national iatrogenic botulism outbreak associated with cosmetic procedures in England, 2025** *V. Wong* (London, United Kingdom), S. Gokool, D. Rajendram, B. Ahmed, R. Pebody, I. Hayden, G. Godbole*

O0343 **11:24** **Fatal respiratory diphtheria and genomic analysis of Corynebacterium diphtheriae ST-574 outbreak, Germany and Poland, 2022–2025** *I. Roewer De Porto* (Berlin, Germany), A. Dangel, L. Schneider, A.A. Zasada, J. Haller, I. Abdelgawad, C. Siffczyk, I. Paradowska-Stankiewicz, O. Wichmann, F. Badenschier, A. Berger, C. Rau, A. Sing*

O0344 **11:36** **Epidemiological characteristics and outcomes of the 2023–2024 cholera outbreak in South Yemen: a retrospective descriptive study from MSF-supported centres** *M. Kassim* (Aden, Yemen), M. Sallam, N.O. Abdulgany, A.M. Farhan, M. Shomasi, A. Abdulhaq, U.Z. Khan, D. Dela Cruz-Diaz, H. De Clerck, S. Lim, K. Moussally, P. Garcia-Vello*

O0345 **11:48** **Echoes of *Vibrio*: seasonal context variables, microbial signatures, and critical illness in cholera infections** *P. Thummalagunta* (Mangalagiri, India), M. Kumar A, D. Debabrata, C.N. Chithra, H. G, S.V. Kutty, R. Upparakadiyala, A. Rajeev*

OS049 **11:00 – 12:00** **Hall A2-2**

1-hour Oral Session

ANT CLN PHEI

From silent malaria infections to severe disease in a globalised world

Chair *Emmanuel Bottieau (Antwerp, Belgium)*
TBA

O0346 **11:00** **Late treatment failures of artemisinin-based combination therapies in imported *Plasmodium falciparum* malaria in France (2013–2024): a case-control and genomic investigation** *S. Boufares* (Paris, France), R. Coppee, A. Cosson, N. Mathieuxx, S. Anthony, Z. Rizwana, S. Veronique, T. Nicolas, H. Sandrine*

O0347 **11:12** **Prevalence of truly asymptomatic malaria and its determinants in a high burden rural district in India: a community-based study from Uttar Pradesh** *R.S. Rath* (Gorakhpur, India), G.R. Dwivedi, H.S. Joshi, A. Singh, P. Kharya, N.M. Agarwal, M. Bisht, D. Upadhyaya, A.R. Koparkar, A.M. Dixit*

O0348 **11:24** **Outpatient management of imported non-severe malaria in the UK: a multi-site clinical safety evaluation** *J. Milburn* (London, United Kingdom), A. Williamson, S. Baljekar, R. Rachman, A. Daunt, N. Richardson, F. Olcott, C. Rodrigues, R. Thangarajah, S. Yeung, M. Arias, C. Jennings, A. Delmonte Sen, J.L. Klein, A. Odedra, N. Jacobs, C. Drapeau, C. Van Halsema, G. O'hara, A. Checkley*

O0349 **11:36** **Host and parasite biomarkers to trigger intravenous antimalarials and prioritise ICU admission in severe imported *Plasmodium falciparum* malaria patients** *D. Camprubí-Ferrer* (Barcelona, Spain), J. Pedreira-Rincon, C. Bertran-Cobo, M. Alguacil, L. Balerdi Sarasola, M.J. Alvarez-Martinez, J. Muñoz, C. Parolo, D. Camprubí Ferrer*

O0350 **11:48** **Whole genome sequencing to inform the epidemiology of *Plasmodium falciparum* malaria in the elimination setting of Malaysia** *K. Tan* (London, United Kingdom), N. Billows, P. Divis, C. Daneshvar, J. Edgeworth, J. Cox-Singh, S. Campino, T. Clark*

OS050 **11:00 – 12:00** **Hall A3-1**

1-hour Oral Session

AMR CLN PED

Personalised approaches to infectious diseases in high-risk haematologic and transplant patients

Chairs *Andreas H. Groll (Münster, Germany)*
Stefan Schwartz (Berlin, Germany)

O0351 **11:00** **The role of rectal swabs in driving empirical antibiotic therapy in febrile neutropenic patients: a quasi-experimental multi-centre study within the REVERSE project** *R. Scardellato* (Verona, Italy), M. Morra, M. Tebon, A.M. Azzini, M.C. Negulescu, A.L. Mohorea-Neata, A. Araújo, M.T. Pérez-Rodríguez, G. Nadali, C. Tecchio, A. Sonpar, J. Rodríguez-Baño, P. Retamar-Gentil, N. Zuabi Garcia, A. Hristea, C.M. Niculae, W. Zingg, E. Tacconelli, E. Carrara*

O0352 **11:12** **Antibiotic discontinuation in paediatric low-risk febrile neutropenia: a multi-centre randomised trial (eSTOP)** *N. Mendoza Palomar* (Barcelona, Spain), N. Mendoza-Palomar, L. Valero-Arrese, B. Espinosa-López, M. Sancosmed-Ron, N. Wörner, S. Melendo-Pérez, M.N. Larrosa-Escartín, M.B. Viñado-Pérez, J. Esperalba-Esquerra, S. Simó-Nebot, P. Mazorra-Roig, A. Faura-Morros, C. Grasa, P. Guerra-García, C. Echecopar-Parente, E. Cendejas-Bueno, B. Herrero-Velasco, D. Quintero-García, M.T. García-Ascaso, M. González-Amores, P. Soler-Palacín*

O0353 **11:24** **Efficacy and safety of peri-transplant probiotic supplementation among allogeneic stem cell transplant recipients: a phase IIb randomised controlled trial** *S. Selvakumar* (Vellore, Tamil Nadu, India), S. Selva Kumar, J.S. John, A. Arumugam, N. Veerasamy, S. Selvarajan, K. Lakshmi, B. George, P. Rupali*

O0354 11:36 **Quantitative assessment of associations between early antibacterial drug exposure and late infective and noninfective complications after allogeneic stem cell transplantation** *M. Yakubovsky* (Tel-Aviv, Israel), R. Ram, R. Ben-Ami*

O0355 11:48 **Infections after invasive biliary procedures in liver transplant recipients: a retrospective single-centre analysis** *A. Lombardi* (Milan, Italy), A. Tonizzo, L. Alagna, G.E. Tontini, M. Michelon, A. Murru, B. Antonelli, G. Viero, A. Celotti, S. Colombo, M. Sagasta, F. Lozio, C. Dibenedettto, V. Scaravilli, P. Lampertico, G. Grasselli, C. Quintini, F. Caprioli, A. Bandera*

LB003 **Hall B0-2**

11:00 – 12:00

ANT CLN **1-hour Oral Session**

Late-breaking antiviral drug trials

Chairs *Laurent Kaiser (Geneva, Switzerland)*
Marta Mora-Rillo (Madrid, Spain)

L0016 11:00 **Positive treatment response of pritelivir achieved in refractory HSV infections in immunocompromised patients, including haematopoietic stem cell and solid organ transplant recipients and oncology patients: PRIOH-1 phase III trial** *R. Chemaly* (Houston, United States), K. Peggs, D. Neofytos, K. Workowski, R. Avery, Y.J. Lee, R. Maves, O. Cornely, J. Stemler, D. Teschner, M. Yong, J. Sasadeusz, S. Dadwal, J. Dickter, A. Birkmann, C. Wat, D.C. Herath, A. Marini, B. Surujbally, M. Sumner, G.A. Papanicolaou*

L0017 11:12 **Implementing a controlled human infection model (CHIM) with a reverse genetics H3N2 (A/Texas/71/2017, clade 3C.3a) influenza challenge virus in healthy volunteers** *V. Cnossen* (Leiden, The Netherlands), G. Groeneveld, O. Engelhardt, J. Samolej, G. Piccini, S. Jochems, W. Huisman, T. Muster, M. Roestenberg, I. Kamerling*

L0018 11:24 **UMIT-1, Phase IB Trial: IV favipiravir and ribavirin for the treatment of CCHF** *I. Bozkurt* (Samsun, Türkiye), H. Bodur, M. Ertek, F. Altuntaş, N. Elaldi, G. İskender, D. Mert, Y. Cosgun, E. Beren Tanik, E. Challenger, C.R. Thompson, L. Read, L. Else, L. Marsh, S.A. Büyüktuna, H. Can Bilek, H. Karadeniz, H. Oksuzoglu, A. Haykır Solay, E. Türkoğlu, M. Arslan, A. Torun, S. Kulari, J. Read, C. Rawcliffe, M. Yıldız, S. Khoo, T. Fletcher*

L0019 11:36 **Long-term viral suppression, and cardiometabolic benefits of switch to ainuovirine coformulated with lamivudine, and tenofovir DF in virologically suppressed people with HIV-1: 144-week, open-label results from the SPRINT post-study** *H. Qin* (Yangzhou, China), Z. Jie*

L0020 11:40 **Rivaroxaban, colchicine and famotidine/loratadine with integrated clinical care for Long COVID, a multi-site, open-label randomised controlled trial** *E. Wall* (London, United Kingdom), G. Prescott, H. Dehbi, C. Watkins, M. Heightman, A. Banerjee*

SY086 **Hall A1-2**

11:00 – 12:00

AMR ANT CLN **1-hour Symposium**

Therapeutic management of carbapenem-resistant Gram-negative infections: where are we globally?

Chairs *Yin Mo (Singapore, Singapore)*
Pranita Tamma (Philadelphia, United States)

S0233 11:00 **Treating carbapenem-resistant Enterobacterales in HIC and LMIC** *Anupa Thampy (Vellore, Tamil Nadu, India)*

S0234 11:30 **Beyond Enterobacterales: advances in the management of carbapenem resistant non-fermenters** *Michele Bartoletti (Milan, Italy)*

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Critically Ill Patients (ESGCIP), European Society of Intensive Care Medicine

---

SY087 **Hall A3-2**

11:00 – 12:00

PED VAX **1-hour Symposium**

The role of the microbiota in vaccine response

Chairs *Zitta Barrella Harboe (Hillerød, Denmark)*
Ed J. Kuijper (Leiden, The Netherlands)

S0235 11:00 **The impact of intestinal microbiota on vaccine response** *Petra Zimmermann (Lucerne, Switzerland)*

S0236 11:30 **Early-life gut microbiome and infant vaccination** *Julie Bines (Parkville, Australia)*

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI), ESCMID Vaccine Study Group (EVASG)

SY083 **Hall ICM 1**

11:00 – 12:00

DX TRN **1-hour Symposium**

Can large language models (LLMs) transform clinical diagnostics from start to finish?

Chairs *Bram Lestrade (Roermond, The Netherlands)*
Mario Ramirez (Lisbon, Portugal)

S0227 11:00 **LLM validation and integration for AST** *Christian Giske (Stockholm, Sweden)*

S0228 11:30 **LLM models in clinical diagnostics: from lab results to patient care** *De Vito Andrea (Sassari, Italy)*

Co-organised with: ESCMID Study Group for AI and Digitalisation (ESGAID), Swiss Society for Microbiology (SSM)

SY084 **Hall ICM 13a**

11:00 – 12:00

PRO **1-hour Symposium**

Moving towards patient-centerd evidence in infectious diseases

Chairs *Colin R. Mackenzie (Neuss, Germany)*
Luigia Scudeller (Pavia, Italy)

S0229 11:00 **Can AI help us to incorporate the patients' perspective into clinical research and guidelines?** *Bernardo Sousa-Pinto (Porto, Portugal)*

S0230 11:30 **Our fight too: empowering patients against AMR** *Vanessa Carter (Altrincham, United Kingdom)*

Co-organised with: ESCMID Guidelines Subcommittee

SY085 **Hall ICM 13b**

11:00 – 12:00

CLN PED **1-hour Symposium**

Early-life respiratory infections and their association with chronic lung disease

Chairs *Susanna Esposito (Parma, Italy)*
Chrysanthi Skevaki (Marburg, Germany)

S0231 11:00 **Long-term impact of early-life exposures including RSV disease on lung function** *Shaakira Chaya (Cape Town, South Africa)*

S0232 11:30 **Rhinovirus infections and asthma in children: mechanisms and at-risk phenotypes** *Manuel E. Soto-Martinez (San Jose, Costa Rica)*

Co-organised with: International Society of Pediatric Respiratory Diseases (INSPiRED)

EF051 **Arena 2**

11:00 – 12:00

AMR ANT **ePoster Flash Session**

Antibiotic use, misuse and stewardship across settings

Chair *Rita Murri (Rome, Italy)*

E0356 11:00 **Understanding factors associated with antibiotic misuse among persons living with HIV at two large HIV clinics in Uganda** *F. Magololo Mutesi* (Kampala, Uganda), N. Mukiza, R. Nakalega, E. Twinomuhwezi, H. Mackline, A. Twimukye, F. Kakooza, A. Kambugu, D.M. Byonanebye, H. Kajumbula*

E0357 11:06 **The global spatiotemporal distribution of**

substandard and falsified antibiotic medicines *L. Adipo* (Oxford, United Kingdom), S. Cavany, C. Caillet, J. Mendes, S.M. Nanyonga, N. Stoesser, C. Dolecek, P. Newton, B. Cooper*

E0358 **11:12** **EU Joint Clinical Assessments: a missed opportunity to recognise the wider benefits of novel antimicrobials?** *M. Hofer* (London, United Kingdom), A. Macfarlane, G. Bray, E. Hamson, G. Hampson*

E0359 **11:18** **Profile of high-volume antibiotic prescribers, a population-based study from the French National Health Data System, 2023** *G. Beraud* (Orleans, France), H. Desmars, A.I. Lecuyer, F. Coustillères, E. Laurent, C. Carvalho, L. Grammatico-Guillon*

E0360 **11:24** **In search of innovative 'alter-biotic treatments': non-traditional therapies and the sociotechnical frameworks they require** *C. Haddad* (Vienna, Austria), A. Albiez, K. Bentley, E. Paterson*

E0361 **11:30** **Laboratory-based antimicrobial stewardship: an Australian and New Zealand perspective** *K. Ryan* (St Leonards, Australia), J. Elvy, M. Otormin, M. Jayawardena, M. Graham*

E0362 **11:36** **European multidisciplinary AMR modified Delphi panel: root causes of undervaluation of novel antibiotics and opportunities for alternative payment models** *E. Broughton* (Berlin, Germany), H. Armstrong, J. Benitez Rodriguez, C. Capdevila, S. Capri, S. Delgado-Collins, L. Diamond, M. Gheorghe, C. Hng, S. Kelly, K.E. Kypreos, M. Larguem, E. Rinaki, N.V. Sipsas, J.P. Stahl, P. Tilleul, J. Torre-Cisneros, A. Townsend, J.A. Valles Callol*

E0363 **11:42** **Achieving Europe's fair share: the need for European countries to complement EU-level pull incentives with national provisions for novel antimicrobials** *E. Damato* (London, United Kingdom), H. Armstrong, R. Lawlor, T. Wilsdon, D. Zhou*

E0364 **11:48** **Off-label antibiotic consumption behaviour increases the threat of antimicrobial resistance** *S. Goel* (Bengaluru, India), D. Batheja, S. Reddy, C. Achar*

EF052 **11:00 – 12:00** **Arena 3**

AMR CLN

ePoster Flash Session

From epidemiology to clinical impact of infections in solid organ transplant recipients

Chair *Patricia Munoz Garcia-Paredes (Madrid, Spain)*

E0365 **11:00** **Tuberculosis incidence in solid organ transplant recipients in Europe: a multi-centre TBnet cohort study** *T.T. Brehm* (Borstel, Germany), B. Lange, S.M. Arend, M. Arias-Guillén, M. Bakker, C. Berastegui, M. Babiker, R. Charif, R. Duarte, H. Flick, R.W. Hofland, J. Ismail, D. Kniepeiss, J. Krepel, N. Krishnan, D. Kuijpers, H. Kunst, F. Van Leth, V. Lezaic, I. Los-Arcos, J. Machová, H. Milburn, S.A. Morais, O.M. Kon, C. Osoro-Suarez, H. Pessegueiro Miranda, D.P. Pesut, A. Rahman, T. Reischig, A. Sánchez-Montalvá, H.E. Spohn, M.T. Stegenga, A.P.J. De Vries, D. Wagner, R. Wobser, C. Lange, M. Sester*

E0366 **11:06** **Comparative risk of tuberculosis in solid organ transplant recipients and matched general population controls** *S. Hosseini-Moghaddam* (Toronto, Canada), D. Fridman, S.S.M. Drover, S.K. Brode, T.K. Marras, F.B. Jamieson, S. Husain, J.C. Kwong*

E0367 **11:12** **Bacterial respiratory infections in solid organ transplant recipients with a focus on atypical pathogens: data from a prospective national cohort** *J. Bisch-Karatas* (Bern, Switzerland), I. Abela, A. Boyd, P. Kohler, N. Khanna, A. Koutsokera, M. Schuurmans, O. Manuel, C. Van Delden, N.J. Mueller, C. Hirzel, L.N. Walti*

E0368 **11:18** **Transplantation confers improved survival in ESBL-E BSI compared with non-transplant patients: insights from two multinational matched cohorts (INCREMENT vs INCREMENT-SOT)** *E. Ruiz Arabi* (Lausanne, Switzerland), E. Ruiz-Arabi, E. Pérez-Nadales, J.A. Marín-Sanz, J.J. Castón, I. Machuca, A. Cano, M. Marín-Sanz, B. Gutiérrez-Gutiérrez, J. Torre-Cisneros*

E0369 **11:24** **Epidemiological patterns of carbapenem resistance in solid organ transplantation: a contemporary multi-centre analysis** *A. Arslan* (Ankara, Türkiye), T. Yanık-Yalçın, A.Ö. Mete, Ş. Acar, T. Arslan-Gülen, G. Çınar, I. Hasanoğlu, E. Olcucuoglu, E. Günal, T. Turunç, V. Avkan-Oguz, M.C. Ergon, M. Yavuz-Çolak, Ö. Azap*

E0370 **11:30** **Infections in paediatric liver transplantation: risk factors and clinical outcomes** *L. Romani* (Rome, Italy), A.C. Epifani, F. Fini, C. Tripiciano, S. Mercadante, S. Bernardi, G. Spagnoletti, A.M. Fratti, R. Somma, V. Tuccio Guarna Assanti Vanessa, L. Dei Giudici, T. Alterio, D. Liccardo, F. Chiusolo, C.F. Perno, A. Pietrobattista, M. Spada, M. De Luca*

E0371 **11:36** **Risk factor analysis for early and late invasive *Candida* infections in solid organ transplant recipients** *D. Neofytos* (Geneva, Switzerland), L. Meyer, J. Frossard, P. Schreiber, O. Manuel, F. Lamoth, N. Khanna, K. Boggian, L. Walti, C. Garzoni, C. Van Delden, N. Mueller*

E0372 **11:42** **Durability of RSV-specific IgG, neutralising activity and T-cell responses after respiratory syncytial virus vaccination in kidney transplant recipients** *S. Bronder* (Homburg, Germany), H. Gruell, S. Lennartz, R. Urschel, D. Fliser, T. Schmidt, D. Schmit, M. Sester*

E0373 **11:48** **Systemic absorption and epithelial lining fluid concentration of inhaled vancomycin in lung transplant recipients** *G. Escudero Arnés* (Barcelona, Spain), G. Escudero, I. Los-Arcos, J. Sacanell, A. Pau, Y. Villena, C. Berastegui, J. Rosado, D. Campany, L. Castellote, B. Saez, L. Domenech, M.T. Martin, M. Culebras, C. Laborda, R. Barquín, S. Luque, O. Len, J. Gavaldà*

EF053 **11:00 – 12:00** **Arena 4**

AMR TRN

ePoster Flash Session

Carbapenem resistance: surveillance, mechanisms, and clinical implications

Chair *Rafael Canton (Madrid, Spain)*

E0374 **11:00** **A nationwide survey of carbapenemase-producing Gram-negative bacilli in bloodstream infections in a paediatric population (2015–2024)** *P.M. Peçanha-Pietrobom* (São Paulo, Brazil), P.Z. Charf, D. Testoni Costa-Nobre, E. Carmo, C.B. Wagner, T.T.F. Rezende, A.S.S. Marinonio, A.P.C. Assef, C.L. Pessoa-Silva, R. Peral, D. Kulek, L. Kraft, M. Pilonetto, C. Kiffer*

E0375 **11:06** **Diffusion of OXA-23 producing *Acinetobacter baumannii* in Zagreb post-pandemic** *B. Bedenic* (Zagreb, Croatia), B. Bedenić, D. Bandić-Pavlović, M. Nađ, M. Kasalo, D. Varda-Brkić, N. Beader, V. Bratić, M. Dobrić, H. Car, J. Vraneš*

E0376 **11:12** **Determination of meropenem heteroresistance in a diverse collection of OXA-48-producing *Klebsiella pneumoniae* clinical isolates** *M. Alcalde-Rico* (Seville, Spain), A. Angós, F. Docobo-Pérez, M. Delgado-Valverde, J.M. Rodríguez-Martínez, L. López-Cerero, Á. Pascual*

E0377 **11:18** **Human serum albumin (HSA) modulates cefiderocol activity in carbapenem-resistant (CR) pathogens** *M.S. Ramirez* (Fullerton, United States), A. Varnado, S. Moheb, K. Lopez, C. Rodriguez, S.D. Sanchez, G. Traglia, F. Pasteran, M.E. Tolmasky, R.A. Bonomo, L.A. Actis, G. Rao*

E0378 **11:24** **Sigma E factor transcriptional regulates the expression of metallo-β-lactamase NDM and mediates heteroresistance** *Y. Wang* (Hangzhou, China), W. Huang, Q. Shi, J. Zhou, R. Weng, H. Hu, J. Quan, Y. Jiang, Y. Yu*

E0379 **11:30** **The role of colistin resistance genes in the formation of colistin-induced tolerant and persister cells in clinical isolates of *Klebsiella pneumoniae*, *Acinetobacter baumannii*, and *Pseudomonas aeruginosa*** *G. Ozcan Kuyucu* (Ankara, Türkiye), G. Ozcan, C. Vatansever, J. Boral, A. Akpinar, S. Menekse, M. Gonen, F. Can*

E0380 **11:36** **Does use of ceftazidime/avibactam increase the risk of in vivo emergence of ceftazidime/avibactam and cefiderocol cross-resistance in KPC-producing *Klebsiella pneumoniae*: a case-control study** *Y.T. Lin* (Taipei, Taiwan), C. Chuang, S.Y. Liu, Y.C. Ho, S.H. Chou, Y.R. Huang, W. Chin, N.W. Hsu, L. Chen*

E0381 **11:42** **Aztreonam/avibactam resistance due to synergistic interplay of ampC-related mutations in carbapenem-resistant Enterobacter spp.** *Y. Zeng* (Chengdu, China), Y. He, Z. Zong*

KN082 **11:00 – 12:00** **Hall ICM 14**

CLN DX

Keynote lecture

Rickettsioses: widespread and neglected

Chairs *Li Yang Hsu* (*Singapore, Singapore*)
Xavier Lescure (*Paris, France*)

K0226 **11:00** *Nicholas Day* (*Bangkok, Thailand*)

ME089 **11:00 – 12:00** **Hall B0-1**

CLN DX

Meet-the-Expert

Global health on the move: advances and strategies in travel medicine

M0239 **11:00** *German Henostroza* (*Birmingham , Al, United States*)
M0240 **11:12** *Andreas Neumayr* (*Basel, Switzerland*)

ME088 **11:00 – 12:00** **Hall ICM 5**

ANT TRN

Meet-the-Expert

To model or not to model? A debate on the role of modelling and simulation in clinical PK trials

M0237 **11:00** *Markus Zeitlinger* (*Vienna, Austria*)
M0238 **11:12** *Lena Friberg* (*Uppsala, Sweden*)

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

FO090 **11:00 – 12:00** **Arena 1**

IPC

Open Forum

IPC nurses corner: building bridges across Europe

Chair *Ermira Tartari* (*Msida, Malta*)

F0241 **11:00** **Training the invisible workforce: what (still) makes sense in cleaning staff education?** *Veronica Weterings* (*Breda, The Netherlands*)
F0242 **11:10** **From recipient to partner: patient involvement in infection prevention** *Erik Briers* (*Hasselt, Belgium*)
F0243 **11:20** **Simulation-based IPC training: the real-life test lab** *Constantinos Tsioutis* (*Nicosia, Cyprus*)
F0244 **11:30** **Reinventing the wheel: hand hygiene meets AI innovation** *Silvana Gastaldi* (*Mazzano, Italy*)

Co-organised with: EUCIC Steering Committee

OS056 **13:30 – 14:30** **Hall A2-2**

CLN PHEI

1-hour Case Session

Not the consult I expected this morning...

Chairs *Flaminia Olearo* (*Berlin, Germany*)
Ryan Rego (*Ceske Budejovice, Czechia*)

O0383 **13:30** **Hidden pathogen: *Mycoplasma hominis* as the cause of a prosthetic vascular infection** *M. Bettencourt Silva** (*Lisbon, Portugal*), *A. Duarte, A.L. Silva, A. Lopes, P. Amorim, L. Mendes Pedro, L. Mendonça, D. Mendes Pedro*
O0384 **13:41** **Non-typhoidal *Salmonella* brain abscesses in a newly-diagnosed HIV patient: a case report** *E.K. Barreda** (*Metro Manila, Philippines*), *A. Estuart, C. Valdez, M.F. Tayzon, M. Saniel*
O0385 **13:52** **A novel case of non-imported *Rickettsia akari* infection in Ireland** *T. Coyne** (*Dublin, Ireland*), *A. Brown*
O0386 **14:03** **When you hear hoofbeats, sometimes it's camels not horses** *J. Anderson** (*Edinburgh, United Kingdom*), *E. Vink, S. Woolley, J. Jervis, R. Sutherland*

OS057 **13:30 – 14:30** **Hall A3-2**

ANT CLN

1-hour Case Session

Mind your Ps: PK/PD

Chairs *Linda Aulin* (*Leiden, The Netherlands*)
Joseph Meletiadis (*Athens, Greece*)

O0388 **13:30** **PK/PD-optimised eravacycline for vancomycin-resistant *Enterococcus faecium* in a liver transplant recipient** *J. Qu** (*Changsha, China*)
O0389 **13:41** **Therapeutic drug monitoring–guided antimicrobial optimisation in thoraco-omphalopagus twins with partially shared hepatic circulation undergoing surgical separation** *B. Monti** (*Monza, Italy*), *E. Ricci, M. Mariani, G. Mattioli, F. Palo, G. Cangemi, A. Cafaro, C. Saffioti, A. Wolfler, G. Spiga, E. Castagnola, A. Moscatelli, A. Mesini*
O0390 **13:52** **First clinical case of aztreonam/avibactam during venovenous ECMO support: is standard dosing adequate?** *A. Pau Parra** (*Barcelona, Spain*), *A. Pau-Parra, S. Luque, L. Doménech Moral, M. Martínez Pla, X. Nuvials, M. Sosa, I. Los-Arcos, A. Conto, F. Lasteros, E. Gallart, O. Castillo, A. Sánchez, S. Garcia, E. Del Barrio, M.Q. Gorgas Torner, R. Ferrer, J. Riera*
O0391 **14:03** **TDM-guided antibiotic therapy in a patient with recurrent *Listeria monocytogenes* meningitis and augmented renal clearance (ARC): from hospitalisation to oral home therapy** *D. Aquilino** (*Naples, Italy*), *P. Grimaldi, L. Alessio, S. De Pascalis, C. Ricozzi, K. Gjeloshi, S. Imbriani, M. Macera, C. Monari, L. Onorato, M. Pisaturo, N. Coppola*
O0392 **14:14** **Virological failure of long-acting cabotegravir/rilpivirine: a multifactorial case involving low drug exposure, high viral reservoir and rapid weight loss** *A. Andrianaki** (*Zurich, Switzerland*), *P. Thoueille, C. Marzolini, M. Huber, H.F. Günthard, I.A. Abela*

OS055 **13:30 – 14:30** **Hall A2-1**

AMR

1-hour Oral Session

Susceptibility testing of phages

Chairs *Annika Yanina Classen* (*Cologne, Germany*)
Marjolein Hensgens (*Utrecht, The Netherlands*)

O0393 **13:30** **Mechanisms of phage-driven resensitisation to aztreonam/avibactam in *Escherichia coli*** *A.M. Örmälä-Tiznado** (*Stockholm, Sweden*), *M. Razavi, S. Patpatia, A. Garcia Navarro, C.G. Giske, C. Tellapragada*
O0394 **13:42** **Impact of antimicrobials on bacteriophage-host interactions in *Pseudomonas aeruginosa*** *Y. Chikhani** (*São Paulo, Brazil*), *C. Siqueira, C. Rubio, R. Farzana, E. Portal, K. Sands, O. Spiller, A. Gales, W. Martins*
O0395 **13:54** **Two years (2024–2025) of bacteriophage susceptibility testing of bacterial isolates from persistent bacterial infections: results from the Israeli Phage Therapy Centre** *R. Nir-Paz** (*Jerusalem, Israel*), *R. Braunstein, O. Yerushalmy, L. Khalifa, A. Rimon, S. Copenhagen-Glazer, R. Hazan*
O0396 **14:06** **Tigecycline-selected tyrosine kinase mutation in *Klebsiella pneumoniae* triggers metabolic rewiring and increased phage susceptibility without affecting virulence** *N.N. Rakhi** (*Oxford, United Kingdom*), *A.K. Lankapalli, W. Martins, T. Lanyon-Hogg, T.R. Walsh*
O0397 **14:18** **Broth microdilution-based phage/antibiotic synergy in Gram-negative pathogens** *A.M. Örmälä-Tiznado** (*Stockholm, Sweden*), *A. Williamson, E. Loo, S. Patpatia, C. Tellapragada, C. Giske*

OS054 **13:30 – 14:30** **Hall B0-2**

AMR DX TRN

1-hour Oral Session

Harnessing artificial intelligence against AMR

Chairs *Fusun Can* (*Istanbul, Türkiye*)
Lorena Lopez Cerero (*Seville, Spain*)

O0398 **13:30** **A machine-learning workflow to investigate cefiderocol uptake defects arising from mutations in the siderophore receptor** *M. Razavi** (*Stockholm,*

Sweden), *C. Tellapragada*, *C.G. Giske*

O0399 **13:42** **Prediction of bacterial antimicrobial resistance based on resistance determinants and whole genome annotation neural networks algorithms** *M. Pulido Toledano** (*Seville, Spain*), *M.R. Pulido*, *F. Sola*, *D. Ayala*, *L. Monge-Olivares*, *R. Ayala*, *I. Portillo-Calderón*, *I. Hernández*, *D. Ruiz*, *L. López-Cerero*

O0400 **13:54** **Seven loci, one threat: Decoding and predicting azithromycin resistance in *Neisseria gonorrhoeae* with machine learning** *M. Krisna** (*Oxford, United Kingdom*), *F. Rudi*, *A. Unitt*, *K. Jolley*, *O. Harrison*

O0401 **14:06** **Domain-aware vs machine-learning imputation for sparse antimicrobial susceptibility data** *M. Raad** (*Strasbourg, France*), *F. Mutisya*, *K. Taylor*, *S. Alavi*, *T. Yokoyama*, *S. Boujaafar*, *P. Berger*, *C. De Turckheim*, *C. Moore*

O0402 **14:18** **Predicting risk of multidrug-resistant tuberculosis using long short-term memory (LSTM) and multimodal programmatic data in the Philippines** *M.I. Saludares** (*Metro Manila, Philippines*), *I.P. Mendoza*, *G.D. Sison*, *R. Destura*, *M. Kato-Maeda*, *F. Jiang*, *K.E. Henson*, *R. Basilio*, *J.E. Bascuña*

SY092 **Hall A3-1**

13:30 – 14:30

1-hour Symposium

PHEI

Fungi in the flow: wastewater as a hidden threat

Chairs *Mihai Mares* (*Iași, Romania*)
Esther Segal (*Tel Aviv, Israel*)

S0214 **13:30** **New EU wastewater directive: why fungi must be included** *Joao Brandao* (*Lisbon, Portugal*)

S0215 **14:00** ***Candida* and *Aspergillus* in the environment: resistance starts here** *Monika Novak Babič* (*Ljubljana, Slovenia*)

Co-organised with: ESCMID Fungal Infection Study Group (EFISG), European Confederation of Medical Mycology (ECMM), Israel Society for Medical Mycology (ISMM), Portuguese Society of Infectious Diseases and Clinical Microbiology, Romanian Society for Medical Mycology and Mycotoxicology (SRMMM), Hellenic Society of Medical Mycology, Spanish Study Group for Medical Mycology of SEIMC (GEMICOMED)

EW095 **Hall ICM 13b**

13:30 – 15:30

2-hour Educational Session

DX PHEI

Updates on emerging and re-emerging vector-borne viral infections

Chairs *Xavier Lescure* (*Paris, France*)
Alfonso J. Rodriguez-Morales (*Pereira, Colombia*)

W0220 **13:30** **Global epidemiological situation and diagnostic challenges of vector-borne viral infections** *Marta Giovanetti* (*Rome, Italy*)

W0221 **13:50** **Translational advances about West Nile virus** *Anna Papa-Konidari* (*Thessaloniki, Greece*)

W0222 **14:10** **Oropouche virus and its emergence** *Felipe Naveca* (*Manaus, Brazil*)

W0223 **14:30** **Changing epidemiology of Dengue: a global outlook** *Gathsaurie Neelika Malavige* (*Nugegoda, Sri Lanka*)

Co-organised with: SBI, Colombian Association of Infectious Diseases, Latin American Society for Travel Medicine, API, Dominican Society of ID, Ecuatorian Society for MM and Pediatric ID, ESCMID Emerging Infections Subcommittee, ESCMID Scientific Affairs Subcommittee

---

SY091 **Hall B0-1**

13:30 – 15:30

2-hour Symposium

AMR IPC

Screening for multidrug-resistant pathogens in various populations: are we doing good?

Chairs *Rita Ng* (*Hong Kong, Hong Kong*)
Spyros Pournaras (*Athens, Greece*)

S0210 **13:30** **Rectal screening and perioperative prophylaxis** *Elda Righi* (*London, United Kingdom*)

S0211 **14:00** **Implications of positive MDR bacterial screen for clinical practice: algorithm for treatment** *Marco Falcone* (*Pisa, Italy*)

S0212 **14:30** **Screening for MDR bacteria and *Candida auris*: lab methods** *Yesim Besli* (*Istanbul, Türkiye*)

S0213 **15:00** **Rectal screen for MDR bacteria in haematological and solid organ transplant patients** *Michael Satlin* (*New York, United States*)

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Infections in the Elderly (ESGIE)

EF058 **Arena 1**

13:30 – 14:30

ePoster Flash Session

CLN TRN

Predicting complications and outcome of sepsis

Chair *Despoina Koulenti* (*London, United Kingdom*)

E0403 **13:30** **The epidemiology of severe clinical manifestations caused by Group A streptococci in Denmark** *C. Evald-Schelde** (*Copenhagen, Denmark*), *T.B. Johannesen*, *S. Hoffmann*, *P.H. Andersen*, *S. Hermann*, *Z.B. Harboe*, *M. Stegger*, *L.S. Vestergaard*, *U. Nygaard*

E0404 **13:36** **Subphenotype and complication-guided adjunctive fosfomycin therapy for *Staphylococcus aureus* bacteraemia: pooled analysis of two randomised trials** *J. García-Larrauri** (*L'hospitalet De Llobregat, Spain*), *F. Escrihuela-Vidal*, *J. López-Contreras*, *G. Euba*, *A. Vázquez*, *S. Gómez-Zorrilla*, *L.E. López-Cortés*, *O. Gasch*, *E. Aparicio-Minguijón*, *R. Escudero-Sánchez*, *M.T. Pérez-Rodríguez*, *M.D. Rodríguez Pardo*, *A. Jover-Sáenz*, *G. García-Pardo*, *J. Rodríguez-Baño*, *M. Pujol*, *J. Carratalà*, *B. Gutiérrez-Gutiérrez*

E0405 **13:42** ***Burkholderia* as a silent antimicrobial resistance driver in lower–middle-income countries: genomic insights from the BALANCE study** *K.J. Hoog** (*Oxford, United Kingdom*), *N. Haque*, *M. Sultana*, *J.B. Joyee*, *F. Humayra*, *M.R. Tasfia*, *S. Afroj*, *C. Abdellaoui*, *R. Zahra*, *M. Hamza*, *B. Hassan*, *K. Shafique*, *G. Fatima*, *K. Onjuro*, *H. Nerima*, *C.R. Achi*, *K. Iregbu*, *P. Nwajiobi-Princewill*, *I.N. Nwafia*, *E. Carretto*, *T.R. Walsh*, *R. Farzana*

E0406 **13:48** **Development and validation of machine learning models for long-term survival prediction in elderly patients admitted to the intensive care unit for acute respiratory infection: the Genially project** *J. Herbert** (*Tours, France*), *A. Kassa-Sombo*, *A. Migeon*, *L. Platel*, *C. Salpétrier*, *A. Guillon*, *L. Grammatico-Guillon*

E0407 **13:54** **Antimicrobial resistance and risk-stratified empiric therapy in community-onset sepsis** *W. Lee** (*London, United Kingdom*), *H. Rastad*, *B. Hernandez*, *N. Zhu*, *D. Ming*, *R. Wilson*, *M. Gilchrist*, *A. Holmes*, *V. Cornelius*, *T. Rawson*

E0408 **14:00** **The role of serum cholinesterase levels in monitoring covert immunosuppression in critically ill patients with septic shock: evidence from a monocentric retrospective analysis** *G. Parruti** (*Pescara, Italy*), *A. Frattari*, *F. Cedrone*, *E. Polilli*, *R. Zocaro*, *P. Fazii*, *V. Fortunato*

E0409 **14:06** **Risk of dementia after bloodstream infection: propensity score matched cohort study** *J. Underwood** (*Cardiff, United Kingdom*), *D. Farewell*, *D. Gillespie*, *A. Akbari*, *N. Harrison*, *H. Ahmed*

E0410 **14:12** **Predicting in-hospital mortality in sepsis patients using machine learning methods in low- and middle-income country (LMIC) settings** *S. Awan** (*Karachi, Pakistan*), *N. Aziz*, *Z. Nasim*, *N. Nasir*

E0411 **14:18** **Integrated immune and endothelial profiling predicts 90-day mortality in postoperative sepsis and septic shock** *R.D. Prieto Utrera** (*Valladolid, Spain*), *M. Bardaji-Carrillo1*, *A. García-Concejo*, *E. Tamayo*, *D. Bernardo*

EF059 **Arena 2**

13:30 – 14:30

ePoster Flash Session

CLN TRN VAX

Decoding herpesviruses: from bench to bedside

Chair *Sylviane Defres* (*Liverpool, United Kingdom*)

E0412 **13:30** **LY6C+ monocyte derived macrophages contribute**

to pathological neuroinflammation in herpes simplex encephalitis *Q. Xue** (*Shanghai, China*), *Z. Shen*

E0413 **13:36** **Development of a risk score to predict encephalitis by herpes simplex virus and varicella zoster virus** *R. Hasbun** (*Houston, United States*), *J. Portugal, A. Heck, P. Bean, R. Habis, J. Probasco, A. Venkatesan*

E0414 **13:42** **Clinical determinants of outcome in chronic active Epstein-Barr virus infection: derivation of a risk stratification score** *Q. Yang** (*Shanghai, China*), *Z. Zhou*

E0415 **13:48** **CXCL9, CXCL10, and CXCL11: sensitive predictors of acute EBV infection** *A. Nikcevic** (*Zagreb, Croatia*), *A. Nikčević, K. Bodulić, L. Radmanić Matotek, G. Tešović, S. Židovec Lepej*

E0416 **13:54** **Distinguishing clinical significance from latent infection: establishing mNGS-based EBV diagnostic cut-offs in blood and CSF** *Y. Cao** (*Shanghai, China*), *X. Li, Y. Qingluan*

E0417 **14:00** **Using QuantiFERON-EBV to measure EBV-specific T-Cell function in thoracic transplant recipients** *Y. Zhao** (*Groningen, The Netherlands*), *L. Gard, K. Damman, E. Verschuuren, V.L.B. Coretta*

E0418 **14:06** **Digital PCR enables high-resolution quantification of HCMV UL123 in clinical and experimental samples** *A.R. Silvain** (*Limoges, France*), *M. Mayeras, E. Guerin, T. Reishig,, O. Bestard, L. Cousi, E. Alezra, A. Koenig, C. Roger, N. Kamar, M. Sester, H. Kaminski, S. Alain*

E0419 **14:12** **Real-world effectiveness of recombinant zoster vaccine in high-risk adult populations in Greece** *V. Petrakis** (*Alexandroupolis, Greece*), *P. Rafailidis, N. Mpampaka, G. Karagiannis, V. Kyrgiannaki, D. Papapazoglou, P. Panagopoulos*

E0420 **14:18** **The recombinant adjuvant zoster vaccine induces similar immune responses in ruxolitinib-treated patients with myelofibrosis and polycythemia vera** *V. Leguizamon** (*Madrid, Spain*), *B. Astibia-Mahillo, E. Mateos, M. Torres, N. Armenteros, A. Fernández-Chávez, M.C. Luengo-Martínez, N. Daza, M. Coiras, V. García-Gutierrez*

EF060 **13:30 – 14:30** **Arena 4**

CLN PHEI

ePoster Flash Session

Zoonotic infections: expect the unexpected

Chair *Manuela Carugati* (*Durham, United States*)

E0421 **13:30** **Clinical characteristics and treatment strategies in a cohort of patients with tularemia: a retrospective multi-centre analysis of 65 cases in Germany** *C. Lübbert** (*Leipzig, Germany*), *B. Arnold, N. Kellner, H. Trawinski, H.M. Orth, D. Tominski, A. Mikolajewska, K. Rothfuss, G. Grupe, D. Ruf, F. Reichert, K. Marx, K. Heuner, D. Jacob*

E0422 **13:36** **Characterisation of tularaemia cases in Southwest Germany and identification of two natural transmission clusters in a clinical high-endemic region Tuniberg/Kaiserstuhl (TuniKa)** *D. Hornuss** (*Freiburg I. Breisgau, Germany*), *H. Von Buttlar, V. Goetz, P. Mathé, J. Klein, M. Leibenguth, L. Chitimia-Dobler, A.S. Claus, M. Scherer-Lorenzen, G. Dobler, S. Rieg, J. Borde*

E0423 **13:42** **Paediatric tularemia: clinical outcomes and immunological insights from an endemic region in Türkiye** *K. Aykac** (*Ankara, Türkiye*), *O. Cakici, B.E. Seyrek, İ.C. Yılmaz, O.O. Demir, İ. Evcili, T. Canavar Yıldırım, M. Yıldırım, E.H. Erdeniz, S.Y. Durmus, A. Sahin, S. Ocal Demir, A.B. Cengiz, M. Gürsel, İ. Gürsel, Y. Ozsurekci*

E0424 **13:48** **Phylogenetic diversity of Mediterranean spotted fever group Rickettsiales: species-level sequencing in a Spanish tertiary hospital (2021–2025)** *E. Gremaldos Mira** (*Valencia, Spain*), *E. Cortés Giménez, J.M. Sahuquillo Arce, A. Hernández Cabezas, J.L. López Hontangas, M.D. Gómez Ruiz*

E0425 **13:54** **Diversity of *Rickettsia* species identified by metagenomics in ticks collected from a Brazilian University** *F. Carvalho** (*São Carlos, Brazil*), *D.S.F. Guedes, G. Montenegro De Campos, A. Sarana Da Silva, C.V.P. Hernandez, B.M. Begalli, L.C. Barci, J.M. Penedo, R.G.D.S. Taliassaqui, T.K.S. Felippe, S.J. Badra, F.D.F. Anibal, S.N. Slavov*

E0426 **14:00** **Epidemiology of toxigenic *Corynebacterium ulcerans* infections in England** *K. Harman** (*London, United Kingdom*), *C. Robin, E. Mugwagwa, T. Patel, R. Cordery, D. Litt, S. Neale, A. Mackintosh, D. Chudasama, R. Pudney*

E0427 **14:06** **First insights into the wild, wild west of *Borrelia* plasmids** *S. Hepner** (*Oberschleissheim, Germany*), *R.E. Rollins, E. Mourkas, K. Kuleshov, S. Casjens, W. Qiu, A. Dangel, D. Velázquez, S.Y. Kovalev, A. Wieser, J. Hübner, A. Sing, V. Fingerle, G. Margos*

E0428 **14:12** **The impact of previous brucellosis treatment on the clinical course of neurobrucellosis: a multi-centre retrospective study** *O. Evlice** (*Van, Türkiye*), *Y. Ezgi, H. Kır, S. Incecik, D. Ertürk, M. Aydın, A.S. İnal, Y. Çakır, Z. Karazeybek, B.B. Sivrikaya, B. Turaç, E. İnci, S.Y. Kaya, Z. Çelik, A. Şabablı Çetin, I.D. Alıravcı, Ö. Özgen, H. Özsüt, M. Çelik, S. Alkan, S. Surme, A. Mert*

E0429 **14:18** **Early markers of severe leptospirosis in French Amazonia, 2007–2022** *L. Epelboin** (*Cayenne, French Guiana*), *P. Le Turnier, M. Zenou, A. Fremery, H. Kallel, N. Higel, A. Kpangon, P. Abboud, F. Djossou, M. Boutrou, M. Nacher*

JS002 **13:30 – 14:30** **Hall ICM 5**

AMR CLN

Journal Session

Late-breaking research from CMI & CMI Comms: on invasive infections and antimicrobial resistance

Chairs *Andre Kalil* (*Omaha, United States*)
Anne-Grete Märtson (*Leiden, The Netherlands*)

J0005 **13:30** **Estimating antibiotic resistance following antibiotic treatment in outpatients: a retrospective study** *Michal Chowers* (*Kfar-Saba, Israel*)

J0006 **13:40** **Clinical utility of the DENOVA score for predicting infective endocarditis in *Enterococcus faecalis* bacteraemia: external validation with decision curve analysis** *Benedetta Varisco* (*Milan, Italy*)

J0007 **13:50** **Challenges in nasal and throat microbiota composition during and after mupirocin and chlorhexidine decolonisation treatment in asymptomatic MRSA carriers: a longitudinal observational study** *Sofie Marie Edslev* (*Copenhagen, Denmark*)

J0008 **14:00** **A multicentre evaluation of metagenomic sequencing for pathogen detection in central nervous system infections** *Rui Zhang* (*Beijing, China*)

J0009 **14:10** **Prevalence of submicroscopic malaria parasitemia among migrant pregnant women: a prospective cohort study** *Léa Docquier* (*Brussels, Belgium*)

J0010 **14:20** **Antenatal corticosteroid treatment and infectious diseases in children and adolescents aged 5–16 years** *Katri Raikkonen* (*Helsinki, Finland*)

Co-organised with: CMI Board of Editors, CMI Communications Board of Editors

---

ME093 **13:30 – 14:30** **Hall ICM 1**

ANT CLN IPC

Meet-the-Expert

Novel therapeutics for *C. difficile* infection

M0216 **13:30** *Eugenie Basseres* (*Houston, United States*)
M0217 **13:42** *Marek Duricek* (*Prague, Czechia*)

Co-organised with: ESCMID Study Group for *Clostridioides difficile* (ESGCD)

ME094 **13:30 – 14:30** **Hall ICM 13a**

CLN PED

Meet-the-Expert

Recent evidence on the role of steroids in paediatric bacterial infections: focus on meningitis and pneumonia

M0218 **13:30** *George A. Syrogiannopoulos* (*Larissa, Greece*)
M0219 **13:42** *Susanna Esposito* (*Parma, Italy*)

FO096 **13:30 – 14:30** **Arena 3**

PRO

Open Forum

Communicating science today: new media, new platforms

Chair *Angela Huttner (Geneva, Switzerland)*

F0224 **13:30** **Influencing in infectious diseases and clinical microbiology: tweet or fly?** *Neil Stone (London, United Kingdom)*

F0225 **13:40** **Starting and sustaining a podcast** *Erin Mccreary (Pittsburgh, United States)*

Co-organised with: CMI Communications Board of Editors

WT005 **13:30 – 14:30** **Poster area**

CLN VAX

Poster Walkthrough

Navigating through infections in immunocompromised hosts

Chair *Simona Ruta (Bucharest, Romania)*

R0041 **P4194 - Long-term outcomes of isoniazid prophylaxis in allogeneic haematopoietic stem-cell transplant recipients: a 15-year cohort study** *Keon Oh (Seoul, Korea, Republic of)*

R0042 **P4138 - Human microRNA hsa-125a-5p as biomarker for predicting late CMV infection in high-risk D+/R- kidney transplant recipients** *Natalia Redondo (Madrid, Spain)*

R0043 **P4166 - Epidemiology of methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant *Enterococcus* spp. (VRE) in Swiss solid organ transplant recipients** *Peter W Schreiber (Zurich, Switzerland)*

R0044 **P4217 - Impact of HHV-6B reactivation on engraftment and outcomes after allogeneic HSCT** *Seyed M (sasan) Hosseini-Moghaddam (Toronto, Canada)*

R0045 **P4236 - Central venous catheter (CVC)-related bloodstream infections (CRBSI) in patients with solid tumours (ST) and haematological malignancies (HM): a propensity-score matched (PSM), non-inferiority, registry-based comparison** *Enrico Schalk (Magdeburg, Germany)*

R0046 **P4146 - Identification and validation of clinical phenotypes in liver transplant donors and recipients to predict early infections and mortality** *Cecilia Bonazzetti (Bologna, Italy)*

R0047 **P4152 - A retrospective analysis of patients receiving organs from HHV-8 positive donors at a large transplant centre** *Benjamin Ravenhill (Cambridge, United Kingdom)*

R0048 **P4189 - Long-term outcomes in liver transplant recipients: comparison between patients living with and without HIV infection** *Adriana Cervo (Modena, Italy)*

R0049 **P4218 - Antibiotic-induced microbiome disturbances in haematological patients undergoing haematopoietic stem cell transplantation: a prospective observational study** *Hanna Montelin (Uppsala, Sweden)*

R0050 **P4148 - Infections and outcomes in elderly solid organ transplant recipients: a multi-centre cohort from Türkiye** *Sibel Altunisik Toplu (Malatya, Türkiye)*

WT008 **13:30 – 14:30** **Poster area**

AMR PED

Poster Walkthrough

Optimising diagnosis and antimicrobial management in paediatric infectious diseases

Chair *Ilias P. Iosifidis (Thessaloniki, Greece)*

R0071 **P2866 - Pharmacokinetics, safety, and tolerability of cefiderocol in paediatric patients aged three months to <18 years with suspected or confirmed Gram-negative bacterial infections in the phase Ib-2 APEKS-PEDI study** *Emmanuel Roilides (Thessaloniki, Greece)*

R0072 **P0700 - Sputum-independent T cell activation-based diagnosis of paediatric tuberculosis: a prospective diagnostic accuracy study in five low- and middle-income countries** *Alia Razid (Munich, Germany)*

R0073 **P0591 - A clinical prediction score for radiological severity of pulmonary tuberculosis in children: an individual participant data analysis** *Akshita Gupta (Munich, Germany)*

R0074 **P0809 - Causes of neonatal sepsis in low- and middle-income countries: a multi-site international cohort study** *Kirsty Sands (Oxford, United Kingdom)*

R0075 **P0818 - Referral of febrile children in a resource-constrained community settings in Asia (spot sepsis)** *Arjun Chandna (London, United Kingdom)*

R0076 **P2821 - Population pharmacokinetics modelling of daptomycin in paediatric patients** *Sylvain Goutelle (Lyon, France)*

R0077 **P4240 - Gut colonisation with MDR Gram-negative organisms and its impact on bacteraemia and sepsis development among children with haematological malignancies** *Reham Khedr (Cairo, Egypt)*

R0078 **P1167 - Comparative effectiveness of clarithromycin and azithromycin for the treatment of pertussis in hospitalised infants: a multi-centre retrospective cohort study in Italy** *Cristina Moracas (Napoli, Italy)*

R0079 **P3024 - Digital training for IPC and AMS in paediatric inpatient units: multicountry implementation and outcomes from TEAM-COACH project** *Olaf Neth (Sevilla, Spain)*

R0080 **P0977 - Incidence of parapneumonic pleural effusion/empyema in children before, during, and after the COVID-19 pandemic (Germany, 2010/11-2024/25)** *Andrea Streng (Würzburg, Germany)*

WT006 **13:30 – 14:30** **Poster area**

IPC PHEI

Poster Walkthrough

Severe infections in ICU: from novel antibiotics to precision monitoring

Chair *Antonios Katsounas (Bochum, Germany)*

R0051 **P0753 - Distinct temporal dynamics of host transcriptomic response between patients with persistent and resolving *Staphylococcus aureus* bacteraemia** *Karishma Chhugani (Los Angeles, United States)*

R0052 **P2610 - Impact of acquired broad-spectrum β-lactamases on susceptibility to oral cephalosporin (ceftibuten) and oral carbapenem (tebipenem) in combination with new β-lactamase inhibitors ledaborbactam and xeruborbactam in *Escherichia coli*** *Christophe Le Terrier (Fribourg, Switzerland)*

R0053 **P2602 - Activity of cefiderocol/xeruborbactam against NDM-producing *Escherichia coli* isolates with PBP3 insertions and decreased susceptibility or resistance to aztreonam/avibactam, cefiderocol, and cefepime/taniborbactam** *Tania Blanco Martín (A Coruña, Spain)*

R0054 **P2826 - Population pharmacokinetics of piperacillin/tazobactam in plasma and epithelial lining fluid of ICU patients with pneumonia: the PNEUDOS study** *Mohd-Hafiz Abdul-Aziz (Brisbane, Australia)*

R0055 **P0884 - NETosis-inducing *Staphylococcus aureus* correlate with mortality and elevated IL-10** *Warren Rose (Madison, United States)*

R0056 **P2669 - Mitoxantrone restores tigecycline activity by inhibiting tet(X4) and disrupting resistance mechanisms in *Escherichia coli*** *Jiao Xie (Xi'an, China)*

R0057 **P2777 - Population pharmacokinetic analysis of piperacillin in critically ill women based on multi-centre data** *Uwe Liebchen (Munich, Germany)*

R0058 **P2876 - Outcomes of cefepime/nacubactam and aztreonam/nacubactam for treatment of cUTI/AP patients with CRE: subgroup analysis of integral-1 study** *Sota Iyama (Tokyo, Japan)*

R0059 **P2883 - Pharmacokinetics, safety and tolerability of ANT3310 combined with meropenem in participants with impaired renal function** *Justine Dao (Labège, France)*

R0060 **P0797 - Continuous vs intermittent infusion of high-dose meropenem in critically ill patients: an observational cohort study** *Anselm Jorda (Vienna, Austria)*

WT007 **13:30 – 14:30** **Poster area**

ANT

Poster Walkthrough

Digital or traditional Antimicrobial Stewardship interventions

Chair — *Rita Murri* (*Rome, Italy*)

R0061 — **P2907 - Global point prevalence survey of antimicrobial consumption and resistance (Global-PPS): monitoring effectiveness of an EMR-assisted pre-authorisation requirement for non-guideline compliant surgical antimicrobial prophylaxis prescriptions at a tertiary hospital in the Philippines** *Janelle Gagelonia* (*Taguig, Philippines*)

R0062 — **P2933 - Implementation experience of an antimicrobial stewardship program in a resource-limited setting: MSF–MOH collaboration in a Mozambican hospital** *Shehezady Cruz* (*Beira, Mozambique*)

R0063 — **P2964 - A mixed-method evaluation and impact assessment of national secondary care (hospitals) antimicrobial stewardship (AMS) tools** *Bee Yean Ng* (*London, United Kingdom*)

R0064 — **P2978 - Hybrid AI2D and rule-based approach for prospective audit feedback (PAF) of piperacillin/tazobactam in suspected acute bacterial lower respiratory tract infections (abLRTI)** *Yvonne Zhou* (*Singapore, Singapore*)

R0065 — **P2915 - Sustained improvement in private practice dentists' antibiotic prescribing following stewardship education and electronic antibiotic dashboards** *Debbie Goff* (*Westerville, Ohio, United States*)

R0066 — **P2969 - From data silos to strategic action: developing a real-time dashboard to inform a local antimicrobial stewardship (AMS) programme** *Mark Gilchrist* (*London, United Kingdom*)

R0067 — **P3010 - Impact of a networked antimicrobial stewardship program with multi-site computer decision support on antibiotic consumption and resistance in four major Australian teaching hospitals 2012-2024** *Pamela Konecny* (*Sydney, Australia*)

R0068 — **P2912 - Optimising antibiotic use in Nigerian secondary hospitals: prescribing patterns, consumption rate and drivers of inappropriate therapy** *Justin Onyebuchi Nwofe* (*Abuja, Nigeria*)

R0069 — **P2946 - From restrictive antibiotic stewardship to a handshake model: early outcomes from the REVERSE project in a tertiary hospital in Northern Italy** *Amina Zaffagnini* (*Verona, Italy*)

R0070 — **P3071 - Evaluation and knowledge mobilisation of the annual English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) report** *Diane Ashiru-Oredope* (*London, United Kingdom*)

SEL — **13:30 – 15:30** — **Hall ICM 14**

Special Session

Selective Pressure

Chairs — *Jacob Moran-Gilad* (*Beer Sheva / Jerusalem, Israel*)
Annabel Niessen (*Utrecht, The Netherlands*)
Josh Nosanchuk (*Bronx, United States*)
José Ramón Paño-Pardo (*Zaragoza, Spain*)
Jesús Rodríguez-Baño (*Seville, Spain*)
Anja Šterbenc (*Ljubljana, Slovenia*)
David Van Duin (*Chapel Hill, United States*)

SEL01 — **13:30** — **Selective Pressure** *Jesús Rodríguez-Baño* (*Seville, Spain*)

OS063 — **14:45 – 15:45** — **Hall A2-1**

1-hour Case Session

CLN PHEI

Malicious *Mycobacteria*

Chair — *Anupa Thampy* (*Vellore, Tamil Nadu, India*)
TBA

O0430 — **14:45** — **Donor-derived renal allograft tuberculosis detected by plasma metagenomic sequencing in two kidney transplant recipients** *A. Diaz Arumir Vergara** (*Jackson, United States*), *A. Diaz-Arumir Vergara*

O0431 — **14:56** — **Leprosy in an Indonesian patient diagnosed after childbirth in a tertiary hospital in Germany** *A. Frenz** (*Dresden, Germany*), *R. Kardashi, S. Meisterfeld, P. Spornraft-Ragaller, K. De With*

O0432 — **15:07** — **XDR-Tuberculosis meningitis in patient with advanced HIV infection: therapeutic challenge with limited treatment options** *M. Schiuma** (*Milan, Italy*), *F. Fama, A. Piubello, F. Saluzzo, D. Bernasconi, M. Schiavini, A. Covizzi, B. Caloni, D. Zizzo, D. Maddalena, M. Bognetti, A. Rizzo, F. Salari, A. Civati, M. Galimberti, A. Riva, S. Antinori, D. Cirillo, A. Gori, A. Torre*

O0433 — **15:18** — **An unexpected case of disseminated MAC infection in a non-HIV immunocompromised thymoma patient** *L. Vos** (*Utrecht, The Netherlands*), *A. Bruns*

O0434 — **15:29** — ***Mycobacterium riyadhense*: a rare emerging NTM in a TB endemic country** *B. Kumar** (*Jodhpur, India*), *A. Sarangal, D. Meena, N. Midha, G. Bohra*

OS062 — **14:45 – 15:45** — **Hall ICM 5**

1-hour Case Session

CLN PHEI

Puzzling parasites

Chairs — *Rodrigo Gurgel-Gonçalves* (*Brasília, Brazil*)
Tin Tin Myaing (*Bangkok, Thailand*)

O0435 — **14:45** — **Rapidly progressive parasitic meningoencephalitis: diagnostic challenges** *C. Silva** (*Vila Nova De Gaia, Portugal*), *C. Nunes-Silva, A. Silva-Pinto, A.S. Santos, C. Gonçalves, R. Baptista, A. Ferreira, S. Xerinda, L. Andrade, J. Ganicho, P. Figueiredo, A. Sarmento, A. Costa, C. Reis, S. Rebelo, S. Guimarães, L. Santos*

O0436 — **14:56** — **Double trouble in the liver: amoebic and staphylococcal abscess in a Belgian MSM without travel history** *M. Moretti** (*Jette, Belgium*), *N. M'rabet, K. Demeyer*

O0437 — **15:07** — **Eosinophilic liver abscess caused by invasive *Fasciola*** *B. Uaudomsataporn** (*Bangkok 10330, Thailand*), *O. Putcharoen*

O0438 — **15:18** — **Learning from the unusual: three autochthonous paediatric cases of *Entamoeba histolytica* colitis in Southern Italy suggesting a new challenge for clinical practice and public health** *R. Astorri** (*Casamassima (bari), Italy*), *M. Bartiromo, R. Melone, A. Di Martino, P. Marzuillo*

O0439 — **15:29** — **Reactivation of *Trypanosoma cruzi* with medullary tropism: an unexpected turn in a patient with HIV** *J. Mateo Gonzalez** (*Valencia, Spain*), *J.I. Mateo-Gonzalez, M. Garcia-Rodriguez, M. Martinez-Serrano, M.D. Ocete-Mochon, V. Abril-Lopez-De-Medrano, E. Ballester-Belda, C. Ricart-Olmos, M. Garcia-Deltoro*

OS064 — **14:45 – 15:45** — **Hall A2-2**

1-hour Oral Session

CLN TRN

Rattle my bones - bone and joint infections

Chairs — *Parham Sendi* (*Bern, Switzerland*)
Andrej Trampuz (*Brisbane, Australia*)

O0440 — **14:45** — **Validation of the KLIC score and development of a new predictive model in a multi-centre cohort of prosthetic joint infections treated with debridement and implant retention** *G. Zumbo** (*Seville, Spain*), *I. Martínez Alemany, J.M. Bravo Ferrer, I. Nieto Diaz De Los Bernardos, J. Praena, A. Del Arco, N. Enrique, C.D. Juan Enrique, B. Francisco, C. Natera, A. Romero Palacios, B. Sobrino, J. Rodriguez Baño, M.D. Del Toro Lopez*

O0441 — **14:57** — **Hypoxia-driven sdhB-mediated antibiotic tolerance impairs prophylactic antibiotics against MRSA in a mouse prosthetic joint infection model** *O. Gordon** (*Jerusalem, Israel*)

O0442 — **15:09** — **The use of [^{18}F]FDG-PET/CT and magnetic resonance imaging in the diagnosis of pyogenic vertebral osteomyelitis secondary to *Staphylococcus aureus* bacteraemia** *I. Johansen** (*Odense C, Denmark*), *S. Olaf Lindvig, T. Benfield, I. Pedersen, S. Hess, F. Rosenvinge, M. Kehrer, I. Somuncu Johansen*

O0443 — **15:21** — **Fatty acid profiling of biofilms formed by *Klebsiella pneumoniae*, *Pseudomonas aeruginosa* and *Staphylococcus aureus*** *E. Torrecilla-Sádaba** (*Madrid, Spain*), *D. Carrizo-Gallardo, L. Sánchez-García, L. Salar-Vidal, J. Esteban, J.J. Aguilera-Correa*

O0444 **15:33** **Investigation of *Staphylococcus aureus* infections in human-derived musculoskeletal *ex vivo* tissue slices** *K. Strenger* (Basel, Switzerland), R. Kühl, A.K. Woischnig, L. Sauteur, M. Morgenstern, M. Clauss, D. Bumann, N. Khanna*

OS065 **14:45 – 15:45** **Hall A3-1**

IPC TRN

1-hour Oral Session

Engineering the gut microbiome: new therapeutics and clinical practice

Chairs *Markus Arnoldini (Zurich, Switzerland)*
Fidelma Fitzpatrick (Dublin, Ireland)

O0445 **14:45** **Randomised double-blinded clinical trial evaluating the effectiveness and safety of secondary prophylaxis with oral vancomycin vs placebo in the prevention of recurrence of *Clostridioides difficile* infection in patients receiving systemic antibiotic therapy (PREVAN TRIAL)** *R. San-Juan* (Madrid, Spain), J. Origüen, M. Fernández-Ruiz, K. Campion, J.T. Silva, F. Lopez-Medrano, J. Villa, B. Diaz-Pollan, A. Callejas, G. Candela, J. Boan, E. Aparicio-Minguijon, M.A. Perez-Jacoiste, I. Rodriguez-Goncer, C. Martin-Arriscado, M. Martinez-Uña, J.M. Ferrari, J.M. Aguado*

O0446 **14:57** **Longitudinal tracking of microbial restoration after faecal microbiota transplantation (FMT)** *D. Guevara Nuñez* (Barcelona, Spain), P. Camps-Massa, L. Saiz-Escobedo, A. Carrera-Salinas, S. Antón, J. Orobitg, M. Bonilla, A. González-Diaz, C. Arajol, J. Guardiola, M.A. Domínguez, S. Martí*

O0447 **15:09** **VE707, a live biotherapeutic product, reduces intestinal vancomycin resistant enterococci in a murine model of pathogen colonisation** *J. Norman* (Cambridge, United States), C. Russell, C. Felix, W. Alsharif, L. Cornacchione, M. Schinn, A. Watson, S. Bedard-Shurtleff, J. Faith, E. Kuijper, B. Olle, G. Medlock, S. Caballero*

O0448 **15:21** **Single-donor lyophilised encapsulated faecal microbiota transplant (cFMT) supports home dosing with dose-to-dose heterogeneity driven by inter-donor microbiome differences** *B. Merrick* (Harrow, United Kingdom), D. Prossomariti, N.M.M. Zain, B. Forbes, C. Sergaki, S.D. Goldenberg*

O0449 **15:33** ***Clostridioides difficile* infection recurrence and antibiotic utilisation following treatment with Food and Drug Administration-approved faecal microbiota products: a multi-centre analysis using Epic Cosmos** *S. Boettcher* (Detroit, United States), R. Kenney, N. Everson, I. Kashat, G. Tengler, A. Soyad, S. Davis, M. Veve*

OS061 **14:45 – 15:45** **Hall ICM 13a**

PRO

1-hour Oral Session

AI applications in CM/ID: speaking the new language (model)

Chairs *Riina Richardson (Manchester, United Kingdom)*
Bernardo Sousa-Pinto (Porto, Portugal)

O0450 **14:45** **Assessing Large Language Model (LLM) performance in abstract screening for an infection-focused systematic review with >16,000 records** *D. Ashiru-Oredope* (London, United Kingdom), O. Quinn, G. Shannon, H. Ollie, L. Timothy, F. Felix, H. Joshua, L. Leo, N. Toby*

O0451 **14:57** **Development of an ESCMID Global AI-based abstract categorisation tool** *G. De Angelis* (Basel, Switzerland), E. Dexter, J. Moran-Gilad*

O0452 **15:09** **AI-assisted infectious disease consultation: concordance analysis between a custom GPT model and specialist recommendations** *S. Karunakara Ramesh* (Tamil Nadu, India), K. Sarika, D. Suresh Kumar, M. Indumathi, B. Rithik Dharan*

O0453 **15:21** **Performance of large language models in management of complex infectious diseases cases** *A. Pradhan* (Oxford, United Kingdom), B.J. Waxse, W. Matias, K. Bowman, C. Nutt, S. Mercaldo, S. Kanjilal, J. Hillis*

O0454 **15:33** **Multimodal artificial intelligence using entire electronic health record and complete pathogen genome data to predict clinical outcomes from life-threatening infection: the SuperbugAI platform** *A. Peleg* (Melbourne, Australia), S. Tyagi, Y. Ramakrishnaiah, J. Hawkey, J. Wisniewski, T. Christian, V. Sikiric, G. Webb, C. Bain, J. Song, A. Stewardson, T. Peel, N. Macesic*

SY097 **14:45 – 15:45** **Hall A3-2**

IPC PHEI

1-hour Symposium

Capacity strengthening in antimicrobial stewardship and infection, prevention and control in LMICs

Chairs *Gloria Cordoba (Copenhagen, Denmark)*
Syed Faisal Mahmood (Karachi, Pakistan)

S0245 **14:45** **What is drive-AMS and what have we learned?** *Jeroen Schouten (Nijmegen, The Netherlands)*

S0246 **15:15** **Drive AMS East Africa, inducing behaviour change in resource-constrained settings** *Igizeneza Acsa (Kigali, Rwanda)*

Co-organised with: International Centre for Antimicrobial Resistance Solutions (ICARS), ESCMID Parity Commission, ESCMID Professional Affairs Subcommittee

---

EF066 **14:45 – 15:45** **Arena 1**

DX

ePoster Flash Session

The escalating problem of antifungal resistance

Chair *Ana Alastruey (Madrid, Spain)*

E0455 **14:45** **Azole fungicides promote *C. auris* resistance to manogepix: a new One Health concern** *A. Boutillier* (Poitiers, France), A. Baillod, J. Moreau, S. Marchand, J. Clarhaut, K. Brunet*

E0456 **14:51** **Clonal emergence and mechanistic insights into amphotericin B resistance in *Candida auris* from Indian hospitals** *P. Kagra* (Delhi, India), S. Yadav, N. Shukla, K. Jain, S. Srivastava, S.L. Kelly, M.F. Alomair, D.C. Lamb, N. Chauhan, A. Chowdhary*

E0457 **14:57** **Clinically relevant gene flow leads to substantial loss of antifungal susceptibility in a rare invasive fungal pathogen** *R. Dai* (Beijing, China), Y. Huang, Y. Xu, M. Zhou, M. Xiao*

E0458 **15:03** **Epidemiological trends and genomic insights from national surveillance of *Candida auris* in Singapore** *K.N. Sein Tun* (Singapore, Singapore), G. Lee, B. Tan, G. Toh, X.Y. Ong, L. Cui, M. Ang, Z. Said, C. Huang, K. Marimuthu*

E0459 **15:09** **Detection of fluconazole resistant *C. parapsilosis* clinical isolates bearing both Y132F and S862C substitutions at MALDI-TOF analysis** *I. Franconi* (Pisa, Italy), B. Tuvo, L. Maltinti, M. Falcone, L. Mancera, A. Lupetti*

E0460 **15:15** **Tandem gene duplications drived rising azole resistance in expanding *Candida* orthopsilosis population** *Y.T. Ning* (Beijing, China), R.C. Dai, Y.C. Xu, T.S. Sun, L. Zhang*

E0461 **15:21** **Nationwide multi-centre surveillance of species distribution and antifungal resistance in** Candida and *Candida* related-bloodstream isolates in Brazil (2023–2025) *F. Guinsburg Hamburger* (São Paulo, Brazil), F. De Camargo Ribeiro, K. Rosa Fernandes Beraldo, R. Tigulini De Souza Bogo, A.L. De Abreu, A.P. D' Alincourt Carvalho Assef, J. Nóbrega De Almeida Júnior, A.L. Colombo*

E0462 **15:27** **Unique genetic clades and frequent zoonotic transmission of Sporothrix brasiliensis with reduced itraconazole susceptibility** *E.F.J. Meijer* (Nijmegen, The Netherlands), M. Rodrigues Trápaga, B. Spruijtenburg, J. Estefânia Dávila Hidalgo, B. Jacomel, I. Martins Madrid, D. Isabel Brayer Pereira, A. Souza Mattei, A. Reis Gomes, R. Osório De Faria, F. Silveira, C. Bittencourt Severo, V. Rodrigues Aquino, A. Paula Giolo Franz, S. De Ávila Botton, R. Maria Zancopé-Oliveira, V. Rodrigues Poester, T. De Groot, M. Orzechowski Xavier*

E0463 **15:33** **High triazole resistance rates of *Aspergillus* fumigatus in Belgian composting facilities** *L. Cuypers* (Leuven, Belgium), L. Vinken, R. Merckx, A. Reséndiz-Sharpe, G. Vande Velde, K. Lagrou*

EF067 **14:45 – 15:45** **Arena 2**

ANT IPC PED

ePoster Flash Session

Infection control and antimicrobial stewardship in neonatal and pediatric critical care

Chair *Irja Lutsar (Tartu, Estonia)*

E0464 **14:45** **Colonisation pressure is associated with infant acquisition of ESBL genes on the neonatal unit** *A. Cook* (London, United Kingdom), M. Berkell, D.R.M. Smith, H. Van Werkhoven, E. Sieswerda, C. Minotti, L. Van Heirstraeten, S. Malhotra-Kumar, J.A. Bielicki*

E0465 **14:51** **First report of a neonatal iIntensive care unit outbreak linked to *Serratia sarumanii* in Latin America: insights from WGS and IR Biotyper** *P. Orlandi Barth* (Porto Alegre, Brazil), W. Latosinski Matos, L. Lutz, L. Rita Konkewicz, D. Castro Pereira, L. Czekster Antochevis, J.V. Barboza Cardoso, L. Quadro Stein, A.L. Barth, A. Francisco Martins*

E0466 **14:57** **Infection prevention surveillance across 29 neonatal units: methods and initial analyses from the NeoIPC Surveillance Network** *G. Karadağ* (Berlin, Germany), A. Bekker, A. Dramowski, B. Loureiro, J. Pérez López, J.I. Pijoan Zubizarreta, P.T. Heath, B. Piening*

E0467 **15:03** **What do surveillance cultures really tell us in neonates?** *P. Favier* (Valencia, Spain), P. Suarez-Urquiza, A. Valentín-Martín, A. Pinilla-González, M. Marco-Piá, M. Gomis-Sánchez, E.M. González-Barberá, M. Cernada-Badia*

E0468 **15:09** **Rapid nanopore sequencing and Average Nucleotide Identity (ANI) to guide a *Serratia marcescens* complex outbreak in a neonatal ward** *R. Sierra* (Geneva, Switzerland), C. Cave, L. Munoz, C. Ougier Riccio, A. Borghesi, R. Pfister, N. Buetti, D. Andrey*

E0469 **15:15** **Searching for the needle in the haystack with the right lens: impact of chromogenic *Serratia* spp. agar to neonatal ICU surveillance** *P. Favier* (Valencia, Spain), P. Suárez-Urquiza, A. Valentín-Martín, A. Pinilla-González, M. Marco-Piá, M. Gomis-Sánchez, M. Cernada-Badía, E.M. González-Barberá*

E0470 **15:21** **The caveats and (im)possibilities of tracking outbreaks directly from swabs in neonates** *S. Ayala Montaño* (Freiburg Im Breisgau, Germany), S. Ayala-Montaño, A.O. Afolayan, I.J. Akintayo, R. Kociurzynski, L. Duarte Dos Santos, C. Schneider, T. Nguyen, M. Kuntz, H. Fuchs, G.A. Häcker, S. Reuter*

E0471 **15:27** **Impact of BARNARDS II: introduction of standard diagnostic protocols on antibiotic stewardship and neonatal outcomes in a NICU** *S. Naqvi* (Islamabad, Pakistan), S. Riaz, M.A. Khan, R. Zahra, E. Rashid, K. Thomson, T. Walsh, B. Hassan*

E0472 **15:33** **Cefiderocol use in paediatric intensive care and neonatal intensive care units: real-world use, safety, and clinical outcomes in a tertiary hospital** *A. Estevez Prieto* (Madrid, Spain), A. Estévez, F. Camero, J. Serrano-Lobo, C. Redondo Galán, M. Slöcker-Barrio, E. Zamora-Flores, M. Sánchez-Luna, P. Muñoz*

EF068 **14:45 – 15:45** **Arena 3**

ANT CLN

ePoster Flash Session

Saving lives, preserving antibiotics: stewardship in the ICU

Chair *Bhanu Sinha (Groningen, The Netherlands)*

E0473 **14:45** **Beyond acceptance rates: what makes antimicrobial stewardship work in intensive care?** *S. Camilleri* (Melbourne, Australia), S. Khumra, A. Thomas, S. Vogrin, A. Batrouney, M. Devchand, S. Motaganahalli, S.J. Warrillow, J.A. Trubiano, G.K. Reynolds, S. Narayanasamy*

E0474 **14:51** **Beyond the 'antibiotic police': ICU clinicians' perspectives on effective antimicrobial stewardship communication** *S. Khumra* (Melbourne, Australia), S. Camilleri, A. Thomas, A. Batrouney, M. Devchand, S. Motaganahalli, S. Warrillow, J. Trubiano, G. Reynolds, S. Narayanasamy*

E0475 **14:57** **Optimising intravenous to oral antibiotic switch in intensive care units: a multi-site audit using UKHSA IVOS criteria across three West Midlands NHS Trusts** *N. Agravedi* (Birmingham, United Kingdom), A. Jenkins, A. Brush, S. Gilani*

E0476 **15:03** **Optimising Prospective Audit Feedback (PAF): hybrid approach combining AI2D (Augmented Intelligence in Infectious Diseases) and rule-based algorithm** *Y. Zhou* (Singapore, Singapore), J.L. Lim, S. Tang, J.S. Chung, Y.B. Wang, A. Kwa*

E0477 **15:09** **Antimicrobial stewardship implementation across intensive care units: insights from a national survey** *A. Van Boekel* (Leiden, The Netherlands), B. Bolhuis, R. Bentvelsen, C. Van Den Berg, L. Van Bodegom-Vos, N. Deetman, D. Dongelmans, W. Falkenburg, E. Van De Garde, J. Haringman, E. De Jong, M. Lambregts, D. De Lange, J. Schouten, C. Den Uil, S. Arbous, M. De Boer, J. Van Paassen*

E0478 **15:15** **Long-term impact of a high-intensity multimodal antimicrobial stewardship programme on broad-spectrum antibiotic consumption and resistance in an adult intensive care unit: an interrupted time series analysis (2013–2025)** *G. Roncancio Villamil* (Medellin, Antioquia, Colombia), G.E. Roncancio-Villamil, A.A. Pineda-Florez, D.A. Diaz-Ospina, A.R. Vargas-Garcia, A.M. Montoya-Duque, C.I. Garcia-Rincon, C.G. Garces-Zamudio*

E0479 **15:21** **Overcoming implementation challenges: achieving sustained excellence in antimicrobial prescribing through prospective audit and feedback in intensive care units** *N. Sandoval* (Guatemala, Guatemala), G. Ozaeta, G. Reyes, C. Karla, P. Abdi, C. Alessandra*

E0480 **15:27** **Reassessing risk in critical illness: antibiotic de-escalation remains a safe practice without increasing adverse events or mortality** *M. Inan Hekimoğlu* (Ankara, Türkiye), E. Gülten, E.M. Sarıcaoglu, A.H. Elhan, F. Yörük*

E0481 **15:33** **Effect of clinical pharmacist-led antibiotic optimisation in a resource limited tertiary ICU in South India lacking dedicated infectious disease physician support** *A. Mohamed Mohideen* (Chengalpattu, India), D. Ganesh, F. Jose, S. Kurian Mathew, M. George*

EF069 **14:45 – 15:45** **Arena 4**

ANT DX

ePoster Flash Session

AI-powered pathogen detection and AMR prediction

Chair *Belen Rodriguez-Sanchez (Madrid, Spain)*

E0482 **14:45** **Leveraging machine learning for predicting urine culture outcomes: a multi-centre prospective study** *Q. Yi* (Beijing, China), X. Zhou, Y. Guo, Y.C. Xu*

E0483 **14:51** **Pilot study for the differentiation of *Clostridium botulinum* group I and *Clostridium sporogenes* using MALDI-TOF MS and unsupervised machine learning** *F. Dematheis* (Munich, Germany), R. Schneider, D. Amort, H. Von Buttler, S. Zange*

E0484 **14:57** **A data-driven framework for *Streptococcus pneumoniae* serotype prediction from mass spectrometry profiles** *J. Zintgraff* (Barracas, Argentina), N. Sánchez Eluchans, M.A. Moscoloni, C.S. Lara*

E0485 **15:03** **Neural network-based predictions of antimicrobial resistance phenotypes in multidrug-resistant *Acinetobacter baumannii* from whole genome sequencing and gene expression** *H. Jia* (Hangzhou, China), X. Li, Y. Zhuang, Q. Yang, Z. Ruan*

E0487 **15:09** **stackPred: AI boosted AMR phenotype prediction for multiple species and antimicrobial agents** *J. Welling* (Essen, Germany), M. Balzer, L. Consten, S. Bletz, J. Buer, V. Chapot, D. Harmsen, E. Heintschel Von Heinegg, A. Mellmann, W. Pölking, F. Salhöfer, F. Schaumburg, N. Scherff, N. Wiesmann, F. Meyer*

E0488 **15:15** **Interpretable machine learning predicts antimicrobial resistance and reveals regulatory mechanisms in ESKAPEE pathogens** *A. Skoulakis* (Lamia, Greece), K. Daniilidis, S. Digenis, C.G. Gkountinoudis, E. Petinaki, A. Hatzigeorgiou*

E0489 **15:21** **MicroBIS: a novel artificial intelligence and machine learning-based digital platform for rapid bacterial identification and antimicrobial resistance prediction to strengthen diagnostics, clinical decision-making, and surveillance in resource-limited healthcare settings across Africa** *A.M. Martin* (Nairobi, Kenya),*

D. Otieno, K. Sam

E0486 **15:27** **Predicting genomics-based antibiotic susceptibilities and treatment-emergent resistance in *Acinetobacter baumannii*** *R. Shields* (Pittsburgh, Pa, United States), E. Solares, L. Bledsoe, L. Williams, K. Hall*

ME099 **14:45 – 15:45** **Hall B0-2**

PHEI

Meet-the-Expert

Pathogens and people: modelling epidemics for preparedness

M0249 **14:45** *William Hanage (Boston, United States)*

M0250 **14:57** *Vittoria Colizza (Paris, France)*

ME098 **14:45 – 15:45** **Hall ICM 1**

AMR DX

Meet-the-Expert

What's new in Antimicrobial Susceptibility Testing (AST)

M0247 **14:45** *Erika Matuschek (Växjö, Sweden)*

M0248 **14:57** *Rafael Canton (Madrid, Spain)*

Co-organised with: EUCAST Steering Committee

OS070 **16:15 – 17:15** **Hall A3-2**

CLN TRN

1-hour Oral Session

Turning mechanisms into clinical strategies in chronic viral hepatitis

Chairs *Ruxandra Calin (Paris, France)*
Yogesh Kumar Gupta (Jaipur, India)

O0491 **16:15** **NTCP-based HBV infection model to define ncRNA drivers of post-transplant HCC recurrence** *S. Aksoy* (Bursa, Türkiye), S. Ak-Aksoy, İ. Sağlık*

O0492 **16:27** **Distinct hepatitis B virus mutational patterns in hepatocellular carcinoma patients vs chronic hepatitis B patients highlight potential biomarkers for cancer progression** *E. Gupta* (Delhi, India), S. Maniraj, R. Agarwal, P. Gautam, C. Bihari, M. Sharma*

O0493 **16:39** **Prophylaxis for hepatitis B virus reactivation in patients undergoing immunosuppressive therapy: is there a continued role for lamivudine?** *G. De Simone* (Rome, Italy), L. Campogiani, V. Malagnino, E. Teti, T. Mulas, M. Compagno, D. Checchi, A.M. Geretti, L. Sarmati*

O0494 **16:51** **Hepatitis C virus reactivation in cancer patients receiving Bruton tyrosine kinase inhibitors** *T. Harrys* (Houston, United States), J. Arvelaez Pasucci, K. Mustafayev, P. Jain, Y. Jiang, E. Yepez Guevara*

O0495 **17:03** **Bulevirtide treatment of HBV-HDV coinfected patients: 12 months of real-life experience** *G.S. Gherlan* (Bucharest, Romania), R.M. Cretu, A. Blidaru, D.S. Lazar, A. Culinescu, A. Condurache, S.M. Ruta, S.A. Florescu, C.P. Popescu*

LB004 **16:15 – 17:15** **Hall B0-2**

IPC PHEI

1-hour Oral Session

Recent and ongoing high impact outbreaks

Chairs *Daniel Grupel (Jerusalem, Israel)*
Barbara Juliane Holzknecht (Copenhagen, Denmark)

L0021 **16:15** **The January 2026 Nipah virus outbreak investigation and successful containment in West Bengal, India: direct report from the field** *S. Banerjee* (Kalyani, India), A. Das, R. Basu, S. Maharatna, R. Sahay, M.K. Kundu, P. Yadav*

L0023 **16:27** **Uncovering a multi-centre outbreak of *Candida viswanathii* candidaemia caused by contaminated milrinone in Italy** *A. Mesini* (Genoa, Italy), V. Di Pilato, D. Contu, M. Castignone, M.L. Ciofi Degli Atti, G. Vrenna, L. Ricotta, C. D'amore, V. Fox, P. Bernaschi, G. Travi, M. Merli, C. Vismara, E. Matarazzo, G. Vento, V. Arena, E. Nardi, A. Marchese, R. Bandettini, G. Spiga, E. Castagnola*

L0022 **16:39** **A complete soil-water-air transmission network for urban melioidosis: source identification and successful intervention in Hong Kong** *T.F. Wong* (Hung Hom, Hong Kong), K.H.G. Siu, W.N.F. Chow*

L0024 **16:51** **Outbreak of NDM-1–producing *Burkholderia contaminans* bloodstream infections linked to contaminated intravenous metoprolol** *M. Fantoni* (Rome, Italy), P. Laurenti, B. Fiori, S. Vincenti, M. Di Donato, R. Murri, M. Wachocka, F. De Maio, M. Cioce, N. Mores, R. Campopiano, C. Pais, G. Vetrugno, T. D'inzeo, B. Posteraro, C. Torti, M. Sanguinetti*

L0025 **17:03** **Ongoing outbreak of *Burkholderia stabilis* ST480 linked to non-sterile cleansing wipes in the United Kingdom: investigation findings and mitigating patient safety risks** *R. Stretch* (London, United Kingdom), A. Carroll, D. Blackman, A. Popay, D. Kenna, M. Day, C. Willis, K. Staniforth, D. Williams, K. Osman, G. Russell, J. Papprill, J. Gordon-Brown, G. Fear, M. Mirfenderesky, D. Jeyaratnam, I. Sinha, C. Searle, C. Patterson, R. Peabody, C. Brown, E. Betts, S. Milligan, J. Elston*

LB005 **16:15 – 17:15** **Hall ICM 1**

ANT

1-hour Oral Session

New drugs and anti-infective solutions

Chairs *Shampa Das (Liverpool, United Kingdom)*
Alasdair Peter Macgowan (Bristol, United Kingdom)

L0026 **A chimeric CXCL8(3–72) K11R/G31P–BPI233 protein modulates neutrophil-driven inflammation and protects against carbapenem-resistant Gram-negative bacteria** *D. Pu* (Beijing, China), J. Zhao, B. Cao*

L0027 **Breaking bacterial communication signals: Anti-QS antibodies to block pathogenicity** *T. Posvai* (Barcelona, Spain), L. Vilaplana, M.P. Marco*

L0028 ***In vivo* efficacy and PK/PD of OSUAB-0284: a preclinical candidate for MRSA** *M. Mitton-Fry* (Columbus, United States), P. Srivastava, A. Landgraf, J. West, C. Mann, R. Kebriaei, T. Murphy, D. Andes*

L0029 **Enzybiotic therapy for species-selective eradication of staphylococcal biofilms** *M. Yousefi* (Warsaw, Poland), P. Haniewicz, M. Zaród, M. Korzeniowska, J. Kornatowski, E. Jagielska, I. Sabała*

L0030 **Investigating the antiviral activity of (±)Bay K8644 against Enterovirus D68** *J.A. Lee* (Taipei, Taiwan), K.C. Yang, L. Jin-Yi*

SY103 **16:15 – 17:15** **Hall A2-1**

DX PHEI

1-hour Symposium

Implementation of WHO Fungal Priority Pathogens List: landscape and challenges

Chairs *Katrien Lagrou (Leuven, Belgium)*
Rita Oladele (Lagos, Nigeria)

S0258 **16:15** **Pilot implementation of WHO's global surveillance system for monitoring antimicrobial resistance (GLASS-AMR) in fungal diseases** *Silvia Bertagnolio (Geneva, Switzerland)*

S0259 **16:45** **WHO global blueprint for the implementation of the Fungal Priority Pathogens List** *Nelesh Govender (Johannesburg, South Africa)*

SY102 **16:15 – 17:15** **Hall B0-1**

AMR ANT TRN

1-hour Symposium

The future of clinical phage susceptibility testing

Chairs *Saima Aslam (San Diego, United States)*
Frédéric Laurent (Lyon, France)

S0256 **16:15** **Bacteriophage potency and quality control: guidelines vs. real life** *Pieter-Jan Ceyssens (Brussels, Belgium)*

S0257 **16:45** **Bacteriophage susceptibility testing: EUCAST**

perspectives on standardisation *Annika Yanina Classen (Cologne, Germany)*

Co-organised with: ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA), EUCAST Steering Committee

---

SY101 **16:15 – 18:15** **Hall A3-1**

PED VAX

2-hour Symposium

Pertussis resurgence: understanding epidemiological trends, immune and vaccine challenges, and policy responses

Chairs *Tina Tan (Chicago, United States)*
Julie Toubiana (Paris, France)

S0252 **16:15** **Tracking pertussis: epidemiological trends and global patterns** *Gayatri Amirthalingam (London, United Kingdom)*

S0253 **16:45** **Pertussis in its most severe forms: risks, realities, and responses** *Carla Rodrigues (Paris, France)*

S0254 **17:15** **Genomic surveillance and emerging strains** *Noémie Lefrancq (Basel, Switzerland)*

S0255 **17:45** **Rethinking pertussis immunity: challenges and innovations in vaccine strategy** *Dimitri Diavatopoulos (Nijmegen, The Netherlands)*

EF071 **16:15 – 17:15** **Arena 1**

VAX

ePoster Flash Session

Risky business: preventing respiratory virus infection in high-risk groups

Chair *Vana Spoulou (Athens, Greece)*

E0496 **16:15** **Real-world effectiveness of maternal influenza vaccination in children under six months: a retrospective cohort study in a tropical setting** *N. Goh* (Singapore, Singapore), E.W. Liang, R. Ho, C. Chiew, R. Li, D. Lye, K. Tan*

E0498 **16:27** **Two-season impact of nirsevimab against RSV hospitalisation in Galicia: findings from the NIRSE-GAL study** *A. Muy Perez* (Santiago De Compostela, Spain), J.L. Razzini, I. Giné-Vázquez, J. Jin, M.I. Santiago-Pérez, O. Pérez-Martínez, M.T. Otero-Barrós, N. Suárez-Gaiche, R. Kramer, L. Platero-Alonso, R.M. Álvarez-Gil, O.M. Ces-Ozores, V. Nartallo-Penas, S. Mirás-Carballal, M. Piñeiro-Sotelo, J.M. González-Pérez, C. Rodríguez-Tenreiro-Sánchez, Á. Manzanares-Casteleiro, A.I. Dacosta-Urbieta, C. Álverez-Smith, I. Rivero-Calle, A. Salas, C. Durán-Parrondo, N. Mallah, F. Martinón-Torres*

E0499 **16:33** **RSV prefusion F vaccine effectiveness in older adults according to Charlson Comorbidity Index: A prespecified analysis of the DAN-RSV trial** *K. Feldballe Bernholm* (Copenhagen, Denmark), M.C.H. Lassen, N. Dyrby Johansen, S. H. Christensen, N. Aliabadi, K.G. Skaarup, D. Modin, K. Hyldekær Janstrup, B. L. Claggett, C. S. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, M. G. Lindholm, A.M. Reimer Jensen, M. Dons, F. Soeskov Davidovski, L. S. Duus, C. I. Ottosen, A. B. Nielsen, J. H. Borchsenius, C. Espersen, G. Köse, F. H. Fussing, L. Køber, S. D. Solomon, J.U. Stæhr Jensen, C. Jean-Marie Martel, M. Goeijenbier, S. Tellerup Nielsen, L. Russell, T. Skovsgaard Itenov, B. D. Gessner, C. Schwarz, E. Gonzalez, M. Skovdal, P. Zhang, E. Begier, T. Biering-Sørensen*

E0500 **16:39** **Immune response and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (adjuvanted RSVPreF3) in immunocompromised (IC) adults with lung or kidney transplant compared to non-IC adults up to 12 months post-vaccination** *K. Oluwayi* (London, United Kingdom), C. Small, D. Kumar, A. Abbas, A. Sánchez-Fructuoso, S. Yamanaga, V.L. Pérez-González, H. Karakizlis, M. Nissen, P.G. Choe, V. Paloschi, S. Chadban, H.A. Hailemariam, C. Gerard, M.P. David, D. Descamps, C. Agutu, V. Hulstrøm*

E0501 **16:45** **Effectiveness of the adapted XBB.1.5. COVID-19 vaccine received as a 2023 autumn dose among immunocompromised persons in six EU/EEA countries, a VEBIS EHR network study** *A. Blake* (Paris, France), J. Humphreys, N. Nicolay, T. Braeye, I. Van Evercooren, C. Holm Hansen, I. Rask, M. Fabiani, A. Mateo-Urdiales, J. Castilla, I. Martínez Baz, A. Machado, A. Brito, R. Ljung, N. Pihlström, S. Monge, K. Olsson, B. Nunes*

E0502 **16:51** **Interim analysis of the effectiveness of conventional and self-amplifying JN.1-adapted mRNA COVID-19 vaccines against symptomatic infection in adults aged 60 years, Japan** *H. Maeda* (Nagasaki, Japan), A. Igarashi, S. Mitsui, K. Suzuki, T. Kutomi, H. Fujino, T. Onoe, T. Kimura, Y. Ichigi, H. Kozai, T. Komazaki, S. Kida, K. Morimoto*

E0503 **16:57** **A novel approach assessing the impact of SARS-CoV-2 variant drift on effectiveness and durability of an XBB.1.5-adapted COVID-19 vaccine using the id.DRIVE platform** *H.R. Volkman* (New York, United States), T.M.P. Tran, M.M. Mustapha, L. De Munter, C. Marques, H. Dunford, J.V. Hernandez-Villena, M. Mitratza, A. Antón, I. Casas Garcia, B. Gruner, G. Icardi, G. Luit Ten Kate, C. Martin, A. Mira-Iglesias, A. Orrico-Sanchez, S. Otero-Romero, G. Rohde, J.L. Nguyen, K. Bollaerts*

E0504 **17:03** **Safety, tolerability, pharmacokinetics, and immunogenicity in a phase I first-in-human study with VYD2311, a SARS-CoV-2-directed monoclonal antibody** *P. Richmond* (Nedlands, Australia), L. Hu, K. Narayan, K. Tosh, R. Gerlach, I. Yacin, D. Wilfret, M. Wingertzahn*

EF072 **16:15 – 17:15** **Arena 3**

DX

ePoster Flash Session

Advances in sepsis diagnostics: improving speed and accuracy

Chair *Özlem Kurt Azap (Ankara, Türkiye)*

E0505 **16:15** **True bacteraemia vs contamination in positive blood cultures: development of a prediction model** *E. Nannini* (Rosario, Argentina), M. Dumas Marucci, J.I. Rodriguez Lia, M. Pallotta, C. Scipione, R. Bonifacio, M. Rinaudo*

E0506 **16:21** **Epidemiology and interpretation of positive blood cultures when polymerase-chain reaction-based blood culture results are "not detected"** *S. Boettcher* (Detroit, United States), R. Kenney, R. Tibbetts, L. Samuel, S. Davis, M. Veve*

E0507 **16:27** **Modeling a point-of-care diagnostic panel implementation for rapid bloodstream infection identification in remote settings: a cost-effectiveness analysis** *K. Bagge* (Copenhagen, Denmark), F.H. Jensen, J.G. Lisby*

E0508 **16:33** **Patient factors associated with circulating bacterial DNA in critically ill sepsis patients** *C. Lannsjö* (Stockholm, Sweden), B. Stammler Jaliff, D. Yu, S. Cajander, A. Bäckman, E. Tina, A. Somell, H. Alpkvist, M. Ullberg, C. Jorns, J. Wernerman, V. Özenci, K. Strålin*

E0509 **16:39** **Culture-free detection of bloodstream bacteria in ICU patients within six hours** *A. Wijen* (Maastricht, The Netherlands), C. Von Wintersdorff, R. Driessen, S. Van Mens, D. Bergmans, P. Savelkoul*

E0510 **16:45** **From culture to clarity in four hours: accelerating clinical management of bloodstream infections** *R. Ahmad* (Hamar, Norway), J. Ali, A. Basavaraj Bellankimath, S. Therese Opgård, E. Varman Manivannan, G. Skov Simonsen*

E0511 **16:51** **Rapid pathogen and antimicrobial resistance detection in bloodstream infections using short subculture and nanopore sequencing** *M. Pitombeira Liborio* (Brisbane, Australia), P. Harris, C. Ravi, K. Ramsay, T. Da Silva Duarte, A. Irwin*

E0512 **16:57** **Rapid identification of bacteraemia-causing microorganisms using MALDI-TOF MS: a comparative study of three in-house methods with two matrices** *Z.C. Karahan* (Ankara, Türkiye), R. Waheed Osman*

E0513 **17:03** **Four-day vs five-day blood culture incubation: a retrospective study of diagnostic performance using the BACT/ALERT VIRTUO system** *K. Tron* (Newcastle, United Kingdom), C. Cullerton, J. Lupton, P. Mpwilu, J. Samuel, D. Weiand*

EF073 **16:15 – 17:15** **Arena 4**

ANT CLN PHEI

ePoster Flash Session

Surveillance of antimicrobial use around the world

Chair *Kalisvar Marimuthu (Singapore, Singapore)*

E0514 **16:15** **The ECRAID Emerging Resistance Index by European region: assessing the index's applicability in different epidemiological contexts** *J. Garlasco* (Verona, Italy), F. Arieti, M. Morra, D.E. Ortiz, E. Addis, M. Tebon, O. Awwad, K. Odoj, M.D. Pezzani, S. Harbarth, E. Presterl, G. Kahlmeter, A. Cassini, A. Savoldi, E. Tacconelli*

E0515 **16:21** **Antibiotic use, rapid escalation practices and access in neonatal sepsis across LMIC tertiary care hospitals: findings from the BARNARDS II cohort** *K. Thomson* (Oxford, United Kingdom), K. Sands, J. Oduwo, C. Achi, R. Farzana, B. Hassan, E. Owinoh, M. Nziliani, A. Ko, K. Iregbu, N. Medugu, T. Akujobi, A. Mairami, A. Aminu, S.A. Suwaid, S. Gambo, Y. Mohammed, J. Abubakar, A.T. Bolajoko, O. Oduyebo, O. Olutekunbi, A. Odedina, I. Nwafia, N. Ukaegbu, C. Nzurumike, T. Amin, S. Arefin, T.N. Shatu, A.T. Promi, T. Haque, R. Tasnim, R. Zahra, E. Rashid, M.I. Shah, S. Riaz, S. Naqvi, S. Naeem, M. Haroon Hamid, S. Shabbir, U. Hussain, A. Mahboob, A.A. Shah, I. Ullah, A. Muhammad, M. Muhammad, S. Amin, M. Khan, S.U.N. Syed, M. Mahrang, T.R. Walsh*

E0516 **16:27** **Global antibiotic use (AMU) patterns in 2023: insights from WHO's global AMU surveillance system (GLASS-AMU)** *D. Tong* (Geneva, Switzerland), M. Escher, A. Muller, V. Ivanovska, D. O'doherty, B. Huttner*

E0517 **16:33** **Scaling a national antimicrobial prescribing surveillance programme incorporating an appropriateness assessment to drive policy and practice** *R. James* (Melbourne, Australia), C. Chen, K. Thursky*

E0518 **16:39** **Being more AWaRe: assessing appropriateness of antimicrobial prescribing against the World Health Organization AWaRe classifications** *C. Chen* (Melbourne, Australia), N. Sivapragasam, N. White, C. Ierano, R. James, L. Marquart-Wilson, L. Hall, K. Thursky*

E0519 **16:45** **How do we define 'appropriate antimicrobial use' in One Health? A global Delphi survey** *R. Scarborough* (Parkville, Australia), C. Ierano, K. Bailey, G. Browning, K. Thursky, R. Biezen, B. Hur, B. Mc Mullan, L. Dowson, A. Schermuly, L. Teoh, L. Hardefeldt*

E0520 **16:51** **The context of antibiotic use in commercial poultry farms in Bangladesh: an anthropological exploration** *S.M.M. Hasan* (Dhaka, Bangladesh), S.A. Prema*

E0521 **16:57** **Real-world use of novel β-lactams in fragile patients with multidrug-resistant Gram-negative infections: insights from an Italian retrospective cohort** *M. Bognetti* (Milan, Italy), F. Fama, C. Conflitti, F. Brivio, M. Piscaglia, M. Schiavini, M.V. Cossu, S. Vimercati, E. Rossin, C. Pagani, S.G. Rimoldi, A. Gori, M. Colaneri, E. Palomba*

E0522 **17:03** **Strengthening antimicrobial stewardship across Europe: EU-JAMRAI2 on frameworks, implementation, and collaborative action on human health** *M. Nunez-Nunez* (Granada, Spain), M. Nuñez Nuñez, B. Bradley-Valdenebro, J.L. Trillo-Contreras, A. López-Navas, R. Fernández-Urrusuno*

KN100 **16:15 – 17:15** **Hall ICM 14**

CLN

Keynote lecture

From post-mortem discoveries to precision care: the evolution of opportunistic fungal infection management in haematological malignancies

Chairs *Murat Akova (Ankara, Türkiye)*
Anuradha Chowdhary (Delhi, India)

K0251 **16:15** *Dimitrios P. Kontoyiannis (Houston, United States)*

ME104 **16:15 – 17:15** **Hall ICM 13a**

CLN PHEI

Meet-the-Expert

Crimean-Congo haemorrhagic fever: best practices and advances in therapeutics and vaccines

M0260 **16:15** *Önder Ergönül (Istanbul, Türkiye)*

M0261 **16:27** *Ali Mirazimi (Stockholm, Sweden)*

Co-organised with: ESCMID Emerging Infections Subcommittee

FO105 **16:15 – 17:15** **Arena 2**

CLN PRO

Open Forum

Science in action: implementation science for effective CM/ID practice in diverse settings

Chair *Rita Murri (Rome, Italy)*

F0262 **16:15** **Implementation science fundamentals: a toolkit for CM/ID practice** *Fabiana Lorencatto (London, United Kingdom)*

F0263 **16:25** **Measuring success: metrics that matter** *José Molina Gil-Bermejo (Seville, Spain)*

F0264 **16:35** **Implementing infection control best practices across diverse resource settings** *Raheelah Ahmad (London, United Kingdom)*

Co-organised with: ESCMID Education Subcommittee, Trainee Association of ESCMID (TAE) Steering Committee

---

OS076 **17:30 – 18:30** **Hall A3-2**

CLN

1-hour Case Session

A zoonotic carnival: masquerade syndromes and unusual presentations

Chairs *Loïc Epelboin (Cayenne, French Guiana)*
Joseph Papaparaskevas (Athens, Greece)

O0523 **17:30** **Buffalopox beyond borders: first imported human case in Europe** *L. Soldevila Langa* (Badalona, Spain), L. Soldevila, L. Valerio, A. Plana, X. Vallès, E. Fernández-Pedregal, S. Roure*

O0524 **17:41** **Fulminant multisystem anthrax with delayed haemorrhagic gastrointestinal involvement: a clinically unique case from an endemic region** *M. Javakhadze* (Tbilisi, Georgia), M. Kobakhidze, L. Goliadze, E. Choladze, M. Kanashvili*

O0525 **17:52** **Imported round cavitary pneumonia: an unusual presentation of murine typhus** *J.R. Le Henaff* (Toulouse, France), G. Grouteau, G. Martin-Blondel, D. Pierre, A. Merckx, G. Moulis, L. Cavalié, P. Floch, R. Gueneau*

O0526 **18:03** **A spectacular differential diagnosis of lung cancer and the elucidation of its origin** *S. Zange* (Munich, Germany), K. Kösters, F. Löhr, E. Mantel, M. Hohls, C. Hinz, F. Dematheis, T. Hoffmann, K. Silberreis, M. Seidel, M. Walter, H. Scholz, W. Roman, D. Lang*

O0527 **18:14** **Seeing the unexpected: intraretinal dirofilariasis** *H. Aldhaheri* (Abu Dhabi, United Arab Emirates), G. Rashwan, A.P. Srinivasulu, R.S. Ganeshan, Z.O.E. Babiker*

OS074 **17:30 – 18:30** **Hall ICM 13a**

CLN PHEI TRN

1-hour Oral Session

Innovations in vector-borne and zoonotic viral infections

Chairs *Casandra Bulescu (Bucharest, Romania)*
Ines Ushiro-Lumb (Marlow, United Kingdom)

O0528 **17:30** **The role of the host genetic background in tick-borne encephalitis** *S. Grygorczuk* (Bialystok, Poland), M. Parczewski, J. Dunaj, P. Czupryna, J. Adamczuk, W. Pawlak-Zalewska, A. Moniuszko-Malinowska*

O0529 **17:42** **Phenotypic characterisation of emerging neurotropic viruses using embryonic stem cell-derived neural cells and brain organoids** *S. Vogiatzis* (Padua, Italy), E. Dal Molin, G. Gori Savellini, R. Pia Falco, M. Severa, C. Lucca, A. Sinigaglia, A. Gianella, G. Ceolotto, M. Bogacheva, I. Weinstein, O. Vapalahti, M. Pacenti, M. Trevisan, E. Coccia, M.G. Cusi, L. Barzon*

O0530 **17:54** **Exploring haematocrit, platelet and leukocyte count trajectories associated with dengue: pooled analysis from Vietnam** *N.L. Vuong* (Ho Chi Minh City, Vietnam), D.T. Trung, T.V. Ngoc, N.M. Nguyet, D.T.H.*

Tam, N.T. Truong, H.T.L. Duyen, N.T.H. Quyen, N.T.T. Kieu, N.V.V. Chau, L.T.H. Tai, N.T.H. Lan, P.K. Lam, C.P. Simmons, S. Yacoub, R.B. Geskus, B.A. Wills

O0531 18:06 **A novel ARPE-19 cell-based assay for assessing interferon-mediated protection and autoantibody neutralisation in ZIKV infection** *A. Ferrari* (Pavia, Italy), I. Cassaniti, F. Rovida, D. Lilleri, S. Croce, F. Trespidi, A. Gervais, S.Y. Zhang, J.L. Casanova, A. Borghesi, F. Baldanti*

O0532 18:18 **One health investigation of Tahyna and Batai orthobunyaviruses and Sindbis alphavirus in Northern Italy, 2021-2024** *E. Dal Molin* (Padua, Italy), M. Pacenti, D. Murova, A. Sinigaglia, A. Giaretta, A. Lavazza, D. Lelli, F. Gobbo, F. Montarsi, L. Barzon*

OS075 **17:30 – 18:30** **Hall ICM 13b**

ANT CLN

1-hour Oral Session

Primary care and long-term care facilities: what´s going on in stewardship?

Chairs *Gaetan Gavazzi (Grenoble, France)*
Bradley Langford (Etobicoke, Canada)

O0533 17:30 **Evaluation of a national training roll out implementing a stewardship toolkit in primary care in England: a quasi-experimental analysis using hybrid time series modelling** *M.X. Lee* (Gloucester, United Kingdom), N.J. Zhu, J. Meadows, R. Ahamad, D.M. Lecky*

O0534 17:42 **Between-practice differences, rather than patient case-mix, drive variation in antibiotic prescribing in UK primary care: evidence from a three-way variance decomposition** *V. Nguyen* (Oxford, United Kingdom), J.V. Robotham, A.S. Walker, D. Eyre, R. Hope, C. Butler, G. Hayward, M. Sharland, K.B. Pouwels*

O0535 17:54 **Antimicrobial use and stewardship activities in Swiss long-term care facilities: data from a national point-prevalence survey** *S. Toppino* (St. Gallen, Switzerland), F. Grässli, S. Kuster, E. Glampedakis, C. Gardiol, T. Kudrnovsky, V. Piezzi, M. Schlegel, P. Kohler, D. Flury*

O0536 18:06 **Assessment of antibiotic prescribing and AWaRe classification compliance in Dutch nursing homes using national surveillance data** *A. Zondag* (Bilthoven, The Netherlands), M. Biesheuvel, J. Polman, K. Halonen, A.P.J. Haenen, S.C. De Greeff*

O0537 18:18 **Impact of an antimicrobial stewardship intervention in residential aged care: a multi-centre, stepped-wedge cluster randomised trial (START Trial)** *N. Jokanovic* (Melbourne, Australia), S.J. Lee, T. Haines, S. Hilmer, Y.H. Jeon, D. Ayton, R.L. Stuart, A. Cheng, A.J. Stewardson, T.N. Peel, A.Y. Peleg*

SY111 **17:30 – 18:30** **Hall A2-1**

PED VAX

1-hour Symposium

How to tackle congenital viral infections

Chairs *Susanne Gjeruldsen Dudman (Oslo, Norway)*
Mike Sharland (London, United Kingdom)

S0275 17:30 **Congenital CMV screening: lessons and implications for prevention** *Dana Wolf (Jerusalem, Israel)*

S0276 18:00 **Opportunities and challenges of vaccination in pregnancy** *Chrissie Jones (Southampton, United Kingdom)*

SY109 **17:30 – 18:30** **Hall B0-1**

CLN DX

1-hour Symposium

New evidence challenging the UTI paradigm

Chairs *Merel Lambregts (Leiden, The Netherlands)*
Arjana Tambic Andrasevic (Zagreb, Croatia)

S0271 17:30 **Urobiomics: detection and utility in the UTI universe** *Nicole De Nisco (Richardson, Texas, United States)*

S0272 18:00 **Complicated UTI: diagnosis and treatment strategies** *Florian Wagenlehner (Giessen, Germany)*

Co-organised with: ESCMID Scientific Affairs Subcommittee, ESCMID Study Group for Urinary Tract Infections (ESGUTI)

SY110 **17:30 – 18:30** **Hall B0-2**

CLN DX

1-hour Symposium

Dosing by breakpoints vs guidelines: are S/I/R results based on the focus of infection best practice or source of confusion?

Chairs *Iva Butic (Zagreb, Croatia)*
Sören Gatermann (Bochum, Germany)

S0273 17:30 **Pro: make AST reports as informative as possible, add different S/I/R results per indication** *Mandy Wootton (Cardiff, United Kingdom)*

S0274 18:00 **Con: don't confuse clinical colleagues, keep S/I/R fixed and add dosages in the guidelines** *Miquel Ekkelenkamp (Utrecht, The Netherlands)*

Co-organised with: Dutch Committee on Antimicrobial Policy

SY107 **17:30 – 18:30** **Hall ICM 1**

CLN DX

1-hour Symposium

Machine learning to fight against MDR *Acinetobacter baumannii*

Chairs *Hege Vangstein Aamot (Lørenskog, Norway)*
Abhilasha Karkey (Kathmandu, Nepal)

S0267 17:30 **AI approaches to improve diagnosis and treatment of MDR-Ab** *Anton Peleg (Melbourne, Australia)*

S0268 18:00 **ML algorithms for distinguishing colonisation from infection by MDR-AB** *Gert Marais (Cape Town, South Africa)*

Co-organised with: ESCMID Study Group for AI and Digitalisation (ESGAID)

SY106 **17:30 – 18:30** **Hall ICM 14**

DX

1-hour Symposium

Year in clinical microbiology

Chairs *Brigitte Lamy (Bobigny, France)*
Holger Rohde (Hamburg, Germany)

S0265 17:30 - *Belen Rodriguez-Sanchez (Madrid, Spain)*

S0266 18:00 - *Surbhi Malhotra-Kumar (Antwerp, Belgium)*

SY108 **17:30 – 18:30** **Hall ICM 5**

TRN VAX

1-hour Symposium

Immunological determinants of host-pathogen interactions in inflammation and immune compromise

Chairs *Silvio Daniel Brugger (Zurich, Switzerland)*
Pontus Naucler (Stockholm, Sweden)

S0269 17:30 **The host side of the equation: immune response diversity in streptococcal infections** *Anna Norrby-Teglund (Stockholm, Sweden)*

S0270 18:00 **Modulation of granulocyte effector response in patients with inflammatory and immunodeficiency disorders** *Srikanth Mairpady Shambat (Zurich, Germany)*

EF077 **17:30 – 18:30** **Arena 1**

CLN DX PHEI

ePoster Flash Session

Diagnosing mycobacterial infections across the globe

Chair *Jakko Van Ingen (Nijmegen, The Netherlands)*

E0538 17:30 **Clinical and microbiological correlation of NTM PCR** *N. Shah* (Svs Road, Mahim West, India), S. Shirole, K. Ajbani, B. Jadeja, S. Gore, S. Ganta, S. Naik, C. Rodrigues, S. Basu, A. Bijwe, U. Agrawal, A. Sunavala*

E0539 **17:36** **Improving tuberculosis diagnosis through AI (CAD4TB) and Stool-Xpert MTB/RIF: a prospective study from Oromia, Ethiopia** *G. Guido* (Bari, Italy), B. Gulo, S. Cotugno, W. Nigussa, K. Bobosha, F.V. Segala, B. Zauli, B. Kenate Sori, G. Putoto, F. Cavallin, G. Madeddu, F.A. Bobbio, N. Veronese, A. Biset Asmare, A. Reta, R. Iatta, S. Abata, M. Miressa, F. Gobbi, L. Guglielmetti, M. Tilahun, A. Saracino, A. Alemseged, F. Manenti, F. Di Gennaro*

E0540 **17:42** **A $26 gold standard *Mycobacterium tuberculosis* complete genome using long read sequencing** *A. Osmaston* (London, United Kingdom), C. Leon, O. Romero, D. Taquiri, P. Avellaneda, J.B. Raez Pereyra, J.L. Perez, S. Huaman, J. Coronel, W. Solano, R. Gilman, A. Torres-Ortiz, G. Tan, B. Sobkowiak, P. Sheen, M. Zimic, L. Grandjean*

E0541 **17:48** **Whole genome sequencing–based clonality assessment of *Mycobacterium simiae* isolates from Lebanon** *M. Antar* (Beirut, Lebanon), Z. Awad, S. Agsous, L. Tabet, C. Allam, M. Abifadel, F. Mougari, J. Najjar-Pellet, E. Cambau*

E0542 **17:54** **Machine learning-assisted differentiation of Mycobacterium tuberculosis complex species from MALDI-TOF mass spectra** *M. Gutiérrez-Pareja* (Madrid, Spain), F. Alcaide, L. Herrera, D. Domingo, V. González-Galán, J. Viñuelas-Bayon, M. Simón-Sacristán, C. Castelló-Abietar, B. Fernández-Pérez, M. Oviaño, L. Fernández-Delgado, A. Candela, E. Abascal, M.J. Ruiz-Serrano, B. Rodríguez-Sánchez, D. Rodríguez-Temporal*

E0543 **18:00** **The last diagnostic line: molecular pathology uncovers missed Mycobacterial infections** *L. Wang* (Shanghai, China), G. Shang, L. Qin, Y. Ji, Q. Miao, B. Hu*

E0544 **18:06** **Consensus-based diagnostic evaluation of a novel tuberculosis IGRA in a low-endemic population** *K. Callebaut* (Bruges, Belgium), T. Chin, V. Verbeke, A. Muyldermans, M. Verhulst, M. Reynders*

E0545 **18:12** **Evaluation of *Mycobacterium tuberculosis* derived cell-free DNA (CF-DNA) based multi-targeted real-time PCR (MRTPCR) from extrapulmonary (EPTB) samples for diagnosis of extrapulmonary tuberculosis (EPTB)** *K. Sharma* (Chandigarh, India), M. Modi*

E0546 **18:18** **Targeted next-generation sequencing-a promising approach in the diagnosis of *Mycobacterium tuberculosis* and drug resistance** *X. Wu* (Shanghai, China)*

EF078 **17:30 – 18:30** **Arena 2**

CLN IPC TRN

ePoster Flash Session

Prevention and management of implant-associated infections: biofilm control and beyond

Chair *Biljana Carevic (Oslo, Norway)*

E0547 **17:30** **Preventing bacterial colonisation of synthetic bone grafts using nanostructured hydroxyapatite and cold atmospheric plasma-treated liquids** *A. Ruiz Sorribas* (Barcelona, Spain), F. Tampieri, C. Canal, M.P. Ginebra*

E0548 **17:36** **Supercritical CO2 as an innovative method to inactivate biofilms on orthopaedic implants** *R. Hafian Al-Homsi* (Madrid, Spain), R. Hafian, A. Cabañas, P. Sanz, L. Calvo*

E0549 **17:42** **Bilayer sol–gel coating prevents *Staphylococcus aureus* prosthetic joint infection and improves bone integration in mice** *J. Aguilera Correa* (Madrid, Spain), B. Toirac, J.J. Aguilera-Correa, Á. Solís-Garrido, A. Mediero, F. Mulero, O. Velyt-Vepryk, J. Esteban, A. Jiménez-Morales*

E0550 **17:48** **Risk factors for early infection after spinal instrumentation surgery: a multi-centre case-control study** *M. Muelas-Fernandez* (Barcelona, Spain), J.A. Iribarren, E. Benavent, A. Marron, J.M. Bravo-Ferrer, H. Vilchez, D. Rodriguez-Montserrat, N. Sopena, M. Riera, O. Gasch, A. Lersundi, M.D. Del Toro, O. Murillo*

E0551 **17:54** **Risk stratification and clinical impact of Gram-negative fracture-related infections** *F. Petrucci* (Rome, Italy), D. De Meo, P. Martini, M. Rivano Capparuccia, G. Iaiani, S. Gumina, C.M. Mastroianni, A. Oliva*

E0552 **18:00** **Keeping it clean when things inflate: evidence gaps in antimicrobial strategies for penile prosthesis surgery** *R. Ghani* (London, United Kingdom), P. Sangster, W.G. Lee, S. Dewan, P. Panesar, G. Satta*

E0553 **18:06** **Rifampicin combination therapy fails to enhance clearance and induces growth delay in a rat model of *Staphylococcus aureus* vascular graft infection** *E. Faddy* (Aarhus N, Denmark), J. Bär, M.I. Johansen, C. Gadeberg, L.B. Carstens, L. Østergaard, L.T. Erikstrup, S. Mairpady Shambat, A. Zinkernagel, R.L. Meyer, N.P. Jørgensen*

E0554 **18:12** **Characteristics, management and outcomes of vascular graft and endograft infections in Eastern Denmark: a retrospective cohort study** *A.J. Christensen* (Hilleroed, Denmark), S. Bjerrum, K. Sörelius, I.H.M. Mathiesen, C. Moser, J. Helweg-Larsen, B.V. Sandholt, D. Faurholt-Jepsen, C. Kraef*

E0555 **18:18** **Antibiotic and surgical treatment in staphylococcal ventriculoperitoneal shunt infections in adults** *I. Pelegrín Senent* (Barcelona, Spain), I. Pelegrín, M. Sanz De Mena, J. Gómez-Junyent, C. Iglesias, M.M. Moreno, A. Siverio, S. Gómez-Zorrilla, L. Sorli, M.M. Montero, J.P. Horcajada*

EF079 **17:30 – 18:30** **Arena 3**

AMR

ePoster Flash Session

Molecular epidemiology and genomic evolution of high-priority MDROs

Chair *Helena Zemlickova (Prague, Czechia)*

E0556 **17:30** **Antimicrobial susceptibility and molecular characterisation of carbapenem-resistant Enterobacterales (CRE) from European medical centres stratified by country (2020-2024)** *H.S. Sader* (North Liberty, United States), J.H. Kimbrough, G. Stone, K. Perez, R. Mendes, M. Castanheira*

E0557 **17:36** **Emergence of new variants of OXA-48 in France** *L. Bientz* (Le Kremlin-Bicêtre, France), R. Nermont, C. Emeraud, T. Naas, R.A. Bonnin, L. Dortet*

E0558 **17:42** **Spread of carbapenemase-producing Serratia spp. in France from 2016 to 2024: a comparative genomic study** *L. Dortet* (Le Kremlin-Bicêtre, France), I. Rezzoug, S. Bernabeau, K. Oucel, A. Birer, A. Jousset, L.M. Gerald, E. Cécile, D. Laurent*

E0559 **17:48** **Molecular epidemiology and resistome of carbapenem-resistant *Klebsiella pneumoniae* isolates from five referral centres in South Africa** *G. Marais* (Cape Town, South Africa), S. Africa, F. Patel, E. Geza, E. Du Toit, F. Franceschi, R.M.A. Da Costa, A. Brink*

E0560 **17:54** **Emergence of vancomycin-variable *Enterococcus faecium* following the expansion of Vancomycin-resistant *E. faecium* in Taiwan** *W.C. Hung* (Kaohsiung, Taiwan)*

E0561 **18:00** **Increase in OXA-48-like carbapenemase-producing Enterobacterales driven by clonal expansion and plasmid dissemination in the Netherlands, 2019-2024** *A. Hendrickx* (Bilthoven, The Netherlands), S. Lansu, A. De Haan, S. Witteveen, J. Bos, F. Landman, C.C.H. Wielders, S.C. De Greeff, D.W. Notermans*

E0562 **18:06** **Plasmid population analysis of *Klebsiella pneumoniae* spanning two decades** *M. Martin* (Silver Spring, United States), E. Nguyen, A. Sapre, T. Luo, B. Jones, V. Rollins, R. Maybank, A. Ong, Y. Kwak, J. Bennett, P. Mc Gann, F. Lebreton*

E0563 **18:12** **High prevalence of ESBL Enterobacterales colonisation in elderly people with high care needs in Liverpool, UK** *J.M. Lewis* (Liverpool, United Kingdom), S. Galllichan, E. Picton-Barlow, C. Mckeown, S. Forrest, M. Moore, S. Todd, M. Taegtmeyer, F.E. Graf, N.A. Feasey*

EF080 **17:30 – 18:30** **Arena 4**

ANT TRN

ePoster Flash Session

Beyond the cocktail: advances in phage therapy

Chair *Maria Vehreschild (Frankfurt Am Main, Germany)*

E0565 **17:30** **Capsule-independent entry route for *Acinetobacter baumannii* phage infection** *H. Oliveira* (Braga, Portugal), S. Lorenz, D. Turner*

E0567	**17:36**	**Exploiting the natural power of phage lysins as novel enzyme-based antibiotics to treat polymicrobial Gram-negative infections** *G. Vandermarliere* (Ghent, Belgium), G. Hermans, D. Grimon, Y. Briers, R. Vázquez, V. Stove, J. De Waele*
E0568	**17:42**	**Hidden lytic potential of human gut phages: discovery of thousands of endolysins and holins** *M. Khan Mirzaei* (Neuherberg, Germany), A.H.A. Elbehery, S. Abdullah, B. Neumann, M.K. Mirzaei, L. Deng*
E0569	**17:48**	**Engineered phage therapy using parenteral and intravesical delivery of CRISPR-Cas armed phages (SNIPR001) in mice increase survival and reduces infection?** *A. Gram* (Copenhagen, Denmark), A. Østergaard Petersen, J. Krause Haaber, E. Van Der Helm, A. Troy, J. Hink, C. Grøndahl*
E0570	**17:54**	**Rational selection of a synergistic phage combination enabled clearance of mouse gut colonisation by carbapenemase-producing *Escherichia coli* ST131** *F. Laumay* (Lyon, France), G. Dalmasso, R. Beyrouthy, C. Baeza, B. Lapras, M. Bonhomme, P. Martins-Simoes, E. Helluin, L. Blazere, V. Bonnin, L. Guillouard, R. Froissart, M. Medina, C. Kolenda, F. Pirot, L. Dortet, R. Bonnin, R. Bonnet, F. Laurent*
E0571	**18:00**	**Exploring phage-amikacin combination against metallo-β-lactamase Gram-negative bacteria in a murine thigh infection model** *P. Paranos* (Athens, Greece), P.C. Georgiou, S. Pournaras, J. Meletiadis*
E0572	**18:06**	**A phage cocktail promotes intestinal decolonisation of multidrug-resistant *Klebsiella pneumoniae*: insights from a 3D *in vitro* microbiota model** *M. Calvigioni* (Pisa, Italy), E. Fausti, C. Ferretti, G. Vozzi, E. Ghelardi, M. Di Luca*
E0573	**18:12**	**Regional therapeutic phages and genomic correlates of susceptibility in refractory/resistant *Pseudomonas* infections: findings from a multi-centre Asian cohort** *A. Kwa* (Singapore, Singapore), Y. Liu, S. Thong, Z.S. Chong, S.H. Tan, Y. Zhong, A. Chan, S. Booraphun, A.Y. Li, P. Domthong, G. Kayastha, Y.H. Lau, P. Chetchotisakd, D. Limmathurotsakul, P.A. Tambyah, B.S. Cooper, Y. Mo*
E0566	**18:18**	**Mechanistic insights and clinical implications of cross-reactive anti-prophage antibodies on phage therapeutic failure** *A. Peleg* (Melbourne, Australia), F. Gordillo Altamirano, D. Subedi, B. Gardiner, J. Hawkey, J. Barr*

ME112 **17:30 – 18:30** **Hall A2-2**

VAX **Meet-the-Expert**

Immunisation strategies for vaccine-preventable arboviral diseases: recent advances and future directions

M0277	**17:30**	*Alfonso J. Rodriguez-Morales (Pereira, Colombia)*
M0278	**17:42**	*Antonio Carlos De Albuquerque Bandeira (Lauro De Freitas, Brazil)*

Co-organised with: ESCMID Vaccine Study Group (EVASG)

Monday, 20 April 2026

EW120 **08:30 – 10:30** **Hall A2-2**

TRN **2-hour Educational Session**

Future of fungi: biomarkers, big data and mycobiome

Chairs *Methee Chayakulkeeree (Bangkok, Thailand)*
Oliver A. Cornely (Cologne, Germany)

W0390	**08:30**	**Next-gen biomarkers for invasive fungal disease** *Laura Alcazar Fuoli (Madrid, Spain)*
W0391	**08:50**	**AI in action: big data and models in fungal infections** *Daniele Roberto Giacobbe (Genoa, Italy)*
W0392	**09:10**	**Pulmonary mycobiome: a missing link in lung health?** *Cecile Angebault (Creteil, France)*
W0393	**09:30**	**Steroids and risk: quantifying IFI susceptibility** *Andrés Henao (Aurora, United States)*

Co-organised with: ESCMID Fungal Infection Study Group (EFISG), European Confederation of Medical Mycology (ECMM), Portuguese Society of Infectious Diseases and Clinical Microbiology, Romanian Society for Medical Mycology and Mycotoxicology (SRMMM), Austrian Society for Medical Mycology (ÖGMM), Belgian Society of Human and Animal Mycology, Spanish Study Group for Medical Mycology of SEIMC (GEMICOMED), Asia Fungal Working Group (AFWG), Taiwan Society of Microbiology

---

EW118 **08:30 – 10:30** **Hall ICM 13a**

IPC **2-hour Educational Session**

Integrating IPC into hospital design: a collaborative approach to safer hospitals

Chairs *Sabiha Essack (Durban, South Africa)*
Constantinos Tsioutis (Nicosia, Cyprus)

W0382	**08:30**	**Building safer hospitals: what is the role of the IPC?** *Margreet C. Vos (Rotterdam, The Netherlands)*
W0383	**08:50**	**Consult your architect: optimising infection control through hospital layout and design** *Marco Gola (Milan, Italy)*
W0384	**09:10**	**Collaborating with operations: HVAC systems in healthcare, balancing airflow and infection control** *Jeffrey Siegel (Toronto, Canada)*
W0385	**09:30**	**Consult your water hygienist: engineering and planning aspects of water systems for safe patient care** *Evdokia Katsemi (Frankfurt, Germany)*

EW119 **08:30 – 10:30** **Hall ICM 13b**

CLN DX **2-hour Educational Session**

Your attention, please! Parasitic infections in immunocompromised patients

Chairs *Miriam José Alvarez Martinez (Barcelona, Spain)*
Hanne Brekke (Oslo, Norway)

W0386	**08:30**	**A deadly duo: immnunosuppression and alveolar echinococcosis** *Ansgar Deibel (Zurich, Switzerland)*
W0387	**08:50**	**Please, do not forget: *Strongyloides* and immunosuppression** *Dora Buonfrate (Negrar, Italy)*
W0388	**09:10**	**Management of visceral leishmaniasis in the immunocompromised** *Jaya Tapadar Née Chakravarty (Varanasi, India)*
W0389	**09:30**	**Double challenge: Chagas diseases and immunosuppression** *Marisa Liliana Fernandez (Ciudad Autónoma De Buenos Aires, Argentina)*

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP), Latin American Society for Travel Medicine, Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica

---

OS081 **08:30 – 10:30** **Hall B0-2**

CLN PED TRN **2-hour Oral Session**

Hot topics in tuberculosis

Chairs *Emmanuelle Cambau (Paris, France)*
Christian Wejse (Aarhus, Denmark)

O0574	**08:30**	**A 3D-bioprinted granuloma platform with controlled syringe-based infection for studying Mtb drug response and host–pathogen interactions** *R. Sorrentino* (Milan, Italy), R. Pinos, P. Miotto, A. Ghodousi, F. Saluzzo, A. Muscetti, C. Scielzo, D.M. Cirillo*
O0575	**08:42**	**Airway microbiome signatures accurately discriminate *Mycobacterium tuberculosis* infection status** *G. Olweny* (Kampala, Uganda), A. Kayongo, M.L. Ntai*
O0576	**08:54**	**A platelet activation signature defines the CSF compartment in early tuberculous meningitis** *K. Skolimowska* (London, United Kingdom), A.G. Davis, T. Reid, N. Bangani, C. Stek, P. Renner, M. Panchoo, R.J. Wilkinson, J.S. Friedland*
O0577	**09:06**	**A randomised comparison of management strategies for drug-induced liver injury associated with tuberculous meningitis treatment** *J. Donovan* (Ho Chi Minh City, Vietnam), N.T.T. Hiep, T.T. Hung, H.D.T. Nghia, L.H.B. Ngoc, N.D. Bang, K. Maharani, P.K.N. Oanh, E. Riwanti, N.T.T. Thuong, E. Kestelyn, D. Imran, R.L. Hamers, R.B. Geskus, N.H. Phu, G.E. Thwaites*

O0578 **09:18** **Genomic epidemiology as a high-resolution tool to investigate local tuberculosis outbreaks** *M.G. López* (Valencia, Spain), A. Blasco-Molla, P. Cano-Jiménez, J.C. Gascó-Laborda, I. Gómez-Navarro, V. Furió, M. Torres-Puente, F.J. Roig-Sena, J. Bellido-Blasco, I. Comas*

O0579 **09:30** **Assessing the diagnostic accuracy of TB transcriptomic signatures in children: insights from the RaPaed-TB study** *A. Razid* (Munich, Germany), O. Baranov, M. Mcclean, Z. Franckling-Smith, H. Zar, C. Khosa, D. Banze, I. Sabi, N. Ntinginya, M. Nliwasa, E. Corbett, R. Semphere, V. Verghese, J. Michael, M. Ninan, E. Saathoff, T. Mchugh, S. Graham, R. Song, P. Nabeta, A. Trollip, M. Nicol, M. Ahmed, M. Hoelscher, N. Heinrich, L. Olbrich, C. Geldmacher, K. Held*

O0580 **09:42** **Tuberculosis infections among rifampicin-resistant tuberculosis household contact persons: a multi-central prospective cohort study (TCCT study)** *F. Zhou* (Shanghai, China), Y. Lan, Q. Yang, W. Zhang, Q. Ruan*

O0581 **09:54** **Phenotypic drug susceptibility testing of *Mycobacterium tuberculosis* in less than a day** *B.M. Tran* (Uppsala, Sweden), J. Larsson, E. Amselem, P. Knagge, J. Elf*

O0582 **10:06** **Are WHO recommended rapid diagnostic tests a panacea for the diagnosis of multidrug-resistant tuberculosis?** *N. Mvelase* (Durban, South Africa), G. Vadivelu, R. Singh, Y. Mahabeer*

O0583 **10:18** **Inadequate access to TB and MDR-TB therapies in the EU and the European economic area: the role of regulatory pathways** *M. Van Der Heijden* (London, United Kingdom), R. Otto-Knapp, C. Årdal*

SY116 **08:30 – 10:30** **Hall A3-1**

AMR DX

2-hour Symposium

Mobile elements and plasmids in Gram-positive pathogens: new frontiers in structure, function and clinical impact

Chairs *Kristin Hegstad (Tromso, Norway)*
Marc Stegger (Copenhagen, Denmark)

S0374 **08:30** **Conjugation and host-range in Gram-positive plasmids: barriers and bridges** *Elisabeth Grohmann (Berlin, Germany)*

S0375 **09:00** ***Enterococcus faecium*: mobile elements and AMR spread** *Jia Qi Beh (Melbourne, Australia)*

S0376 **09:30** **The adaptation of *Staphylococci* for clonal success** *Maria Miragaia (Oeiras, Portugal)*

S0377 **10:00** **Resolving mobile elements and plasmids in Gram-positive pathogens: what new genomics reveals** *Jukka Corander (Oslo, Norway)*

Co-organised with: ESCMID Study Group for Mobile Elements and Plasmids (ESGMAP), ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)

SY117 **08:30 – 10:30** **Hall A3-2**

DX PHEI

2-hour Symposium

How to maintain the microbial safety of transfusion and transplantation?

Chairs *Oscar Len (Barcelona, Spain)*
Anna Papa-Konidari (Thessaloniki, Greece)

S0378 **08:30** **Emerging infections and blood safety: urgent matter** *Heli Harvala (Turku, Finland)*

S0379 **09:00** **Are syphilis and other sexually-transmitted infections a problem for blood safety?** *Thijs Van De Laar (Amsterdam, The Netherlands)*

S0380 **09:30** **Tools to prevent transmission of HHV-8 via organ transplantation** *Ines Ushiro-Lumb (Marlow, United Kingdom)*

S0381 **10:00** **Amyloid beta as a novel transmissible agent** *John Collinge (London, United Kingdom)*

Co-organised with: European Society for Clinical Virology (ESCV)

SY115 **08:30 – 10:30** **Hall B0-1**

AMR TRN

2-hour Symposium

Interconnected microbiomes and resistomes across One Health

Chairs *Debby Bogaert (Edinburgh, United Kingdom)*
John W. A. Rossen (Groningen, The Netherlands)

S0370 **08:30** **Hospital microbiomes as hotspots for emerging resistance: surveillance-to-intervention** *Amy Mathers (Charlottesville, United States)*

S0371 **09:00** **Silent transmission: the genetic bridges between worlds** *Bruno Gonzalez-Zorn (Madrid, Spain)*

S0372 **09:30** **Into the wild: connectivity of wildlife resistomes and antimicrobial resistance across sectors** *Jacob Moran-Gilad (Beer Sheva / Jerusalem, Israel)*

S0373 **10:00** **From barn to city: environmental transmission of livestock-associated microbiota and antimicrobial resistance** *Myrna Maria Theresia De Rooij (Utrecht, The Netherlands)*

SY113 **08:30 – 10:30** **Hall ICM 1**

CLN PHEI

2-hour Symposium

Sepsis 2026: practice-changing insights you can't ignore

Chairs *Thierry Calandra (Epalinges, Lausanne, Switzerland)*
Robin Patel (Rochester, Minnesota, United States)

S0361 **08:30** **ISF-ESCMID Sepsis Award**

S0362 **08:45** **Reversing sepsis mortality in Uganda's refugee settlements: a solar-powered diagnostic revolution** *U. Muhumuza* (Kampala, Uganda), Z. Nahumuza, B.B. Nanyange*

S0363 **09:00** **The new surviving sepsis campaign 2026 guidelines** *Willem Joost Wiersinga (Amsterdam, The Netherlands)*

S0364 **09:30** **Immunotherapy for sepsis: finally there!** *Eleni Karakike (Athens, Greece)*

S0365 **10:00** **Sepsis: year in review** *Annelies Zinkernagel (Zurich, Switzerland)*

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), International Sepsis Forum (ISF)

SY114 **08:30 – 10:30** **Hall ICM 5**

IPC PHEI

2-hour Symposium

Barriers to infectious disease control and treatment in resource-limited settings

Chairs *Nitin Gupta (Manipal, India)*
Priscilla Rupali (Vellore, India)

S0366 **08:30** **Scrub typhus: a neglected tropical disease** *Winsley Rose (Vellore, India)*

S0367 **09:00** **The impact of recent severe flooding events and global funding shifts on HIV in Malawi** *Sam Phiri (Lilongwe, Malawi)*

S0368 **09:30** **Polio eradication in Pakistan: health services, violence, and the 'Long Goodbye'** *Svea Closser (Baltimore, Maryland, United States)*

S0369 **10:00** **Barriers to cholera control in Malawi amidst climate disasters** *Anat Rosenthal (Beer Sheva, Israel)*

EF082 **08:30 – 09:30** **Arena 2**

AMR

ePoster Flash Session

Chasing resistance to anti(retro)virals

Chair *Snjezana Zidovec Lepej (Zagreb, Croatia)*

E0584 **08:30** **Emergence and persistence of RSV-B resistant variants under monoclonal antibody pressure: evidence in a 3D human airway model** *A. Caillault* (Créteil, France), A. Ly, P. Cappy, A. Soulier, J.M. Pawlotsky, L. Softic, S. Fourati*

E0585 **08:36** **Resistance mutations on M2 gene of A(H5N1) viruses: are adamantanes still useful against avian influenza?** *I. Sanz* (Valladolid, Spain), I. Sanz-Muñoz, A. Martín-Toribio, M. Toquero-Asensio, S. Galindo-*

Carretero, L. Sanchez-De Prada, J. Sánchez-Martínez, C. Rodriguez-Crespo, R. Iglesia-Aparicio, C. López-Gonzalo, S. Rojo-Rello, M. Domínguez-Gil, M. Hernández-Pérez, J.M. Eiros

E0586 **08:42** **Emergence of the novel PA-D27G mutation conferring reduced baloxavir susceptibility in influenza A viruses circulating in China, 2018–2025** *B. Sun* (Shanghai, China), H. Wang, X. Zhao, J. Ai, W. Zhang*

E0587 **08:48** **Tracking RSV fusion protein variability across seven decades: risks of resistance to prophylactic antibodies** *F. Serrano Cano* (Antwerp, Belgium), F.I. Serrano-Cano, K. Stobbelaar, S. Van Looy, K. Van Hoorenbeeck, R. Sanjuán, P. Delputte*

E0588 **08:54** **Integrated viral resistance analysis in participants with COVID-19 treated with remdesivir across six phase III clinical studies** *C. Hedskog* (Foster City, Ca, United States), L. Rodriguez, J. Moshiri, D. Han, N. Peinovich, T. Aeschbacher, J. Li, R. Martin, J.K. Perry, R.H. Hyland*

E0589 **09:00** **Ensitrelvir treatment of COVID-19 across multiple global phase III trials resulted in reduced culture positivity and RNA copy number with minimal viral rebound** *A. Hurt* (England, United Kingdom), H. Nobori, H. Sakaguchi, A. Luetkemeyer, D. Verdi, F. Draica, S. Portsmouth, T. Uehara*

E0591 **09:06** **APOBEC-context mutations vs true HIV resistance: evidence from a hospital population in Quito, Ecuador** *G. Sevillano* (Quito, Ecuador), C. Moreno-Izquierdo, M. Granja, J. Zurita, C. Zurita-Salinas*

E0592 **09:12** **Limited emergence of dolutegravir-associated resistance mutations in HIV-1 across Africa** *P. Appiah* (Accra, Ghana), M. Adusei-Poku, B.M. Obeng, R. Osei-Yeboah, E.T. Norgbe, P. Omoniyi, M. Akuka, L. Mac-Ankrah, I. Jamfaru, S. Ankamah, K.O. Duedu, K.W.C. Sagoe*

PM001 **08:30 – 10:30** **Hall A2-1**

DX PHEI

Pipeline Symposium

AI in infectious diseases: the future is now

Chairs *Giorgia Carra (Lausanne, Switzerland)*
Oliver Nolte (Zurich, Switzerland)

D0001 **08:30** **AI: risks and opportunities** *Bram Lestrade (Roermond, The Netherlands)*

D0002 **09:00** **AI: experiences in drug discovery** *Stephan Sieber (Munich, Germany)*

D0003 **09:30** **AI: modelling epidemics and analysing disease outbreaks** *Moritz U. G. Kraemer (United Kingdom)*

D0004 **10:00** **AI in the regulatory field** *Radu Botgros (Amsterdam, The Netherlands)*

SY121 **09:30 – 10:30** **Hall ICM 14**

PHEI

1-hour Symposium

Year in public health

Chairs *Alexandra Mailles (Saint-Maurice, France)*
Rita Oladele (Lagos, Nigeria)

S0394 **09:30** *- David Fisman (Toronto, Canada)*

S0395 **10:00** *- Kurt Hanevik (Bergen, Norway)*

EF083 **09:30 – 10:30** **Arena 1**

AMR DX TRN

ePoster Flash Session

Expanding the role of genomics and proteomics against AMR

Chair *Lorena Lopez Cerero (Seville, Spain)*

E0593 **09:30** **Benchmarking antimicrobial resistance gene prediction tools from metagenomic sequencing data of positive blood cultures** *K. To* (Hong Kong, Hong Kong), A. Li, D. Buhl, A. Chu, W.M. Chan*

E0594 **09:36** **Molecular characterisation of the first CTX-M-15 and OXA-9 β-lactamase-producing *Haemophilus influenzae* isolates in the Iberian Peninsula** *I. Cadenas Jiménez* (L`hospitalet De Llobregat, Spain), A. González-Díaz, M. Pinto, I. Cadenas-Jiménez, S. Duarte, C. Ardanuy, M.M. Ribeiro, S. Marti, P. Bajanca-Lavado*

E0595 **09:42** **Genomic surveillance uncovers polyphyletic, high-risk *Escherichia coli* lineages in apparently healthy children and household livestock** *N. Okumu* (Nairobi, Kenya), E. Cook, O. Cumming, A. Moodley, J. Juma, S. Oyola, J. Ngeranwa, D. Muloi*

E0596 **09:48** ***In vitro* activity of cefiderocol against carbapenemase-producing *E. coli*: phenomics vs genomics for antimicrobial susceptibility prediction** *M. Razavi* (Stockholm, Sweden), C. Tellapragada, P. Jonsson, C. Giske*

E0597 **09:54** **Quantifying the association of resistance with antimicrobial resistance genes in *Escherichia coli* for new β-lactam/β-lactamase-inhibitor/enhancer combinations** *J. Takata* (Oxford, United Kingdom), D. Nagy, V. Pennetta, K. Hopkins, A. Roohi, D. Karageorgopoulos, M.B. Avison, A. Mathers, R. Hope, D. Williams, A. Ledda, J. Robotham, C.S. Brown, P. Bejon, G. Mcvean, A.S. Walker, K.L. Hopkins, S. Lipworth, N. Stoesser*

E0598 **10:00** **K-MARVEL: K-Mer-based antimicrobial resistance virtual exploration lab** *R. Ahmad* (Hamar, Norway), N.S. Mahar, S. Branders, M.G. Grabherr, I. Gupta*

E0599 **10:06** **Early antimicrobial resistance prediction using urinary proteomics and machine learning** *E. Lemann* (Gothenburg, Sweden), A. Marchi, R. Karlsson, A. Polster*

E0600 **10:12** **Genomic characterisation of carbapenem-resistant Enterobacterales (CRE) reveals high-risk clones and patient-environment transmission in a Nigerian tertiary hospital** *B.A. Olanipekun* (Ilorin, Kwara State, Nigeria), L.A. Molano, J. Rehner, A. Afolayan, P. Jung, R. Raheem, A. Fadeyi, A. Keller, A. Shittu, C. Nwabuisi, S. Becker*

E0601 **10:18** **A Next-generation platform for culture-free AMR gene identification in human infections** *T. Mehrotra* (Faridabad, India), B. Das*

EF084 **09:30 – 10:30** **Arena 3**

TRN

ePoster Flash Session

From virus to host and back again: exploring retroviruses

Chair *Anna Maria Geretti (London, United Kingdom)*

E0602 **09:30** **Defining the contribution of T lymphocyte activation and proliferation to the HIV reservoir** *L. Santinelli* (Rome, Italy), L. Bortolani, L. Maddaloni, M. Andreotti, Z. Michelini, C. Falvino, G. Ceccarelli, C.M. Mastroianni, G. D' Ettorre*

E0603 **09:36** **Unexpected high prevalence of HTLV-1 in HIV-1 positive patients: a looming crisis?** *G. Zahra* (Tehran, Iran, Islamic Republic of), A. Letafati, L. Abbasian, S. Sadeghipour Marvi, S.H. Mozhgani, B. Sarshari*

E0604 **09:42** **Immune checkpoint LAG3 overexpression reflects T cell dysfunction in PLWH with low CD4/CD8 ratio** *G. Nunnari* (Catania, Italy), S. Spampinato, G. Scuderi, M. Pinzone, N.L. Parrinello, M. Di Rosa, F. Condorelli, E. Venanzi Rul, A. Marino, R. Bruno, B. Cacopardo, B.M. Celesia, F. Di Raimondo, P. Fagone*

E0605 **09:48** **Near full genome sequencing of HIV-2** *M. Obermeier* (Berlin, Germany), Ö. Yildirim, M. Prentice, R. Ehret*

E0607 **09:54** **Exploring immune correlates of low viral reservoir burden in people living with HIV following early ART initiation: a retrospective longitudinal study from the DZIF TOP-HIV cohort** *M. Figueroa Orozco* (Munich, Germany), E. Grüner, M. Münchhoff, R. Cohen, T. Trenkner, M. Beiersdorfer, A. Hölzemer, J. Roider*

E0608 **10:00** **HIV-1 Subtype definition in the era of whole genome sequencing** *F. Stefanelli* (Genoa, Italy), N. Randazzo, N. Nigro, S. Varesano, M. Ferraris, E. Massaro, V. Paolozzi, M. Ogliastro, L. Taramasso, V. Ricucci*

E0609 **10:06** **Comparison of HIV clusters in metropolitan France and overseas territories** *B. Visseaux* (Frepillon, France), N. Rybak, G. Wartel, L. Nguyen, M. Niang, E. Hedbaut, S. Teixeira, V. Kailainathan, K. Diallo, S. Lastere*

LB006 **11:00 – 12:00** **Hall A1-1**

1-hour Oral Session

PHEI

Late-breaking disease surveillance approaches

Chairs *Megan Carey (Amsterdam, The Netherlands)*
Carla Rodrigues (Paris, France)

L0031 **11:00** **Inferring the global risk of dengue outbreaks** *V. Cabrini* (Singapore, Singapore), M.K.B. Mohamad Rosle, E.L.W. Choo, Y. Chen, J.T. Lim*

L0032 **11:12** **A climate-responsive emerging disease risk projection platform: version 1 release and early adoption opportunities** *J. Abbate* (Montpellier, France), V. Heurteaux*

L0033 **11:24** **Evaluation of a host-based, pathogen-agnostic viral biomarker for early outbreak detection** *R. Mehta* (London, United Kingdom), H. Hopkins, D. Mabey, E. Fitchett, P. Randell, A. Mohamed, M. Mayxay, Q. Bassat, J. Chipanga, C. Christopher, L. Papargyris, H. Wagstaff, S. Ascough, S. Hamilton, M. Levine, J. Herberg, O. Ioana-Diana, L. Maslen, M. Valdivia-Garcia, C. Anthony, E. Chekmeneva, S. Sriskandan*

L0034 **11:36** **Metagenomics surveillance collaboration and analysis programme (mSCAPE): preliminary results from a national metagenomics surveillance pilot** *S. Rokadiya* (London, United Kingdom), N. Groves, R. Graham, A. Aryee, C. Rodrigues, R. Cohring, C. Houlihan, R. Puleston, S.A.J. Wilkinson, T. Brier, J. James, A. Banyard, D. Ward, R. Batra, J. Edgeworth, N.J. Loman, M. Chand*

L0035 **11:48** **Sustained mpox clade I human-to-human spread in DRC calls for continuous variant monitoring** *E. Kinganda-Lusamaki* (Kinshasa, Congo, the Democratic Republic of the), A. Amuri-Aziza, J.C. Makangara Cigolo, R. Lumembe-Numbi, G. Kabamba-Lungenyi, G. Luakanda-Ndelemo, P. Akil-Bandali, T. Wawina-Bokalanga, S. Ahuka Mundeke, J.J. Muyembe-Tamfum, A. Ayouba, E. Delaporte, M. Peeters, P. Mbala-Kingebeni*

OS087 **11:00 – 12:00** **Hall A1-2**

1-hour Oral Session

CLN IPC

Hospital- and ventilator-associated pneumonia: new insights on prevention, diagnosis and treatment

Chairs *Christian Lanckohr (Muenster, Germany)*
Elisabeth Presterl (Vienna, Austria)

O0611 **11:00** **The hospital acquired pneumonia prevention (HAPPEN) study: a multi-centre randomised controlled trial** *B. Mitchell* (Gosford, Australia), N. White, P. Russo, A. Cheng, M. Kiernan*

O0612 **11:12** **Reducing antibiotic treatment duration for ventilator-associated pneumonia (REGARD-VAP): secondary analysis using desirable outcome ranking with response adjusted for duration antibiotic risk and generalised pairwise comparison** *A. Blanco Arévalo* (Barcelona, Spain), A. Blanco-Arevalo, N.A. Binte Mohamed, S. Booraphun, A.Y. Li, P. Domthong, G. Kayastha, Y.H. Lau, P. Chetchotisakd, D. Limmathurotsakul, P.A. Tambyah, B.S. Cooper, Y. Mo*

O0613 **11:24** **Antibiotic duration-response curve for ventilator-associated pneumonia using a target trial emulation** *W.C. Tan* (Singapore, Singapore), J. Quah, S. Booraphun, A.Y. Li, P. Domthong, G. Kayastha, L. Yie Hui, P. Chetchotisakd, D. Limmathurotsakul, P.A. Tambyah, J. Chaisurote, P. Poomthong, A. Kawiwangsanon, K. Semram, S. Kitsaran, P. Wongsrikaew, N. Wetchagama, S. Patamatham, A. Rujisirasankul, A. Narmwong, C. Sodapak, S. Nuntalohit, S. Boonsong, J. Nilsakul, J. Moolasart, A. Phunmanee, A. Panitchote, P. Duangthongphon, P. Pisuttimarn, N. Srisurat, Y. Hwee Seng, G. Maclaren, T.W. Lim, K.L. Chew, S.L. Lim, B.W. Teo, T.J. Lim, L.J. Sun, S. Peng, N. Graves, Y.T. Chew, L.M. Ling, P.Y. Chia, Y.W. Chia, W. Huang, Y.K. Chan, P. Roshan, S. Anil, K. Abhilasha, D. Sabina, F.F. Tuon, B.S. Cooper, Y. Mo*

O0614 **11:36** **Trimethoprim/sulfamethoxazole vs vancomycin for MRSA ventilator-associated pneumonia: a retrospective study** *F. Tuon* (Curitiba, Brazil), A. Salomão, V. Sabbaga Amato, J.P. Telles*

O0615 **11:48** **Impact of antimicrobial stewardship programmes on hospital-acquired and ventilator-associated pneumonia among adults: a systematic review and meta-analysis** *S. Rachina* (Moscow, Russian Federation), N. Ablakimova, D. Strelkova, A. Suvorov, G. Smagulova*

OS088 **11:00 – 12:00** **Hall A1-3**

1-hour Oral Session

CLN DX TRN

Focus on infective endocarditis: from pathogens to prognosis

Chairs *Tatjana Lejko Zupanc (Ljubljana, Slovenia)*
Parham Sendi (Bern, Switzerland)

O0616 **11:00** **BlaZ-associated mortality in patients with *Staphylococcus aureus* endocarditis** *P. Mathé* (Freiburg, Germany), M.T. Leibenguth, M. Hanke, S. Schuster, J. Camp, D. Hornuss, G. Peyerl-Hoffmann, A.J. Kaasch, I. Joost, H. Seifert, W. Kern, S. Rieg*

O0617 **11:12** **Evaluation of different scores for the prediction of infective endocarditis among patients with *Staphylococcus aureus* bacteraemia** *Z. Dennebouy* (Lausanne, Switzerland), M. Padrutt, P. Monney, G. Tzimas, M. Frank, L. Senn, L. Niclauss, M. Kirsch, M. Van Hemelrijck, O. Dzemali, B. Guery, B. Hasse, M. Papadimitriou-Olivgeris*

O0618 **11:24** **Removal of cardiac implanted electronic devices in patients with *Staphylococcus aureus* bacteraemia without endocarditis is not associated with improved survival** *D. Macfadden* (Ottawa, Canada), S. Almoosawy, E. Athan, D. Birnie, J. Davis, W. Gold, M. Golian, J. Johnstone, T. Lee, E. Mcdonald, D. Messika-Zeitoun, S. Ong, M. Cheng, S. Tong, H. Wijeysundera, C. Yu, N. Daneman, L. Lau*

O0619 **11:36** **Characteristics of infective endocarditis caused by *Enterococcus faecium*: a study from the GAMES cohort** *E. Aparicio-Minguijón* (Madrid, Spain), P. Muñoz, M. Machado-Vilchez, M. Valerio-Minero, A. Josune Goikoetxea-Agirre, M.J. Blanco-Vidal, M.Á. Rodriguez-Esteban, C. Hidalgo-Tenorio, G. Ojeda-Burgos, J.M. Miró, R. Parra-Fariñas, V.A. Hortigüela Martin, I. Diego Yagüe, F. López-Medrano*

O0620 **11:48** **Should we extend the use of oral antibiotics in infective endocarditis? the ENDO-ORAL study** *R. Pouy* (Reims, France), B. Rallet, C. Coutureau, M. Blot, F. Bani-Sadr, T. Sixt, M. Moutel, L. Piroth, M. Hentzien*

OS089 **11:00 – 12:00** **Hall A1-4**

1-hour Oral Session

AMR ANT

Mechanistic insights into antimicrobial activity and resistance of Gram-negative bacteria

Chairs *Kwame Ohene Buabeng (Ho, Ghana)*
Thomas Tängdén (Uppsala, Sweden)

O0621 **11:00** **Activity of ciprofloxacin vs delafloxacin in acidic environments: impact of SOS response inactivation in *Escherichia coli*** *M. Murillo Torres* (Seville, Spain), M. Murillo-Torres, K. Alexandre, Á. Pascual, F. Docobo-Pérez, J.M. Rodríguez-Martínez*

O0622 **11:12** **Characterising penicillin-binding protein 2 (PBP2) mutations causing zidebactam resistance in *Pseudomonas aeruginosa*** *M.À. Sastre-Femenia* (Palma, Spain), M.A. Gomis-Font, B. Moya, A. Oliver*

O0623 **11:24** **Spontaneous resistance to siderophore-conjugated β-lactams in *Klebsiella pneumoniae*: diverse mechanisms and fitness effects** *G. Zaborskyte* (Oxford, United Kingdom), G. Zaborskytė, A. Lankapalli, A.J.M. Farley, C.J. Schofield, T.R. Walsh*

O0624 **11:36** **Pre-existing β-lactamase gene diversity reduces ESBL-producing Enterobacterales colonisation risk in patients exposed to ceftriaxone** *Q. Le Bastard* (Nantes, France), R. Gschwind, J. Lao, M.A. Vibet, B. Eric, C. Stéphane, M. Emmanuel, R. Etienne*

O0625 **11:48** **Optimising the treatment regimen with phage cocktails and ceftolozane/tazobactam against carbapenem-resistant *Pseudomonas aeruginosa* endotracheal tube biofilms** *V. Oliveira* (Barcelona, Spain), A. Rocha, A. Soler-Comas, G. Macip, E. Watanabe, M. Ferrer, A. Torres, L. Fernandez-Barat*

OS090 **11:00 – 12:00** **Hall A1-5**

DX PHEI

1-hour Oral Session

Overcoming diagnostic challenges in low resource settings

Chairs *Nitin Gupta (Manipal, India)*
Juliette Severin (Rotterdam, The Netherlands)

O0626 **11:00** **BADLOCK: a rapid, portable, inexpensive diagnostic for bacterial pathogen and resistance detection in resource-limited settings** *D. Roach* (Somerville, United States), P. Sangruji, S. Bhat, R. Bhattacharyya*

O0627 **11:12** **Accelerating bacteraemia management with molecular-AI vs molecular-phenotypic AI antimicrobial recommendations: a prospective study in a resource-limited setting** *J. Gomez De La Torre* (Lima, Peru), J.C. Gómez De La Torre, A. Frenkel, C. Chavez-Lencinas, A. Rendon, Y. Higuchi, L. Alvarado, J.A. Cáceres-Delaguila, D. Minchon-Vizconde, M. Hueda-Zavaleta*

O0628 **11:24** **Microbiology lab implementation in low-resource settings: does it help clinicians reducing antibiotic prescriptions for hospitalised patients?** *H. Nguyen Thi* (Ha Noi, Vietnam), T. Hoang Van, H. Tran Thi, C. Dang Quang, H. Tran Thi Bich, H. Phan Quoc, M. Nguyen Duy, H. Nguyen Ba, H. Phan Van, T. Pham Le, G. Bui Thi Huong, T. Pham Thi Thanh, H. Nguyen Thi Thu, D. Pham Minh, H. Dinh Xuan, K. Bui Xuan, H. Nguyen Thi Bich, L. To Duc, H. Nguyen Ngoc, T. Van Dinh, H. Nguyen Thanh, Y. Nguyen Hai, P. Bui Bich, H. Vu Thi Lan, R. Van Doorn, T. Kesteman*

O0629 **11:36** **Addressing diagnostic limitations in enteric fever in resource-limited settings** *S. Dongol* (Lalitpur, Nepal), N. Maharjan, A. Karkey, C. Parry, B. Basnyat*

O0630 **11:48** **Evaluation of immunochromatographic assays for carbapenemase detection: a multi-centre study within the strengthening a Brazilian system for surveillance and prevention of antimicrobial resistance network (VigiRAM)** *M. Pillonetto* (São José Dos Pinhais, Brazil), L. Kraft, G.A. Gonçalves, H.R.S. D'espindula, D. Kulek, A.P.S. Chacon, J.M. Cieslinski, R.T. Souza, A.L. Abreu, A.P. Assef, B.R. Sued-Karam, I. Cassiano De Oliveira Santos, G. Santos, M.E. Conde*

OS091 **11:00 – 12:00** **Hall A3-2**

TRN

1-hour Oral Session

Intracellular persistence of Gram-negative pathogens: immune evasion and implications for treatment

Chairs *Christian Stephan Lentz (Tromsø, Norway)*
Nina Van Sorge (Amsterdam, The Netherlands)

O0631 **11:00** **OmpA controls intracellular survival of *Acinetobacter baumannii* through TFEB activation and lysosomal remodeling** *Á. Rey Hidalgo* (Seville, Spain), A. Rey-Hidalgo, M. Pérez-Pérez, G. Olgiati, C. Atalaya-Rey, I. Molina-Panadero, Y. Smani*

O0632 **11:12** **Intracellular invasion of osteoblasts by Gram-positive bacteria and the impact of vancomycin eluted from orthopaedic cement** *R. Brull Tuma* (São Paulo, Brazil), L. Batista Campos, M. Muniz De Andrade Silva, M. Neri Lucas Kurihara, I.N. Marcelino Santos, M.A. Midolli Vieira, R.D.C. Sinigaglia, T.A. Tardelli Gomes Do Amaral, M.J. Costa Salles*

O0633 **11:24** **T5SS-Mediated contact-dependent inhibition drives intracellular UPEC persisters contributing to recurrent UTI** *M. Obrebski* (Warsaw, Poland), M. Obrębski, M. Kirzyc, M. Równicki, J. Piwowarski*

O0634 **11:36** **The intracellular state: a fortress of persistence for uropathogenic *Escherichia coli*** *J. Atrissi* (Brussels, Belgium), J.F. Ouédraogo, F. Van Bambeke*

O0635 **11:48** **The human bladder microenvironment and urinary fluid dynamics modulate antibiotic and bacteriophage treatment against uropathogenic *Escherichia coli*** *J. Rohn* (London, United Kingdom), R. Garcia Maset, A. Crowther, V. Chu, D. Di Grande, R.O.A. Jariah, J. Yoon, D. Blumgart, M.A.E. Hodek, N. Yuen, B.O. Murray, L. Pasquina-Lemonche, S.N.H. Alghamdi, A.D. Millard, G. Lutheryn, M.E.K. Haines, M.R.J. Clokie, E. Stride, D. Carugo*

OS085 **11:00 – 12:00** **Hall ICM 13a**

CLN

1-hour Oral Session

Artificial intelligence: emerging applications for medical mycology

Chairs *Toni Gabaldón (Barcelona, Spain)*
Maurizio Sanguinetti (Rome, Italy)

O0636 **11:00** **Machine learning-based predictive model for invasive mould infections in haematology patients: development and validation** *E. Gras* (Barcelona, Spain), C. Teijón-Lumbreras, P. Monzo-Gallo, B. Glemain, T.F. Aiello, A. Gallardo-Pizarro, A. Martinez-Urrea, C. Terrones, A. Castiella, A. Vergara, C. Martínez, M. Suarez-Lledó, J. Esteve, A. Soriano, C. Garcia-Vidal*

O0637 **11:12** **Machine learning for genomic antifungal susceptibility prediction in *Candidozyma auris*** *Y. Zhong* (Liverpool, United Kingdom), G. Alessandro, H. Alex, B. Charlie, H. William*

O0638 **11:24** **Advancing fungal disease impact assessment: development and pilot validation of a semi-automated AI-based surveillance algorithm for invasive aspergillosis** *S. Kleinsteuber* (Leiden, The Netherlands), M. Van Der Beek, J. Buil, P. Verweij, M. Reijers, R. Bruggemann, M. De Boer*

O0639 **11:36** **Evaluation of the performance of large language models in mycological diagnosis** *M. Aras* (Istanbul, Türkiye), M.I. Tosun, N. Samancı, I. Caklovica Kucukkaya, S.A. Ozyar Kurtcu, E. Kırbas, B. Sayar, B. Sancak, D.Y. Metin*

O0640 **11:48** **Machine learning-based gene screening unravels key determinants of caspofungin resistance** *Y. Su* (Beijing, China), Y. Xu*

OS086 **11:00 – 12:00** **Hall ICM 13b**

VAX

1-hour Oral Session

Vaccines: landmark trials and preventive immunisation

Chairs *Joel Mossong (Luxembourg, Luxembourg)*
Oana Sandulescu (Bucharest, Romania)

O0641 **11:00** **Randomised phase III trial of a 9-valent vaccine (ExPEC9V) for prevention of invasive *Escherichia coli* disease (IED) in older adults (E.mbrace)** *K.A. Cohen* (Titusville, United States), C. Mclean, T. Day, M. Peeters, I. Scheys, M.G. Pau, J. Poolman, M. Bonten*

O0642 **11:12** **Avian influenza A (H5N1) clade 2.3.4.4b haemagglutinin–Matrix-M nanoparticle vaccine (H5-MNP) induces neutralising responses and protection against H5N1 challenge in mice** *C. Bennett* (Gaithersburg, United States), R. Draghia Akli, J.F. Trost, B. Zhou, K. Pyles, T.L. Darling, A.C.M. Boon, G.E. Smith*

O0644 **11:36** **High-dose vs standard-dose influenza vaccine effectiveness according to frailty risk: a prespecified analysis of the DANFLU-2 trial** *C. Espersen* (Hellerup, Denmark), N.D. Johansen, D. Modin, K.H. Janstrup, M.M. Loiacono, R.C. Harris, Y. Huang, C.S. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, B.L. Claggett, K.V. Bartholdy, K.F. Bernholm, J.I.M.H. Borchsenius, F.S. Davidovski, L.W. Davodian, M. Dons, L.S. Duus, F.H. Fussing, A.M.R. Jensen, N.E. Landler, A.C.F. Langhoff, M.C.H. Lassen, A.B. Nielsen, C.I. Ottosen, M. Sengeløv, K.G. Skaarup, S.D. Solomon, M.J. Landray, G.H. Gislason, L. Køber, P. Sivapalan, C.J.M. Martel, J.U.S. Jensen, G. Gavazzi, T. Biering-Sørensen*

O0645 **11:48** **Effectiveness of PCV10 and PCV13 against invasive pneumococcal disease in Vietnamese children: a multi-centre matched case–control study** *C. Truong* (Ho Chi Minh, Vietnam), T. Nguyen, N. Speybroeck*

SY124 **11:00 – 12:00** **Hall A2-2**

ANT CLN DX

1-hour Symposium

Innovations in the management of tuberculosis and non-tuberculous mycobacteria

Chairs *Catherine Ong (Singapore, Singapore)*
Onya Opota (Lausanne, Switzerland)

S0323 **11:00** **New diagnostics for mycobacterial infection** *Daniela Maria Cirillo (Milan, Italy)*

S0324 **11:30** **Applying pharmokinetics for the optimisation of mycobacterial treatments** *Elin Svensson* (*Uppsala, Sweden*)

Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)

SY125 **11:00 – 12:00** **Hall A3-1**

CLN IPC

1-hour Symposium

Surgical site infections after solid organ transplantation: an underestimated driver of transplant outcome

Chairs *Wanessa Clemente* (*Belo Horizonte, Brazil*)
Elda Righi (*London, United Kingdom*)

S0325 **11:00** **SSIs after visceral transplantation** *Nicolas Mueller* (*Zurich, Switzerland*)

S0326 **11:30** **SSIs after thoracic transplantation** *Manuela Carugati* (*Durham, United States*)

SY123 **11:00 – 12:00** **Hall ICM 5**

ANT TRN

1-hour Symposium

Going super small: nano-technology in infectious diseases

Chairs *Elisa Borghi* (*Milan, Italy*)
Gregor Fuhrmann (*Erlangen, Germany*)

S0321 **11:00** **Repurposing antimicrobials with ultrasound-triggered nanoscale systems for targeted biofilm drug delivery** *Eleanor Stride* (*Oxford, United Kingdom*)

S0322 **11:30** **Nanotechnologies for precision immunotherapy and infection treatment** *Willem Mulder* (*Eindhoven, The Netherlands*)

EF092 **11:00 – 12:00** **Arena 2**

ANT CLN PHEI

ePoster Flash Session

Antimicrobial stewardship in low resource countries: challenges and solutions

Chair *Igizeneza Acsa* (*Kigali, Rwanda*)

E0646 **11:00** **Antimicrobial prescribing in five primary healthcare centres in northern Syria: a global PPS based period prevalence survey** *F. Abdo** (*Amman, Jordan*), *K. Parikh, Z. Ejielat, A. Boven, A. Versporten, I. Pauwels, E. Vlieghe, A. Luczynska, R. Esguerra, C. Roman*

E0647 **11:06** **Observed vs expected antibiotic use in MSF-supported primary outpatient MSF settings in North-West Syria** *C. Naim** (*Beirut, Lebanon*), *K. Moussally, P. Garcia-Vello, M. Khalife, C. Arias Vicente, A. Almohamad, Z. Ejielat, A. Wetti, B. Alonso, A. Ali, C. Roman, M. Yaacoub, M. Gazal, A. Comelli, A. Farra*

E0648 **11:12** **A practical observational tool to measure antimicrobial stewardship and infection prevention behaviours in a low-resource hospital setting** *C. Bonaconsa** (*Cape Town, South Africa*), *T. Makamu, A. Kona, M. Samkele, E. Charani*

E0650 **11:18** **Tailoring empirical antibiotics to local resistance in severely malnourished hospitalised children in Niger: secondary analysis of a prospective cohort** *C. Langendorf** (*Paris, France*), *A. Delafon-Pariset, N. Peiffer-Smadja, R. Kanapathipillai, C.T. Andersen, S. Garba, N. Sayinzonga-Makombe, E.I. Tassiou, R. Daré, S. Isanaka, C. Amaris Hobson, M. Thy, C. Jimenez, B. Mollo*

E0651 **11:24** **Factors influencing antibiotic use in patients without bacterial infections during the COVID-19 pandemic in a tertiary care centre in a low-middle-income country** *N. Nasir** (*Karachi, Pakistan*), *W. Fazal, Z. Nasim, N.S. Khan*

E0652 **11:30** **Antimicrobial and corticosteroid prescribing for adults with suspected CNS infection in Botswana and Zimbabwe** *C. Coughlan** (*London, United Kingdom*), *T. Mwarumba, R. Suresh, K. Ngoni, G. Manenji, R. Doyle, K. Boyd, C. Northcott, J. Penney, M. Kinsella, I. Mechie, S. Ensor, C. Williams, K. Lechiile, K. Siamisang, L. Owen, E. Gwakuba, T. Milton, T. Machiya, H.E. Barton, P. Ponatshego, K. Seatla, G. Boitshepo, I. Rulaganyang, L. Gwaunza, K. Kranzer, D. Grint, M.W. Tenforde, D.M. Goldfarb, M. Mokomane, M. Mine, G. Ngwende, C. Ndhlovu, J.N. Jarvis, J. Milburn*

E0653 **11:36** **Hospital pharmacists in antimicrobial stewardship in Latin America: roles and challenges** *E. Zavaleta** (*San Jose, Costa Rica*), *J.P. Diaz, R. Mosmann, P. Lichtenberger, R. Quiros*

E0654 **11:42** **Effects of participatory learning and action with primary care doctors on antibiotic prescribing for acute respiratory infections in Vietnam: a pilot cluster randomised study** *M.D. Vu** (*Hanoi, Vietnam*), *N.Y. Nguyen, N.T.H. Nguyen, P.B. Bui, V.T. Khuong, H.T.T. Duong, L.V. Le, G. Coact Investigators, H.R. Van Doorn, N.T.T. Do, S. Nagraj, S. Lewycka*

EF093 **11:00 – 12:00** **Arena 3**

AMR

ePoster Flash Session

MDR pathogens around the globe: mechanisms, risk, and treatment optimisation

Chair *Merica Carev* (*Split, Croatia*)

E0655 **11:00** **Clinical outcomes and risk factors for mortality in serious infections due to carbapenem-resistant *Acinetobacter baumannii* in Asia** *Y. Chang** (*Kaohsiung City, Taiwan*), *A. Manesh, L. Mezzadri, X. Hao, Y. Ding, C. Yang, C. Yiying, S. Kitsaran, H.H. Chua, B. Sotharith, S.S.L.S. Ponnampalavanar, S. Anunnatsiri, M.Z. Mazlan, A.K. Dhiloo, R. Plongla, A.L.H. Kwa, S.F. Mahmood, A.D. Roman, L. Thwaites, K.A. Nguyen, V.T. Phan, S. Wu, D. Chotiprasitsakul, K.J. Wong, H. Wijaya, C.L. Abad, M.O.R. Khalid, G.M.S. Mamun, G.S. Rajahram, H. Guterres, N.H. Huynh, V.G. Tran, N.T. Pham, A. Karkey, S. Gunasekara, R.L. Hamers, R. Sinto, I.N.D. Lubis, M. Wang, M. Moni, P.Y. Liu, Y. Xiao, B. Khanal, L. Priya, Y. Doi, H. Hitoshi, B. Baljin, R. Asli, U. Gurjav, L. Ling, A. Dhungana, L.Y. Hsu, Y. Mo, D.L. Paterson*

E0656 **11:06** **Activity of cefiderocol against *Stenotrophomonas maltophilia* clinical isolates collected in multi-national antimicrobial surveillance studies SIDERO-WT (2014 - 2019) and SENTRY (2020 - 2024)** *Y. Yamano** (*Osaka, Japan*), *C. Longshaw, S.T. Nguen, J.M. Maher, R.E. Mendes, M. Hackel, H. Yamashiro, B.L.M. De Jonge*

E0657 **11:12** **Emergence and characterisation of multi-carbapenemase-producing *Klebsiella pneumoniae* in Italy: genomic features and *in vitro* therapeutic options** *A. Cornacchia** (*Teramo, Italy*), *S. Comini, F. Pomilio, C. Costa, M. Boattini, G. Bianco*

E0658 **11:18** **Epidemiology of penicillin-binding protein 3 variants in carbapenem-resistant *Escherichia coli* isolates from France** *I. Mehidi** (*Le Kremlin-Bicêtre, France*), *A. Birer, A. Jacquemin, A.B. Jousset, P. Glaser, R.A. Bonnin, L. Dortet, S. Oueslati, T. Naas*

E0659 **11:24** **Integrating the ECRAID Emerging Resistance Index (ERI) into antibiotic policy for new antibiotics targeting multidrug-resistant Gram-negative bacteria: a proof-of-concept analysis** *M.D. Pezzani** (*Verona, Italy*), *J. Garlasco, D. Ortiz, K. Odoj, F. Arieti, A. Savoldi, M. Morra, E. Addis, M. Tebon, O. Awwad, A. Cassini, S. Harbarth, E. Presterl, G. Kahlmeter, E. Tacconelli*

E0660 **11:30** **Tracking *Clostridioides difficile* in Ireland: genomic landscape and antimicrobial resistance profiles of clinical isolates, 2022–present** *D. Espadinha** (*Dublin, Ireland*), *N. O' Mara, A. Carroll, T.K. Teoh*

E0661 **11:36** **Profiling of dalbavancin resistance in clinical MRSA through a nationwide genomic survey in China: insights into resistance mechanisms** *Y. Hong** (*Hangzhou, China*), *Y. Chen*

E0662 **11:42** **Molecular epidemiology and antimicrobial resistance of *Mycoplasma genitalium* in Tokyo, 2023–2025** *R. Omachi** (*Saitama, Japan*), *K. Imai, T. Maeda, A. Sato, M. Tanaka, N. Mori*

KN122 **11:00 – 12:00** **Hall ICM 14**

PHEI TRN

Keynote lecture

On virus origin, evolution, and the next pandemic threat

Chairs *Giulia De Angelis (Rome, Italy)*
Jacob Moran-Gilad (Beer Sheva / Jerusalem, Israel)

K0320 **11:00** *Edward Holmes (Sydney, Australia)*

ME127 **11:00 – 12:00** **Hall B0-1**

Meet-the-Expert

DX TRN

Microbiome-based diagnostic tools, are we ready for prime-time?

M0329 **11:00** *Debby Bogaert (Edinburgh, United Kingdom)*
M0330 **11:12** *Gianluca Ianiro (Rome, Italy)*

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI)

ME128 **11:00 – 12:00** **Hall B0-2**

Meet-the-Expert

CLN DX

The returned traveler with eosinophilia: clinical, diagnostic and therapeutic approaches

M0331 **11:00** *Martin Montes (Lima, Peru)*
M0332 **11:12** *Diana Ayoola Mabayoje (London, United Kingdom)*

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP), ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)

ME126 **11:00 – 12:00** **Hall ICM 1**

Meet-the-Expert

AMR DX

Applications of machine learning for predicting virulence and resistance by MALDI-TOF MS: opportunities and challenges

M0327 **11:00** *Adrian Egli (Zurich, Switzerland)*
M0328 **11:12** *Jaroslav Hrabak (Plzen, Czechia)*

FO129 **11:00 – 12:00** **Arena 1**

Open Forum

PRO

Panic vs calm: the pivotal roles of trainees in infectious disease responses

Chair *Casandra Bulescu (Bucharest, Romania)*

F0333 **11:00** **Being in the frontline: shaping public messaging during outbreaks** *Ferenc Balázs Farkas (Budapest, Hungary)*
F0334 **11:10** **From crisis to resilience: the role of early career researchers in outbreak response** *Jules Villa (Paris, France)*
F0335 **11:20** **COVID-19 pandemic memories: what can we learn for future crises?** *Aleksandra Barac (Belgrade, Serbia)*

Co-organised with: ESCMID Emerging Infections Subcommittee, Trainee Association of ESCMID (TAE) Steering Committee

---

PM002 **11:00 – 12:00** **Hall A2-1**

Pipeline Symposium

AMR PHEI

Accelerating access: rethinking HTA to unlock AMR solutions

Chairs *Maarten Postma (Groningen, The Netherlands)*
Charlotte Vernhes (Brussels, Belgium)

D0005 **11:00** **Data: what's available today and where are the key gaps?** *Marlieke De Kraker (Geneva, Switzerland)*
D0006 **11:15** **Full economic value of AMR solutions in HTA** *Michele Cecchini (Paris, France)*
D0007 **11:30** **EU HTA regulation and AMR solutions: lessons from vaccines** *Eliana Biundo (Wavre, Belgium)*

OS096 **13:30 – 14:30** **Hall A2-2**

1-hour Case Session

CLN DX PHEI

Protozoa and microsporidia: rare and emerging

Chairs *Aleksandra Barac (Belgrade, Serbia)*
Emmanuel Bottieau (Antwerp, Belgium)

O0664 **13:30** **A *Plasmodium* vivax case identified only by use of next-generation sequencing** *C.R. Stensvold* (Copenhagen S, Denmark), H.V. Nielsen, J.K. White, J. Szeps, K. Wyss, S. Botero-Kleiven*
O0665 **13:41** ***Leishmania* (Mundinia) procaviensis as an emerging pathogen: first confirmed human infection identified by target-gene sequencing** *A. Andrianaki* (Zurich, Switzerland), D. Weller, F. Grimm, M. Concu, B. Nickel, A. Neumayr, M.B. Kälin*
O0666 **13:52** **Disseminated *Toxoplasma gondii* infection with haemophagocytic lymphohistiocytosis** *D. Walzer* (Freiburg, Germany), C. Kaech, S. Rieg*
O0667 **14:03** **Insights from a fatal case of disseminated albendazole refractory *Annacaliia algerae* myositis** *S. Fernando* (Sydney, Australia), S. Mcginn, S. Ahmer, H.C. Soh, L. Tan, G. Kotsiou*
O0668 **14:14** **Non-resolving cerebral toxoplasmosis in an immunodeficient patient** *J. Olchowski* (Hiafa, Israel), M. Paul*

OS094 **13:30 – 14:30** **Hall ICM 13a**

1-hour Case Session

CLN PHEI

Challenging and complicated viral infections

Chairs *Alexandra Mailles (Saint-Maurice, France)*
Annabel Niessen (Utrecht, The Netherlands)

O0669 **13:30** **Chronic herpes simplex virus type 2 necrotising granulomatous pachymeningitis after glofitamab: an unusual CNS infection in an immunocompromised patient** *N. Jain* (Auckland, New Zealand), B.S. Chen, L. Berkahn, M. Strauss, R. Lane*
O0670 **13:41** **First documented case of a fatal autochthonous Usutu virus infection in an immunocompromised patient in Hungary** *B. Szabo* (Budapest, Hungary), B.G. Szabó, A. Nagy, O. Nagy, A. Koroknai, N. Csonka, D. Korózs, K. Jeszenszky, A. Hardi, N. Deézsi-Magyar, J. Sztikler, Z. Bódi, D. Cadar, G.E. Tóth, L. Veres, E. Barcsay, M. Takács, J. Sinkó*
O0671 **13:52** **But its got to be PML, right? chronic myeloencephalitis 14 year after heart transplant** *L. Lippert* (Berlin, Germany), S. Albus, D. Grund, M. Witzenrath, L. Sander*
O0672 **14:03** **Long-term survivor of BoDV-1 encephalitis: complex immunotherapy, neuroimaging signatures and late viral reactivation: a case report** *I. Masouris* (Munich, Germany), I. Wilkens, D. Grabova, M. Chen, H. Klauß, L. Keidel, D. Hauptstein, C. Eckert, V. Ruf, M. Schmutzer-Sondergeld, M. Brendel, R. Forbrig, G. Höglinger, A. Straube, F. Sörgel, M. Bauswein, D. Tappe, F. Schöberl*
O0673 **14:14** **Changing landscape of paediatric influenza-associated neurological complications: a single-centre case series from northern Italy (2024-2025)** *L. Franzetti* (Milan, Italy), C. Porro, S.M. Bova, C. Giovannini, A. Gadda, A. Rizzo, A. Lombardi, F. Salari, G. Zuccotti, E. Fusco, L. Folgori*

OS095 **13:30 – 14:30** **Hall ICM 13b**

1-hour Oral Session

PRO

Precision pedagogy: AI-driven and data-driven education

Chairs *Sarah Delliere (Paris, France)*
Mary Horgan (Dublin, Ireland)

O0674 **13:30** **Large Language Model-assisted OSCE stations in infectious diseases: faster, high-quality, and well-received by faculty** *S. Villard* (Paris, France), C.A. Hobson, Y. Guedj, L. Khider, A. Mageau, J. Mesnier, M. Sanchez, S. Voicu, S. Peiffer-Smadja, N. Burnichon, A. Faye, T. Mirault, Y. Nguyen, B. Oules, A. Pellat, D.*

Bouzid, M. Thy, N. Peiffer-Smadja

O0675 **13:42** **Intelligent multi-agent systems for antimicrobial stewardship training: a new paradigm in medical education** *Y. Chen* (Hangzhou, China), L. Sun, X. Du, F. Chiu, Y. Yu*

O0676 **13:54** **Large-scale artificial intelligence or medical residency: who achieves greater concordance with ID specialists in antibiogram-guided antibiotic selection?** *M. Lanna* (São Paulo, Brazil), N. Adiwardana, V. Marchetti, J. Veríssimo*

O0677 **14:06** **InfectoCast: a digital ecosystem for infectious diseases education and science communication in Brazil** *K. Faico-Filho* (São Paulo, Brazil), W. Dunke, J. Prats, J. Pinheiro, C. Santos, E. Santos-Junior*

O0678 **14:18** **List of Recommended Names (LoRN) for bacteria of medical importance** *V. Fingerle* (Oberschlossheim, Germany), H. Christensen, M. Göker, M. Kostovski, G. Margos, E. Moore, A. Oren, S. Patrick, U. Reischl, J. Vazqueza-Boland*

SY132 **13:30 – 14:30** **Hall A3-2**

ANT TRN

1-hour Symposium

Innovative methodologies for advancing PK/PD studies

Chairs *Birgit Koch (Rotterdam, The Netherlands)*
Sebastian Wicha (Hamburg, Germany)

S0316 **13:30** **Development and application of organs on chip to study infectious diseases** *Girija Goyal (Boston, United States)*

S0317 **14:00** **Multi-omics approaches to personalise and improve antibiotic efficacy** *Gauri Rao (Rancho Palos Verdes, United States)*

SY130 **13:30 – 14:30** **Hall B0-1**

CLN PED

1-hour Symposium

Special issues of IFI in paediatrics

Chair *Andreas H. Groll (Münster, Germany)*
TBA

S0312 **13:30** **Antifungal prophylaxis in neonates in the era of increased resistance to fluconazole** *Paolo Manzoni (Turin, Italy)*

S0313 **14:00** **Implementation of guidelines in different settings: challenges and solutions** *Laura Ferreras-Antolin (London, United Kingdom)*

Co-organised with: German Society for Pediatric Infectious Diseases (DGPI), German-Speaking Mycological Society, Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. (PEG)

SY131 **13:30 – 14:30** **Hall B0-2**

CLN TRN

1-hour Symposium

Top papers in infections in immunosuppressed patients

Chairs *Carlota Gudiol (Barcelona, Spain)*
Stefan Schwartz (Berlin, Germany)

S0314 **13:30** **Infections in immunocompromised patients: what you need to know** *Effrossyni Gkrania-Klotsas (Cambridge, United Kingdom)*

S0315 **14:00** **Shifting evidence in transplant infectious diseases: key studies that change practice** *Oriol Manuel (Lausanne, Switzerland)*

LB007 **13:30 – 15:30** **Hall ICM 1**

AMR CLN

2-hour Oral Session

The trial run: treatment of ESBL bacteraemia - off to never-never land?

Chairs *Angela Huttner (Geneva, Switzerland)*
David L. Paterson (Singapore, Singapore)
Steven Tong (Melbourne, Australia)

L0036 **13:30** **PipEracillin Tazobactam vs mERoPENem for treatment of bloodstream infections caused by cephalosporin-resistant Enterobacterales (PeterPen)** *M. Paul* (Haifa, Israel), Y. Dishon, L. Leibovici, M. Kristen, K. Afra, C. Condin, T. Bai, J. Strahilevitz, V. Daitch, R. Ben-Ami, M. Chowers, L. Nesher, M. Hershman-Sarafov, A. Carignan, P. Daley, P. Leighanne, J. Eastmond, T. Finn, D. Yahav, T.C. Lee*

L0037 **13:50** **Ertapenem vs meropenem for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales: an ASTARTÉ post hoc analysis** *J. Rodríguez-Baño* (Seville, Spain), F. Cogliati Dezza, L. Barrera Pulido, I. Borreguero Borreguero, F. Docobo Pérez, V. Palomo Jiménez, S. De La Rosa Riestra, J.M. Bravo-Ferrer, Z.R. Palacios-Baena, M.Á. López Zuñiga, F. Cobo, J. Gómez-Junyent, J.P. Horcajada, E. Merino, M. Parra, J. López-Contreras, A. Rivera, D. Sousa Regueiro, M. Pampín Garcia, S. López Cardenas, M.C. Gómez Sánchez, I. Pérez Camacho, S.M. Martín Ramos, E. León Jiménez, A.I. Aller García, M.T. Pérez-Rodríguez, A. Sousa, M. Siller Ruiz, F. Arnaiz De Las Revillas Almajano, L. Gisbert Pérez, J. Goikoetxea Agirre, Á. Cano, F.J. Martínez-Marcos, M.J. García País, R. Escudero-Sánchez, S. De La Villa, J.R. Yuste Ara, M.Á. Esteban-Moreno, A. Ruiz-Sancho, M. Pedrosa Aragón, J.A. Fernández, A.M. Barrios Blandino, H.H. Vilchez-Rueda, R. Álvarez-Marín, A. Romero Palacios, E. García Vázquez, E. Nuño Álvarez, C. Rosso-Fernández, B. Gutiérrez-Gutiérrez, Á. Pascual, L. López-Cerero*

L0038 **14:10** **A decade after the MERINO trial: refusing to grow up?** *David L. Paterson (Singapore, Singapore)*

L0039 **14:20** **When the fairy dust settles: critical appraisal of presented trials** *Angela Huttner (Geneva, Switzerland)*

L0040 **14:30** **Tick tock, AMR clock: how should I treat my next ESBL bacteraemia patient?** *Steven Tong (Melbourne, Australia)*

EF097 **13:30 – 14:30** **Arena 1**

AMR ANT CLN

ePoster Flash Session

Fosfomycin for difficult-to-treat resistant pathogens: is it really a useful weapon?

Chair *Andre Kalil (Omaha, United States)*

E0679 **13:30** **Can the fosfomycin MIC value be used in the evaluation of response to treatment of carbapenemase-producing Enterobacterales infections with fosfomycin-containing regimens?** *M. Törüyenler Coskunpinar* (Ankara, Türkiye), D. Ocal, G. Cinar, L.E. Dogangul Doygun, Z. Tekbas*

E0680 **13:36** **Effectiveness of antibiotic regimens for the treatment of bloodstream infections caused by carbapenem-resistant *Acinetobacter baumannii*: a national, multi-centre study** *F. Serapide* (Catanzaro, Italy), A. Russo, S.P. Gulli, A. Vena, L. Spadafora, M. Bernardi, S. Corcione, G. Ceccarelli, F. Alessandri, C.M. Mastroianni, A. Oliva, E. Venanzi-Rullo, G. Caviglia, A. Cortegiani, M.C. Ippolito, G. Nunnari, F. Di Gennaro, A. Saracino, A. Marino, B. Cacopardo, G. Tiseo, M. Falcone, V. Galfo, C. Iaria, G. Pipitone, A. Cascio, S. Carbonara, L. Montemurro, F.S. Serino, N. Boffa, M. Libanore, F.G. De Rosa, A. Mattei, A. Calabresi, M. Tumbarello, L. Fontanelli Sulekova, C. Pallotto, P. Brugnaro, R. Mascianà, B. Tiri, N. Coppola, G. Calabria, A. Bandera, A. Lombardi, P. Vassalini, N. Carannante, V. Scaglione, M. Meschiari, O. Simonetti, A. Mularoni, F. Bar, C. Mussini, M. Bassetti, G. Biondi-Zoccai*

E0681 **13:42** **Evaluation of fosfomycin including regimens in culture-confirmed carbapenem-resistant Gram-negative pneumonia: analysis of 53 cases** *M.B. Özkara* (Izmir, Türkiye), D. Kaya, M. Mert Vahabi, D. Akyol Seyhan, O. Acet, A. Kaya, A.M. Parmaksızoğlu Aydın, M. Ceylan, F.B. Arıkan, S. İstek, D. Yaman, B. Süllü, D. Verendağ, H.A. Erdem, H. Sipahi, T. Yamazhan, B. Arda, Ş. Aydemir, O.R. Sipahi*

E0682 **13:48** **How and why clinicians use intravenous (IV) fosfomycin in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry** *G. Zhanel* (Winnipeg, Canada), M. Baxter, M. Wong, Y. Mirzanejad, A. Lee, R. Dhami, J. Kosar, D. Werry, N. Irfan, J.F. Tessier, G. Girouard, C. Tascini, T. Von Den Baumen, M. Savoie, A. Serebryanskyy, J. Chan, M. Kucey, A. Walkty, J.*

Karlowsky

E0683 **13:54** **Fosfomycin resistance in Enterobacterales: a comprehensive national surveillance in the Czech Republic** *K. Chudejova* (Plzen, Czechia), V. Mattioni Marchetti, S. Kanova, V. Zaccaria, I. Bitar, J. Hrabak*

E0684 **14:00** **Synergistic activity of fosfomycin and temocillin against GES carbapenemase-producing *Enterobacteriaceae*** *J.L. Rodríguez Ochoa* (Santander, Spain), N. Fraile-Valcárcel, S. García-García, M. Siller-Ruiz, D. Pablo-Marcos, S. García-Fernández, M.P. Roiz-Mesones, A. Ocampo-Sosa*

E0685 **14:06** **Evolution of the *in vitro* activity of fosfomycin against carbapenemase-producing microorganisms in Colombia** *G.A. Muñeton Lopez* (Bogota, Colombia), M.F. Rueda, N.C. Mendoza, J.C. Torres, D. Celis-Giraldo, H. Vergara*

E0686 **14:12** **Discovery and characterisation of gfa, a novel fosfomycin resistance gene family already spread in environmental and clinical bacteria** *N. Kieffer* (Madrid, Spain), L. Ortiz-Miravalles, A. Hipolito, A. Prieto, A. Carvalho, E. Vergara, J.A. Escudro*

E0687 **14:18** **In vitro activity of fosfomycin against *Escherichia coli*, *Klebsiella pneumoniae*, and *Enterococcus faecalis* isolated from urine specimens in Canada: CANWARD surveillance study 2007–2022** *J. Karlowsky* (Winnipeg, Canada), G. Zhanel, H. Adam, M. Baxter, A. Walkty, P. Lagacé-Wiens*

EF098 **13:30 – 14:30** **Arena 2**

ANT CLN

ePoster Flash Session

First, do no harm: allergy, kidney safety and length of stay in antimicrobial stewardship

Chair *Pilar Retamar Gentil (Seville, Spain)*

E0688 **13:30** **ESCMID clinical guidelines on the evaluation and management of a reported antibiotic allergy** *O. Joean* (Jena, Germany), K. Sermet, L. Ashkenazi-Hoffnung, Y. Cakir Kiymaz, K. Blumenthal, C.M. Bonazzetti, A.M. Chiriac, S. Gomez-Zorrilla, E. Karakike, E. Khatamzas, N. Powell, J.A. Trubiano, R. Wijnakker, J. Sandoe, B. Nagavci, M.G.J. De Boer*

E0689 **13:36** **Direct penicillin allergy de-labelling at a pre-anaesthesia consultation: picking the low-hanging fruit?** *S. Deryckere* (Ghent, Belgium), P. De Nocker, H. Lapeere, L. De Baerdemaeker, D. Huis In 't Veld*

E0690 **13:42** **Implementation of a penicillin allergy delabelling service in a UK centre: measuring indicators of success** *B. Morris* (Cambridge, United Kingdom), U. Ahmed, R. Santos, C. Aherne, I. Lowings, X.Y. Thum, S. Nasser, P. Gurugama, T. Gouliouris*

E0691 **13:48** **Penicillin allergy de-labelling by non-specialists in NHS acute care: A UK-wide survey and review of current practice by the PADL-UK survey** *A. Blanshard* (Manchester, United Kingdom), H. Lewis, N. Fleming, P. Howard, T. Locke, R. Payne*

E0692 **13:54** **Patients' experiences of penicillin allergy evaluation and delabeling process in primary care** *T. Langeveld* (Bilthoven, The Netherlands), T. Schoffelen, A. Timen, M. Hulscher, N. Milevska-Kostova*

E0693 **14:00** **Can vancomycin therapeutic drug monitoring detect acute kidney injury before serum creatinine?** *M. Scheetz* (Downers Grove, United States), S. Leech, A. Sathyanarayanan, S. Roy, P. Sabourenkov*

E0694 **14:06** **Vancomycin-induced kidney injury in adult oncology: adjudicated incidence and a pragmatic dosing framework derived from AUC-guided care** *J.P. Telles* (São Paulo, Brazil), D. Coelho Jr, K. Migotto, D. Feriani Da Silva, R. Reghini, G.T. Daiane, F. Lima De Oliveira, P. Caruso, I. França E Silva*

E0695 **14:12** **Development and validation of a prediction model for acute kidney injury risk in patients receiving concomitant vancomycin and piperacillin/tazobactam** *D. Chen* (Macau Sar, Macao), H. Zhang, X. Luo, M. Yu, J. Kan, A. Zhao, W. Ge*

E0696 **14:18** **Saving beds and budgets: real-world efficacy, safety, and pharmacoeconomics of long-acting lipoglycopeptides in a day hospital setting** *A. Marino* (Catania, Italy), E. Venanzi Rullo, G. Pipitone, A. Albanese, A. Franzò, A. De Vito, N. Geremia, C. Iaria, G. Madeddu, B. Cacopardo, G. Nunnari*

EF099 **13:30 – 14:30** **Arena 3**

ANT CLN

ePoster Flash Session

Ask AI how to manage antibiotics!

Chair *Carolina Garcia Vidal (Barcelona, Spain)*

E0697 **13:30** **Evaluating a machine learning-based decision support tool for early antibiotic discontinuation in Lower Respiratory Tract Infections (LRTI): a randomised controlled trial** *S. Tang* (Singapore, Singapore), D. Yii, R. Lim, M.P. Chlebicki, J. Chung, A. Kwa*

E0698 **13:36** **Cost-effectiveness of a machine learning (ML) approach for reducing unnecessary antibiotic use in patients with suspected lower respiratory tract infections (LRTI): an economic analysis of a randomised clinical trial** *Y. Cai* (Singapore, Singapore), N. Nazeha, S. Tang, D. Yii, A.L. Kwa, N. Graves*

E0699 **13:42** **Who's the smartest in the room? benchmarking large language models for antimicrobial stewardship support** *G. Pellejero* (Zaragoza, Spain), Á. Abejez-Arrizabalaga, J. Schouten, T. Schoffelen, E. Morte-Romea, E. Ruizendaal, J. Origüen, M.T. Pérez-Rodríguez, P. Retamar-Gentil, N. Sisamón-Dolader, B. Franco-García, R. Del Hoyo, S. Letona-Giménez, J.R. Paño-Pardo*

E0700 **13:48** **An antibiotic chatbot for providing guideline-based antimicrobial advice** *D. Eyre* (Oxford, United Kingdom), R. Corrigan, L. Hookham, S. Lumley, D. Clarke, K. Jeffery, L. Dunsmure, N. Jones*

E0701 **13:54** **Antimicrobial stewardship programme: a data-driven approach to continuously optimised, locally adapted empirical antibiotic guidelines** *M. Raad* (Sarrebourg, France), T. Yokoyama, S. Boujaafar, F. Mutisya, C. De Turckheim, P. Berger, L. Vezard, M. Valette, C. Moore*

E0702 **14:00** **Investigating UK online antibiotic provision: a covert simulated patient ethnographic study** *S. Boyd* (London, United Kingdom), N. Zhu, R. Jain, A. Parmar, A. Matthews, A. Holmes, R. Ahmad*

E0703 **14:06** **UK outpatient parenteral antimicrobial therapy/complex outpatient antimicrobial therapy (OPAT/COpAT) point prevalence dashboard** *S. Khan* (London, United Kingdom), J. Grayson, M. Gilchrist, A. Seaton*

E0704 **14:12** **Performance of a clinical decision support tool on targeted antibiotic treatment in the emergency department: a retrospective study** *S. Nørgaard Søgaard* (Aabenraa, Denmark), S.N. Søgaard, L. Ward, M.L. Mogensen, C.B. Mogensen, M.B. Cartuliares, H. Skjøt-Arkil*

E0705 **14:18** **Bayesian neural network (BNN) with uncertainty-thresholding for personalised empirical antibiotic guidance, compared to clinician prescribing** *A. Luk* (Oxford, United Kingdom), K. Yuan, J. Wei, S.A. Walker, D. Eyre*

JS003 **13:30 – 14:30** **Hall A3-1**

CLN

Journal Session

Late-breaking research from The Lancet: new interventions for more established pathogens

Chairs *Syeda Saleha Hassan (London, United Kingdom)*
Onisillos Sekkides (London, United Kingdom)

J0011 **13:30** **Clinical effectiveness and bacteriological eradication of three different short-course antibiotic regimens and single dose fosfomycin for uncomplicated lower urinary tract infections in adult women (SCOUT study): a pragmatic, multicentre, multi-arm, open-label, randomised clinical trial** *Carl Llor (Barcelona, Spain)*

J0012 **13:42** **Maribavir for clinically significant cytomegalovirus infection in hematopoietic cell transplantation: a real-world retrospective international study of the Infectious Disease Working Party of EBMT** *Annalisa Paviglianiti (Barcelona, Spain)*

J0013 **13:54** **Characterisation of immune responses targeting highly pathogenic avian influenza A(H5) viruses in health-care workers in the Netherlands: an**

observational, cross-sectional analysis *Rory De Vries (Rotterdam, The Netherlands)*

J0014 14:06 **Whole genome sequencing precision medicine strategy to shorten treatment for rifampicin-resistant tuberculosis (SMARTT): a pragmatic, randomised, single-blinded phase IV medical device trial** *Annelies Van Rie (Wilrijk, Belgium)*

J0015 14:18 **Adjunctive betamethasone treatment of hypoxemic adults hospitalised with mycoplasma pneumoniae community-acquired pneumonia: an open-label, multicentre, randomised, controlled trial** *Karl Hagman (Göteborg, Sweden)*

ME133 13:30 – 14:30 **Hall ICM 5**

ANT TRN

Meet-the-Expert

Membrane vesicles: pathogenic factor and emerging targets for antimicrobial therapies

M0318 13:30 *Maria Kaparakis-Liaskos (Melbourne, Australia)*

M0319 13:42 *Gregor Fuhrmann (Erlangen, Germany)*

PM004 13:30 – 14:30 **Hall A2-1**

PRO PHEI

Pipeline Symposium

Science under pressure: is it business as usual?

Chairs *Till T. Bachmann (Edinburgh, United Kingdom)*
Robert Leo Skov (Copenhagen, Denmark)

D0010 13:30 **A funder's perspective** *Ghada Zoubiane (London, United Kingdom)*

D0011 14:00 **Industry perspective** *Marc Gitzinger (Basel, Switzerland)*

WT009 13:30 – 14:30 **Poster area**

AMR TRN

Poster Walkthrough

Fundamental insights: a guided tour along the best-rated posters in fundamental microbiology and pathogenesis

Chair *Christian Stephan Lentz (Tromsø, Norway)*

R0082 **P3994 - Protective effects of Haemophilus influenzae on epithelial damage induced by *Streptococcus pneumoniae*** *Emi Tanaka (Nagoya, Japan)*

R0083 **P3961 - The biosurvival of *Neisseria meningitidis* in human saliva vs artificial saliva: nothing beats the real thing** *Mia Dierks-Treece (Bristol, United Kingdom)*

R0084 **P4007 - Adaptive evolution of carbapenem-resistant *Klebsiella pneumoniae*: altered virulence and extensive persistence in the GI tract** *Jing Wang (Hong Kong, Hong Kong)*

R0085 **P4134 - Immune correlates of protection in a first-in-human non-typhoidal *Salmonella* challenge study** *Anna Rydlova (London, United Kingdom)*

R0086 **P3991 - Effects of high-fat diet and ApoE gene deficiency on human Coronavirus infection in an ex vivo lung model** *Hsing-Yu Chen (Taipei, Taiwan)*

R0087 **P4042 - Synthetic wound fluid modulates antibiotic susceptibility and biofilm formation in wound pathogens** *Charlotte Morgan (Swansea, United Kingdom)*

R0090 **P4114 - Immunomodulators GM-CSF and plerixafor are advantageous in the treatment of *Pseudomonas aeruginosa* wound-derived sepsis in mice** *Lacie Werner (Silver Spring, Maryland, United States)*

WT010 13:30 – 14:30 **Poster area**

AMR TRN

Poster Walkthrough

AMR in LMICs: from mechanisms to surveillance

Chair *Christina Obiero (Kilifi, Kenya)*

R0091 **P1631 - Diverse population of antimicrobial resistant plasmids carried by Gram-negative bacteria causing neonatal sepsis in low- and middle-income countries** *Kirsty Sands (Oxford, United Kingdom)*

R0092 **P2004 - Comparison of mobile genetic elements found in carbapenemase-producing Enterobacterales isolated from conflict zone clinical samples** *Olena Moshynets (Kyiv, Ukraine)*

R0093 **P1441 - Building a national bacteriology and AMR surveillance network by leveraging the existing tuberculosis laboratory network in a resource limited setting: the Benin experience** *Faridath Massou (Cotonou, Benin)*

R0094 **P1357 - Pathogen distribution and antimicrobial resistance patterns in bloodstream infections across diverse healthcare settings: findings from the BALANCE study** *Refath Farzana (Oxford, United Kingdom)*

R0095 **P1944 - Molecular characteristics and antimicrobial resistance gene profiles of atypical and typical enteropathogenic *Escherichia coli* from clinical and environmental settings in South Africa** *Veronica Ueckermann (Pretoria, South Africa)*

R0096 **P1723 - Resistance plasmidome of neonatal sepsis pathogens in low- and middle-income countries** *Ngoc Minh Nguyen (Antwerp, Belgium)*

R0097 **P1965 - Carriage of antimicrobial resistant bacteria in filth flies collected from five hospital sites across Pakistan** *Teresa Iannetelli (Oxford, United Kingdom)*

R0098 **P1438 - Genomic characterisation of Staphylococcus epidermidis neonatal sepsis isolates across BARNARDS-II clinical sites in Pakistan and Nigeria** *Jawaria Aziz (Cardiff, United Kingdom)*

R0099 **P1261 - Changes in proportions of ESBL-producing E. coli by sequence type after return: a longitudinal follow-up** *Arttu Nousiainen (Helsinki, Finland)*

R0100 **P1404 - Prior antibiotic exposure as a hidden bias in neonatal AMR surveillance: evidence from a multicountry LMIC cohort** *Kathryn Thomson (Oxford, United Kingdom)*

WT011 13:30 – 14:30 **Poster area**

AMR IPC

Poster Walkthrough

Hospital transmission and emerging threats: *Candida auris*, environmental reservoirs, and genomic surveillance of antimicrobial resistance

Chair *Ermira Tartari (Msida, Malta)*

R0101 **P3210 - Epidemiological trends in invasive Candida spp. infections before and after an extreme flooding event in Southern Brazil** *Cezar Vinicius Würdig Riche (Porto Alegre, Brazil)*

R0102 **P3305 - Characterisation of *Candida auris* (*Candidozyma auris*) from a worldwide surveillance program over 12 years** *Mariana Castanheira (North Liberty, Iowa, United States)*

R0103 **P3133 - A resistant invader in hospitals: national summary of *Candida auris* infections in Türkiye** *Elif Agüloğlu-Bali (Ankara, Türkiye)*

R0104 **P1927 - Investigation of a rare human outbreak of mecC-MRSA in Belgium and its genomic links to animal-associated lineages** *Nicolas Yin (Brussels, Belgium)*

R0105 **P1987 - Distribution of antimicrobial resistance genes in hospital wastewater, WWTP effluent, and urban surface water in the northeastern part of the Netherlands** *Carmen Stoffers (Groningen, The Netherlands)*

R0106 **P2010 - Linking clinical and wastewater settings: a comparative genomic analysis of carbapenemase- and ESBL-producing Enterobacterales in Northern Spain** *Mario Sergio Pino Hurtado (Logroño, Spain)*

R0107 **P3158 - *Candidozyma auris* in the Netherlands: no evidence of nosocomial transmission supported by effective infection control policies** *Chiara De Groot (Bilthoven, The Netherlands)*

R0108 **P1268 - Effectiveness of cefepime/enmetazobactam against highly multidrug-resistant bacterial isolates recovered from war-associated wounds in Ukraine** *Jale Boral (Malmo, Sweden)*

R0109 **P1199 - Comprehensive metagenomic surveillance uncovers last-resort antibiotic resistance genes in wastewater** *Prerna Yadav (New Delhi, India)*

R0110 **P2006 - Linking antimicrobial resistance between hospital and wastewater environments via plasmid systems** *Meghana Srinivas (Maynooth, Ireland)*

WT012 **13:30 – 14:30** **Poster area**

Poster Walkthrough

AMR PHEI

Novel insight into AMR epidemiology in One Health perspective

Chair *Helena Zemlickova (Prague, Czechia)*

R0111 **P1714 - PlasmidNL: a web-based interface for tracking plasmid dissemination in the Netherlands** *Gijs Teunis (Bilthoven, The Netherlands)*

R0112 **P1975 - Stable plasmid populations in sewage spread antibiotic resistance** *Alberto J. Martín-Rodríguez (Stockholm, Sweden)*

R0113 **P2011 - Cross-domain plasmid mediated AMR transmission** *Rebekka Koeck (Maastricht, The Netherlands)*

R0114 **P2030 - Evolutionary dynamics and plasmid epidemiology of *Salmonella* infantis in Türkiye: focus on the pESI-like megaplasmid** *Gultekin Unal (Ankara, Türkiye)*

R0115 **P1511 - Predicting antimicrobial susceptibility after one hour of antibiotic exposure** *Ben Nannings (Rotterdam, The Netherlands)*

R0116 **P1573 - LC-MS reveals distinct degradation signatures for carbapenemases including β-lactone formation by OXA-48-like enzymes** *Veronika Pašková (Plzen, Czechia)*

R0117 **P3255 - Molecular detection of C. auris: a comparative evaluation of commercial assays including a new selective *C. auris* broth for clinical laboratory use** *Alexander Maximilian Aldejohann (Würzburg, Germany)*

R0118 **P3308 - Activity of manogepix against *Candida auris***

R0119 **P1559 - Towards a microfluidic PK/PD system for individualised phenotypic antimicrobial susceptibility testing** *Jennifer Lawrence (London, United Kingdom)*

R0120 **P2017 - Genomic wastewater surveillance program reveals emergence of cefiderocol-resistant Enterobacterales in South America** *Johana Becerra (São Paulo, Brazil)*

OS103 **14:45 – 15:45** **Hall A2-2**

1-hour Case Session

CLN IPC

What did you get in the hospital?

Chairs *Christina König (Hamburg, Germany)*
Sara Tomczyk (Berlin, Germany)

O0706 **14:45** **Hospital acquired tularemia: a case report of nosocomial transmission of *Francisella tularensis*** *O. Arce Garcia* (Pozuelo De Alarcon, Spain), M. Simon Sacristan, A. Collazos Blanco, M.F. Ramos Ferriol, M. Rozas Bellido, I. Darid Y Ceron, S. Sanchez Sanchez, G. Arán Toha, S. Medrano Pardo, M.T. Llorente Rodriguez, O. Arce, G. Ramirez Olivencia*

O0707 **14:56** ***Gemella haemolysans* endocarditis in a southern Spain hospital** *P. Monroy* (Malaga, Spain), P. Monroy Moya, L. Balderas Fernández, L. Mora Navas, M.V. García López*

O0708 **15:07** **Nosocomial myiasis: report of two cases and review of the literature** *D. Verendag* (Izmir, Türkiye), D. Verendağ, D. Kaya, H.A. Erdem, N. Bilgili Korkmaz, B. Arda, O.R. Sipahi*

O0709 **15:18** **Difficult-to-treat Gram-positive health-care associated ventriculitis treated with combination antibiotic therapy including fosfomycin: a series of three cases** *G. Parruti* (Pescara, Italy), A. Frattari, F. Spagnuolo, C. Di Iorio, E. Polilli, P. Fazii*

O0710 **15:29** **The unusual outbreak of sepsis in a cancer hospital caused by intrinsically contaminated heparin injection vials** *V. Bajpai Batra* (Varanasi, India), A. Kapoor*

OS101 **14:45 – 15:45** **Hall B0-1**

1-hour Case Session

AMR ANT CLN

Phage therapy for complex infections

Chairs *Zuzanna Drulis-Kawa (Wroclaw, Poland)*
Spyros Pournaras (Athens, Greece)

O0711 **14:45** **Personalised phage therapy for multidrug-resistant infections in thoracic organ transplant recipients** *C. Kuehn* (Hannover, Germany), E. Rubalskii, L. Sedlacek, S. Ruemke, N. Schwerk, J. Gottlieb, A. Haverich, D. Schlüter, G. Hansen, A. Ruhparwar*

O0712 **14:56** **Breaking the cycle of relapse: personalised phage therapy in MDR *Pseudomonas aeruginosa* LVAD infection** *S. Ferin* (Udine, Italy), S. Flammini, P. Della Siega, M. Merelli, D. Pecori, S. Giuliano, C. Tascini*

O0713 **15:07** **Novel antibiotic-phage therapy duo rapidly resolves XDR-AB pneumonia after liver transplant** *W. Wang* (Xian, China)*

O0714 **15:18** **Precision-matched bacteriophage therapy for prosthetic aortic graft infections: a single-centre observational case series** *E. Rubalskii* (Hannover, Germany), S. Ruemke, L. Sedlacek, A. Haverich, D. Schlüter, A. Ruhparwar, C. Kuehn*

O0715 **15:29** **Phage therapy for refractory, native joint *Staphylococcus aureus* arthritis with infected bone necrosis** *M. Dekel* (Tel Aviv, Israel), R. Nir Paz, R. Ben Ami, N. Bishouty, A. Khoury, N. Snir, T. Ben Tov*

OS104 **14:45 – 15:45** **Hall A3-1**

1-hour Oral Session

AMR ANT CLN

Emerging and repurposed therapeutic options in resistant Gram-negatives

Chairs *Jaroslav Hrabak (Plzen, Czechia)*
Giusy Tiseo (Pisa, Italy)

O0716 **14:45** **Treatment strategies for CRKP central nervous system infections after neurosurgery: a prospective observational study comparing intravenous ceftazidime/avibactam and intraventricular/intrathecal polymyxin B sulphate injections** *M. Wang* (Shanghai, China), L. Yang, W. Mei-Hua, L. Nan-Yang, C. Wei, F. Ya-Xin, W. Gang, H. Jin, Z. Jing*

O0717 **14:57** **Clinical and genomic insights into emerging resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing *Klebsiella pneumoniae* (Italy, 2021–2024)** *M. Boattini* (Turin, Italy), S. Comini, G. Ricciardelli, R. Casale, L. Guarrasi, R. Cavallo, C. Costa, P. Gaibani, G. Bianco*

O0718 **15:09** **Clinical outcomes and treatment-emergent resistance of bloodstream infections due to AmpC β-lactamase-producing Enterobacterales** *S. Shah* (Pittsburgh, United States), J. Jawanda, M. O'donnell, R. Shields, L. Clarke, H. Creager, R. Marini, B. Falcione*

O0719 **15:21** **A multi-centre cohort study of tigecycline effectiveness and safety in patients with carbapenem-resistant *Klebsiella pneumoniae* and carbapenem-resistant *Acinetobacter baumannii* co-infection** *D. Chen* (Nanjing, China), S. Wang, N. Hu, P. Liang, J. Liu, H. Xie, H. Zhang, J. He*

O0720 **15:33** **Efficacy of minocycline-based combination therapy in *Stenotrophomonas maltophilia* infections from a randomised controlled trial, and the activity of antimicrobial combinations against isolates as determined by the checkerboard method** *A. Boonyasiri* (Bangkok, Thailand), T. Pongdumbun, S. Tiengrim, Y. Rongrungruang*

OS105 **14:45 – 15:45** **Hall A3-2**

1-hour Oral Session

DX TRN

Decoding inflammation and innovating diagnostics of parasitic diseases

Chairs *Pikka Jokelainen (Copenhagen, Denmark)*
Martin Montes (Lima, Peru)

O0721 **14:45** **Monocyte-dependent antigen specific inflammation in neurocysticercosis is regulated by mitogen activated protein kinases** *L.M. Toribio* (London, United Kingdom), D.L. Chong, H.H. Garcia, J.S. Friedland*

O0722 **14:57** **First cases of male genital schistosomiasis reported in**

Zambia: a pilot study integrating semen-based parasitology, molecular diagnosis and portable ultrasonography *S. España Cueto* (Badalona, Spain), E.C. Sergio, N. Bronwyn, M. Isaac, N. Rhoda, C. Lucas, A. Fiona, V.L. Lisette, W. Bonnie L., C. Maina, M. Tegwen, H. Shinjiro, R. Silvia, P. Roger, K. Sekeleghe, S. J. Russell, S. Kwame, B. Amaya L.*

O0723 15:09 **Evaluating the diagnostic performance of a recombinase polymerase amplification assay compared to polymerase chain reaction for the diagnosis of female genital schistosomiasis using cervicovaginal self-sample swabs** *N. Hrouda* (London, United Kingdom), S. Nanyinza, L. Smith, J. Fitzpatrick, R. Ndubani, M. Cheeba, B. Neufeld, K. Shanaube, B. Webster, A. Bustinduy*

O0724 15:21 **Diagnostic evaluation of parasite-derived microRNAs as serum biomarkers for cystic echinococcosis** *Y. Akyön Yilmaz* (Ankara, Türkiye), S. Orsten, İ. Baysal, M. Sarıkaya, E. Yagmur, O. Bozkurt, E. Ünal, S. Yabanoğlu Çiftçi, H.A. Dinçer, D. Dirim, D. Akıncı, A.B. Doğrul, E. Karaağaoğlu, M. Korkmaz, Y. Akyön, T. Çiftçi, O. Akhan*

O0725 15:33 **Hookworm infection drives inflammation and tissue destruction in tuberculosis** *M. Loader* (London, United Kingdom), S.E. Vásquez Alves, M.R. Verástegui, R.H. Gilman, J.S. Friedland*

OS102 **Hall B0-2**

14:45 – 15:45

1-hour Oral Session

CLN

Pitfalls in modern HIV therapy

Chairs *Justyna Kowalska (Warsaw, Poland)*
Milena Stevanovikj (Skopje, North Macedonia)

O0726 14:45 **A plasma proteomic aging clock reflects reversal of accelerated aging in people with HIV under antiretroviral therapy** *B. Ryan* (Lausanne, Switzerland), M. Ait Oumelloul, S. Rouached, A. Juillerat, L. Giacchetto, I. Schoepf, L. Bartl, C. Dollé, D. Russenberger, P. Nanni, T. Kockmann, M. Stöckle, G. Wandeler, A. Calmy, M. Cavassini, L. Elzi, P. Schmid, J. Fellay, P. Tarr, J. Nemeth*

O0727 14:57 **Effect of 1HP on dolutegravir concentrations** *M. Nicol* (Minneapolis, United States), A. Buzibye, A. Fieberg, B. Dai, P. Nerima, E. Ajilong, C. Waitt, D. Boulware, E. Nalintya, R. Rajasingham*

O0728 15:09 **Renal function, HIV reservoir and immune marker changes after one year of long-acting ART** *L. Maddaloni* (Rome, Italy), L. De Martino, L. Santinelli, C. Falvino, G. Bugani, A. Lazzaro, R. Donà, L. Bortolani, M. Andreotti, Z. Michelini, G. Antonelli, C.M. Mastroianni, C. Scagnolari, G. D' Ettorre*

O0729 15:21 **Doravirine: two vs three-drugs based regimens, a multi-centre observational study** *F. Casari* (Modena, Italy), B. Fontana, A. Cervo, A. Giacomelli, R. Rossotti, M. Menozzi, M. Albertini, G. Menegotto, E. Martini, M.V. Cossu, C. Mussini, G. Guaraldi, C. Gervasoni*

O0730 15:33 **No biomarker evidence of CNS injury after switching to dual therapy with dolutegravir/lamivudine in HIV** *L. Renborg* (Gothenburg, Sweden), A.L. Benedet, A. Yilmaz, S. Nilsson, K. Nyström, K. Blennow, H. Zetterberg, M. Gisslén*

OS100 **Hall ICM 5**

14:45 – 15:45

1-hour Oral Session

TRN

Microbiome-host interplay in intestinal disease and under selection pressure

Chairs *Vincenzo Di Pilato (Genoa, Italy)*
Ed J. Kuijper (Leiden, The Netherlands)

O0731 14:45 **A hit with a scar: amoxicillin alters the infant gut microbiome long-term but without fungal expansion** *J. Hurych* (Helsinki, Finland), R. Ventin-Holmberg, J. Honkanen, V. Castrén, A. Nikkonen, J. Koskimäki, V. Peltola, K. Korpela, P. Saavalainen, K.L. Kolho*

O0732 14:57 **Protease-induced activation of colonic afferent neurons by gut bacterium *Phocaeicola vulgatus*, previously associated with inflammatory bowel disease** *R. Nakhle* (Kingston, Canada), H.M. Wood, K. Blazkova, F.F. Faucher, M. Farquhar, P.M. Sheth, B.L. Schmidt, S.J. Vanner, N.W. Bunnett, M. Bogyo, D.E. Reed, A.E. Lomax*

O0733 15:09 **Recapturing individual inflammatory responses in IBD microbiomes using an *in vitro* colonic model (MiGut)** *I. Moura* (Leeds, United Kingdom), W. Davis Birch, N. Beauchemin, K. Bentley, M. Vulic, M. Henn, A. Buckley, C. Ford, N. Kapur, E. Halvorsen, I. B. Moura*

O0734 15:21 **Development of antibiotic-associated diarrhea in sepsis patients is associated with dysbiosis at baseline** *E. Kyriazopoulou* (Athens, Greece), E. Stylianakis, G. Damoraki, A. Spyrou, S. Symbardi, G. Chrysos, G. Adamis, E. Giamarellos-Bourboulis*

O0735 15:33 **Ecological instability of the gut microbiome during haematopoietic stem cell transplantation** *C. Hajjar* (Beirut, Lebanon), A. Ibrahim, A. Bazarbachi, M. Abifadel*

SY135 **Hall ICM 13b**

14:45 – 15:45

1-hour Symposium

AMR DX

Resistance redefined: how to analyse biofilms and anaerobes

Chairs *Tom Coenye (Ghent, Belgium)*
Efthymia Giannitsioti (Athens, Greece)

S0338 14:45 **Resistance in slow growing anaerobic communities** *Catalina Suzana Stingu (Leipzig, Germany)*

S0339 15:15 **What *in vitro* susceptibility testing does (not) tell you about *in vivo* anti-biofilm activity in the respiratory tract** *Valerie Waters (Toronto, Canada)*

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Anaerobic Infections (ESGAI)

SY134 **Hall ICM 14**

14:45 – 15:45

1-hour Symposium

CLN

Year in infectious diseases

Chairs *Murat Akova (Ankara, Türkiye)*
Yoav Keynan (Winnipeg, Manitoba, Canada)

S0336 14:45 *- Dafna Yahav (Ramat-Gan, Israel)*

S0337 15:15 *- Margaret Ip (Hong Kong, Hong Kong)*

EF106 **Arena 1**

14:45 – 15:45

ePoster Flash Session

PHEI VAX

Latest trends in vaccinology: from current strategies to next-generation vaccines

Chair *David Chien Lye (Singapore, Singapore)*

E0736 14:45 **Long-term impact of a single-dose inactivated hepatitis A vaccine in Korean military recruits: a nationwide cohort analysis (2011–2024)** *J.H. Im* (Incheon, Korea, Republic of), J.S. Lee, S. Cho, D.Y. Kang, D.Y. Lee*

E0737 14:51 **Effectiveness of high-dose vs standard-dose influenza vaccine against recurrent hospitalisations and through extended follow-up: a prespecified analysis of the DANFLU-2 trial** *N.D. Johansen* (Hellerup, Denmark), D. Modin, M.M. Loiacono, R.C. Harris, M. Dufournet, C.S. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, B.L. Claggett, K.H. Janstrup, K.V. Bartholdy, K.F. Bernholm, J.I.M.H. Borchsenius, F.S. Davidovski, L.W. Davodian, M.F. Dons, L.S. Duus, C. Espersen, F.H. Fussing, A.M.R. Jensen, N.E. Landler, A.C.F. Langhoff, M.C.H. Lassen, A.B. Nielsen, C.I. Ottosen, M. Sengeløv, K.G. Skaarup, S.D. Solomon, M.J. Landray, G.H. Gislason, L. Køber, P. Sivapalan, C.J.M. Martel, J.U.S. Jensen, T. Biering-Sørensen*

E0738 14:57 **Effectiveness of high-dose vs standard-dose influenza vaccine in older adults according to age: a prespecified analysis of the FLUNITY-HD study** *K. Hosseini* (Copenhagen, Denmark), N. Dyrby Johansen, D. Modin, J. Pardo-Seco, C. Rodriguez-Tenreiro-Sánchez, M. M. Loiacono, R. C. Harris, R. Van Aalst, A. Chit, C. Schade Larsen, L. Larsen, M. Pareek, L. Wiese, M. Dalager-Pedersen, B. L. Claggett, K. Hyldekær Janstrup, C. Duran-Parrondo,*

M. Piñeiro-Sotelo, M. Dufournet, M. Cribeiro-González, M. Conde-Pájaro, S. Mirás-Carballal, J.M. González-Pérez, S. D. Solomon, P. Sivapalan, C. Jean-Marie Martel, J. Ulrik Stæhr Jensen, F. Martinón-Torres, T. Biering-Sørensen

E0739 **15:03** **Immunogenicity and safety of a higher-dose MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults ≥50 years of age: a phase III randomised controlled trial** *F.R. Albano* (Melbourne, Victoria, Australia), B.J. Essink, W. Vermeulen, C. Andrade, M. Mazur, C. Jamison, R. De Rooij, E. Heijnen, D. Casula, R. Xing, M. Piedrahita, V. Garner*

E0740 **15:09** **Predicting COVID-19 vaccination decision-making profiles among Dutch adults: from survey to national administrative data** *T. Abreu* (Utrecht, The Netherlands), J. Bernardo-Garcia, I. De Wolf, M. Matthijssen, D. Timmermans, V. Buskens*

E0741 **15:15** **Intramuscular SARS-CoV-2 vaccination fails to induce de novo local antibodies in older adults: a Com-COV randomised substudy** *R. Shaw* (Oxford, United Kingdom), T. Dinesh, J. Alderson, S. Belij-Rammerstorfer, S. Bibi, E. Clutterbuck, M.R.N.U. Ramasamy, M. Snape, X. Liu, T. Lambe*

E0742 **15:21** **Vaccines insight, beliefs, and experiences in school-aged children and parents: a questionnaire and structured interview in UK families (VIBES)** *W. Carroll* (Uttoxeter, United Kingdom), A. Jagadish, F. Gilchrist, R. Horne*

E0743 **15:27** **Next-generation vaccines for hepatitis E virus** *J. Situ* (Hongkong, China), X. Ma, Y. Liang, S. Wu, S. Sridhar*

EF107 **Arena 2**

14:45 – 15:45

ePoster Flash Session

AMR IPC

Infection control and prevention around the world: risks, behaviours, and solutions

Chair *Maria João Lopes (Amadora, Portugal)*

E0745 **14:45** **Perception vs practice in hospital cleaning: assessing task-prioritisation between hospital cleaning staff and IPC practitioners, an interim analysis** *A. Kearney* (Dublin, Ireland), M. Fallon, J. Doyle, B. Fletcher, A.F. Talento, R. Cunney, C. Cahir, D. Fitzgerald Hughes, B. Mitchell, M. Kiernan*

E0746 **14:51** **Environmental reservoirs of carbapenemase-producing organisms (CPO) in intensive care unit (ICU) hand hygiene (HH) sinks and haemodialysis (HD) wall boxes: investigation and control measures** *J. Guerrero* (Scarborough, Canada), S. Paramalingam, J. Lerma, M. Pekelny, S. Arefin, A. Garga, M. O'connor, R. Lovinsky*

E0747 **14:57** **Hospital surfaces as reservoirs of carbapenemase- and ESBL-producing bacteria in hospitals across Bangladesh, Nigeria and Pakistan** *A. Cooke* (Oxford, United Kingdom), J. Rzaska, R. Farzana, B. Hassan, C. Achi, M. Nieto-Rosado, L. Wilson, S. Langhorne, A. Sindhu, J. Oduwo, E. Owinoh, R. Zahra, E. Rashid, M.I. Shah, A. Mahboob, A.A. Shah, H. Naz, A. Muhammad, S. Ali, W. Sombul, M. Khan, S.U. Nisa, A. Khan, S. Riaz, S. Naqvi, J. Zafar, H. Hamid, A. Sajid, R. Razzaq, K. Iregbu, N. Medugu, T. Akujobi, F.Z.Z. Abdu, A. Aminu, S.A. Suwaid, S. Gambo, Y. Mohammed, J. Abubakar, A. Panti, O. Oduyebo, O. Olutekunbi, F. Okenla, I. Nwafia, P. Nwachukwu, S. Chukwuma, T. Sultana, S. Arefin, P.I. Disha, N. Tasnim, T. Hossain, T. Haque, T.R. Walsh, K. Sands, K.M. Thomson*

E0748 **15:03** **CRE colonisation as a marker for CRE ventilator-associated pneumonia (VAP): insights from a 15-month ICU cohort in Rome** *L. Campogiani* (Rome, Italy), A.M.A. Crea, L. Alborghetti, P. Vitale, I. Spalliera, M. Zordan, A.M. Geretti, V. Malagnino, M. Iannetta, L. Sarmati*

E0749 **15:09** **Behavioral insights and motivational challenges within infection control committees: mixed-methods study using COM-B and TDF frameworks** *T. Yanık Yalçın* (Ankara, Türkiye), A. Pehlivanlı, B. Gönülal, F. Callak Oku, B. Madran, E. Sargın Altunok, Ş. Keske, M. Aydın, Ö. Kurt Azap, Ö. Ergönül, H. Akalın*

E0750 **15:15** ***Candidozyma auris* colonisation: point-prevalence and long-lerm outcomes in a tertiary university hospital** *M. Gamaletsou* (Athens, Greece), D. Basoulis, A. Karapanou, E. Apostolidi, S. Zerva, A.R. Andritsou, K. Panteli, C. Psarakis, K. Reppas, A. Rigatou, D. Stefani, A. Strikou, D. Mpora, D. Petraki, M. Sampanis, S. Zagkavierou, K. Theodoridou, T. Koliou, S. Kritikou, A. Millioni, E. Giannitsioti, E. Mastrogianni, F. Ntziora, A. Anastasopoulou, M. Samarkos, M. Psichogiou, N.V. Sipsas, G. Vrioni*

E0751 **15:21** **A 20-year single-centre retrospective study on the impact of hospital environmental factors on the incidence of candidaemia** *A. Bedini* (Modena, Italy), G. Franceschi, S. Esperti, S. Generoso, L. Benassi, U. Calvi, M. Meschiari, E. Franceschini, C. Venturelli, C. Mussini*

E0752 **15:27** **Swiss minimum requirements for infection prevention and control: results of a national survey** *A. Sonpar* (Zurich, Switzerland), C. Balmelli, M. Eder, A. Metsini, Z. Zhang, W. Zingg*

E0753 **15:33** **A multi-modal intervention with patient engagement to reduce Multidrug-Resistant Organisms (MDROs) in post-acute care** *L. Mody* (Ann Arbor, United States), M. Cassone, K. Gibson, G. Vijayasiri, E. Snitkin, S. Saint, S. Krein, M. Janevic, J. Thiel, A. Nguyen, T. Bej, O. Hicks, N. El Chakhtoura, L. Min, A. Galecki, T. Greene, M.C. Roghmann, L. Chigurupati, F. Perez, R. Jump*

EF108 **Arena 3**

14:45 – 15:45

ePoster Flash Session

CLN PED

Little patients, big challenges: tackling bacterial infections in children

Chair *Christina Obiero (Kilifi, Kenya)*

E0754 **14:45** ***Klebsiella pneumoniae*: a leading cause of neonatal sepsis from 13 hospitals in Nigeria, Pakistan and Bangladesh** *K. Sands* (Oxford, United Kingdom), K. Thomsom, C. Achi, R. Farzana, B. Hassan, A. Cooke, J. Rzaska, A.K. Lankapalli, J. Oduwo, E. Owinoh, N. Haque, R. Farzana, T.A. Sumi, P.I. Disha, S.K. Sara, T. Haque, K. Iregbu, N. Medugu, T. Akujobi, K. Abdulraheem, A. Aminu, S.A. Suwaid, S. Gambo, Y. Mohammed, J. Abubakar, A. Adamu, O. Oduyebo, O. Olutekunbi, O. Ogunsanya, I. Nwafia, S. Chukwuma, P. Nwachukwu, R. Zahra, E. Rashid, M.I. Shah, A. Mahboob, A.A. Shah, I. Ullah, A. Muhammad, S. Ali, S. Amin, M. Khan, S. Arif, S.U. Nisa, S. Riaz, S. Naqvi, I. Zeb, M. Haroon Hamid, U. Hussain, S. Shabbir, T.R. Walsh*

E0755 **14:51** **Antibiotic dosing practices in neonates in low- and middle-income countries: model-based comparison with guidelines and implications for target attainment and toxicity** *W. Van Os* (Leiden, The Netherlands), K.M. Thomson, K. Sands, T.R. Walsh, C.R. Achi, B. Hassan, R. Farzana, E. Owinoh, J. Oduwo, K. Iregbu, N. Medugu, T. Akujobi, A. Mairami, A. Aminu, S.A. Suwaid, S. Gambo, Y. Mohammed, J. Abubakar, S.M. Zainu, O. Oduyebo, O. Olutekunbi, A. Odedina, I. Nwafia, J. Unigwe, C. Onyejekwe, T.A. Sumi, B. Majumder, S.B. Proma, T. Haque, R. Khatun, T. Hossain, E. Rashid, R. Zahra, M.I. Shah, A. Mehboob, A.A. Shah, I. Ullah, A. Muhammad, M. Muhammad, S. Amin, M. Khan, S.U.N. Syed, M. Mahrang, S. Riaz, S. Naqvi, R. Hamza, M.H. Hamid, M. Malik, R. Temur, R. Sajjad, J.G.C. Van Hasselt*

E0756 **14:57** **Antibiotic resistance genes in meconium of newborns very early after admission to neonatal intensive care unit** *A. Ftergioti* (Thessaloniki, Greece), M. Simitsopoulou, A. Kontou, K. Sarafidis, E. Roilides, E. Iosifidis*

E0757 **15:03** **Stool-based real-time PCR platform as a non-invasive frontline diagnostic tool for paediatric pulmonary tuberculosis: a cross-sectional study from a tertiary care paediatric centre** *A. Soni* (Noida, India), S. Nandwani, S.B. Mathur, B. Kumar*

E0758 **15:09** **Predictors of outcomes of paediatric diphtheria in sub-Saharan Africa: a systematic review and meta-analysis** *I.A. Rufai* (Sokoto, Nigeria), S. Abubakar, F. Shagari*

E0759 **15:15** **Post-pandemic resurgence and epidemiology of group A *Streptococcus* infection in children** *N. Tan* (Singapore, Singapore), W.J.W.H. Goh, C.Y. Chong, J. Li, C.F. Yung, K.C. Thoon, K.Q. Kam, K.D. Nadua, C.W.X. Seow, Y. Yelen, M. Maiwald, S.B. Yusof, K.P.L. Wong, C.Y. Woo, N.W.S. Tee, L. Cui, M. Ang*

E0760 **15:21** **IPSCC 2005 and Phoenix Sepsis Score in children under 60 days: strengths and diagnostic pitfalls** *L. Di Meglio* (Rome, Italy), G. Lorenzetti, M. Roversi, C. Tripiciano, S. Mercadante, M. Di Giuseppe, S. Chiurchiù, M. De Luca*

E0762 15:33 **Epidemiology and antibiotic use for pertussis and pertussis-like cough in Italian children: a population study (2010–2024, PEDIANET)** *E. Gres* (Padua, Italy), G. Sturniolo, S. Masenello, D. Dona, G. Brigadoi, A. Cantarutti, C. Giaquinto, V. Baldo, E. Barbieri*

PM005 **14:45 – 15:45** **Hall A2-1**

PRO PHEI

Pipeline Symposium

From AI for evidence synthesis to decision making

Chairs *David Eyre (Oxford, United Kingdom)*
Holger Rohde (Hamburg, Germany)

D0012 14:45 **AI decision support in antibiotic prescribing - novel aspects and direction** *Daniele Roberto Giacobbe (Genoa, Italy)*

D0013 15:15 **AI for ESCMID guideline development - a perspective on feasibility and safety** *José Molina Gil-Bermejo (Seville, Spain)*

MOVIE **14:45 – 18:30** **Hall ICM 13a**

PRO PHEI

Special Session

Behind the scenes: don't look up

Chairs *Diane Ashiru-Oredope (London, United Kingdom)*
Ana Raquel Freitas (Porto, Portugal)
William Hanage (Boston, United States)
Holger Rohde (Hamburg, Germany)
Luigia Scudeller (Pavia, Italy)
Sotirios Tsiodras (Athens, Greece)

OS110 **16:15 – 17:15** **Hall A2-2**

ANT CLN TRN

1-hour Case Session

New and novel approaches to complex infections

Chairs *Rekha Pai Mangalore (Melbourne, Australia)*
Jacques Simkins (Miami, United States)

O0763 16:15 **Allogeneic cytomegalovirus-specific T cell therapy in a small-bowel transplant recipient with multidrug-resistant CMV infection** *L. Van Den Bogaart* (Lyon, France), E. Frobert, T. Antonini, J.H. Dalle, J.Y. Mabrut, T. Perpoint, L. Reppel, D. Bensoussan, F. Ader*

O0764 16:26 **Faecal Microbiota Transplantation (FMT) as a novel therapy for refractory chronic norovirus infection in immunocompromised hosts: clinical response and metagenomic analysis** *K. Chaw* (Brisbane, Australia), K. Garnham, M. Buller, S. Schlebusch, T. Badrick, V. Grey, M. Sullivan, A. Sai, B. Koh, I. Gosbell*

O0766 16:48 **Daratumumab and belimumab for patients with neutralising anti-interferon-γ autoantibodies mediated adult-onset immunodeficiency: a case series** *Y.T. Weng* (Taipei, Taiwan), M.T. Tsai, H.Y. Sun, K.Y. Lin, Y.S. Huang, W.T. Tsai, C.Y. Yao, B.C. Guo, J.T. Wang, S.C. Chang, A. Cheng*

O0767 16:59 **Refractory resistant *Salmonella* empyema successfully treated with compassionate adjunctive bacteriophage therapy** *J. Chung* (Singapore, Singapore), Y.Y. Chua, E.C.Y. Sng, J.M.F. Chien, A. Taha, W.M. Chew, K.J. Goh, S. Thong, N.G.S. Chua, A.L.H. Kwa*

OS109 **16:15 – 17:15** **Hall ICM 13b**

CLN PHEI

1-hour Case Session

Melioidosis finds new destinations

Chairs *Yogesh Kumar Gupta (Jaipur, India)*
Maria João Lopes (Amadora, Portugal)

O0768 16:15 **First documented blood culture-confirmed melioidosis case in Mozambique: implications for awareness, surveillance, and diagnosis** *S. Cruz* (Beira, Mozambique), C. Raimundo, L. Andela, N. Joao, J. Marcos, C. Joyce, Z. Seni, M. Barrios, A. Dicko, C. Monjane, A. Comelli, F. Gordillo, P. Garcia-Vello*

O0769 16:26 **Saving the spleen: importance of timely diagnosis in relapsing melioidosis** *W. Khot* (Navimumbai, India)*

O0770 16:37 **Rhino-orbital melioidosis masquerading as invasive fungal sinusitis: a case report** *N. Kaur* (Jodhpur, India), T. Kanagiri, D. Kumar, V. Tak, G.K. Bohra*

O0771 16:48 **Ruptured aneurysm unmasking disseminated melioidosis: a case report** *M.L. Panes* (Manila, Philippines), J. Poblete, C. Ramos*

O0772 16:59 **A rare case of melioidosis reactivation in Germany twelve years after travel to Thailand** *T. Cronen* (Berlin, Germany), S. Schaber, F. Bremer, H. Müller-Redetzky, A. Uhrig*

OS111 **16:15 – 17:15** **Hall A3-2**

AMR ANT DX

1-hour Oral Session

Novel aspects of susceptibility testing methods

Chairs *Arjana Tambic Andrasevic (Zagreb, Croatia)*
Andreas Voss (Groningen, The Netherlands)

O0773 16:15 **Prospective assessment of heteroresistance to first-line β-lactams in Gram-negative bloodstream infections** *D. Squitieri* (Rome, Italy), G. Menchinelli, B. Berinson, N. Degel-Brossmann, B. Posteraro, M. Sanguinetti, H. Rohde*

O0774 16:27 **Comparative evaluation of agar dilution and Etest against broth microdilution for ceftobiprole susceptibility testing in methicillin-resistant *Staphylococcus aureus*: a multi-centre study in China** *F. Zhu* (Hangzhou, China), Y. Chen*

O0775 16:39 **Implementation of cost-effective antimicrobial susceptibility testing in resource-constrained settings: lessons from the BALANCE study** *R. Farzana* (Oxford, United Kingdom), E. Carretto, N. Haque, M. Rahman, A. Monir, R.A. Ansary, S. Shahid, S.T. Reza, N. Haque, E. Kibaru, G. Ganda, D. Adera, K. Onjuro, C. Achi, K. Iregbu, P. Nwajiobi-Princewill, K. Abdulraheem, F. Kilani, J. Udeh, A. Aminu, A.M. Idris, J.D. Joshua, I.N. Nwafia, A. Nkiruka, C.I. Chiedu, R. Zahra, M. Hamza, B. Hassan, A. Naqvi, G. Guljanan, K. Shafique, G. Fatima, R. Siddiqi, M. Idrees, A. Khattak, N. Rehman, K. Hoog, C. Abdellaoui, S. Langhorne, A. Sindhu, M. Christodoulou, E. Owinoh, F. Demetrio, T.R. Walsh*

O0776 16:51 **An innovative fluorogenic assay for reliable detection of staphylococcal penicillinase** *C. Dupieux* (Lyon, France), P. Martins-Simoes, B. Youenou, G. Antoniotti, F. Vandenesch, A. Tristan, F. Laurent*

O0777 17:03 **Comparation of piperacillin/tazobactam susceptibility testing with a Microscan system and the novel rapid system QuickMIC** *L. Lopez Cerero* (Seville, Spain), M. Sánchez-Ruiz De La Muela, M. Oliva-Sánchez, L. Monge-Olivares, I. Portillo-Calderón, M. Pulido, L. López-Cerero, A. Pascual*

SY139 **16:15 – 17:15** **Hall A3-1**

PHEI

1-hour Symposium

Setbacks to strength: re-imagining global health partnerships at times of geopolitical uncertainty

Chairs *Tetiana Melnyk (Paris, France)*
Marc Jean Struelens (Rochefort, Belgium)

S0347 16:15 **Effects on the global HIV pandemic** *Mosa Moshabela (Cape Town, South Africa)*

S0348 16:45 **Come back stronger: WHO's strategic plans for fighting infections in a globalised world** *Maria Van Kerkhove (Geneva, Switzerland)*

Co-organised with: Dutch Society for Medical Microbiology (NVMM), ESGPHM, ESGVM, Mèdecins Sans Frontières (MSF), European AIDS Clinical Society (EACS)

SY138 **16:15 – 17:15** **Hall B0-1**

1-hour Symposium

AMR ANT CLN

Bacteriophages in implant-related infections: translating a century-old concept into a modern solution for AMR

Chairs *Gina Suh* (*Rochester, Minnesota, United States*)
Andrej Trampuz (*Brisbane, Australia*)

S0345 **16:15** **Bacteriophage therapy in cardiac and orthopaedic device-related infection** *Tristan Ferry* (*Lyon, France*)

S0346 **16:45** **Challenges and future directions of phagotherapy in multidrug-resistant implant infections** *Thomas Fintan Moriarty* (*Davos, Switzerland*)

Co-organised with: ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)

SY137 **16:15 – 18:15** **Hall B0-2**

2-hour Symposium

AMR ANT

Stronger together: rational design and use of antibiotic combination therapies

Chairs *Sandrine Marchand* (*Poitiers, France*)
Anouk Edwina Muller (*The Hague, The Netherlands*)

S0341 **16:15** **Combination therapies in tuberculosis: how to design and evaluate new regimen** *Elin Svensson* (*Uppsala, Sweden*)

S0342 **16:45** **Towards rational breakpoints for antibiotic combination therapies** *Sebastian Wicha* (*Hamburg, Germany*)

S0343 **17:15** **Antibiotic combination therapies: can we suppress resistance?** *Linda Aulin* (*Leiden, The Netherlands*)

S0344 **17:45** **Optimal off-patent antimicrobial combinations regimens for Gram-negative infections** *Joe Standing* (*London, United Kingdom*)

EF112 **16:15 – 17:15** **Arena 1**

ePoster Flash Session

ANT CLN

Respiratory bacterial infections: challenges and advances

Chair *Margaret Ip* (*Hong Kong, Hong Kong*)

E0785 **16:15** **Evolution of the respiratory microbiological profile in people with cystic fibrosis undergoing treatment with elexacaftor/tezacaftor/ivacaftor** *B.S. Orena** (*Milan, Italy*), *F. Girardi, E. Tomassini, D. Girelli, M. D'accico, F. Blasi, V. Daccò, A. Callegaro, L. Cariani*

E0778 **16:21** **Invasive pneumococcal disease in a Portuguese hospital: 19-year retrospective study** *C. Batista** (*Oporto, Portugal*), *S. Araújo, C. Azeredo, C. Bacelar, J. Oliveira, F. Reis, L. Neto, T. Dos Santos, E. Pena, M.J. Gonçalves, F. Duarte, S. Rocha, S. Jordão, M. Guimarães, A. Read, R. Correia De Abreu, C. Soeiro*

E0779 **16:27** **Re-emergence of Chlamydia pneumoniae after the COVID-19 pandemic: a retrospective PCR-based study in a Spanish tertiary hospital (2019–2025)** *P. Suárez Urquiza** (*Valencia, Spain*), *E. Cortés Giménez, E. Gremaldos Mira, P. Suarez-Urquiza, A. Hernández Cabezas, J.L. López Hontangas, M.D. Gómez Ruiz*

E0780 **16:33** **Procalcitonin and lung ultrasonography-guided antibiotherapy in patients with lower respiratory tract infection in Swiss emergency departments: a pragmatic stepped-wedge cluster-randomised trial: The PLUS-IS-LESS study** *N. Boillat-Blanco** (*Lausanne, Switzerland*), *C. Bessat, E. Garcia, R. Bingisser, M. Schwendinger, T. Bulaty, Y. Fournier, V. Della Santa, M. Pfeil, D. Schwab, J. D. Leuppi, N. Geigy, S. Steuer, F. Roos, M. Christ, A. Sirova, A. Atzl, F. Napieralski, O. Manuel, I. Locatelli, W. Albrich, O. Hugli*

E0781 **16:39** **Effect of clarithromycin on inflammatory proteomic expression in community-acquired pneumonia: secondary analysis of the ACCESS trial** *E. Stylianakis** (*Athens, Greece*), *K. Tsiakos, V. Tzavara, L. Skorda, K. Iliopoulou, G. Adamis, G. Niotis, K. Akinosoglou, N. Kakavoulis, G. Chrysos, S. Gerakari, T. Kontopoulou, G.N. Dalekos, I.C. Papanikolaou, M.G. Netea, V. Kumar, E.J. Giamarellos-Bourboulis*

E0782 **16:45** **Antimicrobial-associated acute kidney injury in patients hospitalised with community-acquired pneumonia** *R.S. Knudsen** (*Hvidovre, Denmark*), *C. Leding, H. Løvendahl Jørgensen, M. Fally, P. Ravn, L. Kolte, S. Bastrup Israelsen, T. Benfield*

E0783 **16:51** **Efficacy of β-lactam monotherapy vs clindamycin or addition of metronidazole in peritonsillar abscess: an observational study with a focus on *Fusobacterium necrophorum*** *D. Nygren** (*Lund, Sweden*), *M. Loggarfve, E. Lindberg, K. Holm, M. Gisselson-Solén*

E0784 **16:57** **A randomised, double-blind, placebo-controlled trial of the safety and microbiological activity of bacteriophage therapy in cystic fibrosis participants chronically colonised with *Pseudomonas aeruginosa*** *P. Tamma** (*Philadelphia, United States*), *T. Hamasaki, M. Souli, D. Van Tyne, D. Pride, S. Nayak, K. Moon, E. Raterman, K. Greenwood-Quaintaince, D. Ellison, A. Filippov, M. Nikolich, T. Lodise, D. Conrad, A. Jaunarajs, Z. Wintrob, D. Albon, P. Allyn, T. Barto, J. Billings, L. Caverly, A. Graham, W. Hunt, R. Jain, J. Koff, K. Mcbennett, D. Miller, P. Mohabir, B. Morrissey, K. Patel, J. Wang, N. West, M. Bates, J. Leonard, G. Sah, M. Chiu, B. Evans, H. Geres, C. Koscianski, U. Rappo, J. Fackler, H. Chambers, S. Evans, R. Patel, V. Fowler, R. Schooley*

EF113 **16:15 – 17:15** **Arena 2**

ePoster Flash Session

CLN PHEI

Parasitic diseases in a changing world: climate, mobility, and clinical impact

Chair *Camilla Rothe* (*Munich, Germany*)

E0788 **16:15** **Estimating unreported malaria cases in England: a capture-recapture study** *P. Charlotte** (*London, United Kingdom*), *C. Patterson, A. Simbo, D. Turner, S. Leinster, P. Katwa, P. Veal, A. Checkley, C. Redman, C.A. Gibb, C. Williams, P. Chiodini*

E0789 **16:21** **Paediatric imported malaria infections with a non-falciparum species: a 2011-2023 retrospective study in France** *C. Melenotte** (*Paris, France*), *V. Joste, M. Thellier, F. Gay, F. Sorge, J. Toubiana, O. Lortholary, F. Lanternier, P.H. Consigny, L. Musset, B. Pradines, P. Buffet, S. Houzé*

E0791 **16:27** **The PK6 project: a test-and-treat operational strategy for *Plasmodium* vivax elimination among hard-to-reach illegal gold miners in French Guiana** *D. Patarot** (*Cayenne, French Guiana*), *M. Oberlis, T. Levarato, M. Rozé, P. Feller, L. Houssais, A. Carfantan, M. Boutrou, Y. Lazrek, L. Musset, F. Mubenga, C. Michaud, L. Epelboin*

E0792 **16:33** **Leishmaniasis as an opportunistic infection in HIV patients in Europe: lack of guidelines harmonisation and limited diagnostic arsenal** *G. Zaremba** (*Warsaw, Poland*), *A. Papadopoulos, K. Protopapas, M. Stevanovikj, N. Yancheva, S. Dragaš, A.Ç. İnkaya, C. Oprea, J. Begovac, Z. Bartovská, M. Zlámal, O. Beran, D. Jilich, A. Schembri, R. Matulionyte, I. Gmizic, D. Maric, J. Tomažič, E. Golovco, H. Tiberiu, B. Lakatos, T. Balayan, A. Vassilenko, A. Verhaz, N. Bolokadze, V. Krasniqi, J. Kowalska, A. Harxhi*

E0793 **16:39** **Leishmaniasis in a Spanish tertiary hospital (2018-2025): epidemiological trends, clinical and diagnostic characteristics of a re-emerging disease** *E. Gremaldos Mira** (*Valencia, Spain*), *E. Cortés Giménez, A. Ruiz Gaitán, P. Suárez Urquiza, A. Hernández Cabezas, J.L. López Hontangas, M.D. Gómez Ruiz*

E0794 **16:45** **Serum circulating anodic antigen as test-of-cure for schistosomiasis in migrants: what is the impact?** *L.C. Vaccari** (*London, United Kingdom*), *I. Chaudhry, J. Martin, C. Sen, N. Longley, G. Godbole, S. Eisen, L. Nabarro*

E0795 **16:51** **Three decades of echinococcosis in southern Madrid: insights into an endemic zoonosis** *A.N. Ruiz Benito** (*Leganes, Spain*), *V. Anton Berenguer, K.M. Pinto Tapia, M.D. Martín Rodrigo, S.M. Quevedo Soriano, S. Gómez De Frutos, F.J. Merino Fernández, J.M. Rubio Muñoz, M.D. Flores Chávez*

EF114 **16:15 – 17:15** **Arena 3**

ePoster Flash Session

DX IPC

Controlling *Clostridioides difficile* infections and hospital related challenges

Chair *Kerrie Davies (Leeds, United Kingdom)*

E0796 **16:15** **Most recurrent *Clostridioides difficile* infections reflect persistent infection or repeat exposure: findings from whole genome sequencing in Wales, UK** *R. Polani Chandrasekar* (Cardiff, United Kingdom), L. Campbell, T. Connor, N. Craine, V. Daniel, H. Hughes, V. Mcclure, T. Morris, M. Perry, R. Phillips, D. Williams, M. Morgan*

E0797 **16:21** **Evaluation and comparison of three methods for the detection of *Clostridioides difficile* toxin in faecal samples** *R. Asif* (Cardiff, United Kingdom), P. Talagtag, F. Ismail, S. Mitchell, M. Perry, S. Jones*

E0798 **16:27** **Gut microbiome characterisation in inflammatory bowel disease and *Clostridioides difficile* infection** *E. Reigadas* (Madrid, Spain), S. Vázquez-Cuesta, I. Marín, M. Díaz-Navarro, G. Álvarez-Calatayu, C. Sánchez, M. Guembe, A. Visedo, E. Bouza, P. Muñoz, L. Menchén, R. Samaniego, R. Bañares*

E0799 **16:33** **Screening for asymptomatic carriage of *Clostridium difficile*: results from a two year intervention** *M. Gilboa* (Ramat Gan, Israel), N. Barde, E. Meltzer, Y. Peretz, I. Levy, S. Amit, G. Rahav, N. Pinas-Zade, B. Mechnik, G. Regev-Yochay*

E0800 **16:39** ***Clostridioides difficile* infection in Europe: are we meeting best practices?** *M. Krutova* (Prague, Czechia), J. Prehn, W.K. Smits, O. Burduniuc, M. Wilcox, E. Kuijper*

E0801 **16:45** **Epidemiological trends in *Clostridioides difficile* infections in France, 2019-2024: TRACE national population-based study** *M. Decalonne* (Tours, France), M.H. Pham-Hi, C. Gaborit, C. Salpétrier, N. Khanafer, C. Daniau, F. Barbut, L. Grammatico-Guillon*

E0802 **16:51** **Exploring patient experiences of infection prevention and control across a range of healthcare associated infections: the stories behind the numbers** *M. Skally* (Dublin, Ireland), J. Strawbrige, C. Cox, J. Heritage, S. Rajesh, A. Walsh, C. Finn, P. Conran, K. Bennett, H. Humphreys, F. Fitzpatrick*

E0803 **16:57** **From insight to impact: leveraging opportunity mapping to drive system-wide reductions in CLABSI, CAUTI, *C. difficile*, and MRSA over a three-year period** *G. Rosello* (Miami, United States), J. Somani, C. Ghaemmaghami, D. Zambrana, H. Clark, C. Biggs, L. Abbo*

E0804 **17:03** **Wipe-based solutions for hand hygiene: do they really work?** *A. Barry* (Salisbury, United Kingdom), G. Moore*

KN136 **16:15 – 17:15** **Hall ICM 14**

Keynote lecture

CLN DX

Viral infection in the immunocompromised: from discovery to emerging therapies

Chairs *Maddalena Giannella (Bologna, Italy)*
Monica Slavin (Melbourne, Australia)

K0340 **16:15** *Hans H. Hirsch (Tromsø, Norway)*

ME140 **16:15 – 17:15** **Hall ICM 1**

Meet-the-Expert

AMR IPC

Artificial intelligence in antimicrobial stewardship and infection control: from prediction to precision

M0349 **16:15** *Damien Ming (London, United Kingdom)*
M0350 **16:27** *José Ramón Paño-Pardo (Zaragoza, Spain)*

ME141 **16:15 – 17:15** **Hall ICM 5**

Meet-the-Expert

CLN DX PED

Children are not small adults: interactive paediatric cases

M0351 **16:15** *Julie Toubiana (Paris, France)*
M0352 **16:27** *Ulrich Von Both (Munich, Germany)*

PM006 **16:15 – 18:15** **Hall A2-1**

Pipeline Symposium

DX PHEI

The value of diagnostics and enhancing utilisation

Chairs *Till T. Bachmann (Edinburgh, United Kingdom)*
Betsy Wonderly Trainor (Boston, United States)

D0014 **16:15** **Adoption and implementation in infection diagnostics – the long and winding road** *Jane Freeman (Leeds, United Kingdom)*

D0015 **16:45** **Beyond the test: social and organizational realities of implementing RTI diagnostics in primary care** *Sibyl Anthierens (Wilrijk, Belgium)*

D0016 **17:15** **What are diagnostics actually worth? Rethinking value beyond accuracy** *Brooke Nichols (Boston, United States)*

D0017 **17:45** **From great science to routine clinical use** *Matthew Mckillip (Chicago, United States)*

ART **16:15 – 17:15** **Hall A1-3**

Special Session

The art of food safety

Chairs *Leonard Leibovici (Yahud, Israel)*
Joel Mossong (Luxembourg, Luxembourg)

LB008 **17:30 – 18:30** **Hall A1-4**

1-hour Oral Session

CLN IPC

Late-breaking trials in surgical infection prevention

Chairs *Ili Margalit (Ramat Gan, Israel)*
Eli Perencevich (Iowa City, Iowa, United States)

L0041 **17:30** **Improvement in staff behavior during surgical procedures to prevent postoperative complications (ARIBO^2): a cluster randomised trial.** *G. Birgand* (Nantes, France), N. Jacquet, E. Tavernier, C. Gaborit, T. Haudebourg, N. Mauduit, C. Leux, D. Lepelletier, L. Grammatico-Guillon, J.C. Lucet, B. Giraudeau*

L0042 **17:42** **Polyhexanide vs mupirocin and chlorhexidine for pre-operative *Staphylococcus aureus* decolonisation in elective spine surgery (SPADE): a pilot randomised controlled trial** *R. Sommerstein* (Lucerne, Switzerland), J. Krebs, M. Grigorov, T. Poetzel, F. Michael, D. Bratelj, C. Capone, X. Zhou, J. Stoyanov*

L0043 **17:54** **One day of antibiotic treatment is non-inferior to four to seven days in patients with acute cholangitis after adequate biliary drainage: a multi-centre randomised controlled trial (COBRA)** *A. Overdevest* (Amsterdam, The Netherlands), E. Sieswerda, S. Haal, J.A. Bogaards, K.S. Boparai, F. Ter Borg, M.A. Brink, F. Van Delft, V.K. Dik, L.P.L. Gilissen, M. Hadithi, W.L. Hazen, F. Van Der Heide, W.J. Den Hollander, A. Inderson, P.J.F. De Jonge, S.D. Kuiken, J.M. Munneke, B. Opsteeg, L.E. Perk, A.C. Poen, J.W. Poley, R. Quispel, R.C.H. Scheffer, D.W. Schölvinck, E.J. Van Soest, A.C.I.T.L. Tan, W.J. Thijs, N.G. Venneman, R.C. Verdonk, F.P. Vleggaar, W. Van De Vrie, J.M. Vrolijk, R.L.J. Van Wanrooij, P.W. Weijenborg, M.G.W. Dijkgraaf, J.M. Prins, R.P. Voermans*

L0045 **18:06** **Effectiveness of an AI-based augmented reality tool for hand hygiene: preliminary findings of a cluster randomised controlled trial** *L. Yang* (Hong Kong, Hong Kong), Y. Lai, J. Meng, Y. Li, J. Lu, S. Lu, J. Chen, C.F. Ho, E. Tartari, G. Birgand*

L0044 **18:18** **Epidemiology, medical-surgical approach, and clinical and functional outcomes in fracture-related infection: an international multi-centre study from ESGIAI** *M. Del Toro* (Seville, Spain), B. Dahiri, R. García, M. Papadimitriou-Olivgeris, H. Ernandes, F. Almeida, J. Gomez-Junyent, O. Lesens, T. Martínez-Pascual, I. Contadini, D. Vaznaisiene, J.A. Iribarren-Loyarte, G. Euba, R. Escudero, J. Courjon, M.H. Ezzelarab, B. Sobrino-Díaz, A. Muñoz-Gómez, J. Rodríguez-Baño*

OS116 **17:30 – 18:30** **Hall A2-2**

AMR CLN TRN

1-hour Oral Session

Challenging the *status quo* in herpesvirus therapy

Chairs *Sylviane Defres (Liverpool, United Kingdom)*
Dionysios Neofytos (Geneva, Switzerland)

O0805 **17:30** **ABI-5366-101: a phase Ib study of a novel, oral, long-acting, investigational HSV helicase-primase inhibitor in recurrent genital herpes** *M. Bloch* (Sydney, New South Wales, Australia), E. Gane, C. Sellwood, A. Edwards, W. Hayter, T. Tonkin, K. Kaluhin, D. Smith, G. Wang, J. Liu, S. Knox, K. Zomorodi, K. Kitrinos, A. Gaggar, J. Sasadeusz*

O0806 **17:42** **Helicase-primase inhibitor adibelivir (IM-250) shows potent antiviral activity against HSV clinical and acyclovir-resistant isolates and achieves therapeutic exposure in phase I/Ib studies** *G. Kleymann* (Munich, Germany), A. Blank, M. Bergamino, J. Burhenne, D. Czock, C. Gege, Z. Haiying, A.C. Pérez-Osorio, B. Madarampalli, K.R. Jerome, N. Pretzsch, D. Huzly, V. Falcone, T. Hoffmann*

O0807 **17:54** **Updated use of CHARMD, a comprehensive herpesviruses antiviral resistance mutation database and HSA tool for easy cytomegalovirus genotyping interpretation** *S. Alain* (Limoges, France), V. Tilloy, D. Diaz-Gonzalez, S. Chou, G. Andrei, F. Baldanti, G. Boivin, H. Hirsch, T. Lazzarotto, M. Marcos-Angeles, D. Michel, W.D. Rawlinson, S. Hantz*

O0808 **18:06** **Clinical experience of maribavir use for the treatment of refractory or resistant cytomegalovirus infection in solid-organ transplant recipients** *M. Jayne* (London, United Kingdom), A. Stafford, K. Fung, G. Jones, R. Evans, M. Harber, R. Westbrook, J. Ryan, J. Potts, A. Marshall, M. Lanzman, N. Kanani Alviri, D. Cunningham, T. Haque, J. Hart, B. Patterson*

O0809 **18:18** **Delayed treatment alters pharmacodynamics of anti-CMV drugs** *L. Sudarsono* (Leiden, The Netherlands), K. Puspitasari, X. Liu, C. Van Hasselt, A.G. Märtson*

OS117 **17:30 – 18:30** **Hall A3-2**

ANT CLN TRN

1-hour Oral Session

PK/PD-based antimicrobial dosing optimisation in children

Chairs *William Couet (Poitiers, France)*
Iris K. Minichmayr (Vienna, Austria)

O0810 **17:30** **Population pharmacokinetics of cefotaxime for optimising dosing in paediatric meningitis and bacteraemia** *Z.X. Mun* (Melbourne, Australia), A. Boast, A. Lei, A. Di Carlo, R. Chiletti, A. Daley, D. Fuhs, G. Gonis, B. Mcwhinney, A. Moody, R. Nation, J. Ungerer, C. Landersdorfer, A. Gwee*

O0811 **17:42** **Ceftazidime/avibactam in neonates and infants < three months old: population pharmacokinetic (PopPK) analysis and PopPK model application** *E. Soto* (Sandwich, United Kingdom), J.L. Yan, P. Irani, R. England*

O0812 **17:54** **Population pharmacokinetic/pharmacodynamic analyses of cefiderocol for paediatric patients** *D. Yamaguchi* (Osaka, Japan), T. Katsube*

O0813 **18:06** **Optimising posaconazole dosing in children through population PK modelling and simulation** *M.L. Vuong* (Leuven, Belgium), O. Elkayal, J. Standing, S. Boonsathorn, Z. Kane, S. Bentley, A. Tragiannidis, A. Groll, J. Nickless, A. Brothers, A. Uyttebroeck, R. Valenzuela, J. Morales, I. Spriet, E. Dreesen*

O0814 **18:18** **Evaluation of optimal empirical antibiotic combinations for neonatal sepsis in low- and middle-income countries: a pharmacokinetic/pharmacodynamic approach** *W. Van Os* (Leiden, The Netherlands), K.M. Thomson, K. Sands, T.R. Walsh, R. Zahra, G. Chan, D. Bekele, S. Solomon, A. Rucogoza, J.B. Mazarati, K. Iregbu, S.N.C. Uwaezuoke, A.B. Mairami, F.Z. Modibbo, L.I. Audu, S. Gambo, A. Aliyu, J.G.C. Van Hasselt*

OS115 **17:30 – 18:30** **Hall ICM 1**

CLN DX TRN

1-hour Oral Session

Functional and translational advances in microbiome analysis

Chairs *Lena Biehl (Cologne, Germany)*
Maurizio Sanguinetti (Rome, Italy)

O0815 **17:30** **Validation of microbiome-guided fluorescence *in situ* hybridisation (MG-FISH) in clinical microbiology: integrating next-generation sequencing with molecular microbiome imaging** *J. Kikhney* (Leipzig, Germany), Z. Xiong, K. Sarbandi, M. Muchova, D. Von Schöning, A. Moter*

O0816 **17:42** **Machine learning-based optimisation of long-read 16S rRNA sequencing parameters enhances species-level microbiome classification** *A.K. Bari* (Groningen, The Netherlands), B.J. Olij, J.H.E. De Lange, T.T. Severs, B. Sinha, J.W.A. Rossen, B.B. Xavier*

O0817 **17:54** **Salivary host–microbe interactions reveal pathogenic signatures in early colorectal cancer** *S. Rezasoltani* (Aachen, Germany), H. Asadzadeh Aghdaei, G. Conrads*

O0818 **18:06** **Culturomics-guided bacterial extracellular vesicle profiling reveals the gut microbiota's role in patients with CTLA4 deficiency** *R. Magdy Wasfy* (Montreal, Canada), C. Morin, M. Naegele Aranguren, C. Masse, J. Poudrier, E.L. Falcone*

SY144 **17:30 – 18:30** **Hall A3-1**

AMR CLN

1-hour Symposium

Update on STIs: epidemiology, drug resistance and role of DoxyPEP

Chairs *Arjan Harxhi (Tirana, Albania)*
Jean-Michel Molina (Paris, France)

S0357 **17:30** **The impact of travel on the global epidemiology of STIs** *Zofia Bartovska (Prague, Czechia)*

S0358 **18:00** **Impact of DoxyPEP on the human microbiome and resistome** *Victoria Chu (San Francisco, California, United States)*

Co-organised with: ESCMID Education Subcommittee, ESCMID Fungal Infection Study Group (EFISG), ESCMID Study Group for Sexually Transmitted Infections (ESTISG), ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC)

SY143 **17:30 – 18:30** **Hall B0-1**

DX PHEI

1-hour Symposium

The future of pathogen surveillance: molecular data without borders

Chairs *Adrian Egli (Zurich, Switzerland)*
Paula Mölling (Örebro, Sweden)

S0355 **17:30** **The Swiss Pathogen Surveillance Platform: a model for international collaboration and data sharing** *Tim-Christoph Roloff (Zurich, Switzerland)*

S0356 **18:00** **Lessons learned from the Trakka Data Sharing Ecosystem in Australia and beyond** *Benjamin Peter Howden (Melbourne, Australia)*

Co-organised with: ESCMID Study Group for Epidemiological Markers (ESGEM), ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Swiss Society for Microbiology (SSM)

SY142 **17:30 – 18:30** **Hall ICM 13b**

PHEI

1-hour Symposium

Redefining One Health

Chairs *Pikka Jokelainen (Copenhagen, Denmark)*
Sonja Lofmark Behrendtz (Solna, Sweden)

S0353 **17:30** **New theoretical frameworks for One Health** *Julianne Meisner (Seattle, United States)*

S0354 **18:00** **New operational frameworks for One Health** *Jakob Zinsstag (Basel, Switzerland)*

EF118 **17:30 – 18:30** **Arena 1**

DX PHEI

ePoster Flash Session

Beyond culture: spectroscopy for pathogen identification and typing

Chair *Angela Novais (Porto, Portugal)*

E0820 **17:30** **FTIR spectral fingerprinting for rapid identification of high-risk Shiga toxin–producing *Escherichia coli* serotypes** *L. Díaz-Formoso* (A Coruna, Spain), S. Sánchez, G. Bou, M. Oviaño*

E0821 **17:36** **Automated discrimination of *E. coli* from Shigella spp. using FT-IR spectroscopy and machine learning** *M. Cordovana* (Bremen, Germany), N. Mauder, A.B. Pranada, C. Hess, W. Geissdoerfer, F. Pankok, U. Loderstaedt, S. Scheithauer, D. Dekker, A.E. Zautner, J. Overhoff, M. Werner, A. Wille, P. Warnke, T. Koeller, P. Morales, M. Suleiman, A. Perez-Lopez, J. Jiménez-Rodríguez, P. Garcia, G. Da Silva Collar, N. Kehl Moreira, A.L. Barth, J. Caierao, O. Join-Lambert, A.A. Muntean, C. Ghitulescu, C. Daniela, M.I. Popa, R.M. Hagen, U. Schotte, H. Frickmann*

E0823 **17:48** **Development of surface-enhanced Raman spectra coupled with machine learning analysis for differentiation of closely related species within *Enterobacter cloacae* complex** *Y. Li* (Beijing, China), M. Zhou, X. Xu, Y. Xu, B. Gu, J. Gu*

E0824 **17:54** **Discriminating old from new: application of Fourier-transform infrared spectroscopy (FTIR) to the reappearance of *Pseudomonas aeruginosa* in cystic fibrosis and primary ciliary dyskinesia** *M. Rossitto* (Rome, Italy), S. Raimondi, M. Cristiano, G. Vrenna, V. Fox, V. Tuccio Guarna Assanti, N. Essa, M.S. Lepanto, G. Foglietta, E. Montemitro, F. Alghisi, F. Majo, L. Cristiani, A. Boni, N. Ullmann, R. Cutrera, C.F. Perno, P. Bernaschi*

E0825 **18:00** **Performance of a machine learning algorithm for FTIR-based typing of NDM-producing *Klebsiella pneumoniae* in a hospital outbreak** *C. Garrido* (Santiago, Chile), J. Jimenez, M. Lecerasi, A. Wozniak, G. Arratia, P. García*

E0826 **18:06** **Serotyping of *Haemophilus influenzae* strains and *Yersinia enterocolitica* by Fourier-transform infrared (FTIR) spectroscopy** *S. Zimmermann* (Heidelberg, Germany), C. Janssen, J. Rau, M. Cordovana, N. Mauder, T.T. Lam*

E0827 **18:12** **Fourier-transform infrared spectroscopy as a tool for *Streptococcus pneumoniae* serotyping: optimisation of the PCV15-classifier (Version 2.0)** *J. Caierão* (Porto Alegre, Brazil), G. Rosa Da Cunha, C. Tondolo Romero, N. Kehl Moreira, A.L. De Oliveira Gonçalves, J. Cover Salvador, A. Luis Barth, C.A. Gomes Dias*

E0828 **18:18** **Comparative evaluation of FTIR spectroscopy and whole genome sequencing for typing *Salmonella enteritidis*** *S. Suto* (Zagreb, Croatia), S. Šuto, N. Pražić, T. De Zan, M. Kvaternik Celjak, J. Knežević, J. Vraneš*

EF119 **17:30 – 18:30** **Arena 2**

CLN DX

ePoster Flash Session

When fungi break the rules: rare pathogens in unusual sites

Chair *Johan Maertens (Leuven, Belgium)*

E0829 **17:30** ***Candida* prosthetic joint infections, including multidrug-resistant *Candida auris*, at Hospital La Fe: a 15-patient 15-year experience (2010–2025)** *L. Brusca Vidao* (Valencia, Spain), S. Giner Almaraz, J. Frasquet, P. Suárez Urquiza, P. Muñoz Brell, E. Gremaldos, C. Castillo Martínez, J.L. López Hontangas, A. Ruiz-Gaitán*

E0830 **17:36** **Clinical features and outcomes of cryptococcosis associated with Bruton tyrosine kinase inhibitors: a multi-centre retrospective study and literature review** *R. Manchon* (Paris, France), C. Julien, D. Roos-Weil, B. Elodie, B. Charlotte, P. Thomas, O. Lortholary, C. Sharon, F. Lanternier, S. Monica, O. Paccoud*

E0831 **17:42** **Beyond hepatosplenic candidiasis: the changing face of paediatric chronic disseminated yeast infection** *M. Husain* (Paris, France), F. Alby Laurent, J. Guitard, M. Gits-Muselli, B. Brethon, F. Lanternier*

E0832 **17:48** **Rezafungin for *Candida* osteoarticular infections: the REZ-GEIO project** *S. De La vilLa Martinez* (Madrid, Spain), S. De La Villa, J. Guinea, J. Gómez Junyent, L. Ramos Merino, R. Escudero Sánchez, B. Sobrino, M.J. Moya, A. Muñoz, E. Múñez, M. Sánchez Somolinos, P. Sanz Ruiz, P. Muñoz*

E0833 **17:54** **From detection to decision-making: clinical utility of plasma microbial cell-free DNA sequencing for invasive mould infections** *M. Al Mohajer* (Houston, United States), R. Berger, N. Howard, S. Grant*

E0834 **18:00** **Prospective evaluation of itraconazole for the treatment of Jorge Lobo's disease (lobomicose)** *A. Nishikaku* (São Paulo, Brazil), J. Nobrega De Almeida Jr, F. Gonçalves, R.R. Durlacher, M.R. De Sousa Trindade, A. Panizza Jalkh, M. De Melo Teixeira, M.D.V. Martino, A. Satie Nishikaku*

E0835 **18:06** **Severe histoplasmosis in intensive care units: a multi-centre retrospective study in France** *L. Chantelot* (Paris, France), H. Kallel, L. Camous, E. Dufranc, L. Zafrani, T. Urbina, A. Curtiaud, F. Boissier, P. Szychowiak, D. Roux, A. Rouze, A. Robert, N. Heming, F. Pene, R. Sonneville, S. Hraiech, G. Voiriot, G. Martin Blondel, J. Hayon, G. Jolly, N. Issa, E. Blanchard, F. Ader, M. Decavele, B. Peiffer, F. Botterel, A. Adenis, F. Lanternier, K. Razazi*

E0836 **18:12** **Multi-centre outbreak of both *Magnusiomyces capitatus* and *Magnusiomyces clavata* in Italy** *B. Spruijtenburg* (Nijmegen, The Netherlands), E. De Carolis, C. Magri, M. Sanguinetti, T. De Groot, V. Di Pilato, M. Mikulska, J.B. Buil, E.F.J. Meijer*

EF120 **17:30 – 18:30** **Arena 3**

AMR DX

ePoster Flash Session

Advances in AMR diagnostics

Chair *Tomislav Kostyanev (Esbjerg, Denmark)*

E0838 **17:30** **Evaluation of a new CRISPR-Cas-based assay for the detection of *bla*KPC in bacterial isolates** *A. Valência Siqueira* (Massachusetts, United States), A. VALÊNCIO Siquiera, A.C. Gales, P.J.M. Bispo*

E0840 **17:36** **PathCrisp: a next-generation CRISPR diagnostic platform for rapid detection of antimicrobial resistance** *M. Naik* (English, India), K. Bs, S. Annes, D. Hafiz, D. Bhagchandanii, V. Hegde, V. Chandru, V. Gupta, R. Arora*

E0841 **17:42** **Rapid aptamer-based biosensor for identifying *K. pneumoniae* strains and testing meropenem–colistin susceptibility** *K.N. Yilmaz* (Kars, Türkiye), N. Ciftci, Z.O. Uygun*

E0842 **17:48** **Digital AST Annotator: standardising Kirby–Bauer reading with an open-source app** *A. Guerrero-López* (Zurich, Switzerland), A. Diversi, E. Sosa, A.G. Monsalve, A. Egli*

E0843 **17:54** **Comparative evaluation of a real-time PCR assay vs conventional culture for detecting carbapenemase-producing Gram-negative bacteria in rectal swabs** *A. Tychala* (Thessaloniki, Greece), P. Trikoupis, Z. Sereni, Z. Tsinaris, G. Kagkalou, O. Vasilaki, K. Kouirouxis, P. Mantzana, E. Protonotariou, L. Skoura*

E0844 **18:00** **MIC creep in the shadows: an interactive dashboard for forecasting MIC trends in newer antimicrobials against MDR pathogens across WHO regions** *N. Nityadarshini* (New Delhi, India), J. Biswas, T. Bordoloi*

E0845 **18:06** **Explaining phenotypic carbapenem resistance in GeneXpert-negative Gram-negative bacteria and evaluating concordance with whole genome sequencing** *S. Alotaibi* (Riyadh, Saudi Arabia), A. Alomani, S. Alharbi, M. Alghoribi, L. Faqih, T. Abdulrahman, F. Alasmari*

ME145 **17:30 – 18:30** **Hall ICM 5**

CLN DX VAX

Meet-the-Expert

Implementing WHO hepatitis guidelines in LMICs: challenges and perspectives

M0359 **17:30** *Olufunmilayo Lesi (Geneva, Switzerland)*

M0360 **17:42** *Zeinab Said* (*Cairo, Egypt*)

Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), Society for the Study of liver Diseases in Africa (SOLDA), Slovenian Society for Infectious Diseases, British Infection Association (BIA)

PM007 **17:30 – 18:30** **Arena 4**

Policy Forum

AMR PHEI

From global research priorities to national and local impact: implementing AMR priority research agendas

Chair *Benedikt Huttner* (*Geneva, Switzerland*)

D0018 **17:30** **Challenges and opportunities on the implementation of the OHPRA** *Sabiha Essack* (*Durban, South Africa*)

D0019 **17:45** **Implementing global research agendas on AMR: tracking research projects and activities** *Lesley Ann Ogilvie* (*Berlin, Germany*)

D0020 **18:00** **Aligning national research projects with global research agendas** *Gloria Cordoba* (*Copenhagen, Denmark*)

D0021 **18:15** **Promoting global research agendas for policy makers** *Geneviève Boily-Larouche* (*Toronto, Canada*)

Tuesday, 21 April 2026

OS122 **08:30 – 09:30** **Hall A1-2**

1-hour Oral Session

CLN DX

Moving from culture to molecular diagnostics in implant-associated infections

Chairs *Thomas Fintan Moriarty* (*Davos, Switzerland*)
Marjan Wouthuyzen-Bakker (*Groningen, The Netherlands*)

O0847 **08:30** **Rapid novel molecular method for enhanced detection of periprosthetic joint infection** *E. Morreel** (*Maastricht, The Netherlands*), *P. Savelkoul, I. Van Loo*

O0848 **08:42** **Enhancing diagnostics in orthopaedic infections: clinical impact of syndromic multiplex PCR compared to traditional culture** *F. De Winter** (*Turnhout, Belgium*), *N. Van Beek, J. Frans, T. Goegebuer, W. Schuermans, E. Van Even, P. Verbeeck, D. Van Der Beek, H. Nailis*

O0849 **08:54** **Optimising culture strategies in chronic orthopedic device-related infections: do blood culture bottles deliver?** *J. Van Heuverswyn** (*Ghent, Belgium*), *H. Hamerlinck, D. Huis In 't Veld, S. Vandendriessche, B. Verhasselt, J. Boelens*

O0850 **09:06** **Pathogen spectrum of aortic graft infections uncovered by combined microbiologic testing and *in situ* metagenomic sequencing** *Q. Miao** (*Shanghai, China*), *J. Yue, Y. Chen, Y. Luo, H. Liu, Y. Kan, B. Hu*

O0851 **09:18** **Utility of metagenomic sequencing of microbial cell-free DNA as a diagnostic tool in vascular graft and endograft infections: a cross-sectional study** *R.A. Nielsen** (*Aarhus, Denmark*), *M. Eneberg, A.M.F. Eskildsen, M. Albertsen, N.P. Jørgensen, J. Budtz-Lilly, L.J. Østergaard, N.B. Stærke*

LB009 **08:30 – 09:30** **Hall A1-3**

1-hour Oral Session

CLN

Late-breaking clinical trials in sepsis management

Chairs *Jean-Francois Timsit* (*Paris, France*)
Steven Tong (*Melbourne, Australia*)

L0046 **08:30** **Imipenem/cilastatin-funobactam for hospital-acquired/ventilator-associated bacterial pneumonia: a multinational phase III trial (REITAB-2)** *K. Chang** (*Beijing, China*), *Y. Wang, C. Wang, Z. Tang, J. Yin, J. Zhao, Y. Wang, T. Mei, A. Li, H. Li, Q. Jiang, P. Wang, F. Ye, L. Ding, Z. Liu, F. Yin, X. Mo, H. Qu, Y. Xia, J. Wang, J. Wu, S. Yang, R. Lin, G. Lv, H. Luo, B. Liu, J. Gu, F. Wei, J. Zhu, H. Liang, S. Qiu, H. Mai, X. Zhu, R. Yu, G. Han, T. Lou, H. Wang, J. Zhang, Y. Li, H. Wang, H. Lu, T. Xin, C. Li, X. Wang, X. Zhang, H. Gao, H. Wang, A. Pan, Q. Wang, J. Cao, Y. Zhu, Z. Xiao, L. Pan, S. Peng, X. Ding, Q. Chi, H. Xu, F. Liu, A. Guo, J. Zhan, Q. Zhang, R. Guo, J. Li, D. Zhu, H. Zhao, A. Cano Yuste, T. Huynh, I. Biney, K. Remy, B. Cao*

L0047 **08:42** **LOw-dose CT cOmPared to Lung UltraSonography vs standard of care-based strategies for the diagnosis of pneumonia in the elderly: a multi-centre randomised controlled trial (OCTOPLUS)** *V. Prendki** (*Geneva, Switzerland*), *N. Garin, A. Platon, E. Bernasconi, T. Ruder, A. Poncet, J. Stirnemann, W. Hautz*

L0048 **08:54** **A multi-centre, randomised controlled clinical trial to study the impact of bedside model-informed precision dosing of vancomycin in severely ill neonates and children: BENEFICIAL trial** *P. De Cock** (*Ghent, Belgium*), *R. Colman, A. Smits, F. Piersigilli, M. Renard, A. Van Damme, A. Clarysse, E. Dhont, S. Vanhaesebrouck, V. Bordon, L. Boland, B. De Wilde, A. Amza, L. Vanlanduyt, T.V.A. Nguyen, F. Cools, J. Van Der Werff Ten Bosch, D. Vens, F. Derriks, L. Houtekie, M. Reiner, D. Van Der Linden, P. Schelstraete*

L0049 **09:06** **Use of procalcitonin point-of-care test to guide de-escalation of empiric antibiotic therapy in adult patients with sepsis in a tertiary hospital in Bangladesh (PROCALBAN): a randomised, controlled, open-label trial** *F.U.H. Chowdhury** (*Oxford, United Kingdom*), *R.A.M.E. Uddin, M. Ali, P.K. Dutta, D. Das, A.H. Hanif, M. Kar, F.B. Jahangir, S.I. Khan, M.M. Huq, A.A. Sayeed, M.H.O. Roshid, N.U. Chy, M.A. Hossain, M.A. Sattar, M. Schilstra, E. De Jong, C. Schultsz, M. Nijsten, M.J. Uddin, A. Ghose, K. Plewes, L. Pisani, P. Guerin, M. Mukaka, A.M. Dondorp*

L0050 **09:18** **Adjunctive clindamycin for treatment of *Staphylococcus aureus* bacteraemia: a randomised controlled trial within the S. aureus Network Adaptive Platform (SNAP)** *A. Bowen** (*Wembley, Australia*)

EW152 **08:30 – 10:30** **Hall A3-1**

2-hour Educational Session

PED VAX

Vaccination during pregnancy: for the mother, and for the child

Chairs *Olivier Epaulard* (*Grenoble, France*)
Ulrich Heininger (*Basel, Switzerland*)

W0479 **08:30** **Burden of vaccine-preventable infections in pregnant women** *Shamez Ladhani* (*London, United Kingdom*)

W0480 **08:50** **Mother-to-child transmission of antibodies: how and when** *Marta Nunes* (*Lyon, France*)

W0481 **09:10** **Vaccination of pregnant women to protect the child: successes and hurdles** *Pawel Stefanoff* (*Stockholm, Sweden*)

W0482 **09:30** **Vaccination during pregnancy: from doctors to mother-to-be, who is hesitant?** *Emilie Karafillakis* (*London, United Kingdom*)

Co-organised with: ESCMID Vaccine Study Group (EVASG)

EW151 **08:30 – 10:30** **Hall ICM 13a**

2-hour Educational Session

DX PHEI

Bird flu is no longer just for birds: from strategic planning to public health readiness

Chairs *Edoardo Colzani* (*Solna, Sweden*)
Barbara Rath (*New Orleans, United States*)

W0475 **08:30** **What drives pandemic risk? Virus, population and policy factors influencing Influenza H5N1 spread** *Benjamin Cowling* (*Pokfulam, Hong Kong*)

W0476 **08:50** **Surveillance in action: diagnostic tools for early detection of zoonotic influenza human infections** *Kanta Subbarao* (*Quebec City, Canada*)

W0477 **09:10** **Zoonotic influenza: from signals to public health response actions** *Angeliki Melidou* (*Stockholm, Sweden*)

W0478 **09:30** **Antivirals and vaccines: readiness for a future influenza pandemic** *Marco Cavaleri* (*Amsterdam, Belgium*)

Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Society for Influenza and other Respiratory Viruses (ISIRV), European Centre for Disease Prevention and Control (ECDC)

OS121 **08:30 – 10:30** **Hall B0-1**

2-hour Oral Session

AMR

Genomic epidemiology and emerging bacterial resistance

Chairs *Valeria Bortolaia (Copenhagen, Denmark)*
João Pires (Oslo, Norway)

O0852 **08:30** **Long-term persistence and cross-reservoir transmission of antimicrobial resistant Serratia marcescens: a genomic epidemiology study** *J. Lay* (Melbourne, Australia), J. Lacey, R. Patwa, A.Y. Peleg, B. Vezina, N. Macesic*

O0853 **08:42** **High prevalence of NDM-5-producing *Escherichia coli* with Penicillin-Binding Protein 3 Mutations in Germany: An emerging threat?** *J.B. Hans* (Berlin, Germany), L.M. Höfken, S. Möller, N. Pfennigwerth, F. Reichert, M. Sandfort, M.A. Fischer, T. Semmler, T. Eckmanns, G. Werner, S. Haller, S. Gatermann*

O0854 **08:54** **A decade of evolving *Pseudomonas aeruginosa* resistance: epidemiology and antimicrobial trends (2014–2024)** *D. Mendes Pedro* (Lisbon, Portugal), M. Meneses, C. Mimoso Santos, A. Bruschy Fonseca, Á. Ayres Pereira, E. Valadas, J. Melo Cristino, C. Caneiras*

O0855 **09:06** **Associations between antidepressant prescribing and antibiotic resistance in *Escherichia coli* urinary tract infections in Scotland** *L. Ciaccio* (Dundee, United Kingdom), B.J. Parcell, H. Wang, J. Danial, F. Kerr, J. Mcewen, A. Morrison, D. O'driscoll, A. Seaton, K.N. Barnett, C.A. Marwick*

O0856 **09:18** **Integrated genomic surveillance of carbapenemase-producing *Klebsiella pneumoniae* in Germany in 2023-2024 revealed frequent case imports from abroad and local outbreaks** *M. Sandfort* (Berlin, Germany), L.M. Höfken, F. Reichert, M.A. Fischer, S. Möller, J.B. Hans, H. Öhler, D. Said, N. Pfennigwerth, T. Eckmanns, G. Werner, S.G. Gatermann, S. Haller*

O0857 **09:30** **The emergence and spread of NDM-type carbapenemase-producing *Acinetobacter baumannii* clones in Hungary** *A. Hanczvikkel* (Budapest, Hungary), D. Göbhardter, E. Ungvári, N. Derzsy, A. Darab, L. Jánvári, L. Holub, L. Majoros, K. Kamotsay, M. Farkas, A. Kark, K. Mályi, B. Roskó, M.A. Peti, Á. Tóth*

O0858 **09:42** **Clonal complex 398 emerging as community- and healthcare-associated methicillin-resistant *Staphylococcus aureus* in the Czech Republic 2017-2024** *J. Tkadlec* (Prague, Czechia), A. Rozsypalkova, S. Polivkova, P. Drevinek, J. Gooskens, M. Krutova*

O0859 **09:54** **Epidemiological and molecular insights of community- and hospital-acquired MRSA in Antwerp, Belgium** *D. De Smet* (Antwerp, Belgium), S. Van Goethem, P. Van Lint, W. Verstrepen, B.B. Xavier, R. Naesens*

O0860 **10:06** **Antimicrobial resistance in the zoonotic pathogen *Capnocytophaga canimorsus*: global distribution of resistance genes and their phenotypic impact** *Z. Germuskova* (Zurich, Switzerland), E. Pronzini, T. Roloff, H. Seth-Smith, K.K. Søgaard, E.M. Broens, F. Renzi, A. Egli*

SY148 **08:30 – 10:30** **Hall A1-1**

2-hour Symposium

CLN DX

Advancing diagnostic strategies for detecting bacteraemia across the globe

Chairs *Christina Obiero (Kilifi, Kenya)*
Agnes Maria Sonnevend (Pécs, Hungary)

S0463 **08:30** **Rethinking bacteraemia: how diagnostic innovation is improving outcomes** *Kai Sohn (Stuttgart, Germany)*

S0464 **09:00** **From PCR to whole genome: the molecular revolution in bacteraemia diagnosis** *Kwan Ki Karrie Ko (Singapore, Singapore)*

S0465 **09:30** **Low-tech blood culture techniques and protocols: what is truly necessary?** *Liselotte Hardy (Antwerp, Belgium)*

S0466 **10:00** **Needs and barriers for performing blood cultures in resource limited settings** *Makeda Semret (Montreal, Canada)*

Co-organised with: ESCMID Parity Commission, ESCMID Professional Affairs Subcommittee

SY149 **08:30 – 10:30** **Hall A2-1**

2-hour Symposium

CLN TRN

The role of the microbiome in shaping clinical outcomes in immunocompromised patients

Chairs *Nicolas Benech (Lyon, France)*
Maria Vehreschild (Frankfurt Am Main, Germany)

S0467 **08:30** **The role of the microbiome in immune reconstitution after cancer therapy** *Kate Markey (Seattle, United States)*

S0468 **09:00** **Targeting the gut microbiome: an emerging trend in haematopoietic stem cell transplantation** *Jonathan Peled (New York, United States)*

S0469 **09:30** **Optimising cancer treatment through gut microbiome modulation** *Maria Rescigno (Pieve Emanuele, Italy)*

S0470 **10:00** **Role of microbiome in GVHD** *Mette Hazenberg (Amsterdam, The Netherlands)*

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI), ESCMID Study Group for Infections in Compromised Hosts (ESGICH)

SY150 **08:30 – 10:30** **Hall A2-2**

2-hour Symposium

DX

The real-world impact of IVDR on patient care: threat or opportunity?

Chairs *Antti Hakanen (Turku, Finland)*
David Ong (Rotterdam, The Netherlands)

S0471 **08:30** **Implications of IVDR on clinical decision making and patient care** *Erlangga Yusuf (Rotterdam, The Netherlands)*

S0472 **09:00** **IVDR impact on molecular diagnostic workflows** *Maurizio Sanguinetti (Rome, Italy)*

S0473 **09:30** **How metrology can support IVDR and outbreak response** *Esmeralda Valiente (Berlin, Germany)*

S0474 **10:00** **IVDR from a European policy perspective** *Gülşen Özkaya Şahin (Lund, Sweden)*

Co-organised with: Clinical Microbiologists of Finland, Dutch Society for Medical Microbiology (NVMM), ESCMID Ethics Advisory Committee, ESCMID Professional Affairs Subcommittee, Nordic Society of Clinical Microbiology and Infectious Diseases (NSCMID), UEMS, Biomed Alliance

SY147 **08:30 – 10:30** **Hall ICM 1**

2-hour Symposium

ANT CLN

The what and how of using AI in antimicrobial stewardship

Chairs *Mark G. J. De Boer (Leiden, The Netherlands)*
Mark Gilchrist (London, United Kingdom)

S0459 **08:30** **An introduction and overview of the evolving use of AI in antimicrobial stewardship** *Bradley Langford (Etobicoke, Canada)*

S0460 **09:00** **Responsible use of AI in prediction modeling for real-life clinical practice tools** *Pontus Naucler (Stockholm, Sweden)*

S0461 **09:30** **The role of ChatGPT and AI chatbots in optimising antibiotic therapy: believe or disbelieve?** *Alexis Maillard (Paris, France)*

S0462 **10:00** **Is AI the key to acceleration of Antimicrobial Stewardship in LMICs?** *Mike Nsubuga (Bristol, United Kingdom)*

Co-organised with: ESCMID Study Group for AI and Digitalisation (ESGAID), ESCMID Study Group for Antimicrobial stewardship (ESGAP), Society of Infectious Diseases Pharmacists (SIDP)

SY146 **08:30 – 10:30** **Hall ICM 5**

2-hour Symposium

CLN DX TRN

Fungal OMICS: from bench to bedside

Chairs *Lottie Brown (London, United Kingdom)*
Josh Nosanchuk (Bronx, United States)

S0455 **08:30** **Evolutionary genomics of emerging fungal pathogens** *Toni Gabaldón (Barcelona, Spain)*

S0456 **09:00** **Host transcriptome response to *Candida auris* extracellular vesicles** *Lysangela Ronalte Alves (Curitiba, Brazil)*

S0457 **09:30** **How *Candida* drives oral cancers: host and pathogen omics** *Attila Gacser (Szeged, Hungary)*

S0458 **10:00** **Functional consequences of mycobiota on host immunity** *Tobias Hohl (New York, United States)*

EF123 **08:30 – 09:30** **Arena 2**

CLN

ePoster Flash Session

Novel aspects on epidemiology and therapeutics of urinary tract infections

Chair *Suzanne Geerlings (Amsterdam, The Netherlands)*

E0863 **08:30** **Characterising complicated urinary tract infections (POS-cUTI): preliminary results of a multinational prospective cohort (POST-cUTI / ECRAID)** *J.M. Bravo-Ferrer* (Seville, Spain), E. Rubio Martin, N. Maldonado, B. Gallego, E. Moreno, F. Cogliati Dezza, R. Compagnone, I. Portillo, A. Barac, F. Arieti, O. Awwad, P. De Nardo, A. Cano, P. Clevenbergh, N. Merchante, A. Hernandez-Torres, E. Frangou, E. Merino, T. Lafon, T. Ten Doesschate, O. Sandulescu, B. Koprivica, P. Andrade, A. Ternhag, M. Samarkos, M. Bokhari, A. Bandera, L. Jacquin, E. Iosifidis, E. Durante-Mangoni, D. Chadwick, J. Rupp, P. Muñoz-Garcia, A. Røder, D. Viglino, J. Van Laethem, B. Kjurchikj, G. Marchetti, S. Tsiodras, M. David, A.R. Veiga-Ferraz, J.R. Paño-Pardo, C. Kirakli, N. Catorze, M. Tumbarello, M. Akova, I. Gentile, A. Bartoloni, L. Radulovic, C. Constantinou, M. Bonten, L.P.G. Derde, E. Cappelli, E. Tacconelli, J. Rodríguez-Baño*

E0864 **08:36** **Clinical effectiveness of four different short-course antibiotic regimens in adult women with bacteriological confirmation of urinary tract infection** *R. Monfa* (Barcelona, Spain), R. Monfà, A. García-Sangenís, R. Morros, C. Llor, D. Ouchi, S. Fernández-García, C. Miranda-Jiménez, A. Moragas, M. Aguilar-Sánchez, A. Leiva, A. Troncoso-Mariño, J. Marín-Cañada, R. Rodríguez, J.M. Molero, M.A. Sánchez-Calavera*

E0865 **08:42** **Proteomic endotypes in patients with *Escherichia coli* pyelonephritis** *L. Bolinder* (Stockholm, Sweden), T. Sutantiwanichkul, A. Reepalu, A. Linder, L. Mellhammar, M. Sundqvist, D. Nestor, C. Unge, A. Färnert, H. Janols, M. Lipcsey, J. Sundén-Cullberg, S. Cajander, M. Uhlén, F. Edfors, K. Strålin*

E0866 **08:48** **Predicting antibiotic resistance risk in urinary tract infections using machine learning to support safer empirical prescribing in hospitalised children and adults** *L. Aerts* (Basel, Switzerland), D. Malpetti, S. Bouizaguen, C. Berchtold, P. Neuschwander, G. Greub, L. Azzimont, J.A. Bielicki*

E0867 **08:54** **Nitrofurantoin for *Neisseria gonorrhoeae* urethritis? an *in vitro* and *in vivo* study in *Galleria mellonella*** *C. Kenyon* (Antwerp, Belgium), I. Kanesaka, I. De Baetselier, S. Abdellati, T. De Block, T. Vanbaelen, R. Naesens, B. Britto Xavier, S. Manoharan-Basil*

E0868 **09:00** **The effectiveness of a weekly antimicrobial stewardship intervention on antibiotic prescriptions in Dutch nursing homes: a randomised controlled trial** *L. Van Buul* (Amsterdam, The Netherlands), K. Paap, M. Schim Van Der Loeff, S. Kuil*

E0869 **09:06** **In private facilities, expensive medications are sometimes used as a first choice: attitudes and practice of health care workers in the management of UTIs in Kampala, Uganda** *J. Kapisi* (Kampala, Uganda), D. Ekusai-Sebatta, N. Miriam, P. Kirabo, J. Enomut, M. Iwami, H. Kajumbula, F. Kitutu, C.E. Moore*

E0870 **09:12** **Clinical symptom improvement and resolution following uUTI treatment with gepotidacin: a post-hoc subgroup analysis** *J. Diaz-Regañon* (Madrid, Spain), K. Gupta, D. Powell, R. Banerjee, J. Bablani, S. Janmohamed, M. Ramírez*

CGR **08:30 – 10:30** **Hall ICM 14**

CLN

Special Session

Clinical grand rounds

Chair *Robert C. Read (Southampton, United Kingdom)*

Chairs *Yoav Keynan (Winnipeg, Manitoba, Canada)*
Nina Khanna (Basel, Switzerland)
Dimitrios P. Kontoyiannis (Houston, United States)
David L. Paterson (Singapore, Singapore)
Priscilla Rupali (Vellore, India)
Monica Slavin (Melbourne, Australia)

CGR01 **08:30** **Case 1** *R. Gorfinkel* (Beer Sheva, Israel), O. Rouvio, L. Nesher*

CGR02 **08:40** **Case 2** *S. Showalter* (Aurora, Co, United States), J. Boguniewicz*

CGR03 **08:50** **Case 3** *R. Patel* (London, United Kingdom), E. Jabbari, T. Bharucha, L. Nabarro, T. Saifee, G. Banerjee, S. De Saram, C. Hoskote, R. Jager, J. Jones, G. Godbole, H. Manji*

CGR04 **09:00** **Case 4** *L. Saint* (Chapel Hill, North Carolina, United States)*

CGR05 **09:10** **Case 5** *J. Erber* (Munich, Germany), L. Hinterwaldner, C. Corredor Obregon, J. Schneider, S. Zange, C.D. Spinner, T. Lahmer*

CGR06 **09:20** **Case 6** *P. Chabert* (Dumbéa, New Caledonia), J. Colot, E. Couadau*

CGR07 **09:30** **Case 7** *T. Cartau* (Caen, France), A. Dujardin, R. Verdon*

Co-organised with: Infectious Disease Society of America (IDSA)

OS125 **09:30 – 10:30** **Hall A1-4**

TRN

1-hour Oral Session

Regulatory, metabolic, and evolutionary mechanisms shaping *Staphylococcus aureus* pathogenesis

Chairs *Frédéric Laurent (Lyon, France)*
Marc Stegger (Copenhagen, Denmark)

O0871 **09:30** **Investigating antibiotic tolerance among clonal pairs of *Staphylococcus aureus* derived from cystic fibrosis lung infections** *A. Deventer* (St Andrews, United Kingdom), J. Pearson, J. Hobbs*

O0872 **09:42** **Whole genome CRISPRi-seq reveals a cation-proton antiporter as a critical determinant of *Staphylococcus aureus* survival in monocytes like cells** *A. Iizuka* (Basel, Switzerland), M.V. Mazzuoli, E. Demirbilek, A.K. Woischnig, D. Bumann, J.W. Veening, A. Zinkernagel, N. Khanna*

O0873 **09:54** **Integrating phylodynamics and GWAS to uncover drivers of meticillin-sensitive *Staphylococcus aureus* bacteraemia and colonisation** *D. Aggarwal* (London, United Kingdom), A.J. Van Tonder, L. Du Plessis, W. Figueroa, B. Blane, K.L. Bellis, C. Raisen, X. Ba, E. Lay, E. Nickerson, L. Bedford, R. Saunderson, W. Smith, B. Warne, T. Gouliouris, M.E. Torok, M.A. Holmes, J. Parkhill, F. Coll, S.J. Peacock, E.M. Harrison*

O0874 **10:06** ***Streptococcus pneumoniae* weaponises its own electrical signature to launch ROS attack against Staphylococcus aureus** *X. Wu* (Hangzhou, China), L. Liu, Y. Wang, Y. Jiang, Y. Yu*

O0875 **10:18** **Simple sequence repeats power *Staphylococcus aureus* adaptation** *R. Guérillot* (Melbourne, Australia), A.S. Hayes, A. Hachani, S.G. Giulieri, L. Donovan, L.M. Judd, L.K. Sharkey, A. Gonçalves Da Silva, T. Seemann, T.P. Stinear, B.P. Howden*

OS124 **09:30 – 10:30** **Hall ICM 13b**

ANT CLN

1-hour Oral Session

Facing severe bacterial infections in neonates and children

Chairs *Dana Danino (Beer Sheva, Israel)*
Johannes Hübner (Munich, Germany)

O0876 **09:30** **Appropriateness of empirical antibiotic therapy and mortality in neonatal sepsis across LMIC hospitals** *K. Thomson* (Oxford, United Kingdom), C. Achi, B.*

Hassan, R. Farzana, K. Sands, O.B. Spiller, L.C. Jones, J. Rzaska, A. Cooke, J. Aziz, C. Farley, C. Philips, J. Spencer, J. Oduwo, E. Owinoh, K. Iregbu, N. Medugu, C. Chieze, K. Abdulraheem, F.Z. Zango Abdi, A. Aminu, R.Y. Khalid, M. Bello, Y. Mohammed, J. Abubakar, A.T. Bolajoko, O. Oduyebo, O. Olutekunbi, A. Odedina, I. Nwafia, S. Ihezuruoha, U. Ibekwe, N. Haque, S.B. Proma, S. Arefin, S. Khatun Sara, R. Khatun, R. Zahra, E. Rashid, M.I. Shah, A. Mahboob, A.A. Shah, I. Ullah, A. Muhammad, M. Muhammad, S. Amin, M. Khan, S.U.N. Syed, S. Arif, S. Riaz, S.S. Gul, S. Naqvi, H. Hamid, R. Sajjad, A. Sajid, T.R. Walsh

O0877 **09:42** **Revising vancomycin dosing recommendations in critically ill children using a population PK approach based on unbound concentrations** *A.T.V. Nguyen* (Ghent, Belgium), S. Carter, F. Kloprogge, J. Standing, V. Stove, D. Sarah, E. Dhont, D. Vens, P. De Paepe, P. De Cock*

O0878 **09:54** **Epidemiology and vaccine coverage of group B streptococcal disease in infants zero-three months old in the Netherlands, 1987-2023** *M. Groenveld* (Amsterdam, The Netherlands), D. Jamrozy, M.C. Brouwer, D.H. Visser, D. Van De Beek, M.W. Bijlsma, N.M. Van Sorge*

O0879 **10:06** **Population validation of Phoenix criteria for identifying paediatric sepsis** *S.H. He* (Hong Kong, China), J.Z. Zhang, L.C.N. Chan, A. Lin, K.Y. Yeung, M.C.I. Kuok, J.W.C.H. Cheng, D.C.Y. Au, C.Y. Chow, T.W. Wong, W.K. Wong, E. Chan, H.M. Young, E.M. Wong, K.M. Ho, A. Lee, C. Rhee, H.S. Lam, L. Ling*

O0880 **10:18** **Oral step-down antibiotic therapy in children with infective endocarditis: the EndoChild retrospective study** *M. Husain* (Paris, France), M. Potie, P. Labe, P. Parize, J. Cohen, E. Bille, D. Khraiche, J. Toubiana*

SY153 **09:30 – 10:30** **Hall A3-2**

AMR PHEI

1-hour Symposium

Pro/con debate: is One Health essential or a distraction in AMR related policies?

Chairs *Elena Carrara (Verona, Italy)*
Timothy R. Walsh (Oxford, United Kingdom)

S0483 **09:30** **AMR is the quintessential One Health issue** *Sabiha Essack (Durban, South Africa)*

S0484 **10:00** **One Health is distracting us from addressing policy gaps** *Heiman Wertheim (Nijmegen, The Netherlands)*

EF126 **09:30 – 10:30** **Arena 1**

CLN DX TRN

ePoster Flash Session

Clinical and diagnostic insights into invasive fungal diseases

Chair *Cecile Angebault (Creteil, France)*

E0881 **09:30** **Detection of Mucorales antigen in serum samples using a newly developed lateral-flow device** *J. Rousselot* (Besançon, France), L. Millon, E. Scherer, A.P. Bellanger, C.R. Thornton*

E0882 **09:36** **High rates of *Candida* colonisation in European neonates: a sub-analysis of the NeoVanc randomised controlled trial** *L.F. Hill* (London, United Kingdom), L. Ferreras-Antolin, M.N. Clements, F. Shahed, J. Fermin Luque, I. Monahan, T. Planche, M.A. Turner, I. Lutsar, E. Roilides, M. Sharland, J.A. Lindsay, P.T. Heath*

E0883 **09:42** **Epidemiology, resistance patterns, and outcomes of candidaemia acquired in Italian intensive care units: insights from the GIVITI Network (2020-2024)** *G. Scaglione* (Milan, Italy), M. Colaneri, M. Offer, G. Montrucchio, C.G.I. Genovese, B. Viaggi, F. Dore, G. Tricella, L. Dalfino, G. Monti, A. Gori, E.P.I. Palomba, S. Finazzi*

E0884 **09:48** **CandEYE: serial non-mydriatic fundoscopy in patients with candidaemia** *I. Reinhold* (Cologne, Germany), J. Müller, L. Altay, A. Lentzsch, K. Löw, E. Mackevic, J. Salmanton-García, C. Cursiefen, O.A. Cornely, R. Sprute*

E0885 **09:54** **Clinical, laboratory and financial evaluation of diagnostic testing for invasive *Aspergillus* infections in haemato-oncology patients with neutropenic fever in a large U.K. teaching hospital** *J. Moore* (Cambridge, United Kingdom), W. Hamilton, P. Patel, A. King, J. Mason, D. Enoch*

E0886 **09:54** **Diagnostic value of galactomannan in tracheobronchial aspirate for *Aspergillus* infection in lung transplant recipients (the GALACTBAS study)** *A. Monforte Pallares* (Barcelona, Spain), A. Monforte, M.T. Martín-Gómez, C. Berastegui, E. Márquez-Algaba, J. Sacanell, J. Rosado, A. Falcó-Roget, G. Escudero, J. Casanovas, C. Kirkegaard-Biosca, B. Sáez-Giménez, V. Monforte, J. Gavaldà, O. Len, I. Los-Arcos*

E0887 **10:00** **Fungal diagnostic approach among hospitalised patients receiving polyene vs azole in US, 2021-2024** *E. Harvey* (Baltimore, United States), M. Zilberberg, A. Knee, Q. Andan, B. Nathanson, T. Sandison, K. Marr, A. Shorr*

E0888 **10:12** ***Pneumocystis jirovecii* pneumonia in solid organ transplant recipients: a cross-sectional study in France** *A. Alanio* (Paris, France), K. Sitbon, T. Obadia, M. Desnos-Ollivier, D. Garcia-Hermoso, V. Bru, G. Desoubeaux, E. Guemas, M.F. Durieux, F. Morio, F. Robert-Gangneux, J. Bonhomme, F. Lanternier, O. Lortholary*

E0889 **10:18** **A qPCR identification scheme to detect the most common mycetoma causative agents in Africa** *W. Van De sanDe* (Rotterdam, The Netherlands), A. Watson, S. Bakhiet, E. Siddig, C. Pab Minlekib, R. Mohammed, W. Zandijk, M. Konings, A. Fahal, M. Faye, F. Mazraati Tajabadi, J. Errington, D. Sow*

EF127 **09:30 – 10:30** **Arena 3**

AMR DX IPC

ePoster Flash Session

Genomic surveillance for infection prevention and outbreak investigation

Chair *Richard V. Goering (Omaha, Nebraska, United States)*

E0890 **09:30** **From potential to practice: an internationally transferable roadmap for implementing whole genome sequencing in infection prevention and control** *J. Price* (Brighton, United Kingdom), J. Otter, E. Jauneikaite*

E0892 **09:36** **Exploring filth flies as sentinels of hospital environments in 16 countries and regions: high prevalence of clinically relevant antimicrobial-resistant bacteria observed in resource-limited settings** *K. Sands* (Oxford, United Kingdom), E.A. Portal, T. Iannetelli, S. Premchand-Branker, T. Beard, M. Li, K. Cook, A.K. Lankapalli, V. Dougnon, A. Gaye, A. Opazo-Capurro, A.M. Soliman, M.H. Legese, J. Acolatse, E. Carretto, E.G. Kibaru, O. Sy, K. Iregbu, A. Zukowska, M.C. Seck, A.R. Mansaray, H. Kuo, C. Graham, P. Nel, C. Achi, T.R. Walsh*

E0893 **09:42** **Genomic insights into carbapenem-resistant *Klebsiella pneumoniae* from bloodstream infections in Crete, Greece** *K. Tryfinopoulou* (Heraklion, Greece), G.C. Karfaki, D. Marinopoulou, T. Iatridi, M. Malliarou, E. Skliva, D. Stafylaki, E. Chatzidospyridaki, S. Karakonstantis, P. Ioannou, D. Kofteridis, A. Psaroulaki, D. Chochlakis*

E0894 **09:48** **ST11 on the move: recurrent capsule switching and the rise of KL62** *Y. Feng* (Chengdu, China), Z. Zong*

E0895 **09:54** **Outbreak of carbapenemase-carrying plasmids in Urology: implications of bladder irrigation pipe systems** *A. Freijo Cancio* (Seville, Spain), A. Freijo, M. Delgado-Valverde, J. Rodriguez-Baño, R. López-Marquez, A. Pascual, L. López-Cerero*

E0896 **10:06** **Genomic epidemiology of multidrug-resistant *Enterobacteriaceae* in intensive care units: a one year prospective study in adult intensive care units of three French university hospitals** *F. Gravey* (Caen, France), C. Bernachot, K. Le Neindre, D. Ducheyron, J.B. Decros, F. Tamion, S. Boyer, T. Clavier, J. Maizel, H. Dupont, N. Lemaitre, J. Brochart, H. Marini, S. Galopin, M. Godet, S. Le Hello, C. Jeanne-Leroyer, O. Join-Lambert*

E0897 **10:12** **Evaluation of the applicability of nanopore-only whole genome sequencing for *Pseudomonas aeruginosa* outbreak investigation in the ICU setting: a multi-centre study** *J. Dingemans* (Hasselt, Belgium), S. Vandersanden, P. Hilkens, F. Crombé, D. De Geyter, A.M. Van Den Abeele, P. Bruynseels, J. Frans, P. Vandecandelaere, A. Boel, R. Cartuyvels, K. Magerman*

E0898 10:18 ***Pseudomonas aeruginosa*** **genome adaptations in bleached sink traps** *D. Hocquet* (Besançon, France), T. Chautrand, L. Masson, C. Couchoud, B. Valot*

EF128 **09:30 – 10:30** **Arena 4**

CLN PED TRN

ePoster Flash Session

CNS infections at a crossroad: rising lineages, host susceptibility and novel mechanisms

Chair *Maria Diletta Pezzani (Verona, Italy)*

E0899 09:30 **Epidemiology, clinical characteristics and outcomes of invasive meningococcal disease caused by two hypervirulent serogroup W strains belonging to the ST11 clonal complex in England (2010-2019)** *C. Isitt* (Stockholm, Sweden), H. Campbell, J. Lucidarme, S. Clark, P.T. Heath, R. Borrow, S.N. Ladhani*

E0900 09:36 **Antimicrobial exposure but not vaccination predicts oropharyngeal *Neisseria meningitidis* clearance among men who have sex with men** *M.F. Lucente* (Milan, Italy), F. Ranaldi, A.R. Raccagni, N. Capra, R. Lolatto, C. Candela, M. Ripa, G. Catalano, A. Castagna, S. Nozza*

E0901 09:42 **Global expansion of a CTX-M-15-chromosomally integrated *Escherichia coli* ST1193 sublineage (ST1193-B1-Rx) identified in neonatal meningitis in France, 2000–2023** *Y. Benhadid-Brahmi* (Paris, France), K. La, G. Geslain, J. De Larminat, P. Bidet, A. Cointe, L. Armand, C. Courroux, S. Bonacorsi, A. Birgy*

E0903 09:48 **Asplenia and functional hyposplenia in community-acquired bacterial meningitis in adults** *E. Schepers* (Amsterdam, The Netherlands), V. Boon, E. Drost, M. Brouwer, D. Van De Beek*

E0904 09:54 **Neurological manifestations attributable to *Mycoplasma pneumoniae* in adults during the 2023–2024 epidemic: clinical features, management, and outcomes** *M. Holub* (Paris, France), A. Gavaud, C. Louapre, A. Bleibtreu, C. Cazanave, V. Pourcher, M. Le Marechal, G. Martin Blondel, R. Palich*

E0905 10:00 **Increasing importance of *Streptococcus anginosus* group as a cause of invasive streptococcal infection in the UK: a retrospective longitudinal observational study** *E. Gil* (London, United Kingdom), J. Hatcher, S. De Saram, T. Patel, T. Lamagni, R. Guy, M. Marks, J. Brown*

E0906 10:06 **In experimental neurolisteriosis, the matrix metalloproteinases inhibitor cipemastat protects the brain from apoptotic neuronal injury** *D. Grandgirard* (Bern, Switzerland), E. Stahovic, M. Erhardt, S.L. Leib*

E0907 10:12 **Rhbdl2 modulates inflammation, coagulation and vascular responses in experimental pneumococcal meningitis** *D. Bakker* (Amsterdam, The Netherlands), R. Koning, M. Van Roon, V. Jaspers, M. Brouwer, D. Beek*

OS131 **11:00 – 12:00** **Hall A1-1**

TRN

1-hour Oral Session

Bacterial adaptation: from colonization to pathogenesis

Chairs *Michael Bachman (Ann Arbor, Michigan, United States)*
Elisabeth Grohmann (Berlin, Germany)

O0908 11:00 ***Listeria monocytogenes*** **clonality within the brain revealed by sequence tag-based analysis of microbial populations (STAMP)** *K. Toms* (Paris, France), P. Gastineau, J. Gaillard, P. Thouvenot, S. Levallois, M. Lecuit*

O0909 11:12 **Integrated multi-omics reveals coordinated *Staphylococcus aureus* metabolic, iron transport, and stress responses to human serum** *A. Hachani* (Melbourne, Australia), W. Mujchariyakul, C. Walsh, S. Giulieri, C. Cramond, K.A. Lecao, T. Stinear, B. Howden, R. Guerillot*

O0910 11:24 **IgaA mutation enhances extracellular polysaccharides production and virulence via Rcs phosphorelay in *Enterobacter cloacae complex*** *Y. Li* (Beijing, China), M. Zhou, Y. Xu*

O0911 11:36 **Transcriptional reprogramming driving enterococcal persistence unveiled by RNA-sequencing** *J. Guerreiro* (Lisboa, Portugal), C. Geraldes, C. Silva, F. Vale, E. Cunha, L. Tavares, J. Fernandes Guerreiro, M. Oliveira*

O0912 11:48 **Polymicrobial biofilm communities potentiate host damage in a 3D human bladder microtissue model** *R. Garcia Maset* (Oxford, United Kingdom), A. Crowther, V. Chu, I. White, L. Pasquina-Lemonche, M. Hadjifrangiskou, E. Stride, D. Carugo, J. Rohn*

OS132 **11:00 – 12:00** **Hall A1-3**

IPC

1-hour Oral Session

Modernising surgical site infection surveillance: AI, automation and patient-centred monitoring

Chairs *Gabriel Birgand (Nantes, France)*
Martin Wolkewitz (Freiburg, Germany)

O0913 11:00 **Impact of a computerised decision support system on the adequacy of surgical antibiotic prophylaxis (SAP) and surgical site infections (SSI)** *A. Agostinho* (Geneva, Switzerland), L. Hermant, E. Chalot, J. Sobel, W. Rey, D. Teixeira, J. Goncerut, A. Freitas, J. Achcar, F. Bellissimo-Rodrigues, S. Harbarth*

O0914 11:12 **Transforming free text into usable data: large language models to support automated surgical site infection surveillance** *E. Chalot* (Geneva, Switzerland), A. Agostinho, J. Sobel, D. Teixeira, S. Harbarth, M. Abbas*

O0915 11:24 **Explainable artificial intelligence models for predicting surgical site infections: a scoping review of predictive features and model transparency** *S. Lu* (Hong Kong, China), R. Sun, Y. Liu, E. Tartari Bonnici, L. Yang, L. Zhou*

O0916 11:36 **National surveillance of surgical site infections in Belgium: results and evolution of the Sciensano NSIH-SSI program** *T. Tamminga* (Brussels, Belgium), K. Mertens, L. Van Imshoot*

O0917 11:48 **Patient-reported, prospective, and digital surveillance of post-caesarean surgical site infections in the outpatient setting: the SECURE Sectio study** *K. Last* (Bonn, Germany), M.N. Kröncke, M. Jaskolski, E. Früchtl, F. Droop, N. Scholten, N.T. Mutters, B. Strizek*

OS133 **11:00 – 12:00** **Hall A1-5**

ANT CLN PHEI

1-hour Oral Session

Community-acquired pneumonia: know your enemies, treat them well

Chairs *Aurélien Dinh (Garches, France)*
Annabel Niessen (Utrecht, The Netherlands)

O0918 11:00 **Pneumococcal pneumonia in adults, re-emergence of vaccine serotypes: a prospective multi-centre cohort study in Germany, 2020-2023** *C. Bahrs* (Vienna, Austria), N. Rose, G. Barten-Neiner, C. Fleischmann-Struzek, M.P.G. Van Der Linden, G. Rohde, J. Rupp, M. Witzenrath, J. Rademacher, M.W. Pletz*

O0919 11:12 **Incidence and burden of medically and non-medically-attended Mycoplasma pneumoniae, 2024-2025** *J. King* (Marshfield, United States), J. Petrie, B. Kieke, O. Alonge, W. Meng, Z. Zheng, I. Leony Lasso, Y. Park, E.C. Newbern, C. Canan, J. Meece, E. Viscidi, E.J. Anderson, H. Nguyen*

O0920 11:24 **Genomic surveillance reveals global spread of macrolide-resistant *Bordetella pertussis* linked to vaccine changes** *J. Feng* (Shanghai, China), C. Min*

O0921 11:36 **Real-world applicability of a three-day antibiotic regimen for community-acquired pneumonia: a ten-year retrospective study across four Swiss university centres** *T. Brahier* (Lausanne, Switzerland), J. Regina, G. Carra, M. Méan, N. Boillat Blanco*

O0922 11:48 **Cardiovascular risk of clarithromycin use in patients hospitalised with community-acquired pneumonia** *S. Bastrup Israelsen* (Hvidovre, Denmark), M. Fally, P. Ravn, L. Kolte, M. Schmidt, T. Benfield, A. Matthews*

OS134 **11:00 – 12:00** **Hall A2-2**

CLN DX

1-hour Oral Session

Changing landscape of opportunistic infections in the immunocompromised host

Chairs *Malgorzata Mikulska (Genoa, Italy)*
Lior Nesher (Beersheba, Israel)

O0923 **11:00** **MUCOPS interventional trial: blood Mucorales PCR screening in high-risk haematology patients** *Y. Vanbiervliet* (Leuven, Belgium), R. Aerts, E. Boon, T. Mercier, A. Schauwvlieghe, K. Beuselinck, K. Lagrou, J. Maertens*

O0924 **11:12** **Severe infections after CD19-directed chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphoma, a retrospective real-life study from the DESCAR-T registry (LYSA)** *T. Morris* (Saint-Etienne, France), A. Fayard, V. Dupont, E. Daguenet, C. Thieblemont, E. Bachy, G. Manson, C. Herbaux, I. Yakoub-Agha, T. Gastinne, D. Blaise, L. Roulin, F.X. Gros, P. Bories, R. Houot, S. Le Gouill, E. Botelho-Nevers, L. Fouillet, J. Cornillon*

O0925 **11:24** **Strategies for management of human cytomegalovirus (HCMV) reactivation in haematopoietic stem cell transplant recipients (HSCTRs) in the era of letermovir** *D. Lilleri* (Pavia, Italy), I. Cassaniti, D. Mele, M. Michele, F. Zavaglio, G. Grassia, N. Polverelli, D. Russo, A. Algarotti, T. Lazzarotto, F. Bonifazi, P. Chiusolo, F. Baldanti*

O0926 **11:36** **Transplantation and geographic medicine: analysis of data from the Spanish National Transplant Organisation (ONT), 2015-2024** *F. Norman* (Madrid, Spain), B. Mahillo, M.D. Corbacho-Loarte, M. Gonzalez-Sanz, S. Chamorro-Tojeiro, F. Gioia, D. Gayoso-Cantero, B. Dominguez-Gil, J. Fortun, P. Martin-Davila*

O0927 **11:48** **Risk factors for invasive mold infections in heart transplant recipients: a nationwide matched case-control study** *B. Hoellinger* (Strasbourg, France), E. Epailly, F. Vuotto, V. Letscher-Bru, S. Loridant, C. Goeminne, R. Coelho, G. Laurent, S. Guendouz, G. Melica, F. Botterel, D. Maubon, A. Boignard, S. Pattier, F. Morio, C. Chabanne, J.P. Gangneux, K. Blanchart, J. Bonhomme, S. Grosjean, F. Dalle, C. Nafeh-Bizet, L. Favennec, B. Pilmis, J. Guilhaire, A. Gigandon, G. Pasquier, V. Dupasquier, C. Vignals, M. Lefranc, P. Tirard-Collet, L. Sebbag, L. Van Den Bogaart, F. Lanternier, M. Saito, F. Danion*

OS135 **11:00 – 12:00** **Hall A3-2**

AMR PHEI

1-hour Oral Session

Harnessing wastewater for surveillance of AMR

Chairs *Henry-Michel Cauchie (Belvaux, Luxembourg)*
Amy Mathers (Charlottesville, United States)

O0928 **11:00** **Longitudinal wastewater metagenomics allows genomic and clinical surveillance of human-associated viruses** *M. Karatas* (Leuven, Belgium), M. Bloemen, J. Swinnen, L. Close, M. Van Ranst, E. Wollants, J. Matthijnssens*

O0929 **11:12** **From influent to effluent: antibiotic resistance gene dynamics in WWTPs** *C. Stoffers* (Groningen, The Netherlands), M. Lokate, L. Gard, A. Voss, J.W.A. Rossen*

O0930 **11:24** **Associations between antimicrobials and antimicrobial resistance genes in urban wastewater** *M. Penney* (Calgary, Canada), D. Kuzma, K. Aleshia, M. Kayla, O. Christine, D. Kristine, A. Emily, A. Nicole, W. Barbara, L. Jangwoo, W. Benson, C. Rhonda, M. Janine, V. Laura, P. Chloe, R.M. Elissa, D. Bruce, N. Diego, B. Herman, C. John, K.H. Susana, H. Casey, P. Michael*

O0931 **11:36** **Hospital use of ciprofloxacin and sulfamethoxazole correlates with their concentrations in hospital wastewater in Norway, 2019-2025** *H.J. Espvik* (Oslo, Norway), M. Grung, C. Vogelsang, K.M. Gravningen*

O0932 **11:48** **Cross-compartment genomic epidemiology of cephalosporin- and carbapenem-resistant Enterobacterales: an international multi-centre study in patients, hospital aquatic environments and wastewater** *N. Macesic* (Melbourne, Australia), N. Hassoun-Kheir, M. Andre, D. Andrey, M. Beiers, X. Bertrand, B. Burri, D. Haber, S. Harbarth, J. Hawkey, M. Karram, L. Opatowski, M. Paul, R. Patwa, R. Sierra, K. Van Hoorde, M. De Kraker, A. Peleg*

OS129 **11:00 – 12:00** **Hall ICM 13a**

ANT TRN

1-hour Oral Session

Making phages GMP-ready: the manufacturing challenge

Chair *Jean-Paul Pirnay (Brussels, Belgium)*
TBA

O0933 **11:00** **Consensus-based guideline on personalised bacteriophage therapy** *S. Würstle* (Frankfurt, Germany), S. Lieberknecht-Jouy, M. Vehreschild, A. Classen*

O0935 **11:12** **Virulent phage infection triggers prophage induction and lysogenic conversion in *Staphylococcus aureus*: implications for therapeutic phage production safety and virulence dynamic** *P.A. Pastouriaux* (Lyon, France), M. Bonhomme, P. Martins-Simoes, L. Blazere, E. Helluin, K. Royet, M. Medina, C. Kolenda, F. Laurent, F. Laumay*

O0936 **11:24** **Tailoring the next generation bacteriophage therapy with a cell-free system** *S.C. Nang* (Melbourne, Australia), H.H.Y. Yu, H. Wickremasinghe, X. Li, J. Zhao, J. Li*

O0937 **11:36** **Implementation of the first French public platform for the production of GMP-grade therapeutic phages at reasonable cost** *F. Laurent* (Lyon, France), L. Frédéric, M. Medina, B. Lapras, C. Kolenda, C. Marchand, F. Laumay, C. Merienne, M. Bonhomme, F. Pirot*

OS130 **11:00 – 12:00** **Hall ICM 13b**

CLN PHEI

1-hour Oral Session

Navigating clinical realities in travelers and migrant populations

Chairs *Andreas Neumayr (Basel, Switzerland)*
Elaine Maria Seles Dorneles (Lavras, Minas Gerais, Brazil)

O0938 **11:00** **Safety of the dengue vaccine TAK-003 and risk factors for developing adverse events in travellers from non-endemic areas: a real-world prospective multi-centre pharmacovigilance study in Spain** *D. Camprubí-Ferrer* (Barcelona, Spain), D. Camprubí Ferrer, M. Saloni, L. Valerio, J. Villar, V. Lopez-Lopez, C. Bertran-Cobo, D. Garcia, E. Jurado, M.L. Machado, C. Masuet, S. Cuevas Marin, I. Gonzalez Nieto, D. Herena García, R. Morales, A. Gomila-Grange, I. Vera, F. Vila, N. Martin, T. De Alba, N. Morales Llorente, E. Gorriz Hidalgo, J. Muñoz*

O0939 **11:12** **Cluster of rash dominant dengue fever in newly arrived Chinese expatriates at Bangalore (India): a sentinel event in travel health** *A. Mb* (Bangalore Rural, India), S. Banti, D. Shobha, R. Surendran*

O0940 **11:24** **AdMiRE study: development and validation of a WHO-aligned tool to assess healthcare access and antibiotic use among migrant populations in Europe: a multicountry Delphi and psychometric study on behalf of ESGITM group** *G. Guido* (Bari, Italy), A. Abbara, M. Asaduzzaman, F.B. Farkas, K. Diabate, A. Duvignaud, V. Holmberg, S. Ibrahim, S. Jordao, R. Papagni, L. Jung, B. Lakatos, M. Orcutt, A. Saracino, A. Requena-Méndez, E. Romancenco, M. Schiavone, C. Shortall, C. Napoli, D. Mosca, P. Luga, J. Llenas García, E. Nicastri, A. Corpolongo, P. Bodenman, E. Florence, F. Eick, L. Závorszky, S. Severoni, C.M. Wejse, F. Di Gennaro*

O0941 **11:36** **Imported leishmaniasis in Europe (2000–2024): a systematic review of travel-related case reports** *J. Acosta España* (Quito, Ecuador), S.M. Alcocer-Veintimilla, V.A. Pillajo-Gangotena, J.D. Acosta-España, A. Abbara, M. González-Sanz, A. Rodriguez-Morales*

O0942 **11:48** **Seroprevalence of *Burkholderia pseudomallei* among international travelers: a preliminary result** *Q.M. Ali* (Bangkok, Thailand), G. Zschebek, C.M.S. Cagape, N. Saiprom, S. Tandhavanant, R. Phunpang, M.N. Burtnick, P.J. Brett, T. Siripoon, H.A. Imad, C. Chewapreecha, W. Cheirakul, N. Chantratita, W. Matsee*

SY158 **11:00 – 12:00** **Hall A1-4**

1-hour Symposium

DX TRN

Detecting parasites using metagenomics and proteomics

Chairs *Hanne Brekke (Oslo, Norway)*
Dora Buonfrate (Negrar, Italy)

S0439 **11:00** **Unmasking hidden worlds: the power of metagenomics in parasitology** *Francesco Asnicar (Trento, Italy)*

S0440 **11:30** **From proteomics to the bench** *Momar Ndao (Montreal, Quebec, Canada)*

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)

SY159 **11:00 – 12:00** **Hall A2-1**

1-hour Symposium

DX PHEI

To AI or not to AI: latest trends in digital innovation for respiratory virus detection and management

Chairs *Benjamin Cowling (Pokfulam, Hong Kong)*
Esmeralda Valiente (Berlin, Germany)

S0441 **11:00** **Using AI-enabled diagnostics to strengthen biosecurity and address gaps in servicing remote populations** *Holly Seale (Sydney, Australia)*

S0442 **11:30** **Latest trends in AI-supported respiratory virus surveillance and monitoring** *Jude Kong (Toronto, Canada)*

Co-organised with: Australasian Society for Infectious Diseases (ASID), ESCMID Study Group for Respiratory Viruses (ESGREV), International Pediatric Association (IPA)

SY160 **11:00 – 12:00** **Hall A3-1**

1-hour Symposium

AMR ANT

Emerging resistance to new antibiotics: are we already losing the newest tools?

Chairs *Ana Gales (São Paulo, Brazil)*
Thomas Tängdén (Uppsala, Sweden)

S0443 **11:00** **Current prevalence and clinical impact of resistance to new drugs** *Timothy R. Walsh (Oxford, United Kingdom)*

S0444 **11:30** **How to minimise resistance to new drugs** *Elena Carrara (Verona, Italy)*

SY157 **11:00 – 12:00** **Hall B0-1**

1-hour Symposium

AMR ANT

Personalised antimicrobial stewardship for resistant pathogens: beyond clinical trials

Chairs *Lorenzo Guglielmetti (Negrar Di Valpolicella, Verona, Italy)*
Tomislav Kostyanev (Esbjerg, Denmark)

S0437 **11:00** **blaNDM-producing Enterobacterales: optimal selection of adjuvant β-lactamase inhibitors** *Jacob Strahilevitz (Jerusalem, Israel)*

S0438 **11:30** ***Mycobacterium tuberculosis* mutations associated with drug resistance: the way forward** *Iñaki Comas (Valencia, Spain)*

SY155 **11:00 – 12:00** **Hall ICM 1**

1-hour Symposium

CLN PED VAX

Year in paediatric ID

Chairs *Julia Anna Bielicki (London, United Kingdom)*
Hervé Haas (Nice, France)

S0433 **11:00** **Epidemiology, diagnosis, treatment** *Ulrich Von Both (Munich, Germany)*

S0434 **11:30** **Infection prevention and vaccines** *Dana Danino (Beer Sheva, Israel)*

SY156 **11:00 – 12:00** **Hall ICM 5**

1-hour Symposium

AMR IPC

Decoding resistance: the new ESCMID guidelines to halt transmission of multidrug-resistant Gram-negatives

Chairs *Ana Budimir (Zagreb, Croatia)*
Andreas Voss (Groningen, The Netherlands)

S0435 **11:00** **The ESCMID blueprint for prevention: a deep dive into the new guidelines** *Evelina Tacconelli (Verona, Italy)*

S0436 **11:30** **Making the guidelines stick: innovative implementation strategies for effective uptake** *Bianca Albers (Zurich, Switzerland)*

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee

---

EF136 **11:00 – 12:00** **Arena 2**

ePoster Flash Session

AMR DX

Novel aspects in antimicrobial susceptibility testing and resistance detection

Chair *Alberto Antonelli (Florence, Italy)*

E0943 **11:00** **Rapid MALDI-TOF MS synergy testing to guide combination therapy in critical infections** *M. Bexkens* (Rotterdam, The Netherlands), S. Van Den Berg, C. De Vogel, W. De Jong, A. Muller*

E0944 **11:06** **NANOMUR: innovative nanomotion technology for antibiotic susceptibility testing: a game-changer for urinary tract infections?** *A. Delfino* (Lausanne, Switzerland), D.C. Cẩn, O.Y. Chén, A. Sturm, D. Cichocka, G. Greub*

E0945 **11:12** **Not all MIC plates are equal: method-driven shifts in cefiderocol susceptibility for NDM-producing Enterobacterales** *M. Bouillon* (Caen, France), C. Isnard, S. Le Hello, F. Gravey*

E0946 **11:18** **A multi-centre evaluation of routine susceptibility testing methods for linezolid using a clinical *Enterococcus* strain collection** *S. De Koster* (Edegem, Belgium), S. Van Kleef-Van Koeveringe, J. Boelens, N. Botteldoorn, P.J. Ceyssens, M. Chemais, C. Deckers, S. Desmet, S. Gils, T.D. Huang, B. Lissoir, K. Magerman, C. Meex, K. Floré, A.M. Van Den Abeele, E. Van Honacker, K. Vernelen, I. Verstreken, V. Matheeussen, S. Vandamme*

E0947 **11:24** **Challenges of phenotypic antimicrobial susceptibility testing of *Enterococcus faecium* for vancomycin using semi-automated systems and their causes** *T. Ruegamer* (Cologne, Germany), C. Arz, A. Hiergeist, R. Arazo Del Pino, U. Reischl, P.G. Higgins, A. Gessner, A. Dudakova, M. Simon, J. Jantsch*

E0948 **11:30** **Waiting for the answer: validation of newly implemented VITEK 2 automated susceptibility testing cards can cause treatment delays in an intensive care unit population** *S. Boettcher* (Detroit, United States), A. Abed, N. Everson, R. Kenney, R. Tibbetts, L. Samuel, M. Veve*

E0949 **11:36** **Utility of tetracycline susceptibility as a predictor of doxycycline activity in non-diphtheriae Corynebacterium: a retrospective analysis** *K. Barrett* (Rochester, United States), O. Abu Saleh, M. Fida*

E0950 **11:42** ***In vitro* evaluation of cefiderocol against *Achromobacter xylosoxidans* isolates from people with cystic fibrosis** *F. Tolio* (Verona, Italy), G. Toccacieli, A. Bertoncelli, A. Mazzariol*

E0951 **11:48** **Rethinking ESBL Detection in Enterobacterales: Comparison of EUCAST and CLSI Guidelines and Development of a Clavulanate-Free Algorithm** *L.K. Muhsal* (Osnabrueck, Germany), A. Hamprecht*

EF137 **11:00 – 12:00** **Arena 3**

ePoster Flash Session

VAX

Bacterial vaccine pipeline: focus on *Staphylococcus* and *Klebsiella*

Chair *Guido Werner (Wernigerode, Germany)*

E0952 **11:00** **AntiPan: a genome-informed in silico pipeline for advancing subunit vaccine discovery against *Staphylococcus aureus*** *M. Elhadidy* (Giza, Egypt), M.S. Ibrahim, J.A. Fahmy, M.A. Helal, F.T. Hakim, L.R. Sidarous, N.E. Attallah, S. Abouelhadid, E. Badr*

E0954 **11:12** **Kp-OMV4: a broadly active OMV vaccine against Klebsiella pneumoniae** *B. Cano Castaño* (Madrid, Spain), B. Cano-Castaño, S. Prieto Martin-Gil, A. Tajuelo Moreno-Palancas, E. Gato, P. Miguela-Villoldo, D. Fousteris, A. Peláez García, F. Docando, D. Megias, A.J. Martín-Galiano, A. Pérez, M.J. Mcconnell*

E0955 **11:18** **Wide strain coverage and protection predicted for K-Vax, a vaccine for prevention of disease by *K. pneumoniae* presenting OmpA and OmpK36 assembled into chimeric LPS-null whole-cells of *A. baumannii*** *A. Rodríguez Rosado* (Dos Hermanas, Spain), A.I. Rodriguez-Rosado, A. Alonso-Del Valle, J. Sa Pessoa, R. Calderon-Gonzalez, M. Garcia-Lopez, L. Del Pozo-Acebo, M. Cordero-Alba, M.J. Mcconnell, J.A. Bengoechea, J.J. Infante*

E0956 **11:24** **Broad computational and experimental screening of antigenic loops in the *Klebsiella pneumoniae* porinome** *A. Pérez Gómez* (Madrid, Spain), S. Prieto Martin-Gil, A. Tajuelo, B. Cano, D. Fousteris, L. Vaughan, P. Miguela-Villoldo, E. Gato, A. Pérez, A.J. Martín Galiano, M.J. Mcconnel*

E0957 **11:30** **Assessment of KpiD as a promising antigen for vaccine development against *Klebsiella pneumoniae*** *A. Tajuelo Moreno-Palancas* (Madrid, Spain), A. Tajuelo, S. Prieto Martín-Gil, L. Vaughan, B. Cano-Castaño, P. Miguela-Villoldo, D. Fousteris, V. Mas, A.J. Martín-Galiano, M.J. Mcconnell, A. Pérez, E. Gato*

E0958 **11:36** **Developing an outer membrane vesicle-based vaccine against *Klebsiella pneumoniae*** *K. Winter* (Vancouver, Canada), K. Chu, N. Wilks, S. Cai, A. Tejani, W.L. Kuan, I. Hadad, L. Presley, T. Harn, M. Lo, M. Sadarangani*

E0959 **11:42** **Cost-effectiveness analysis of PCV21, an adult specific 21-valent pneumococcal conjugate vaccine, vs PCV20 in adults in Germany** *L. Lang* (Munich, Germany), P. Mueller, M. Simuzingili, M. De Lepper, K. Owusu-Edusei*

E0960 **11:48** **Development of a non-invasion intranasal vaccine for *Klebsiella pneumoniae* urinary tract infection** *L.K. Siu* (Zhunan, Taiwan), M.H. Huang*

EF138 **11:00 – 12:00** **Arena 4**

VAX

ePoster Flash Session

Pneumococcal vaccines: impact and serotype dynamics

Chair *Ron Dagan (Beer-Sheva, Israel)*

E0961 **11:00** **The first comprehensive whole genome sequencing of *Streptococcus pneumoniae* from the Arabian Gulf region: Implications for vaccine strategies** *A. Senok* (Dubai, United Arab Emirates), S. Verma, L. Mohamed, E. Kaambo, S. Boucherabine, M. Senghore, A. Nabi, M. Habou, F. Jabeen, A. Alatoom, N. Abdulrazzaq, W. Jamal, R. Nassar, E. Mokaddas, D. Everett*

E0962 **11:06** **Dominance of PCV13-nonPCV10 serotypes in paediatric invasive pneumococcal infections in Serbia after sequential PCV programs** *N. Vuckovic Opavski* (Belgrade, Serbia), M. Jovicevic, J. Kabic, D. Kekic, Z. Vasiljevic, O. Hadzic Simovic, S. Laban Nestorovic, T. Djordjevic, D. Medic, L. Ranin, I. Gajic*

E0963 **11:12** **Serotype evolution and sequence types of *Streptococcus pneumoniae* meningitis isolates before and after PCV13 introduction in Algeria** *S. Bouheraoua* (Algiers, Algeria), A.E. Deghmane, K. Hebbachi, R. Laliam, F. Djedjig, C. Bentchouala, R. Abi Ayad, S. Mahrane, M.K. Taha, H. Tali Maamar*

E0964 **11:18** **Assessing the impact of different pneumococcal conjugate vaccine (PCV) programs on invasive pneumococcal disease (IPD) using population based surveillance in Ontario** *A. Mcgeer* (Toronto, Canada), A. Shigayeva, Z. Zhong, C. Amirov, A. Belhaj, S. Chakrabarti, D. Chen, W. Gold, A. Golden, L. Goneau, C. Kandel, S. Krajden, R. Lovinsky, I. Martin, L. Matukas, T. Mazzulli, M. Muller, J. Nadarajah, K. Ostrowska, N. Rau, D. Ricciuto, D. Richardson, D. Rose, M. Saffie, V. Sales, A. Simor, C. Vermeiren*

E0965 **11:24** **Would implementing a risk-based or an age-based PCV20 vaccination program in adults 60+ years in Brazil be cost effective and budget saving?** *L. Huang* (Collegeville Pa, United States), R.F. Alexandre, A. Claro, R. Ferreira, D. Pachito*

E0966 **11:30** **Estimated impact of pneumococcal conjugate vaccine implementation on disease burden and mortality: strategies to guide PCV program introduction in low-resource settings** *T. Ngamprasertchai* (Bangkok, Thailand), V. Mahd-Adam, W. Pan-Ngum*

E0967 **11:36** **Long-term persistence of pneumococcal antibodies five years after sequential PCV13 and PPSV23 vaccination in kidney transplant recipients: indications for revaccination** *L. Van De Sand* (Essen, Germany), B. Wilde, K. Völk, O. Witzke, M. Lindemann, N. Mülling*

E0968 **11:42** **Effect of introducing pneumococcal conjugate vaccines into nationalimmunisation programmes on antimicrobial-resistant *Streptococcus pneumoniae* disease burden across 188 countries: a synthetic-control study** *Z. Chen* (Shanghai, China), C. Zhihui, L. Zhonghua, W. Jing, Y. Xiangru, J. Jialin, Z. Wenhong*

KN154 **11:00 – 12:00** **Hall ICM 14**

TRN VAX

Keynote lecture

Genetics underlying susceptibility and immunity to infection

Chairs *Jan A.J.W. Kluytmans (Utrecht, The Netherlands)*
Gülşen Özkaya Şahin (Lund, Sweden)

K0432 **11:00** *Filomeen Haerynck (Ghent, Belgium)*

Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

ME161 **11:00 – 12:00** **Hall A1-2**

CLN

Meet-the-Expert

Clinical challenges and management strategies for slowly progressing cutaneous infections

M0445 **11:00** *Maria Luisa Aznar (Barcelona, Spain)*

M0446 **11:12** *Richard Odame Phillips (Kumasi, Ghana)*

Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC)

FO162 **11:00 – 12:00** **Arena 1**

PRO

Open Forum

Integrating Sustainable Development Goals (SDGs) 3 and 5 in policy and practice

Chair *Sabine Bélard (Tübingen, Germany)*

F0447 **11:00** **From policy to practice: gender equality in the SDG framework** *Irit Nachtigall (Berlin, Germany)*

F0448 **11:10** **Gender and access to infectious disease diagnostics and treatment** *Daniela Fusco (Hamburg, Germany)*

F0449 **11:20** **Integrating gender and community realities into AMR for SDGs 3 & 5 in Sub-Saharan Africa** *Judith Asin (Nairobi, Kenya)*

Co-organised with: Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V.

OS140 **13:30 – 14:30** **Hall A1-1**

CLN DX

1-hour Oral Session

Transforming diagnostic microbiology with AI

Chairs *Benjamin Peter Howden (Melbourne, Australia)*
Mariska Leeflang (Amsterdam, The Netherlands)

O0970 **13:30** **Democratising MALDI-TOF AMR prediction: from Transformers to simple Neural Networks without accuracy loss, reducing energy costs via knowledge**

distillation *A. Guerrero-López** (*Zurich, Switzerland*), *L. De Ancos Villa*

O0971 **13:42** **A novel auditable diagnostic support system using constrained retrieval-augmented generation improves accuracy and efficiency in parasitology morphology identification** *C.C. Hung** (*New Taipei, Taiwan*)

O0972 **13:54** **ParaScout: microscopic helminth detection using AI** *R. Zonneveld** (*Amsterdam, The Netherlands*), *S. Slavenburg, C. Tieken, R. Koelewijn, L. Van Lieshout, I. Feoktistov, J. Van Hellemond*

O0973 **14:06** **Transformer AI in clinical microbiology: ProkBERT improves detection of plasmids and mobile genetic elements** *G. Lorenzin** (*Trento, Italy*), *M. Carlin, D. Krizsán, B. Ligeti*

O0974 **14:18** **Accuracy of Gram stain interpretation by smartphone-based computer-aided diagnosis app in blood culture samples** *K. Ebisawa Furui** (*Kobe, Japan*), *G. Ohji, K. Yamamoto, I. Miyatsuka, A. Moriya, K. Akamatsu, H. Nomoto, M. Kurokawa, K. Ohnuma, M. Kusuki, Y. Uemura, N. Ohmagari*

SY166 **13:30 – 14:30** **Hall A1-4**

IPC PHEI

1-hour Symposium

One Health beyond AMR: the challenge of *Clostridioides difficile* infection control outside the hospital

Chairs *Marcela Krutova* (*Prague, Czechia*)
Ana Vale (*Dublin, Ireland*)

S0406 **13:30** ***Clostridioides difficile* in extra-human sources** *Mónica Oleastro* (*Lisbon, Portugal*)

S0407 **14:00** **Dynamics of transmission of *Clostridioides difficile* within and outside the hospital** *Semeh Bejaoui* (*Bologna, Italy*)

Co-organised with: ESCMID Study Group for *Clostridioides difficile* (ESGCD), ESCMID Study Group for Veterinary Microbiology (ESGVM)

SY165 **13:30 – 14:30** **Hall B0-1**

AMR TRN

1-hour Symposium

Beneath the caspule of *Klebsiella pneumoniae*: hypervirulence, fitness and adaptive evolution

Chairs *Christian Stephan Lentz* (*Tromsø, Norway*)
Shiri Navon-Venezia (*Ariel, Israel*)

S0404 **13:30** **What constitutes hypervirulence during *Klebsiella pneumoniae* infection?** *Yunn-Hwen Gan* (*Singapore, Singapore*)

S0405 **14:00** **Adaptive evolution and in-host dissemination of *Klebsiella pneumoniae*** *Michael Bachman* (*Ann Arbor, Michigan, United States*)

EW169 **13:30 – 15:30** **Hall A2-1**

CLN

2-hour Educational Session

UTIs off the beaten path: complex patients, complex choices

Chairs *Suzanne Geerlings* (*Amsterdam, The Netherlands*)
Angela Huttner (*Geneva, Switzerland*)

W0416 **13:30** **UTI in kidney-transplant patients: what's new and what's safe?** *Dionysios Neofytos* (*Geneva, Switzerland*)

W0417 **13:50** **UTI and bacteriuria in pregnancy: two and the same?** *Barbara Trautner* (*St. Louis, United States*)

W0418 **14:10** **UTI in patients with stones and stents: rocks and hard places** *Lorenz Leitner* (*Zurich, Switzerland*)

W0419 **14:30** **UTI in neurogenic bladder/spinal cord injury patients** *Ruxandra Calin* (*Paris, France*)

Co-organised with: ESCMID Study Group for Urinary Tract Infections (ESGUTI)

EW170 **13:30 – 15:30** **Hall A2-2**

CLN DX

2-hour Educational Session

Take the right path: tips on HIV resistance management in the era of new antiretrovirals

Chairs *Claudia Cortes* (*Santiago, Chile*)
Botond Lakatos (*Budapest, Hungary*)

W0420 **13:30** **State-of-the art approach to HIV resistance analysis** *Ivailo Alexiev* (*Sofia, Bulgaria*)

W0421 **13:50** **Epidemiology of HIV resistance in Europe and beyond** *Dimitrios Paraskevis* (*Athens, Greece*)

W0422 **14:10** **HIV resistance management in the era of long-acting antivirals** *Dan Otelea* (*Bucharest, Romania*)

W0423 **14:30** **Drug resistance testing for optimising HIV management** *Anna Maria Geretti* (*London, United Kingdom*)

Co-organised with: Euroguidelines in Central and Eastern Europe Network Group, ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR), Dat'AIDS Working Group

---

EW171 **13:30 – 15:30** **Hall A3-1**

ANT CLN

2-hour Educational Session

Managing bloodstream infections and endocarditis in the context of drug injection or homelessness

Chairs *Brigitte Lamy* (*Bobigny, France*)
Aneta Nyčová (*Praha, Czechia*)

W0424 **13:30** **Epidemiology and features of bloodstream infections among PWID** *Asko Jarvinen* (*Helsinki, Finland*)

W0425 **13:50** **Alternative antibiotic regimens and delivery strategies for infective endocarditis in PWID** *Burcu Isler* (*Gold Coast, Australia*)

W0426 **14:10** **Is combination treatment necessary for *Staphylococcus aureus* infections?** *Sara Grillo* (*Barcelona, Spain*)

W0427 **14:30** **Oral antibiotics for bacteraemia in people who use drugs** *Pierre Tattevin* (*Rennes, France*)

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES)

EW172 **13:30 – 15:30** **Hall A3-2**

CLN DX

2-hour Educational Session

Transplant infectious diseases: real-world challenges through the eyes of the next generation

Chairs *Roy Chemaly* (*Houston, United States*)
Nathan Peiffer-Smadja (*Paris, France*)

W0428 **13:30** **Understanding and applying cell-mediated immunity in transplant infectious diseases** *Carla Walti* (*Basel, Switzerland*)

W0429 **13:50** **CNS complications in patients treated with CAR-T cells** *Marjorie Batista* (*São Paulo, Brazil*)

W0430 **14:10** **How much is enough? Rational empiric therapy in febrile immunocompromised patients** *Yuri Vanbiervliet* (*Leuven, Belgium*)

W0431 **14:30** **Challenges for diagnostic stewardship in transplant recipients** *Ankit Mittal* (*Hyderabad, India*)

Co-organised with: ESCMID Study Group for Antimicrobial Stewardship (ESGAP), ESCMID Study Group for Infections in Compromised Hosts (ESGICH), ESCMID Study Group for Infectious Diseases of the Brain (ESGIB), ESCMID Scientific Affairs Subcommittee, ESCMID Study Group for Respiratory Viruses (ESGREV), International Immunocompromised Host Society (ICHS)

EW167 **13:30 – 15:30** **Hall ICM 13a**

PRO

2-hour Educational Session

Inside the black box: leading and developing clinical guidelines

Chairs *Blin Nagavci* (*Gjakova, Kosovo*)
Luigia Scudeller (*Pavia, Italy*)

W0408 **13:30** **How to chair a guideline panel and survive** *Mark G. J. De Boer* (*Leiden, The Netherlands*)

W0409 **13:50** **Deconstructing guidelines: how to ensure and assess their trustworthiness** *Mical Paul* (*Haifa, Israel*)

W0410 **14:10** **Pitfalls in developing guidelines: conflicts of interest, panel composition, and updating** *José Ramón Paño-Pardo* (*Zaragoza, Spain*)

W0411 **14:30** **More than a logo: the strategic role of societies in guideline development** *Marcus Zervos* (*Detroit, United States*)

Co-organised with: ESCMID Guidelines Subcommittee, CMI Board of Editors

---

EW168 **13:30 – 15:30** **Hall ICM 13b**

CLN DX

2-hour Educational Session

A diagnostic odyssey: how to enhance diagnostic stewardship

Chairs *Polona Maver Vodicar* (*Ljubljana, Slovenia*)
Neven Papic (*Zagreb, Croatia*)

W0412 **13:30** **Should I order an IGRA test? Could this be a mycobacterial infection?** *Christoph Lange* (*Borstel, Germany*)

W0413 **13:50** **Do I have antibodies or just anxiety? Gen Z gets real about serology** *Jean-Luc Murk* (*Blaricum, The Netherlands*)

W0414 **14:10** **PCR tests: the superheroes of infection detection... or just really good sidekicks?** *Snjezana Zidovec Lepej* (*Zagreb, Croatia*)

W0415 **14:30** **Serum, culture, PCR: but wait, fungi still have a few tricks up their sleeve!** *Katrien Lagrou* (*Leuven, Belgium*)

OS139 **13:30 – 15:30** **Hall ICM 5**

CLN DX TRN

2-hour Oral Session

Clinical metagenomics: from sample processing to actionable results

Chairs *Hege Vangstein Aamot* (*Lørenskog, Norway*)
John W. A. Rossen (*Groningen, The Netherlands*)

O0975 **13:30** **From sample to treatment in four hours: bringing metagenomics precision to complicated UTI diagnostics and management** *R. Ahmad** (*Hamar, Norway*), *A.B. Bellankimath, S. Branders, K. Isabell, A. Jawad, A. Fatemeh, T.E.B. Johansen, C. Imirzalioglu, T. Hain, F. Wagenlehner*

O0976 **13:42** **Multi-centre evaluation of the EasySeq Full-Length 16S Sequencing kit for bacterial identification in clinical samples** *T.T. Severs** (*Zwolle, The Netherlands*), *L. Gard, J.W.A. Rossen, L.B. Van Alphen, R.M. Koeck, P.W. Smit, R.Y. Yahiaoui, S.P.F. Matamoros, B. Van Den Bosch, P. Koopman, R. Cartuyvels, J. Dingemans, M.J.R. Ivens, S.D. Pas, S.A. Boers*

O0977 **13:54** **Rapid species identification in community-acquired bacteraemia using a short pre-culturing step followed by 16S nanopore sequencing** *D. Nestor** (*Orebro, Sweden*), *M. Ekström, S. Cajander, P. Mölling, M. Sundqvist*

O0978 **14:06** **Insights from over 11,000 clinical samples in over five years of routine metagenomics in Germany** *S. Grumaz** (*Duisburg, Germany*), *J. Becher, C. Disqué, K. Rensing, J. Bottlang, D. Borda-Molina, P. Stevens*

O0979 **14:18** **MetaGENomic Sequencing to detect Infections in SOTR (Solid Organ Transplant Recipients): interim analysis of the mGENiSIS registry** *S. Khalil** (*Houston, United States*), *A. Chandorkar, D.W. Charles, L. Fontana, T. Taylor, I. Kaur, D.R. Kaul, Z. Raglow, J. Schaenman, K. Obeid, S. Nair, C.E. Harris, R.O. Adekunle, A. Mills, S. Yang, J.R. Shah, L. Ogawa, H. Hassouna, J. Polega, J. Morillas, P. Vijayvargiya, S. Imam, N. Vissichelli, M. Morales, R. Shrestha, J. Hand, Z. Esquer, J. Goldman, E. Eichenberger, M.R. Sohail*

O0980 **14:30** **Implementation of respiratory metagenomics during the 2024/25 autumn/winter season in a large UK specialist referral hospital** *M. Ibrahim** (*Southampton, United Kingdom*), *S. Green, N. Norton, E. Pelosi, J. Swabe, C. Mckenzie, A. Alcolea-Medina, L.B. Snell, D. Ward, A. Dushianthan, M. Grocott, J. Edgeworth, K. Saeed*

O0981 **14:42** **Rapid hybridisation capture workflow for targeted metagenomics of respiratory infections** *O.E. Torres Montaguth** (*London, United Kingdom*), *A. Busam, L.M. Martin Bernal, T. Brooks, I. Ringue, G. Kuczmar, A. Kopec, S. Buddle, L. Ahmed, R. Williams, J. Brown, S. Morfopoulou, J. Breuer*

O0982 **14:54** **Ultra-rapid µCaler hybrid-capture tNGS with a fully automated workstation for comprehensive detection of respiratory pathogens** *W. Feili** (*Beijing, China*), *Y. Liping, G. Shan, X. Bangxiang, Z. Jiaying, Z. Lili, Z. Yulin*

O0983 **15:06** **The world's first direct from raw sample to report NGS platform: delivering rapid BSI pathogen ID and AMR from whole blood clinical samples** *S. Reed** (*London, United Kingdom*), *R. Samuel, E. Brown, D. Seth, D. Dylan, E. Oscar, S. Yazmine, P. Hannah, P. Maria, S. Laura, E. Liz, M.B. Joanna, M. Raegan, L. William, P. Marie, G. Flavia, S. Shagun, D. Jennifer, S. Peter, G. Hailey, C. Giselle, K. Daniel, W. Jason, C. Brandon, N. Cristian, R. Jonathan, M. Christian, P. Shane, V. Steven, D. Miroslav, J. Isaac, M.C. Fraser, M. Daniel, W. David, W. Graham, W. Michele*

O0984 **15:18** **An open-source, on-site nanopore sequencing workflow for rapid microbial cell-free DNA (mcfDNA) detection in bloodstream infections** *M. Banz** (*Jena, Germany*), *S. Hagel, M. Pletz, C. Brandt*

SY164 **13:30 – 15:30** **Hall A1-2**

PED VAX

2-hour Symposium

From childhood to adulthood: overcoming barriers in vaccine prevention

Chairs *Hervé Haas* (*Nice, France*)
Tina Tan (*Chicago, United States*)

S0400 **13:30** **Meningococcal disease: how and why do vaccination schedules differ across Europe ?** *Adam Finn* (*Bristol, United Kingdom*)

S0401 **14:00** **Measles: lessons learned from a recent epidemic in the era of vaccine hesitancy** *Adriana Pistol* (*Bucharest, Romania*)

S0403 **14:30** **Pneumococcal disease prevention: a lifespan approach** *Robert Cohen* (*Creteil, France*)

Co-organised with: Société de Pathologie Infectieuse de Langue Française, French Pediatric Infectious Diseases Group (GPIP), Infectious Diseases Society of America (IDSA)

SY163 **13:30 – 15:30** **Hall ICM 1**

AMR

2-hour Symposium

Global landscape of AMR surveillance in Gram-negative bacteria

Chairs *Patrick Mcgann* (*Silver Spring, Maryland, United States*)
Paul A. Tambyah (*Singapore, Singapore*)

S0396 **13:30** **Insights from the genomic surveillance of CRE in Europe: ongoing challenges** *Lemonia Skoura* (*Thessaloniki, Greece*)

S0397 **14:00** **Current epidemiology of CRAb in Europe: diagnostic advances** *Paul G. Higgins* (*Cologne, Germany*)

S0398 **14:30** **Revolutionising informal AMR data sources vs traditional interfaces** *Tin Tin Myaing* (*Bangkok, Thailand*)

S0399 **15:00** **Genomic insights into AMR surveillance: lessons from South and South-East Asia** *Balaji Veeraraghavan* (*Vellore, India*)

Co-organised with: AMR Action Subcommittee, ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Public Health Microbiology (ESGPHM), ECDC, International Society for Infectious Diseases

---

EF141 **13:30 – 14:30** **Arena 2**

IPC

ePoster Flash Session

New threats to occupational health

Chair *Biljana Carevic* (*Oslo, Norway*)

E0985 13:30 **SIREN RespOME study: *Staphylococcus aureus* nasal and throat colonisation in a UK healthcare worker cohort** *V. Hall* (London, United Kingdom), S. Foulkes, K. Bellis, A. Atti, E.M. Harrison, J. Islam*

E0986 13:36 **Healthcare worker KAP tools regarding flu and COVID-19 vaccination: reliability and structural stability pre- and post-campaign** *M. Latorre-Millán* (Saragossa, Spain), A. Milagro, I. Ezpeleta, J.M. Álvarez-Zarate, L. Clusa*

E0987 13:42 **Healthcare workers' infection prevention strategies in primary healthcare facilities of rohingya refugee camps in Bangladesh** *S.M.M. Hasan* (Dhaka, Bangladesh), S.A. Prema*

E0989 13:48 **Late diagnosis of infectious diseases and disease transmission among health care workers in a tertiary care hospital** *R. Tafveez* (Karachi, Pakistan), A. Ali, S. Farhan, N. Virani, R. Roshan, S.F. Mahmood*

E0990 13:54 **Prioritising healthcare workers for Lassa fever vaccination in Nigeria** *D. Smith* (Paris, France), T.D. Hollingsworth, K. Holohan, O.O. Ayodeji, K.B. Pouwels, S. Okogbenin*

E0991 14:00 **Do we spread bacteria when 'shooting' disposable gloves after use?** *F. Schaumburg* (Münster, Germany), J. Skorning, T. Grebe, P. Neuhaus*

E0992 14:06 **Bridging the know-do gap: evaluation of a multimodal intervention to increase infection prevention competency of healthcare workers in Bangladeshi hospitals** *S.A. Sumon* (Dhaka, Bangladesh), M.G.D. Harun*

E0993 14:12 **Evaluating mask performance through total inward leakage: a human volunteer study** *K. Lassing* (Nijmegen, The Netherlands), H. Wertheim, P. Scheepers*

EF142 **13:30 – 14:30** **Arena 3**

DX

ePoster Flash Session

Next-generation diagnostics for reproductive health

Chair *Mauricio Farfan (Santiago, Chile)*

E0995 13:30 **Hologic Panther system in the diagnosis of bacterial vaginosis, vulvovaginal candidiasis, and *Trichomonas vaginalis* vaginitis** *N. Aparisi* (Valencia, Spain), N. Aparisi Valero, M. Palomeque Matos, A. Orts Fullana, L. Andrés Eslava, J.L. Ramos Martí, V. Marqués Nova, L. Suarez Lopez, M.G. Ferrando Cerda, M.J. Lahiguera Abalos, N. Talón Costa, L. Sempere Mira, C. Gimeno Cardona, D. Ocete Mochón*

E0997 13:36 **High-throughput multiplex PCR for detection of infertility-associated STIs in gynecologist-referred patients** *B. Cullhaj* (Tirana, Albania), I. Marku, D. Sino*

E0998 13:42 **Diagnostic accuracy of Xpert CT/NG assay at the point-of-care for the detection of neonatal *Chlamydia trachomatis* and *Neisseria gonorrhoeae* infection: cohort study in Papua New Guinea** *L. Braunack-Mayer* (Bern, Switzerland), M.A. Riddell, A. Mengi, L.M. Vallely, P.H. Cunningham, M. Starr, H. Wand, B.D. Spycher, R. Guy, M. Laman, W.S. Pomat, A.J. Vallely, N. Low*

E0999 13:48 **Detection of *Treponema pallidum* in saliva and its application to molecular epidemiology** *K. Imai* (Saitama, Japan), Y. Ohama, A. Sato, M. Tanaka, R. Omachi, S.I. Nakayama, M. Tokano, N. Tarumoto, T. Maeda, Y. Akeda*

E1000 13:54 **Expanding diagnostic options for STIs: qPCR screening using routine liquid cytology samples** *H. Alonso* (San Mateo De Gállego, Spain), E. Teresa, E. Villarreal, M. Lopez, S. Aznar, S. Lucea, M. Barco*

E1001 14:00 **A pragmatic approach to scaling STI screening in low-resource settings: pooled '3-in-1' Xpert® CT/NG testing achieves high predictive performance at reduced costs among Indonesian MSM** *R. Hamers* (Jakarta, Indonesia), S. Suwarti, Y.W. Anggraini, N. Kawi, H. Luis, J. Jeny, D.P. Rahmawati, E.P. Sihotang, M. Oktaviani, P.P. Januraga, E. Sukmaningrum, E. Yunihastuti, E.J. Sanders, S. Wignall, K. Gedela*

E1002 14:06 **Large-scale molecular surveillance of bacterial STIs in Brazil: a four-year multi-state analysis of over 335,000 RT-PCR tests for *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and *Mycoplasma genitalium*** *V. Passarelli* (São Paulo, Brazil), P. Cappellano, C. Dos Santos Lazar, F. Goldemberg, M. Chiarastelli Salomão, A. Martins Fontes, F. Marques Rodrigues, J. De Sá, F.H. Da Silva, C. Granato, G. Hughes, S. Figueiredo Costa*

SY173 **14:30 – 15:30** **Hall A1-5**

1-hour Symposium

IPC

Future-proofing IPC: smarter strategies for tomorrow's challenges

Chairs *Elisabeth Presterl (Vienna, Austria)*
Andreas F. Widmer (Füllinsdorf, Switzerland)

S0451 14:30 **Advancing prevention of catheter-associated infections: from care bundles to integrated multimodal IPC strategies** *Camelia Bogaert (Gent, Belgium)*

S0452 15:00 **From firefighting to foresight: shifting IPC from reactive to proactive** *Nico Tom Mutters (Bonn, Germany)*

EF143 **14:30 – 15:30** **Arena 1**

AMR ANT PHEI

ePoster Flash Session

Shaping policy for antimicrobial use and AMR

Chair *Benedikt Huttner (Geneva, Switzerland)*

E1004 14:30 **An intersectionality-based policy analysis of antimicrobial resistance in national action plans in WHO European region** *E. Magrini* (Rome, Italy), C. Shortall, C. Naim, E. Short, A. Abbara*

E1005 14:36 **Carbon impact of blood-culture utilisation changes during a global supply constraint** *E. Chan* (Melbourne, Australia), P. Kinsella, C. O'shea, K. Cronin, K. Bond, S. Mcalister, F. Mcgain*

E1006 14:42 **The environmental impact of antibiotic treatment: a life-cycle analysis of intravenous-inpatient, -outpatient and oral treatment options** *P. Elders* (Amsterdam, The Netherlands), B. Joosten, T. De Vries, L. Kouwenberg, E. Cohen, E. Van Bree, F. De Haes, S. Geerlings, J. Hovius, K. Sigaloff*

E1007 14:48 **Towards a global health equity framework for antimicrobial resistance: mapping indicators across disciplines, domains, and levels of aggregation** *T. Makamu* (Cape Town, South Africa), C. Bonaconsa, S. Mkhumbuzi, A. Kona, M. Mendelson, E. Charani*

E1008 14:54 **Strengthening public health policies for antimicrobial resistance: insights from the EU-JAMRAI 2 sustainability guidance tool** *B. Davido* (Paris, France), D. Merillon, M. Fuentes-Braesch*

E1009 15:00 **Valuing sustainable access to antibiotics: stakeholder reasoning on trade-offs, preparedness, and ethical priorities in Sweden, Italy, and Bulgaria** *M. Torre* (Rome, Italy), M. Ancillotti, D. Mascalzoni, R. Biasiotto, A. Diukendjieva, G. Kyosovska, C. Munthe, E. Baraldi, S. Wagrell*

E1011 15:06 **Impact of World Health Organization's AWaRe antibiotics on the gut microbiome: a systematic review and meta-analysis** *A. Di Gallo* (Milan, Italy), E. Crivellaro, A. Banfi, L. Barcellini, S. Panelli, C. Giaroni, E. Fusco, G. Zuccotti, M. Sharland, L. Folgori*

EF144 **14:30 – 15:30** **Arena 4**

CLN PHEI

ePoster Flash Session

Clinical and epidemiological perspectives on neglected parasitic and fungal diseases

Chair *Jaya Tapadar Née Chakravarty (Varanasi, India)*

E1012 14:30 **Effectiveness of PAIR and aspiration for hepatic hydatid cysts: ten years of experience from a UK referral centre** *L. Blundell* (London, United Kingdom), M. Bojorquez-Segura, M. James, D. Lawrence, T. Pissanou, G. Godbole, Z. Amin, L. Nabarro*

E1013 14:36 **Structured treatment interruption in alveolar echinococcosis: patient selection and predictors of successful outcome** *A.L. Allgaeuer* (Ulm, Germany),*

L. Heinzmann, L. Peters, W. Jiang, B. Gruener

E1014 **14:42** **Epidemiological and molecular study of relapse cases of infection with the microsporidia *Enterocytozoon bieneusi*** *C. Nourrisson* (Clermont-Ferrand, France), M. Moniot, P. Combes, F. Dalle, D. Costa, P. Poirier*

E1015 **14:48** **Intestinal microsporidiosis in immunocompetent individuals: data from the French NRC CMAP (2018–2024)** *P. Poirier* (Clermont-Ferrand, France), C. Nourrisson, P. Combes, M. Moniot, L. Favennec, F. Dalle, D. Costa*

E1016 **14:54** **The skin to heart connection: linking scabies and skin infections to rheumatic heart disease in a New Zealand national cohort study** *S. Gupta* (Auckland, New Zealand), S. Thornley*

E1017 **15:00** **Scabies prevalence in children under five years old in Ecuadorean remote indigenous communities after the cessation of ivermectin administration** *A. Garcia Mingo* (London, United Kingdom), A. García-Mingo, M. Castro Aliaga, M. Caicedo Orobio, E. Salazar, R. Basu Roy, V. Velasco Tirado, M. Cáceres Alonso, M. González Sanz*

E1018 **15:06** **Epidemiological shifts in visceral leishmaniasis incidence, relapse, and mortality in Brazil: analysis using National Notifiable Diseases Information System** *D.G. Assefa* (Dilla, Ethiopia), G. Cota, J.P. Wilson, J.A. Mendes, C. Naylor, R. Peploe, S. Singh-Phulgenda, M.S. Saito, P.J. Guerin, P. Dahal*

E1019 **15:12** **Epidemiological and clinical features of leishmaniasis in a tertiary hospital in Brazil** *O.H. Pradi Guenther* (Curitba, Brazil), E. Dyminski Parente Ribeiro, F. Tomiotto-Pellissier*

E1020 **15:18** **A ten-year follow-up of *Leishmania donovani* transmission dynamics during the visceral leishmaniasis elimination campaign in India** *A.K. Singh* (Varanasi, India), S. Sundar, E. Hasker*

ME174 **14:30 – 15:30** **Hall A1-3**

CLN DX

Meet-the-Expert

How to use serological tests for Lyme borreliosis

M0453 **14:30** *Mariska Leeflang (Amsterdam, The Netherlands)*

M0454 **14:42** *Ram B. Dessau (Slagelse, Denmark)*

Co-organised with: ESCMID Study Group for Lyme Borreliosis (ESGBOR)